data_1znu_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 1znu _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 58.5 m . . . . . 0 N--CA 1.453 -0.307 0 N-CA-C 108.301 -1.0 . . . . 0.0 108.301 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 90.93 -15.76 60.06 Favored Glycine 0 CA--C 1.531 1.042 0 O-C-N 124.483 1.115 . . . . 0.0 110.96 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 15.6 tt0 -88.76 162.72 16.07 Favored 'General case' 0 C--N 1.325 -0.471 0 O-C-N 124.541 0.789 . . . . 0.0 110.316 179.999 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 53.0 p -120.39 134.97 55.18 Favored 'General case' 0 C--N 1.324 -0.502 0 O-C-N 124.496 1.123 . . . . 0.0 110.425 179.998 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . 0.417 ' O ' ' CD1' ' A' ' 19' ' ' TRP . 13.8 p -105.05 49.06 0.82 Allowed 'General case' 0 C--N 1.325 -0.487 0 O-C-N 124.487 1.117 . . . . 0.0 108.334 179.982 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 37.9 t -59.12 -23.37 24.35 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 O-C-N 124.491 1.12 . . . . 0.0 109.327 179.986 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -82.89 -32.69 26.04 Favored Glycine 0 CA--C 1.531 1.033 0 O-C-N 124.477 1.111 . . . . 0.0 110.985 -179.967 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 125.64 10.8 4.3 Favored Glycine 0 CA--C 1.53 0.997 0 O-C-N 125.068 1.099 . . . . 0.0 110.959 178.183 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 83.6 m -150.19 165.38 33.08 Favored 'General case' 0 C--N 1.325 -0.495 0 O-C-N 124.493 0.761 . . . . 0.0 110.398 179.947 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 91.4 m -118.45 141.85 48.14 Favored 'General case' 0 C--N 1.325 -0.473 0 O-C-N 124.498 1.124 . . . . 0.0 108.29 -179.976 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 13.0 t-20 -89.79 -39.9 12.81 Favored 'General case' 0 C--N 1.325 -0.488 0 O-C-N 124.526 1.141 . . . . 0.0 109.342 179.959 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' THR . . . . . 0.497 ' CG2' ' SG ' ' A' ' 15' ' ' CYS . 17.6 m -62.32 142.99 95.9 Favored Pre-proline 0 C--N 1.325 -0.49 0 O-C-N 124.458 1.099 . . . . 0.0 110.383 -179.989 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . 0.481 ' HD2' ' CG2' ' A' ' 12' ' ' THR . 20.3 Cg_endo -74.9 132.06 15.12 Favored 'Trans proline' 0 N--CA 1.453 -0.875 0 O-C-N 124.524 1.802 . . . . 0.0 110.983 -168.314 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 74.37 12.46 82.04 Favored Glycine 0 CA--C 1.53 1.023 0 O-C-N 124.465 1.103 . . . . 0.0 110.962 179.935 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.497 ' SG ' ' CG2' ' A' ' 12' ' ' THR . 67.3 m -96.71 127.64 42.89 Favored 'General case' 0 C--N 1.325 -0.465 0 N-CA-C 108.307 -0.997 . . . . 0.0 108.307 179.97 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 77.5 p -95.15 152.85 17.99 Favored 'General case' 0 C--N 1.325 -0.457 0 O-C-N 124.511 1.132 . . . . 0.0 110.383 -179.986 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 54.1 t -77.72 93.86 4.35 Favored 'General case' 0 C--N 1.325 -0.493 0 O-C-N 124.487 1.117 . . . . 0.0 108.33 179.983 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' SER . . . . . 0.512 ' O ' ' C ' ' A' ' 19' ' ' TRP . 3.1 t -100.41 65.9 1.23 Allowed 'General case' 0 C--N 1.324 -0.526 0 O-C-N 124.494 1.121 . . . . 0.0 109.992 174.321 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' TRP . . . . . 0.524 ' CG ' ' HA ' ' A' ' 20' ' ' PRO . 0.0 OUTLIER -36.93 147.89 0.2 Allowed Pre-proline 0 C--N 1.325 -0.472 0 O-C-N 124.52 1.138 . . . . 0.0 108.009 -173.973 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . 0.524 ' HA ' ' CG ' ' A' ' 19' ' ' TRP . 18.5 Cg_endo -74.98 -12.11 23.98 Favored 'Cis proline' 0 C--N 1.36 1.176 0 C-N-CA 121.023 -2.49 . . . . 0.0 111.047 -8.5 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.492 ' O ' ' C ' ' A' ' 18' ' ' SER . 3.7 p -99.33 -179.55 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 O-C-N 124.5 1.125 . . . . 0.0 109.232 -173.465 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 43.2 m -101.32 168.4 9.57 Favored 'General case' 0 C--N 1.325 -0.478 0 O-C-N 124.509 1.131 . . . . 0.0 108.3 179.99 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' THR . . . . . 0.471 ' CG2' ' CB ' ' A' ' 18' ' ' SER . 0.7 OUTLIER -144.95 164.95 29.56 Favored 'General case' 0 C--N 1.325 -0.478 0 O-C-N 124.553 1.158 . . . . 0.0 110.383 -179.983 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . 0.423 ' HB3' ' CG2' ' A' ' 29' ' ' VAL . 0.0 OUTLIER -133.87 117.55 16.94 Favored 'General case' 0 C--N 1.325 -0.463 0 O-C-N 124.539 1.149 . . . . 0.0 110.298 179.969 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 74.0 m-20 57.68 23.42 9.43 Favored 'General case' 0 C--N 1.326 -0.456 0 O-C-N 124.447 1.092 . . . . 0.0 109.332 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 84.01 24.59 48.11 Favored Glycine 0 CA--C 1.53 0.993 0 O-C-N 124.52 1.137 . . . . 0.0 110.994 179.986 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 9.6 mt -143.67 130.32 10.37 Favored Pre-proline 0 C--N 1.325 -0.471 0 O-C-N 124.485 0.756 . . . . 0.0 109.339 -179.992 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 20.1 Cg_endo -74.95 89.32 1.16 Allowed 'Trans proline' 0 N--CA 1.453 -0.899 0 O-C-N 124.5 1.79 . . . . 0.0 110.981 -168.294 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.423 ' CG2' ' HB3' ' A' ' 24' ' ' ARG . 22.4 m . . . . . 0 C--N 1.325 -0.496 0 O-C-N 124.501 1.125 . . . . 0.0 109.312 179.991 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 64.8 m . . . . . 0 N--CA 1.453 -0.294 0 N-CA-C 108.305 -0.998 . . . . 0.0 108.305 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 89.63 -17.35 53.02 Favored Glycine 0 CA--C 1.53 0.979 0 O-C-N 124.507 1.129 . . . . 0.0 111.03 179.999 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 14.8 tt0 -87.94 162.62 16.78 Favored 'General case' 0 C--N 1.325 -0.499 0 O-C-N 124.491 0.759 . . . . 0.0 110.291 179.99 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 40.0 p -121.52 137.71 54.61 Favored 'General case' 0 C--N 1.326 -0.445 0 O-C-N 124.497 1.123 . . . . 0.0 110.424 179.98 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . 0.448 ' O ' ' CD1' ' A' ' 19' ' ' TRP . 14.3 p -105.87 51.13 0.76 Allowed 'General case' 0 C--N 1.325 -0.487 0 O-C-N 124.511 1.132 . . . . 0.0 108.289 -179.967 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 6.0 t -59.1 -24.74 27.99 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 O-C-N 124.482 1.114 . . . . 0.0 109.312 179.994 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -83.91 -33.8 20.18 Favored Glycine 0 CA--C 1.53 0.969 0 O-C-N 124.45 1.093 . . . . 0.0 110.982 -179.992 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 126.27 13.96 3.09 Favored Glycine 0 CA--C 1.53 1.012 0 O-C-N 125.044 1.085 . . . . 0.0 111.031 177.78 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 28.8 m -149.91 163.64 37.54 Favored 'General case' 0 C--N 1.325 -0.483 0 O-C-N 124.509 0.77 . . . . 0.0 110.364 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . 0.409 ' SG ' ' O ' ' A' ' 16' ' ' THR . 90.2 m -120.55 143.13 48.75 Favored 'General case' 0 C--N 1.325 -0.475 0 O-C-N 124.481 1.113 . . . . 0.0 108.331 179.987 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 76.2 m-20 -89.96 -46.99 8.14 Favored 'General case' 0 C--N 1.325 -0.462 0 O-C-N 124.462 1.101 . . . . 0.0 109.287 -179.968 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' THR . . . . . 0.498 ' CG2' ' SG ' ' A' ' 15' ' ' CYS . 20.7 m -55.23 142.71 57.66 Favored Pre-proline 0 C--N 1.325 -0.489 0 O-C-N 124.524 1.14 . . . . 0.0 110.343 -179.958 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . 0.475 ' HD2' ' CG2' ' A' ' 12' ' ' THR . 20.3 Cg_endo -74.92 132.0 15.03 Favored 'Trans proline' 0 N--CA 1.453 -0.872 0 O-C-N 124.572 1.827 . . . . 0.0 111.028 -168.334 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 74.76 12.29 82.92 Favored Glycine 0 CA--C 1.53 1.011 0 O-C-N 124.478 1.111 . . . . 0.0 110.956 179.976 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.498 ' SG ' ' CG2' ' A' ' 12' ' ' THR . 69.6 m -95.52 126.02 40.52 Favored 'General case' 0 C--N 1.324 -0.507 0 N-CA-C 108.262 -1.014 . . . . 0.0 108.262 -179.986 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' THR . . . . . 0.409 ' O ' ' SG ' ' A' ' 10' ' ' CYS . 29.1 p -93.75 156.2 16.81 Favored 'General case' 0 C--N 1.325 -0.492 0 O-C-N 124.526 1.141 . . . . 0.0 110.387 179.999 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 51.6 t -81.34 94.06 6.69 Favored 'General case' 0 C--N 1.325 -0.498 0 O-C-N 124.531 1.144 . . . . 0.0 108.291 179.997 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' SER . . . . . 0.514 ' O ' ' C ' ' A' ' 19' ' ' TRP . 1.9 m -101.07 66.39 1.14 Allowed 'General case' 0 C--N 1.325 -0.488 0 O-C-N 124.552 1.157 . . . . 0.0 109.989 174.26 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' TRP . . . . . 0.531 ' CG ' ' HA ' ' A' ' 20' ' ' PRO . 0.0 OUTLIER -36.74 148.19 0.19 Allowed Pre-proline 0 C--N 1.325 -0.481 0 N-CA-C 107.964 -1.124 . . . . 0.0 107.964 -174.019 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . 0.531 ' HA ' ' CG ' ' A' ' 19' ' ' TRP . 18.2 Cg_endo -75.03 -11.87 24.19 Favored 'Cis proline' 0 C--N 1.361 1.192 0 C-N-CA 120.967 -2.514 . . . . 0.0 110.997 -8.474 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.487 ' O ' ' C ' ' A' ' 18' ' ' SER . 2.2 t -100.2 179.92 0.58 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 O-C-N 124.521 1.138 . . . . 0.0 109.285 -173.386 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 57.0 m -101.63 168.43 9.48 Favored 'General case' 0 C--N 1.325 -0.491 0 O-C-N 124.494 1.121 . . . . 0.0 108.312 179.987 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -145.25 165.06 29.47 Favored 'General case' 0 C--N 1.325 -0.476 0 O-C-N 124.558 1.161 . . . . 0.0 110.427 179.975 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . 0.462 ' HB3' ' CG2' ' A' ' 29' ' ' VAL . 1.3 ttt-85 -132.81 116.26 16.32 Favored 'General case' 0 C--N 1.324 -0.5 0 O-C-N 124.523 1.139 . . . . 0.0 110.327 -179.991 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 78.4 m-20 57.79 23.08 9.21 Favored 'General case' 0 C--N 1.324 -0.502 0 O-C-N 124.501 1.126 . . . . 0.0 109.291 179.996 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 84.78 23.51 49.54 Favored Glycine 0 CA--C 1.529 0.968 0 O-C-N 124.487 1.117 . . . . 0.0 111.012 -179.966 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 7.2 mt -142.46 129.93 11.26 Favored Pre-proline 0 C--N 1.325 -0.497 0 O-C-N 124.496 0.762 . . . . 0.0 109.288 -179.935 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 20.2 Cg_endo -74.98 89.59 1.15 Allowed 'Trans proline' 0 N--CA 1.453 -0.876 0 O-C-N 124.534 1.807 . . . . 0.0 110.987 -168.323 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.462 ' CG2' ' HB3' ' A' ' 24' ' ' ARG . 32.6 m . . . . . 0 C--N 1.325 -0.479 0 O-C-N 124.487 1.117 . . . . 0.0 109.276 179.997 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 32.9 m . . . . . 0 N--CA 1.453 -0.282 0 N-CA-C 108.28 -1.008 . . . . 0.0 108.28 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 88.54 -16.01 55.02 Favored Glycine 0 CA--C 1.531 1.044 0 O-C-N 124.503 1.127 . . . . 0.0 110.985 -179.992 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 16.4 tt0 -90.21 161.92 15.49 Favored 'General case' 0 C--N 1.325 -0.483 0 O-C-N 124.515 0.774 . . . . 0.0 110.329 179.982 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 37.3 p -122.67 135.99 54.75 Favored 'General case' 0 C--N 1.324 -0.518 0 O-C-N 124.481 1.113 . . . . 0.0 110.417 179.992 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . 0.406 ' SG ' ' O ' ' A' ' 5' ' ' CYS . 15.3 p -102.65 53.04 0.79 Allowed 'General case' 0 C--N 1.325 -0.484 0 O-C-N 124.528 1.142 . . . . 0.0 108.281 -179.971 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 15.6 t -59.43 -24.51 28.41 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 O-C-N 124.471 1.107 . . . . 0.0 109.331 179.97 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -84.54 -30.96 25.79 Favored Glycine 0 CA--C 1.53 0.982 0 O-C-N 124.485 1.116 . . . . 0.0 110.992 179.97 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 122.6 13.26 4.74 Favored Glycine 0 CA--C 1.53 1.012 0 O-C-N 124.953 1.031 . . . . 0.0 110.979 178.611 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 5.9 m -150.14 158.76 44.5 Favored 'General case' 0 C--N 1.325 -0.497 0 O-C-N 124.512 0.772 . . . . 0.0 110.41 179.973 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . 0.403 ' SG ' ' O ' ' A' ' 16' ' ' THR . 97.2 m -114.3 141.58 47.41 Favored 'General case' 0 C--N 1.325 -0.461 0 O-C-N 124.491 1.12 . . . . 0.0 108.307 -179.971 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 64.3 t30 -89.83 -44.5 9.91 Favored 'General case' 0 C--N 1.325 -0.48 0 O-C-N 124.518 1.136 . . . . 0.0 109.284 -179.965 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' THR . . . . . 0.5 ' CG2' ' SG ' ' A' ' 15' ' ' CYS . 18.9 m -57.65 142.85 77.07 Favored Pre-proline 0 C--N 1.325 -0.472 0 O-C-N 124.487 1.117 . . . . 0.0 110.348 -179.987 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . 0.478 ' HD2' ' CG2' ' A' ' 12' ' ' THR . 20.3 Cg_endo -75.01 130.57 13.38 Favored 'Trans proline' 0 N--CA 1.452 -0.925 0 O-C-N 124.488 1.783 . . . . 0.0 111.026 -168.328 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 75.59 14.09 82.36 Favored Glycine 0 CA--C 1.531 1.034 0 O-C-N 124.518 1.136 . . . . 0.0 110.975 -179.989 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.5 ' SG ' ' CG2' ' A' ' 12' ' ' THR . 62.3 m -95.69 129.54 42.86 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 108.274 -1.01 . . . . 0.0 108.274 -179.971 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' THR . . . . . 0.403 ' O ' ' SG ' ' A' ' 10' ' ' CYS . 7.7 p -95.54 152.35 18.5 Favored 'General case' 0 C--N 1.325 -0.481 0 O-C-N 124.491 1.12 . . . . 0.0 110.388 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 45.6 t -81.67 94.92 7.06 Favored 'General case' 0 C--N 1.325 -0.497 0 O-C-N 124.515 1.134 . . . . 0.0 108.328 179.999 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' SER . . . . . 0.514 ' O ' ' C ' ' A' ' 19' ' ' TRP . 1.2 t -104.13 67.05 0.84 Allowed 'General case' 0 C--N 1.324 -0.504 0 O-C-N 124.551 1.157 . . . . 0.0 109.98 174.221 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' TRP . . . . . 0.564 ' CG ' ' HA ' ' A' ' 20' ' ' PRO . 0.1 OUTLIER -36.1 147.23 0.19 Allowed Pre-proline 0 C--N 1.325 -0.485 0 O-C-N 124.502 1.127 . . . . 0.0 108.011 -174.257 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . 0.564 ' HA ' ' CG ' ' A' ' 19' ' ' TRP . 18.1 Cg_endo -74.98 -14.0 23.26 Favored 'Cis proline' 0 C--N 1.36 1.136 0 C-N-CA 121.014 -2.494 . . . . 0.0 110.996 -8.659 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.484 ' O ' ' C ' ' A' ' 18' ' ' SER . 3.0 m -97.67 177.83 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.478 0 O-C-N 124.496 1.123 . . . . 0.0 109.294 -173.075 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 52.9 m -102.18 172.5 6.86 Favored 'General case' 0 C--N 1.325 -0.485 0 O-C-N 124.477 1.111 . . . . 0.0 108.317 179.98 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' THR . . . . . 0.486 ' CG2' ' CB ' ' A' ' 18' ' ' SER . 6.5 p -145.56 165.1 29.64 Favored 'General case' 0 C--N 1.324 -0.504 0 O-C-N 124.539 1.149 . . . . 0.0 110.416 -179.982 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . 0.463 ' HB3' ' CG2' ' A' ' 29' ' ' VAL . 0.1 OUTLIER -131.89 112.97 12.9 Favored 'General case' 0 C--N 1.325 -0.464 0 O-C-N 124.459 1.099 . . . . 0.0 110.293 179.986 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 2.6 m-80 57.12 22.96 7.99 Favored 'General case' 0 C--N 1.326 -0.451 0 O-C-N 124.498 1.124 . . . . 0.0 109.319 -179.986 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 86.15 25.3 37.56 Favored Glycine 0 CA--C 1.53 0.985 0 O-C-N 124.522 1.139 . . . . 0.0 111.016 -179.986 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 7.9 mt -143.37 130.01 10.48 Favored Pre-proline 0 C--N 1.325 -0.477 0 O-C-N 124.511 0.771 . . . . 0.0 109.3 179.983 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 20.2 Cg_endo -74.97 85.99 1.46 Allowed 'Trans proline' 0 N--CA 1.453 -0.891 0 O-C-N 124.55 1.816 . . . . 0.0 111.043 -168.34 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.463 ' CG2' ' HB3' ' A' ' 24' ' ' ARG . 21.6 m . . . . . 0 C--N 1.325 -0.469 0 O-C-N 124.512 1.133 . . . . 0.0 109.3 179.995 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 37.6 m . . . . . 0 N--CA 1.453 -0.304 0 N-CA-C 108.294 -1.002 . . . . 0.0 108.294 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 91.42 -21.64 34.21 Favored Glycine 0 CA--C 1.531 1.06 0 O-C-N 124.505 1.128 . . . . 0.0 110.999 179.989 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 16.0 tt0 -85.23 161.1 19.71 Favored 'General case' 0 C--N 1.325 -0.466 0 O-C-N 124.541 0.789 . . . . 0.0 110.274 -179.987 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 72.5 p -121.94 136.2 54.91 Favored 'General case' 0 C--N 1.325 -0.457 0 O-C-N 124.445 1.09 . . . . 0.0 110.455 179.996 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . 0.426 ' O ' ' CD1' ' A' ' 19' ' ' TRP . 15.2 p -102.1 53.78 0.8 Allowed 'General case' 0 C--N 1.325 -0.493 0 O-C-N 124.573 1.17 . . . . 0.0 108.283 -179.978 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 4.7 t -59.5 -24.85 29.54 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 O-C-N 124.515 1.135 . . . . 0.0 109.302 -179.993 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -85.42 -32.97 18.11 Favored Glycine 0 CA--C 1.53 0.991 0 O-C-N 124.524 1.14 . . . . 0.0 110.978 -179.979 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 124.31 15.34 3.4 Favored Glycine 0 CA--C 1.53 0.983 0 O-C-N 125.021 1.071 . . . . 0.0 110.977 178.057 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 6.0 m -150.17 158.95 44.7 Favored 'General case' 0 C--N 1.325 -0.48 0 O-C-N 124.494 0.761 . . . . 0.0 110.397 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 74.9 m -117.8 141.75 48.07 Favored 'General case' 0 C--N 1.325 -0.476 0 O-C-N 124.496 1.123 . . . . 0.0 108.302 179.975 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 4.6 m120 -89.7 -47.62 7.81 Favored 'General case' 0 C--N 1.325 -0.475 0 O-C-N 124.498 1.124 . . . . 0.0 109.294 179.997 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' THR . . . . . 0.498 ' CG2' ' SG ' ' A' ' 15' ' ' CYS . 20.8 m -53.87 142.75 43.57 Favored Pre-proline 0 C--N 1.325 -0.479 0 O-C-N 124.442 1.089 . . . . 0.0 110.392 -179.975 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . 0.472 ' HD2' ' CG2' ' A' ' 12' ' ' THR . 20.2 Cg_endo -75.04 130.78 13.54 Favored 'Trans proline' 0 N--CA 1.453 -0.866 0 O-C-N 124.443 1.759 . . . . 0.0 110.928 -168.237 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 75.36 13.55 82.75 Favored Glycine 0 CA--C 1.53 0.986 0 O-C-N 124.497 1.123 . . . . 0.0 111.022 -179.978 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.498 ' SG ' ' CG2' ' A' ' 12' ' ' THR . 64.2 m -95.54 126.65 40.97 Favored 'General case' 0 C--N 1.325 -0.476 0 N-CA-C 108.316 -0.994 . . . . 0.0 108.316 -179.967 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 17.6 p -94.0 155.23 17.24 Favored 'General case' 0 C--N 1.325 -0.485 0 O-C-N 124.48 1.112 . . . . 0.0 110.437 179.991 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 43.4 t -83.4 94.27 7.94 Favored 'General case' 0 C--N 1.325 -0.48 0 O-C-N 124.482 1.114 . . . . 0.0 108.325 -179.965 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' SER . . . . . 0.518 ' O ' ' C ' ' A' ' 19' ' ' TRP . 47.9 t -102.53 66.67 0.98 Allowed 'General case' 0 C--N 1.325 -0.497 0 O-C-N 124.486 1.116 . . . . 0.0 109.971 174.166 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' TRP . . . . . 0.545 ' CG ' ' HA ' ' A' ' 20' ' ' PRO . 0.0 OUTLIER -36.0 147.3 0.18 Allowed Pre-proline 0 C--N 1.325 -0.485 0 O-C-N 124.483 1.114 . . . . 0.0 108.022 -174.167 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . 0.545 ' HA ' ' CG ' ' A' ' 19' ' ' TRP . 18.3 Cg_endo -74.94 -13.69 23.34 Favored 'Cis proline' 0 C--N 1.36 1.159 0 C-N-CA 121.006 -2.498 . . . . 0.0 111.038 -8.513 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.49 ' O ' ' C ' ' A' ' 18' ' ' SER . 1.1 p -98.42 177.75 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 O-C-N 124.512 1.132 . . . . 0.0 109.305 -173.083 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 56.6 m -102.1 170.52 8.05 Favored 'General case' 0 C--N 1.325 -0.472 0 O-C-N 124.502 1.126 . . . . 0.0 108.271 -179.983 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 1.1 p -144.98 164.86 29.86 Favored 'General case' 0 C--N 1.325 -0.466 0 O-C-N 124.561 1.163 . . . . 0.0 110.423 179.974 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . 0.463 ' HB3' ' CG2' ' A' ' 29' ' ' VAL . 7.5 ttt180 -132.87 116.91 17.08 Favored 'General case' 0 C--N 1.325 -0.488 0 O-C-N 124.476 1.11 . . . . 0.0 110.341 179.966 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 75.7 m-20 57.39 23.37 8.89 Favored 'General case' 0 C--N 1.325 -0.48 0 O-C-N 124.452 1.095 . . . . 0.0 109.278 -179.991 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 83.89 25.22 46.26 Favored Glycine 0 CA--C 1.53 1.004 0 O-C-N 124.453 1.096 . . . . 0.0 110.995 -179.982 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 10.0 mt -144.22 131.19 10.31 Favored Pre-proline 0 C--N 1.325 -0.492 0 O-C-N 124.516 0.774 . . . . 0.0 109.268 179.995 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 20.1 Cg_endo -74.97 89.08 1.18 Allowed 'Trans proline' 0 N--CA 1.453 -0.872 0 O-C-N 124.462 1.77 . . . . 0.0 110.986 -168.308 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.463 ' CG2' ' HB3' ' A' ' 24' ' ' ARG . 33.5 m . . . . . 0 C--N 1.325 -0.485 0 O-C-N 124.443 1.09 . . . . 0.0 109.327 179.99 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 52.7 m . . . . . 0 N--CA 1.453 -0.279 0 N-CA-C 108.32 -0.993 . . . . 0.0 108.32 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 100.81 -10.16 58.75 Favored Glycine 0 CA--C 1.53 0.995 0 O-C-N 124.527 1.142 . . . . 0.0 110.997 -179.976 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 14.6 tt0 -99.17 162.77 12.87 Favored 'General case' 0 C--N 1.325 -0.484 0 O-C-N 124.51 0.77 . . . . 0.0 110.262 -179.96 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 80.9 p -120.12 138.09 53.77 Favored 'General case' 0 C--N 1.326 -0.446 0 O-C-N 124.541 1.151 . . . . 0.0 110.395 179.945 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . 0.431 ' O ' ' CD1' ' A' ' 19' ' ' TRP . 14.5 p -107.72 51.26 0.75 Allowed 'General case' 0 C--N 1.325 -0.482 0 O-C-N 124.515 1.134 . . . . 0.0 108.301 179.999 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 15.0 t -59.15 -23.89 25.86 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.468 0 O-C-N 124.461 1.101 . . . . 0.0 109.28 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -85.68 -34.07 14.5 Favored Glycine 0 CA--C 1.53 1.025 0 O-C-N 124.523 1.139 . . . . 0.0 111.019 179.981 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 126.19 17.57 2.44 Favored Glycine 0 C--N 1.344 0.993 0 O-C-N 125.223 1.19 . . . . 0.0 111.003 177.32 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -150.34 166.02 31.29 Favored 'General case' 0 C--N 1.325 -0.488 0 O-C-N 124.534 0.785 . . . . 0.0 110.377 -179.987 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . 0.41 ' SG ' ' O ' ' A' ' 16' ' ' THR . 80.1 m -125.97 142.76 51.38 Favored 'General case' 0 C--N 1.325 -0.468 0 O-C-N 124.485 1.116 . . . . 0.0 108.285 179.996 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 4.3 m-20 -89.99 -48.3 7.3 Favored 'General case' 0 C--N 1.324 -0.514 0 O-C-N 124.489 1.118 . . . . 0.0 109.286 -179.992 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' THR . . . . . 0.504 ' CG2' ' SG ' ' A' ' 15' ' ' CYS . 18.9 m -53.04 142.78 34.79 Favored Pre-proline 0 C--N 1.326 -0.453 0 O-C-N 124.497 1.123 . . . . 0.0 110.417 179.971 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . 0.476 ' HD2' ' CG2' ' A' ' 12' ' ' THR . 20.1 Cg_endo -75.01 131.39 14.22 Favored 'Trans proline' 0 N--CA 1.453 -0.906 0 O-C-N 124.495 1.787 . . . . 0.0 110.969 -168.3 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 74.2 15.11 80.15 Favored Glycine 0 CA--C 1.53 0.999 0 O-C-N 124.46 1.1 . . . . 0.0 110.984 179.965 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.504 ' SG ' ' CG2' ' A' ' 12' ' ' THR . 63.7 m -97.47 125.93 42.44 Favored 'General case' 0 C--N 1.325 -0.483 0 N-CA-C 108.285 -1.006 . . . . 0.0 108.285 179.996 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' THR . . . . . 0.41 ' O ' ' SG ' ' A' ' 10' ' ' CYS . 18.6 p -94.11 158.61 15.53 Favored 'General case' 0 C--N 1.324 -0.504 0 O-C-N 124.489 1.118 . . . . 0.0 110.393 -179.993 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 42.4 t -81.72 94.11 6.93 Favored 'General case' 0 C--N 1.325 -0.473 0 O-C-N 124.467 1.104 . . . . 0.0 108.334 179.951 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' SER . . . . . 0.517 ' O ' ' C ' ' A' ' 19' ' ' TRP . 2.5 t -100.98 65.57 1.11 Allowed 'General case' 0 C--N 1.325 -0.457 0 O-C-N 124.475 1.109 . . . . 0.0 109.989 174.214 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' TRP . . . . . 0.525 ' CG ' ' HA ' ' A' ' 20' ' ' PRO . 0.0 OUTLIER -36.64 148.04 0.19 Allowed Pre-proline 0 C--N 1.324 -0.507 0 O-C-N 124.489 1.118 . . . . 0.0 108.0 -174.067 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . 0.525 ' HA ' ' CG ' ' A' ' 19' ' ' TRP . 18.1 Cg_endo -75.02 -11.49 24.25 Favored 'Cis proline' 0 C--N 1.361 1.186 0 C-N-CA 121.017 -2.493 . . . . 0.0 110.97 -8.309 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.502 ' O ' ' C ' ' A' ' 18' ' ' SER . 3.2 p -100.5 -179.6 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 O-C-N 124.499 1.124 . . . . 0.0 109.291 -173.528 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 60.4 m -101.67 167.01 10.39 Favored 'General case' 0 C--N 1.326 -0.456 0 O-C-N 124.526 1.141 . . . . 0.0 108.316 179.999 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' THR . . . . . 0.466 ' CG2' ' CB ' ' A' ' 18' ' ' SER . 0.8 OUTLIER -144.45 165.7 27.22 Favored 'General case' 0 C--N 1.324 -0.517 0 O-C-N 124.487 1.117 . . . . 0.0 110.412 179.958 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . 0.426 ' HB3' ' CG2' ' A' ' 29' ' ' VAL . 15.0 ttt180 -135.18 120.2 18.67 Favored 'General case' 0 C--N 1.325 -0.495 0 O-C-N 124.542 1.151 . . . . 0.0 110.293 -179.958 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 28.5 t-20 56.46 25.42 9.64 Favored 'General case' 0 C--N 1.324 -0.5 0 O-C-N 124.493 1.121 . . . . 0.0 109.296 179.977 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 79.41 27.93 53.78 Favored Glycine 0 CA--C 1.529 0.966 0 O-C-N 124.457 1.098 . . . . 0.0 111.021 179.999 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 40.1 mt -146.8 132.49 9.32 Favored Pre-proline 0 C--N 1.325 -0.469 0 O-C-N 124.47 0.747 . . . . 0.0 109.26 -179.986 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 20.1 Cg_endo -74.99 87.52 1.32 Allowed 'Trans proline' 0 N--CA 1.453 -0.895 0 O-C-N 124.543 1.812 . . . . 0.0 110.968 -168.319 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.426 ' CG2' ' HB3' ' A' ' 24' ' ' ARG . 18.2 m . . . . . 0 C--N 1.325 -0.465 0 O-C-N 124.532 1.145 . . . . 0.0 109.287 179.993 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 72.9 m . . . . . 0 N--CA 1.452 -0.336 0 N-CA-C 108.332 -0.988 . . . . 0.0 108.332 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 83.42 -10.96 57.67 Favored Glycine 0 CA--C 1.53 0.981 0 O-C-N 124.551 1.157 . . . . 0.0 110.988 179.981 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 7.7 pt-20 -100.28 171.59 7.68 Favored 'General case' 0 C--N 1.325 -0.46 0 O-C-N 124.493 0.76 . . . . 0.0 110.346 179.994 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.45 ' CG2' HG23 ' A' ' 21' ' ' VAL . 67.8 p -129.62 145.1 51.52 Favored 'General case' 0 C--N 1.325 -0.486 0 O-C-N 124.469 1.106 . . . . 0.0 110.455 179.997 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . 0.429 ' O ' ' CD1' ' A' ' 19' ' ' TRP . 22.6 p -107.35 56.41 0.64 Allowed 'General case' 0 C--N 1.324 -0.524 0 O-C-N 124.52 1.138 . . . . 0.0 108.292 -179.95 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.4 t -59.45 -24.87 29.46 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 O-C-N 124.508 1.13 . . . . 0.0 109.284 -179.956 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -84.85 -35.1 13.55 Favored Glycine 0 CA--C 1.53 1.009 0 O-C-N 124.509 1.13 . . . . 0.0 110.981 -179.986 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 125.48 17.22 2.67 Favored Glycine 0 C--N 1.344 1.025 0 O-C-N 125.055 1.091 . . . . 0.0 111.047 177.698 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 2.4 m -150.33 155.62 39.99 Favored 'General case' 0 C--N 1.326 -0.45 0 O-C-N 124.484 0.755 . . . . 0.0 110.436 179.969 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 94.5 m -110.89 140.56 45.26 Favored 'General case' 0 C--N 1.325 -0.477 0 O-C-N 124.501 1.126 . . . . 0.0 108.268 -179.969 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 30.5 m-20 -90.01 -38.74 13.41 Favored 'General case' 0 C--N 1.325 -0.477 0 O-C-N 124.47 1.106 . . . . 0.0 109.306 -179.999 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' THR . . . . . 0.491 ' CG2' ' SG ' ' A' ' 15' ' ' CYS . 15.6 m -65.58 143.25 98.58 Favored Pre-proline 0 C--N 1.325 -0.474 0 O-C-N 124.521 1.138 . . . . 0.0 110.43 179.988 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . 0.483 ' HD2' ' CG2' ' A' ' 12' ' ' THR . 20.3 Cg_endo -74.92 131.05 13.96 Favored 'Trans proline' 0 N--CA 1.453 -0.894 0 O-C-N 124.496 1.787 . . . . 0.0 110.976 -168.302 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 75.04 15.13 81.25 Favored Glycine 0 CA--C 1.53 1.02 0 O-C-N 124.504 1.128 . . . . 0.0 110.97 179.963 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.491 ' SG ' ' CG2' ' A' ' 12' ' ' THR . 64.3 m -98.1 127.61 44.14 Favored 'General case' 0 C--N 1.325 -0.464 0 N-CA-C 108.308 -0.997 . . . . 0.0 108.308 179.971 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 71.0 p -94.28 152.25 18.81 Favored 'General case' 0 C--N 1.325 -0.484 0 O-C-N 124.48 1.112 . . . . 0.0 110.44 179.97 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 47.4 t -78.18 98.09 5.72 Favored 'General case' 0 C--N 1.325 -0.492 0 O-C-N 124.479 1.112 . . . . 0.0 108.243 -179.951 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' SER . . . . . 0.509 ' O ' ' C ' ' A' ' 19' ' ' TRP . 10.8 t -104.78 65.89 0.76 Allowed 'General case' 0 C--N 1.324 -0.51 0 O-C-N 124.553 1.158 . . . . 0.0 109.958 174.442 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' TRP . . . . . 0.542 ' CG ' ' HA ' ' A' ' 20' ' ' PRO . 0.0 OUTLIER -36.88 147.87 0.2 Allowed Pre-proline 0 C--N 1.325 -0.489 0 O-C-N 124.505 1.128 . . . . 0.0 107.99 -174.18 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . 0.542 ' HA ' ' CG ' ' A' ' 19' ' ' TRP . 18.1 Cg_endo -75.04 -12.57 24.07 Favored 'Cis proline' 0 C--N 1.36 1.144 0 C-N-CA 120.974 -2.511 . . . . 0.0 110.957 -8.505 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.488 ' O ' ' C ' ' A' ' 18' ' ' SER . 4.4 p -98.09 178.85 0.6 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 O-C-N 124.521 1.138 . . . . 0.0 109.289 -173.628 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . 0.402 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 1.7 m -101.95 168.51 9.36 Favored 'General case' 0 C--N 1.325 -0.477 0 O-C-N 124.49 1.119 . . . . 0.0 108.348 -179.993 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -145.34 168.31 20.8 Favored 'General case' 0 C--N 1.325 -0.488 0 O-C-N 124.486 1.116 . . . . 0.0 110.399 -179.976 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . 0.468 ' HB3' ' CG2' ' A' ' 29' ' ' VAL . 29.3 ttt-85 -144.64 119.39 9.85 Favored 'General case' 0 C--N 1.324 -0.506 0 O-C-N 124.514 1.133 . . . . 0.0 110.332 -179.979 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 17.9 t-20 57.42 23.28 8.84 Favored 'General case' 0 C--N 1.325 -0.491 0 O-C-N 124.506 1.129 . . . . 0.0 109.293 -179.997 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 83.44 24.27 51.37 Favored Glycine 0 CA--C 1.53 0.974 0 O-C-N 124.514 1.134 . . . . 0.0 111.027 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 19.1 mt -147.3 128.27 7.09 Favored Pre-proline 0 C--N 1.325 -0.463 0 O-C-N 124.464 0.744 . . . . 0.0 109.325 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 20.2 Cg_endo -74.97 80.96 2.31 Favored 'Trans proline' 0 N--CA 1.453 -0.891 0 O-C-N 124.474 1.776 . . . . 0.0 110.972 -168.271 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.468 ' CG2' ' HB3' ' A' ' 24' ' ' ARG . 17.6 m . . . . . 0 C--N 1.325 -0.46 0 O-C-N 124.482 1.114 . . . . 0.0 109.289 -179.982 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 80.8 m . . . . . 0 N--CA 1.453 -0.319 0 N-CA-C 108.317 -0.994 . . . . 0.0 108.317 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 82.75 -10.69 55.96 Favored Glycine 0 CA--C 1.53 0.992 0 O-C-N 124.525 1.141 . . . . 0.0 111.042 -179.993 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 7.6 pt-20 -100.28 171.87 7.51 Favored 'General case' 0 C--N 1.325 -0.478 0 O-C-N 124.497 0.763 . . . . 0.0 110.288 179.98 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 46.1 p -128.92 144.36 51.16 Favored 'General case' 0 C--N 1.326 -0.452 0 O-C-N 124.463 1.102 . . . . 0.0 110.394 179.965 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . 0.526 ' O ' ' CD1' ' A' ' 19' ' ' TRP . 15.1 p -103.08 52.39 0.78 Allowed 'General case' 0 C--N 1.325 -0.472 0 O-C-N 124.505 1.128 . . . . 0.0 108.291 -179.984 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.8 t -59.26 -25.01 29.26 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 O-C-N 124.502 1.127 . . . . 0.0 109.328 -179.986 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -84.63 -32.91 20.68 Favored Glycine 0 CA--C 1.529 0.966 0 O-C-N 124.522 1.138 . . . . 0.0 110.982 179.988 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 124.4 14.63 3.55 Favored Glycine 0 CA--C 1.531 1.049 0 O-C-N 124.892 0.995 . . . . 0.0 110.97 177.996 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 49.1 m -150.29 165.15 33.88 Favored 'General case' 0 C--N 1.325 -0.468 0 O-C-N 124.483 0.755 . . . . 0.0 110.374 -180.0 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 98.4 m -118.37 141.4 48.57 Favored 'General case' 0 C--N 1.326 -0.449 0 O-C-N 124.458 1.099 . . . . 0.0 108.272 -179.989 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 47.2 t30 -89.89 -39.84 12.79 Favored 'General case' 0 C--N 1.325 -0.467 0 O-C-N 124.51 1.131 . . . . 0.0 109.33 179.973 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' THR . . . . . 0.498 ' CG2' ' SG ' ' A' ' 15' ' ' CYS . 16.9 m -64.68 143.02 98.64 Favored Pre-proline 0 C--N 1.325 -0.472 0 O-C-N 124.495 1.122 . . . . 0.0 110.377 -179.993 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . 0.48 ' HD2' ' CG2' ' A' ' 12' ' ' THR . 20.1 Cg_endo -75.01 130.65 13.46 Favored 'Trans proline' 0 N--CA 1.453 -0.875 0 O-C-N 124.502 1.791 . . . . 0.0 110.955 -168.298 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 76.22 12.82 83.85 Favored Glycine 0 CA--C 1.53 0.979 0 O-C-N 124.514 1.134 . . . . 0.0 111.02 -179.987 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.498 ' SG ' ' CG2' ' A' ' 12' ' ' THR . 64.9 m -95.7 127.48 41.76 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 108.318 -0.993 . . . . 0.0 108.318 179.964 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 29.9 p -94.5 150.16 20.53 Favored 'General case' 0 C--N 1.325 -0.472 0 O-C-N 124.456 1.098 . . . . 0.0 110.466 179.958 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 37.5 t -76.96 96.18 4.31 Favored 'General case' 0 C--N 1.324 -0.523 0 O-C-N 124.557 1.161 . . . . 0.0 108.283 179.988 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' SER . . . . . 0.51 ' O ' ' C ' ' A' ' 19' ' ' TRP . 1.8 m -102.31 65.51 0.95 Allowed 'General case' 0 C--N 1.325 -0.482 0 O-C-N 124.506 1.128 . . . . 0.0 110.003 174.326 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' TRP . . . . . 0.54 ' CG ' ' HA ' ' A' ' 20' ' ' PRO . 0.0 OUTLIER -36.71 148.05 0.19 Allowed Pre-proline 0 C--N 1.325 -0.498 0 O-C-N 124.525 1.141 . . . . 0.0 108.008 -173.995 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . 0.54 ' HA ' ' CG ' ' A' ' 19' ' ' TRP . 18.5 Cg_endo -74.93 -12.53 23.78 Favored 'Cis proline' 0 C--N 1.36 1.149 0 C-N-CA 121.03 -2.487 . . . . 0.0 111.015 -8.509 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.487 ' O ' ' C ' ' A' ' 18' ' ' SER . 5.8 p -98.87 177.38 0.69 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 O-C-N 124.475 1.11 . . . . 0.0 109.324 -173.279 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . 0.404 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 1.8 m -102.07 169.74 8.56 Favored 'General case' 0 C--N 1.324 -0.507 0 O-C-N 124.521 1.138 . . . . 0.0 108.314 179.973 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -149.5 165.05 33.35 Favored 'General case' 0 C--N 1.324 -0.518 0 O-C-N 124.49 1.119 . . . . 0.0 110.429 -179.931 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . 0.461 ' HB3' ' CG2' ' A' ' 29' ' ' VAL . 10.9 ttt85 -141.22 119.68 12.32 Favored 'General case' 0 C--N 1.325 -0.488 0 O-C-N 124.49 1.119 . . . . 0.0 110.289 179.952 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . 0.405 ' O ' ' OD1' ' A' ' 25' ' ' ASN . 16.5 t-20 57.58 22.71 8.47 Favored 'General case' 0 C--N 1.325 -0.488 0 O-C-N 124.534 1.146 . . . . 0.0 109.329 -179.965 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 83.9 23.93 50.85 Favored Glycine 0 CA--C 1.53 0.997 0 O-C-N 124.533 1.146 . . . . 0.0 110.975 179.978 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 13.8 mt -145.93 128.37 7.94 Favored Pre-proline 0 C--N 1.325 -0.48 0 O-C-N 124.551 0.795 . . . . 0.0 109.281 179.976 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 20.3 Cg_endo -74.98 77.42 3.13 Favored 'Trans proline' 0 N--CA 1.453 -0.892 0 O-C-N 124.503 1.791 . . . . 0.0 111.014 -168.327 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.461 ' CG2' ' HB3' ' A' ' 24' ' ' ARG . 36.0 m . . . . . 0 C--N 1.325 -0.458 0 O-C-N 124.527 1.142 . . . . 0.0 109.259 -179.994 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 87.2 m . . . . . 0 N--CA 1.452 -0.33 0 N-CA-C 108.322 -0.992 . . . . 0.0 108.322 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 91.31 -15.27 61.6 Favored Glycine 0 CA--C 1.53 1.023 0 O-C-N 124.504 1.127 . . . . 0.0 110.98 179.996 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 15.2 tt0 -88.3 162.25 16.7 Favored 'General case' 0 C--N 1.324 -0.509 0 O-C-N 124.534 0.785 . . . . 0.0 110.291 179.98 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 47.7 p -120.73 131.83 54.73 Favored 'General case' 0 C--N 1.325 -0.484 0 O-C-N 124.456 1.098 . . . . 0.0 110.389 -179.993 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . 0.417 ' SG ' ' O ' ' A' ' 5' ' ' CYS . 14.6 p -100.11 52.08 0.9 Allowed 'General case' 0 C--N 1.325 -0.46 0 O-C-N 124.502 1.126 . . . . 0.0 108.316 179.963 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 11.9 t -59.27 -24.84 28.8 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 O-C-N 124.496 1.123 . . . . 0.0 109.318 179.951 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -84.54 -32.0 23.19 Favored Glycine 0 CA--C 1.53 0.983 0 O-C-N 124.503 1.127 . . . . 0.0 111.008 -179.945 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 123.84 15.91 3.44 Favored Glycine 0 CA--C 1.53 0.992 0 O-C-N 124.896 0.998 . . . . 0.0 110.996 178.112 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 62.2 m -150.11 165.57 32.41 Favored 'General case' 0 C--N 1.325 -0.476 0 O-C-N 124.508 0.769 . . . . 0.0 110.413 179.975 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . 0.405 ' SG ' ' O ' ' A' ' 16' ' ' THR . 96.9 m -122.15 143.45 49.55 Favored 'General case' 0 C--N 1.325 -0.464 0 O-C-N 124.512 1.133 . . . . 0.0 108.295 179.999 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 12.0 m-20 -90.11 -47.03 8.07 Favored 'General case' 0 C--N 1.324 -0.511 0 O-C-N 124.505 1.128 . . . . 0.0 109.26 -179.984 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' THR . . . . . 0.504 ' CG2' ' SG ' ' A' ' 15' ' ' CYS . 20.9 m -54.6 142.68 51.54 Favored Pre-proline 0 C--N 1.325 -0.461 0 O-C-N 124.462 1.101 . . . . 0.0 110.431 179.985 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . 0.476 ' HD2' ' CG2' ' A' ' 12' ' ' THR . 20.1 Cg_endo -74.99 131.36 14.21 Favored 'Trans proline' 0 N--CA 1.453 -0.867 0 O-C-N 124.531 1.806 . . . . 0.0 110.977 -168.295 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 74.69 14.91 80.94 Favored Glycine 0 CA--C 1.53 1.028 0 O-C-N 124.495 1.122 . . . . 0.0 111.024 179.989 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.504 ' SG ' ' CG2' ' A' ' 12' ' ' THR . 63.9 m -96.08 134.58 38.95 Favored 'General case' 0 C--N 1.325 -0.483 0 N-CA-C 108.297 -1.001 . . . . 0.0 108.297 179.987 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' THR . . . . . 0.405 ' O ' ' SG ' ' A' ' 10' ' ' CYS . 82.7 p -101.11 152.97 19.98 Favored 'General case' 0 C--N 1.325 -0.466 0 O-C-N 124.445 1.091 . . . . 0.0 110.401 179.975 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 41.3 t -79.71 94.41 5.72 Favored 'General case' 0 C--N 1.325 -0.481 0 O-C-N 124.52 1.138 . . . . 0.0 108.363 179.942 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' SER . . . . . 0.517 ' O ' ' C ' ' A' ' 19' ' ' TRP . 17.5 t -101.45 65.48 1.05 Allowed 'General case' 0 C--N 1.325 -0.488 0 O-C-N 124.456 1.097 . . . . 0.0 110.002 174.236 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' TRP . . . . . 0.563 ' CG ' ' HA ' ' A' ' 20' ' ' PRO . 0.1 OUTLIER -36.14 147.01 0.19 Allowed Pre-proline 0 C--N 1.325 -0.477 0 O-C-N 124.515 1.134 . . . . 0.0 107.997 -174.129 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . 0.563 ' HA ' ' CG ' ' A' ' 19' ' ' TRP . 18.2 Cg_endo -74.97 -13.76 23.37 Favored 'Cis proline' 0 C--N 1.36 1.166 0 C-N-CA 121.009 -2.496 . . . . 0.0 111.003 -8.557 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.485 ' O ' ' C ' ' A' ' 18' ' ' SER . 0.9 OUTLIER -97.35 178.04 0.63 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 O-C-N 124.449 1.093 . . . . 0.0 109.29 -173.148 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 36.8 m -101.72 170.48 8.14 Favored 'General case' 0 C--N 1.325 -0.461 0 O-C-N 124.549 1.156 . . . . 0.0 108.289 -179.991 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -146.88 166.81 25.61 Favored 'General case' 0 C--N 1.325 -0.487 0 O-C-N 124.483 1.115 . . . . 0.0 110.404 179.985 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . 0.462 ' HB3' ' CG2' ' A' ' 29' ' ' VAL . 2.5 ttt180 -139.05 119.28 13.61 Favored 'General case' 0 C--N 1.325 -0.487 0 O-C-N 124.514 1.134 . . . . 0.0 110.327 179.995 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 81.1 m-20 57.16 22.99 8.08 Favored 'General case' 0 C--N 1.325 -0.478 0 O-C-N 124.515 1.134 . . . . 0.0 109.333 -179.973 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 83.7 25.58 45.64 Favored Glycine 0 CA--C 1.53 0.997 0 O-C-N 124.519 1.137 . . . . 0.0 110.968 179.949 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 12.9 mt -145.57 130.38 9.01 Favored Pre-proline 0 C--N 1.325 -0.488 0 O-C-N 124.457 0.739 . . . . 0.0 109.309 179.991 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 20.1 Cg_endo -75.01 82.48 2.0 Allowed 'Trans proline' 0 N--CA 1.453 -0.91 0 O-C-N 124.505 1.792 . . . . 0.0 110.955 -168.309 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.462 ' CG2' ' HB3' ' A' ' 24' ' ' ARG . 28.2 m . . . . . 0 C--N 1.325 -0.465 0 O-C-N 124.528 1.142 . . . . 0.0 109.346 179.951 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 93.5 m . . . . . 0 N--CA 1.453 -0.287 0 N-CA-C 108.32 -0.993 . . . . 0.0 108.32 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 95.54 -15.2 63.66 Favored Glycine 0 CA--C 1.53 1.03 0 O-C-N 124.486 1.116 . . . . 0.0 110.995 179.987 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 15.1 tt0 -86.4 161.82 18.47 Favored 'General case' 0 C--N 1.325 -0.459 0 O-C-N 124.504 0.767 . . . . 0.0 110.287 -179.992 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 48.0 p -119.03 132.23 56.03 Favored 'General case' 0 C--N 1.324 -0.508 0 O-C-N 124.505 1.128 . . . . 0.0 110.406 179.987 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . 0.427 ' O ' ' CD1' ' A' ' 19' ' ' TRP . 14.3 p -102.18 51.29 0.82 Allowed 'General case' 0 C--N 1.324 -0.509 0 O-C-N 124.531 1.144 . . . . 0.0 108.295 -179.965 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 6.6 t -59.27 -24.5 27.89 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 O-C-N 124.458 1.099 . . . . 0.0 109.289 -179.97 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -85.52 -34.31 14.25 Favored Glycine 0 CA--C 1.53 0.976 0 O-C-N 124.503 1.127 . . . . 0.0 111.041 -180.0 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 125.1 16.75 2.86 Favored Glycine 0 CA--C 1.53 1.0 0 O-C-N 124.945 1.026 . . . . 0.0 111.043 177.818 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 2.6 m -150.21 157.92 43.6 Favored 'General case' 0 C--N 1.325 -0.473 0 O-C-N 124.533 0.784 . . . . 0.0 110.414 -179.963 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . 0.411 ' SG ' ' O ' ' A' ' 16' ' ' THR . 84.0 m -118.59 144.56 46.03 Favored 'General case' 0 C--N 1.325 -0.471 0 O-C-N 124.487 1.117 . . . . 0.0 108.313 179.989 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 76.1 m-20 -89.86 -51.78 5.32 Favored 'General case' 0 C--N 1.325 -0.481 0 O-C-N 124.512 1.133 . . . . 0.0 109.314 179.977 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' THR . . . . . 0.505 ' CG2' ' SG ' ' A' ' 15' ' ' CYS . 22.0 m -49.72 142.58 12.19 Favored Pre-proline 0 C--N 1.325 -0.49 0 O-C-N 124.551 1.157 . . . . 0.0 110.405 179.982 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . 0.473 ' HD2' ' CG2' ' A' ' 12' ' ' THR . 20.2 Cg_endo -74.99 131.7 14.59 Favored 'Trans proline' 0 N--CA 1.452 -0.947 0 O-C-N 124.45 1.763 . . . . 0.0 111.011 -168.267 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 74.36 13.78 81.31 Favored Glycine 0 CA--C 1.53 1.022 0 O-C-N 124.49 1.118 . . . . 0.0 111.009 -179.978 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.505 ' SG ' ' CG2' ' A' ' 12' ' ' THR . 67.4 m -96.31 126.18 41.34 Favored 'General case' 0 C--N 1.324 -0.504 0 N-CA-C 108.336 -0.987 . . . . 0.0 108.336 179.971 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' THR . . . . . 0.411 ' O ' ' SG ' ' A' ' 10' ' ' CYS . 30.8 p -94.24 158.32 15.65 Favored 'General case' 0 C--N 1.325 -0.481 0 O-C-N 124.482 1.114 . . . . 0.0 110.387 -180.0 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 42.4 t -82.37 94.99 7.5 Favored 'General case' 0 C--N 1.325 -0.484 0 O-C-N 124.524 1.14 . . . . 0.0 108.339 179.968 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' SER . . . . . 0.515 ' O ' ' C ' ' A' ' 19' ' ' TRP . 3.0 t -100.54 65.57 1.19 Allowed 'General case' 0 C--N 1.325 -0.463 0 O-C-N 124.526 1.141 . . . . 0.0 109.993 174.198 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' TRP . . . . . 0.532 ' CG ' ' HA ' ' A' ' 20' ' ' PRO . 0.0 OUTLIER -36.73 147.47 0.2 Allowed Pre-proline 0 C--N 1.325 -0.484 0 N-CA-C 107.958 -1.127 . . . . 0.0 107.958 -173.93 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . 0.532 ' HA ' ' CG ' ' A' ' 19' ' ' TRP . 18.2 Cg_endo -75.04 -12.83 23.99 Favored 'Cis proline' 0 C--N 1.36 1.184 0 C-N-CA 120.968 -2.513 . . . . 0.0 111.003 -8.478 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.492 ' O ' ' C ' ' A' ' 18' ' ' SER . 16.3 m -98.05 179.24 0.58 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.494 0 O-C-N 124.514 1.134 . . . . 0.0 109.293 -173.478 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 51.9 m -101.77 168.08 9.68 Favored 'General case' 0 C--N 1.325 -0.488 0 O-C-N 124.54 1.15 . . . . 0.0 108.311 179.979 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' THR . . . . . 0.447 ' OG1' ' CB ' ' A' ' 18' ' ' SER . 0.8 OUTLIER -146.97 168.06 22.44 Favored 'General case' 0 C--N 1.325 -0.458 0 O-C-N 124.515 1.135 . . . . 0.0 110.382 179.999 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . 0.465 ' HB3' ' CG2' ' A' ' 29' ' ' VAL . 0.3 OUTLIER -141.54 119.69 12.12 Favored 'General case' 0 C--N 1.325 -0.468 0 O-C-N 124.506 1.128 . . . . 0.0 110.279 179.993 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 17.5 t-20 57.84 23.07 9.27 Favored 'General case' 0 C--N 1.326 -0.455 0 O-C-N 124.479 1.112 . . . . 0.0 109.303 179.967 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 82.43 23.34 56.78 Favored Glycine 0 CA--C 1.53 1.019 0 O-C-N 124.467 1.104 . . . . 0.0 110.976 179.992 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 11.9 mt -143.53 129.62 10.19 Favored Pre-proline 0 C--N 1.325 -0.498 0 O-C-N 124.461 0.742 . . . . 0.0 109.331 -179.997 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 20.5 Cg_endo -74.92 82.53 1.97 Allowed 'Trans proline' 0 N--CA 1.453 -0.861 0 O-C-N 124.516 1.798 . . . . 0.0 111.031 -168.343 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.465 ' CG2' ' HB3' ' A' ' 24' ' ' ARG . 27.4 m . . . . . 0 C--N 1.325 -0.484 0 O-C-N 124.489 1.118 . . . . 0.0 109.343 179.982 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 69.1 m . . . . . 0 N--CA 1.452 -0.328 0 N-CA-C 108.276 -1.009 . . . . 0.0 108.276 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 93.89 -15.7 62.51 Favored Glycine 0 CA--C 1.53 1.004 0 O-C-N 124.524 1.14 . . . . 0.0 110.995 179.97 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 15.5 tt0 -86.75 162.53 17.8 Favored 'General case' 0 C--N 1.326 -0.446 0 O-C-N 124.474 0.749 . . . . 0.0 110.322 -179.971 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 65.9 p -120.16 132.97 55.59 Favored 'General case' 0 C--N 1.325 -0.486 0 O-C-N 124.452 1.095 . . . . 0.0 110.398 179.961 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . 0.425 ' SG ' ' O ' ' A' ' 5' ' ' CYS . 13.8 p -102.44 49.96 0.84 Allowed 'General case' 0 C--N 1.325 -0.457 0 O-C-N 124.449 1.093 . . . . 0.0 108.279 -179.981 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 15.1 t -59.09 -24.0 25.97 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 O-C-N 124.562 1.164 . . . . 0.0 109.351 179.947 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -83.61 -33.67 21.45 Favored Glycine 0 CA--C 1.53 1.0 0 O-C-N 124.488 1.118 . . . . 0.0 111.033 179.972 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 126.88 10.85 3.74 Favored Glycine 0 C--N 1.345 1.074 0 C-N-CA 119.774 -1.203 . . . . 0.0 110.989 177.917 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -149.92 166.96 28.0 Favored 'General case' 0 C--N 1.325 -0.496 0 O-C-N 124.522 0.778 . . . . 0.0 110.416 -179.994 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . 0.412 ' SG ' ' O ' ' A' ' 16' ' ' THR . 80.2 m -121.8 146.37 47.14 Favored 'General case' 0 C--N 1.325 -0.469 0 O-C-N 124.484 1.115 . . . . 0.0 108.293 179.996 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 22.2 t30 -92.41 -44.17 8.83 Favored 'General case' 0 C--N 1.325 -0.479 0 O-C-N 124.518 1.136 . . . . 0.0 109.306 -179.995 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' THR . . . . . 0.5 ' CG2' ' SG ' ' A' ' 15' ' ' CYS . 18.4 m -57.75 142.89 77.62 Favored Pre-proline 0 C--N 1.324 -0.506 0 O-C-N 124.495 1.122 . . . . 0.0 110.391 179.976 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . 0.475 ' HD2' ' CG2' ' A' ' 12' ' ' THR . 20.3 Cg_endo -74.96 131.68 14.62 Favored 'Trans proline' 0 N--CA 1.453 -0.879 0 O-C-N 124.533 1.807 . . . . 0.0 111.003 -168.335 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 76.42 7.23 85.08 Favored Glycine 0 CA--C 1.53 0.985 0 O-C-N 124.428 1.08 . . . . 0.0 111.007 179.985 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.5 ' SG ' ' CG2' ' A' ' 12' ' ' THR . 69.2 m -92.14 126.28 37.16 Favored 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 108.283 -1.006 . . . . 0.0 108.283 -179.998 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' THR . . . . . 0.412 ' O ' ' SG ' ' A' ' 10' ' ' CYS . 34.3 p -95.28 156.52 16.29 Favored 'General case' 0 C--N 1.325 -0.484 0 O-C-N 124.543 1.152 . . . . 0.0 110.378 179.997 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 42.7 t -80.99 94.12 6.49 Favored 'General case' 0 C--N 1.325 -0.478 0 O-C-N 124.532 1.145 . . . . 0.0 108.276 -179.964 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' SER . . . . . 0.518 ' O ' ' C ' ' A' ' 19' ' ' TRP . 3.6 t -100.36 65.51 1.22 Allowed 'General case' 0 C--N 1.325 -0.484 0 O-C-N 124.506 1.128 . . . . 0.0 110.006 174.172 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' TRP . . . . . 0.544 ' CG ' ' HA ' ' A' ' 20' ' ' PRO . 0.0 OUTLIER -36.3 147.42 0.19 Allowed Pre-proline 0 C--N 1.325 -0.465 0 N-CA-C 107.992 -1.114 . . . . 0.0 107.992 -173.981 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . 0.544 ' HA ' ' CG ' ' A' ' 19' ' ' TRP . 18.3 Cg_endo -75.03 -12.92 23.97 Favored 'Cis proline' 0 C--N 1.36 1.166 0 C-N-CA 121.035 -2.485 . . . . 0.0 110.981 -8.374 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.494 ' O ' ' C ' ' A' ' 18' ' ' SER . 4.6 p -99.02 179.16 0.6 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.5 0 O-C-N 124.502 1.126 . . . . 0.0 109.292 -173.284 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 53.3 m -101.63 168.9 9.18 Favored 'General case' 0 C--N 1.325 -0.473 0 O-C-N 124.476 1.11 . . . . 0.0 108.358 179.986 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' THR . . . . . 0.441 ' OG1' ' CB ' ' A' ' 18' ' ' SER . 0.8 OUTLIER -148.36 167.54 24.97 Favored 'General case' 0 C--N 1.325 -0.488 0 O-C-N 124.5 1.125 . . . . 0.0 110.389 -179.986 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . 0.446 ' HB3' ' CG2' ' A' ' 29' ' ' VAL . 1.4 ttt85 -137.72 120.04 15.8 Favored 'General case' 0 C--N 1.325 -0.472 0 O-C-N 124.493 1.121 . . . . 0.0 110.263 -179.961 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 58.4 t30 56.3 23.33 7.11 Favored 'General case' 0 C--N 1.325 -0.48 0 O-C-N 124.521 1.138 . . . . 0.0 109.288 179.972 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 81.99 28.85 40.08 Favored Glycine 0 CA--C 1.53 0.992 0 O-C-N 124.513 1.133 . . . . 0.0 111.014 -179.988 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 22.9 mt -147.27 130.2 7.96 Favored Pre-proline 0 C--N 1.325 -0.461 0 O-C-N 124.513 0.772 . . . . 0.0 109.284 179.957 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 20.2 Cg_endo -75.0 84.28 1.69 Allowed 'Trans proline' 0 N--CA 1.453 -0.881 0 O-C-N 124.488 1.783 . . . . 0.0 110.995 -168.332 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.446 ' CG2' ' HB3' ' A' ' 24' ' ' ARG . 30.4 m . . . . . 0 C--N 1.326 -0.447 0 O-C-N 124.482 1.114 . . . . 0.0 109.308 179.962 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 16.7 m . . . . . 0 N--CA 1.453 -0.303 0 N-CA-C 108.314 -0.995 . . . . 0.0 108.314 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 92.96 -20.03 48.24 Favored Glycine 0 CA--C 1.53 1.021 0 O-C-N 124.49 1.119 . . . . 0.0 111.001 179.97 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 15.6 tt0 -83.86 162.07 20.67 Favored 'General case' 0 C--N 1.325 -0.475 0 O-C-N 124.487 0.757 . . . . 0.0 110.353 179.976 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 53.3 p -123.13 132.84 54.24 Favored 'General case' 0 C--N 1.325 -0.478 0 O-C-N 124.455 1.097 . . . . 0.0 110.371 -179.98 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . 0.404 ' SG ' ' O ' ' A' ' 5' ' ' CYS . 16.4 p -100.34 55.22 0.9 Allowed 'General case' 0 C--N 1.326 -0.447 0 O-C-N 124.508 1.13 . . . . 0.0 108.337 179.94 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 9.6 t -59.33 -25.35 30.52 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 O-C-N 124.45 1.094 . . . . 0.0 109.245 -179.944 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -83.79 -30.68 28.68 Favored Glycine 0 CA--C 1.529 0.964 0 O-C-N 124.52 1.138 . . . . 0.0 111.006 179.991 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 122.3 14.23 4.55 Favored Glycine 0 CA--C 1.53 1.013 0 O-C-N 125.006 1.062 . . . . 0.0 110.988 178.694 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 42.5 m -149.95 164.15 36.2 Favored 'General case' 0 C--N 1.325 -0.484 0 O-C-N 124.54 0.788 . . . . 0.0 110.362 -180.0 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . 0.401 ' SG ' ' O ' ' A' ' 16' ' ' THR . 97.2 m -120.45 140.98 50.59 Favored 'General case' 0 C--N 1.326 -0.447 0 O-C-N 124.467 1.104 . . . . 0.0 108.292 179.991 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 37.6 t30 -89.74 -45.02 9.59 Favored 'General case' 0 C--N 1.325 -0.463 0 O-C-N 124.493 1.121 . . . . 0.0 109.298 179.977 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' THR . . . . . 0.5 ' CG2' ' SG ' ' A' ' 15' ' ' CYS . 18.3 m -56.02 143.05 63.9 Favored Pre-proline 0 C--N 1.326 -0.453 0 O-C-N 124.462 1.101 . . . . 0.0 110.417 179.973 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . 0.481 ' HD2' ' CG2' ' A' ' 12' ' ' THR . 20.2 Cg_endo -74.97 130.3 13.18 Favored 'Trans proline' 0 N--CA 1.452 -0.917 0 O-C-N 124.508 1.793 . . . . 0.0 110.987 -168.329 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 75.12 15.29 81.19 Favored Glycine 0 CA--C 1.53 0.995 0 O-C-N 124.442 1.089 . . . . 0.0 111.035 -179.999 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.5 ' SG ' ' CG2' ' A' ' 12' ' ' THR . 57.6 m -96.62 129.88 43.92 Favored 'General case' 0 C--N 1.325 -0.489 0 N-CA-C 108.323 -0.991 . . . . 0.0 108.323 179.999 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' THR . . . . . 0.401 ' O ' ' SG ' ' A' ' 10' ' ' CYS . 21.6 p -95.99 152.7 18.28 Favored 'General case' 0 C--N 1.325 -0.472 0 O-C-N 124.497 1.123 . . . . 0.0 110.366 -179.965 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 45.0 t -82.99 95.86 8.14 Favored 'General case' 0 C--N 1.325 -0.498 0 O-C-N 124.483 1.115 . . . . 0.0 108.285 179.973 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' SER . . . . . 0.514 ' O ' ' C ' ' A' ' 19' ' ' TRP . 34.6 p -105.88 66.39 0.72 Allowed 'General case' 0 C--N 1.326 -0.453 0 O-C-N 124.464 1.102 . . . . 0.0 110.023 174.144 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' TRP . . . . . 0.588 ' CG ' ' HA ' ' A' ' 20' ' ' PRO . 0.8 OUTLIER -35.79 146.7 0.19 Allowed Pre-proline 0 C--N 1.324 -0.51 0 O-C-N 124.552 1.158 . . . . 0.0 107.975 -174.399 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . 0.588 ' HA ' ' CG ' ' A' ' 19' ' ' TRP . 18.2 Cg_endo -75.04 -14.83 22.94 Favored 'Cis proline' 0 C--N 1.36 1.159 0 C-N-CA 120.954 -2.519 . . . . 0.0 111.005 -8.67 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.491 ' O ' ' C ' ' A' ' 18' ' ' SER . 2.2 t -96.38 175.97 0.74 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.479 0 O-C-N 124.496 1.122 . . . . 0.0 109.31 -172.992 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 33.4 m -102.47 170.13 8.24 Favored 'General case' 0 C--N 1.325 -0.481 0 O-C-N 124.465 1.103 . . . . 0.0 108.298 179.977 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' THR . . . . . 0.44 HG23 ' CB ' ' A' ' 18' ' ' SER . 1.0 OUTLIER -141.7 168.4 19.85 Favored 'General case' 0 C--N 1.325 -0.469 0 O-C-N 124.483 1.115 . . . . 0.0 110.427 179.949 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . 0.447 ' HB3' ' CG2' ' A' ' 29' ' ' VAL . 0.1 OUTLIER -137.0 115.33 11.77 Favored 'General case' 0 C--N 1.325 -0.478 0 O-C-N 124.514 1.133 . . . . 0.0 110.297 -179.984 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 86.9 m-20 57.2 21.84 6.98 Favored 'General case' 0 C--N 1.325 -0.47 0 O-C-N 124.48 1.113 . . . . 0.0 109.295 -179.986 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 87.15 25.52 33.73 Favored Glycine 0 CA--C 1.531 1.049 0 O-C-N 124.464 1.102 . . . . 0.0 110.966 179.975 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 12.8 mt -145.03 130.29 9.3 Favored Pre-proline 0 C--N 1.325 -0.485 0 O-C-N 124.535 0.785 . . . . 0.0 109.289 -179.961 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 20.1 Cg_endo -74.97 79.99 2.53 Favored 'Trans proline' 0 N--CA 1.452 -0.927 0 O-C-N 124.515 1.797 . . . . 0.0 111.008 -168.285 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.447 ' CG2' ' HB3' ' A' ' 24' ' ' ARG . 18.0 m . . . . . 0 C--N 1.325 -0.482 0 O-C-N 124.51 1.131 . . . . 0.0 109.307 -179.99 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 83.6 m . . . . . 0 N--CA 1.454 -0.266 0 N-CA-C 108.297 -1.001 . . . . 0.0 108.297 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 103.53 -21.09 40.1 Favored Glycine 0 CA--C 1.53 1.01 0 O-C-N 124.515 1.135 . . . . 0.0 110.989 179.981 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 28.5 tt0 -84.4 150.45 25.33 Favored 'General case' 0 C--N 1.324 -0.5 0 O-C-N 124.456 0.739 . . . . 0.0 110.333 179.977 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 66.0 p -109.74 129.91 55.57 Favored 'General case' 0 C--N 1.325 -0.499 0 O-C-N 124.508 1.13 . . . . 0.0 110.429 -179.983 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . 0.42 ' SG ' ' O ' ' A' ' 5' ' ' CYS . 14.2 p -97.16 51.06 1.09 Allowed 'General case' 0 C--N 1.325 -0.474 0 O-C-N 124.523 1.14 . . . . 0.0 108.292 -179.988 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 9.4 t -59.03 -24.74 27.78 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 O-C-N 124.481 1.113 . . . . 0.0 109.317 179.966 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -83.96 -32.6 23.3 Favored Glycine 0 CA--C 1.53 1.028 0 O-C-N 124.512 1.132 . . . . 0.0 110.989 179.999 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 124.73 14.21 3.54 Favored Glycine 0 C--N 1.344 1.004 0 O-C-N 125.103 1.12 . . . . 0.0 111.013 177.972 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -149.6 166.73 28.39 Favored 'General case' 0 C--N 1.325 -0.476 0 O-C-N 124.501 0.765 . . . . 0.0 110.384 179.95 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . 0.406 ' SG ' ' O ' ' A' ' 16' ' ' THR . 75.9 m -123.78 141.96 51.54 Favored 'General case' 0 C--N 1.326 -0.449 0 O-C-N 124.466 1.104 . . . . 0.0 108.279 -179.981 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 34.0 t-20 -89.87 -43.07 10.86 Favored 'General case' 0 C--N 1.325 -0.457 0 O-C-N 124.492 1.12 . . . . 0.0 109.29 -179.998 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' THR . . . . . 0.496 ' CG2' ' SG ' ' A' ' 15' ' ' CYS . 20.2 m -58.35 142.8 81.17 Favored Pre-proline 0 C--N 1.325 -0.485 0 O-C-N 124.427 1.079 . . . . 0.0 110.355 -179.981 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . 0.478 ' HD2' ' CG2' ' A' ' 12' ' ' THR . 20.2 Cg_endo -74.99 131.59 14.48 Favored 'Trans proline' 0 N--CA 1.453 -0.868 0 O-C-N 124.501 1.79 . . . . 0.0 110.997 -168.322 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 74.1 13.73 80.91 Favored Glycine 0 CA--C 1.53 1.025 0 O-C-N 124.482 1.114 . . . . 0.0 110.985 179.975 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.496 ' SG ' ' CG2' ' A' ' 12' ' ' THR . 66.8 m -97.29 125.93 42.19 Favored 'General case' 0 C--N 1.325 -0.469 0 N-CA-C 108.313 -0.995 . . . . 0.0 108.313 179.97 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' THR . . . . . 0.406 ' O ' ' SG ' ' A' ' 10' ' ' CYS . 68.9 p -93.48 156.07 16.97 Favored 'General case' 0 C--N 1.325 -0.483 0 O-C-N 124.481 1.113 . . . . 0.0 110.383 -179.969 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 43.1 t -82.26 91.53 6.78 Favored 'General case' 0 C--N 1.325 -0.486 0 O-C-N 124.535 1.147 . . . . 0.0 108.301 -179.985 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' SER . . . . . 0.522 ' O ' ' C ' ' A' ' 19' ' ' TRP . 3.8 m -98.87 65.81 1.54 Allowed 'General case' 0 C--N 1.325 -0.488 0 O-C-N 124.477 1.111 . . . . 0.0 110.008 174.052 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' TRP . . . . . 0.55 ' CG ' ' HA ' ' A' ' 20' ' ' PRO . 0.1 OUTLIER -35.63 147.12 0.17 Allowed Pre-proline 0 C--N 1.325 -0.5 0 O-C-N 124.556 1.16 . . . . 0.0 107.971 -173.996 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . 0.55 ' HA ' ' CG ' ' A' ' 19' ' ' TRP . 18.4 Cg_endo -74.91 -13.48 23.37 Favored 'Cis proline' 0 C--N 1.36 1.16 0 C-N-CA 121.01 -2.496 . . . . 0.0 111.037 -8.647 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.503 ' O ' ' C ' ' A' ' 18' ' ' SER . 2.2 t -99.11 177.91 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 O-C-N 124.472 1.108 . . . . 0.0 109.288 -173.032 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 69.3 m -101.98 169.1 8.98 Favored 'General case' 0 C--N 1.325 -0.485 0 O-C-N 124.501 1.126 . . . . 0.0 108.288 -179.957 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 1.1 p -144.26 160.54 40.82 Favored 'General case' 0 C--N 1.325 -0.484 0 O-C-N 124.458 1.099 . . . . 0.0 110.398 179.982 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . 0.458 ' HB3' ' CG2' ' A' ' 29' ' ' VAL . 1.1 ttt85 -132.23 118.33 19.37 Favored 'General case' 0 C--N 1.325 -0.471 0 O-C-N 124.537 1.148 . . . . 0.0 110.292 -179.985 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 76.2 m-20 57.47 24.55 10.37 Favored 'General case' 0 C--N 1.324 -0.514 0 O-C-N 124.535 1.147 . . . . 0.0 109.289 -179.973 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 82.59 23.36 56.43 Favored Glycine 0 CA--C 1.53 1.024 0 O-C-N 124.586 1.179 . . . . 0.0 111.002 179.982 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 8.0 mt -143.26 129.91 10.52 Favored Pre-proline 0 C--N 1.325 -0.499 0 O-C-N 124.548 0.793 . . . . 0.0 109.337 179.978 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 20.1 Cg_endo -74.99 81.95 2.1 Favored 'Trans proline' 0 N--CA 1.453 -0.87 0 O-C-N 124.511 1.795 . . . . 0.0 110.997 -168.279 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.458 ' CG2' ' HB3' ' A' ' 24' ' ' ARG . 21.9 m . . . . . 0 C--N 1.325 -0.477 0 O-C-N 124.517 1.136 . . . . 0.0 109.312 179.991 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 83.5 m . . . . . 0 N--CA 1.453 -0.301 0 N-CA-C 108.28 -1.007 . . . . 0.0 108.28 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 91.62 -17.58 55.75 Favored Glycine 0 CA--C 1.53 1.006 0 O-C-N 124.431 1.082 . . . . 0.0 110.994 -179.961 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 15.5 tt0 -85.59 161.72 19.17 Favored 'General case' 0 C--N 1.325 -0.471 0 O-C-N 124.47 0.747 . . . . 0.0 110.314 179.976 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 47.5 p -120.54 132.0 54.96 Favored 'General case' 0 C--N 1.325 -0.498 0 O-C-N 124.52 1.138 . . . . 0.0 110.456 179.978 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . 0.417 ' SG ' ' O ' ' A' ' 5' ' ' CYS . 14.5 p -98.97 51.64 0.96 Allowed 'General case' 0 C--N 1.325 -0.475 0 O-C-N 124.475 1.109 . . . . 0.0 108.286 -179.977 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 9.0 t -59.22 -24.99 29.07 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 O-C-N 124.497 1.123 . . . . 0.0 109.288 -179.988 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -84.32 -32.25 23.18 Favored Glycine 0 CA--C 1.53 0.979 0 O-C-N 124.507 1.129 . . . . 0.0 111.062 179.961 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 124.37 13.98 3.75 Favored Glycine 0 CA--C 1.529 0.969 0 O-C-N 125.024 1.073 . . . . 0.0 111.036 178.176 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 45.8 m -149.93 164.76 34.58 Favored 'General case' 0 C--N 1.325 -0.47 0 O-C-N 124.514 0.773 . . . . 0.0 110.427 179.995 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . 0.405 ' SG ' ' O ' ' A' ' 16' ' ' THR . 94.2 m -121.67 143.16 49.5 Favored 'General case' 0 C--N 1.325 -0.491 0 O-C-N 124.469 1.106 . . . . 0.0 108.254 -179.955 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 76.1 m-20 -90.26 -47.84 7.53 Favored 'General case' 0 C--N 1.325 -0.458 0 O-C-N 124.439 1.087 . . . . 0.0 109.273 -179.982 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' THR . . . . . 0.503 ' CG2' ' SG ' ' A' ' 15' ' ' CYS . 19.5 m -53.16 142.7 36.3 Favored Pre-proline 0 C--N 1.325 -0.474 0 O-C-N 124.495 1.122 . . . . 0.0 110.397 180.0 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . 0.473 ' HD2' ' CG2' ' A' ' 12' ' ' THR . 20.4 Cg_endo -74.94 131.63 14.59 Favored 'Trans proline' 0 N--CA 1.453 -0.856 0 O-C-N 124.495 1.787 . . . . 0.0 110.975 -168.328 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 73.97 15.81 79.64 Favored Glycine 0 CA--C 1.53 0.977 0 O-C-N 124.524 1.14 . . . . 0.0 110.984 179.953 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.503 ' SG ' ' CG2' ' A' ' 12' ' ' THR . 63.8 m -97.64 131.5 44.15 Favored 'General case' 0 C--N 1.325 -0.47 0 N-CA-C 108.265 -1.013 . . . . 0.0 108.265 -179.991 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' THR . . . . . 0.405 ' O ' ' SG ' ' A' ' 10' ' ' CYS . 73.1 p -98.37 154.68 17.67 Favored 'General case' 0 C--N 1.325 -0.494 0 O-C-N 124.533 1.145 . . . . 0.0 110.405 -180.0 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 44.4 t -82.19 94.69 7.33 Favored 'General case' 0 C--N 1.325 -0.478 0 O-C-N 124.461 1.101 . . . . 0.0 108.261 -179.976 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' SER . . . . . 0.517 ' O ' ' C ' ' A' ' 19' ' ' TRP . 40.8 t -102.23 66.02 0.98 Allowed 'General case' 0 C--N 1.325 -0.494 0 O-C-N 124.506 1.129 . . . . 0.0 109.964 174.045 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' TRP . . . . . 0.561 ' CG ' ' HA ' ' A' ' 20' ' ' PRO . 0.1 OUTLIER -35.92 147.13 0.18 Allowed Pre-proline 0 C--N 1.325 -0.464 0 O-C-N 124.48 1.112 . . . . 0.0 108.02 -174.211 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . 0.561 ' HA ' ' CG ' ' A' ' 19' ' ' TRP . 18.3 Cg_endo -75.03 -13.9 23.44 Favored 'Cis proline' 0 C--N 1.36 1.148 0 C-N-CA 120.991 -2.504 . . . . 0.0 110.972 -8.69 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.484 ' O ' ' C ' ' A' ' 18' ' ' SER . 0.8 OUTLIER -97.63 177.0 0.69 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 O-C-N 124.512 1.132 . . . . 0.0 109.301 -172.977 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 52.7 m -102.0 171.19 7.65 Favored 'General case' 0 C--N 1.325 -0.493 0 O-C-N 124.508 1.13 . . . . 0.0 108.292 -179.995 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -148.83 168.09 23.92 Favored 'General case' 0 C--N 1.325 -0.486 0 O-C-N 124.543 1.152 . . . . 0.0 110.342 179.993 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . 0.468 ' HB3' ' CG2' ' A' ' 29' ' ' VAL . 8.6 ttt180 -140.57 118.67 11.94 Favored 'General case' 0 C--N 1.326 -0.451 0 O-C-N 124.459 1.099 . . . . 0.0 110.335 179.982 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 14.6 t-20 58.2 22.75 9.51 Favored 'General case' 0 C--N 1.325 -0.465 0 O-C-N 124.494 1.121 . . . . 0.0 109.319 -179.967 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 82.72 22.67 57.69 Favored Glycine 0 CA--C 1.53 0.982 0 O-C-N 124.435 1.085 . . . . 0.0 111.012 -179.997 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 6.2 mt -141.68 130.56 12.28 Favored Pre-proline 0 C--N 1.325 -0.467 0 O-C-N 124.478 0.752 . . . . 0.0 109.286 -179.985 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 20.1 Cg_endo -74.98 83.82 1.75 Allowed 'Trans proline' 0 N--CA 1.453 -0.904 0 O-C-N 124.468 1.773 . . . . 0.0 110.975 -168.258 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.468 ' CG2' ' HB3' ' A' ' 24' ' ' ARG . 35.5 m . . . . . 0 C--N 1.325 -0.477 0 O-C-N 124.507 1.13 . . . . 0.0 109.29 179.982 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 99.6 m . . . . . 0 N--CA 1.453 -0.286 0 N-CA-C 108.316 -0.994 . . . . 0.0 108.316 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 91.78 -26.92 10.83 Favored Glycine 0 CA--C 1.53 1.015 0 O-C-N 124.477 1.11 . . . . 0.0 111.005 179.98 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 25.3 tt0 -81.46 152.73 27.22 Favored 'General case' 0 C--N 1.326 -0.453 0 O-C-N 124.49 0.759 . . . . 0.0 110.258 -179.959 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 76.2 p -113.26 134.88 54.38 Favored 'General case' 0 C--N 1.325 -0.495 0 O-C-N 124.519 1.137 . . . . 0.0 110.394 179.962 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . 0.41 ' SG ' ' O ' ' A' ' 5' ' ' CYS . 15.0 p -98.79 52.65 0.99 Allowed 'General case' 0 C--N 1.326 -0.454 0 O-C-N 124.495 1.122 . . . . 0.0 108.332 179.965 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 8.6 t -59.32 -24.73 28.68 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 O-C-N 124.492 1.12 . . . . 0.0 109.301 -179.97 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -84.13 -34.06 18.79 Favored Glycine 0 CA--C 1.529 0.968 0 O-C-N 124.505 1.128 . . . . 0.0 110.975 -179.984 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 126.54 14.63 2.85 Favored Glycine 0 C--N 1.345 1.047 0 O-C-N 125.13 1.135 . . . . 0.0 110.998 177.776 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -150.0 166.94 28.15 Favored 'General case' 0 C--N 1.325 -0.488 0 O-C-N 124.53 0.782 . . . . 0.0 110.413 179.981 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . 0.408 ' SG ' ' O ' ' A' ' 16' ' ' THR . 72.8 m -124.22 141.78 51.78 Favored 'General case' 0 C--N 1.324 -0.52 0 O-C-N 124.54 1.15 . . . . 0.0 108.343 179.946 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 32.4 t-20 -89.65 -43.29 10.84 Favored 'General case' 0 C--N 1.325 -0.474 0 O-C-N 124.527 1.142 . . . . 0.0 109.335 -180.0 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' THR . . . . . 0.498 ' CG2' ' SG ' ' A' ' 15' ' ' CYS . 20.0 m -57.67 142.71 77.41 Favored Pre-proline 0 C--N 1.326 -0.448 0 O-C-N 124.505 1.128 . . . . 0.0 110.399 179.989 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . 0.472 ' HD2' ' CG2' ' A' ' 12' ' ' THR . 20.1 Cg_endo -75.01 132.33 15.28 Favored 'Trans proline' 0 N--CA 1.453 -0.895 0 O-C-N 124.506 1.793 . . . . 0.0 110.99 -168.306 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 73.62 13.28 80.37 Favored Glycine 0 CA--C 1.529 0.969 0 O-C-N 124.476 1.11 . . . . 0.0 111.016 -179.98 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.498 ' SG ' ' CG2' ' A' ' 12' ' ' THR . 68.7 m -97.49 125.65 42.3 Favored 'General case' 0 C--N 1.325 -0.479 0 N-CA-C 108.29 -1.004 . . . . 0.0 108.29 -179.983 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' THR . . . . . 0.408 ' O ' ' SG ' ' A' ' 10' ' ' CYS . 70.7 p -93.61 156.82 16.5 Favored 'General case' 0 C--N 1.325 -0.491 0 O-C-N 124.558 1.161 . . . . 0.0 110.437 179.977 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 42.7 t -82.86 94.98 7.8 Favored 'General case' 0 C--N 1.325 -0.482 0 O-C-N 124.447 1.092 . . . . 0.0 108.315 -179.993 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' SER . . . . . 0.52 ' O ' ' C ' ' A' ' 19' ' ' TRP . 1.0 OUTLIER -102.48 66.39 0.97 Allowed 'General case' 0 C--N 1.325 -0.486 0 O-C-N 124.494 1.121 . . . . 0.0 109.968 173.987 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' TRP . . . . . 0.554 ' CG ' ' HA ' ' A' ' 20' ' ' PRO . 0.1 OUTLIER -35.51 147.15 0.17 Allowed Pre-proline 0 C--N 1.326 -0.453 0 O-C-N 124.497 1.123 . . . . 0.0 108.0 -174.085 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . 0.554 ' HA ' ' CG ' ' A' ' 19' ' ' TRP . 18.3 Cg_endo -75.0 -13.85 23.39 Favored 'Cis proline' 0 C--N 1.36 1.135 0 C-N-CA 120.967 -2.514 . . . . 0.0 111.013 -8.645 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.495 ' O ' ' C ' ' A' ' 18' ' ' SER . 2.8 p -99.13 178.08 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 O-C-N 124.512 1.132 . . . . 0.0 109.34 -172.964 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 66.7 m -102.29 172.75 6.71 Favored 'General case' 0 C--N 1.325 -0.471 0 O-C-N 124.486 1.116 . . . . 0.0 108.301 179.993 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' THR . . . . . 0.441 ' CG2' ' CB ' ' A' ' 18' ' ' SER . 8.4 p -146.59 159.31 43.61 Favored 'General case' 0 C--N 1.325 -0.467 0 O-C-N 124.486 1.117 . . . . 0.0 110.391 -179.985 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . 0.462 ' HB3' ' CG2' ' A' ' 29' ' ' VAL . 0.5 OUTLIER -131.81 117.68 18.87 Favored 'General case' 0 C--N 1.325 -0.483 0 O-C-N 124.498 1.124 . . . . 0.0 110.291 179.965 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 78.8 m-20 57.52 23.4 9.14 Favored 'General case' 0 C--N 1.325 -0.469 0 O-C-N 124.491 1.119 . . . . 0.0 109.298 -179.987 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 84.04 23.01 53.71 Favored Glycine 0 CA--C 1.53 0.99 0 O-C-N 124.428 1.08 . . . . 0.0 110.983 179.988 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 8.1 mt -143.06 129.99 10.71 Favored Pre-proline 0 C--N 1.325 -0.481 0 O-C-N 124.476 0.751 . . . . 0.0 109.29 179.972 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 20.2 Cg_endo -74.99 85.66 1.5 Allowed 'Trans proline' 0 N--CA 1.453 -0.88 0 O-C-N 124.508 1.794 . . . . 0.0 110.965 -168.287 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.462 ' CG2' ' HB3' ' A' ' 24' ' ' ARG . 33.5 m . . . . . 0 C--N 1.325 -0.472 0 O-C-N 124.542 1.151 . . . . 0.0 109.324 179.968 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . 0.406 ' SG ' ' O ' ' A' ' 23' ' ' THR . 20.0 m . . . . . 0 N--CA 1.452 -0.333 0 N-CA-C 108.302 -0.999 . . . . 0.0 108.302 . . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 108.48 -11.0 36.03 Favored Glycine 0 CA--C 1.53 0.985 0 O-C-N 124.524 1.14 . . . . 0.0 111.011 179.982 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 15.4 mt-10 -99.99 164.4 12.01 Favored 'General case' 0 C--N 1.326 -0.449 0 O-C-N 124.465 0.744 . . . . 0.0 110.282 -179.975 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 76.5 p -122.22 134.81 54.7 Favored 'General case' 0 C--N 1.325 -0.499 0 O-C-N 124.455 1.097 . . . . 0.0 110.44 179.99 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . 0.441 ' SG ' ' O ' ' A' ' 5' ' ' CYS . 11.8 p -101.7 48.23 0.89 Allowed 'General case' 0 C--N 1.325 -0.475 0 O-C-N 124.493 1.121 . . . . 0.0 108.295 -179.965 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 27.0 t -59.06 -23.61 24.82 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 O-C-N 124.511 1.132 . . . . 0.0 109.266 -179.992 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -87.82 -29.14 21.78 Favored Glycine 0 CA--C 1.53 1.027 0 O-C-N 124.51 1.132 . . . . 0.0 111.002 179.986 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 121.7 16.1 4.24 Favored Glycine 0 CA--C 1.531 1.036 0 O-C-N 124.964 1.038 . . . . 0.0 111.015 178.398 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 89.8 m -150.18 166.29 30.3 Favored 'General case' 0 C--N 1.325 -0.493 0 O-C-N 124.513 0.772 . . . . 0.0 110.415 179.942 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . 0.407 ' SG ' ' O ' ' A' ' 16' ' ' THR . 87.9 m -124.38 143.95 50.31 Favored 'General case' 0 C--N 1.325 -0.476 0 O-C-N 124.526 1.141 . . . . 0.0 108.306 179.979 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 18.9 t30 -89.78 -50.44 6.05 Favored 'General case' 0 C--N 1.325 -0.486 0 O-C-N 124.489 1.118 . . . . 0.0 109.353 179.978 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' THR . . . . . 0.505 ' CG2' ' SG ' ' A' ' 15' ' ' CYS . 18.5 m -52.32 142.77 28.4 Favored Pre-proline 0 C--N 1.325 -0.479 0 O-C-N 124.464 1.102 . . . . 0.0 110.406 -179.999 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . 0.473 ' HD2' ' CG2' ' A' ' 12' ' ' THR . 20.1 Cg_endo -74.95 129.52 12.47 Favored 'Trans proline' 0 N--CA 1.453 -0.892 0 O-C-N 124.504 1.792 . . . . 0.0 110.991 -168.284 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . 0.415 ' HA3' ' NH1' ' A' ' 24' ' ' ARG . . . 76.01 15.15 81.58 Favored Glycine 0 CA--C 1.53 0.997 0 O-C-N 124.497 1.123 . . . . 0.0 110.999 179.988 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.505 ' SG ' ' CG2' ' A' ' 12' ' ' THR . 55.9 m -95.78 126.33 40.97 Favored 'General case' 0 C--N 1.325 -0.481 0 N-CA-C 108.282 -1.007 . . . . 0.0 108.282 -179.952 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' THR . . . . . 0.407 ' O ' ' SG ' ' A' ' 10' ' ' CYS . 12.3 p -92.45 154.36 18.54 Favored 'General case' 0 C--N 1.325 -0.497 0 O-C-N 124.51 1.131 . . . . 0.0 110.408 -179.998 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 21.9 t -83.59 94.81 8.16 Favored 'General case' 0 C--N 1.324 -0.508 0 O-C-N 124.497 1.123 . . . . 0.0 108.3 -179.996 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' SER . . . . . 0.517 ' O ' ' C ' ' A' ' 19' ' ' TRP . 1.1 t -102.68 68.06 1.02 Allowed 'General case' 0 C--N 1.325 -0.474 0 O-C-N 124.501 1.126 . . . . 0.0 110.011 174.02 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' TRP . . . . . 0.544 ' CG ' ' HA ' ' A' ' 20' ' ' PRO . 0.0 OUTLIER -36.03 147.02 0.19 Allowed Pre-proline 0 C--N 1.325 -0.5 0 O-C-N 124.501 1.125 . . . . 0.0 107.972 -174.213 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . 0.544 ' HA ' ' CG ' ' A' ' 19' ' ' TRP . 18.2 Cg_endo -75.04 -14.34 23.23 Favored 'Cis proline' 0 C--N 1.361 1.194 0 C-N-CA 120.988 -2.505 . . . . 0.0 110.998 -8.67 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.478 ' O ' ' C ' ' A' ' 18' ' ' SER . 3.8 p -97.61 178.46 0.61 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 O-C-N 124.508 1.13 . . . . 0.0 109.277 -172.984 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 35.3 m -102.14 172.76 6.71 Favored 'General case' 0 C--N 1.326 -0.439 0 O-C-N 124.497 1.123 . . . . 0.0 108.279 -179.97 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' THR . . . . . 0.488 ' CG2' ' CB ' ' A' ' 18' ' ' SER . 5.9 p -145.53 160.57 41.42 Favored 'General case' 0 C--N 1.325 -0.497 0 O-C-N 124.51 1.131 . . . . 0.0 110.446 179.965 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . 0.415 ' NH1' ' HA3' ' A' ' 14' ' ' GLY . 15.1 tpt180 -127.92 114.69 17.5 Favored 'General case' 0 C--N 1.325 -0.485 0 O-C-N 124.515 1.134 . . . . 0.0 110.304 -179.984 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 66.1 t30 57.07 25.55 10.94 Favored 'General case' 0 C--N 1.325 -0.49 0 O-C-N 124.496 1.123 . . . . 0.0 109.281 -179.997 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 82.74 22.18 58.46 Favored Glycine 0 CA--C 1.53 1.019 0 O-C-N 124.487 1.117 . . . . 0.0 110.999 -179.999 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 52.3 mt -140.35 132.23 14.37 Favored Pre-proline 0 C--N 1.325 -0.475 0 O-C-N 124.512 0.772 . . . . 0.0 109.261 179.996 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 20.2 Cg_endo -75.0 86.29 1.44 Allowed 'Trans proline' 0 N--CA 1.453 -0.89 0 O-C-N 124.465 1.771 . . . . 0.0 110.967 -168.321 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.408 ' CG2' ' HB3' ' A' ' 24' ' ' ARG . 19.0 m . . . . . 0 C--N 1.325 -0.477 0 O-C-N 124.467 1.104 . . . . 0.0 109.311 179.983 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 79.0 m . . . . . 0 N--CA 1.453 -0.306 0 N-CA-C 108.295 -1.002 . . . . 0.0 108.295 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 82.82 -9.74 58.93 Favored Glycine 0 CA--C 1.53 0.994 0 O-C-N 124.501 1.126 . . . . 0.0 111.057 -179.966 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 11.4 pt-20 -100.24 167.85 10.17 Favored 'General case' 0 C--N 1.326 -0.446 0 O-C-N 124.495 0.762 . . . . 0.0 110.272 -179.99 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 50.9 p -127.07 143.94 51.15 Favored 'General case' 0 C--N 1.325 -0.481 0 O-C-N 124.52 1.138 . . . . 0.0 110.392 179.998 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . 0.418 ' HB2' ' N ' ' A' ' 9' ' ' THR . 20.5 p -104.26 56.98 0.71 Allowed 'General case' 0 C--N 1.324 -0.5 0 O-C-N 124.494 1.121 . . . . 0.0 108.324 179.976 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 4.9 t -59.48 -24.74 29.18 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 O-C-N 124.493 1.121 . . . . 0.0 109.319 179.981 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -85.23 -33.94 15.95 Favored Glycine 0 CA--C 1.53 1.016 0 O-C-N 124.527 1.142 . . . . 0.0 110.952 -179.932 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 125.14 17.3 2.75 Favored Glycine 0 CA--C 1.53 1.023 0 O-C-N 124.889 0.994 . . . . 0.0 111.005 177.766 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 9' ' ' THR . . . . . 0.418 ' N ' ' HB2' ' A' ' 5' ' ' CYS . 32.1 m -150.38 164.01 36.92 Favored 'General case' 0 C--N 1.325 -0.485 0 O-C-N 124.495 0.762 . . . . 0.0 110.397 179.978 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . 0.405 ' SG ' ' O ' ' A' ' 16' ' ' THR . 74.9 m -118.55 142.41 47.63 Favored 'General case' 0 C--N 1.325 -0.485 0 O-C-N 124.505 1.128 . . . . 0.0 108.312 -179.998 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 3.9 m120 -90.87 -40.9 11.49 Favored 'General case' 0 C--N 1.325 -0.469 0 O-C-N 124.485 1.115 . . . . 0.0 109.275 -179.998 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' THR . . . . . 0.5 ' CG2' ' SG ' ' A' ' 15' ' ' CYS . 17.5 m -63.76 142.82 98.09 Favored Pre-proline 0 C--N 1.325 -0.484 0 O-C-N 124.483 1.115 . . . . 0.0 110.426 -179.993 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . 0.475 ' HD2' ' CG2' ' A' ' 12' ' ' THR . 20.1 Cg_endo -74.97 130.73 13.58 Favored 'Trans proline' 0 N--CA 1.453 -0.876 0 O-C-N 124.481 1.779 . . . . 0.0 110.969 -168.246 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 77.16 10.37 86.29 Favored Glycine 0 CA--C 1.53 1.022 0 O-C-N 124.511 1.132 . . . . 0.0 111.001 179.985 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.5 ' SG ' ' CG2' ' A' ' 12' ' ' THR . 68.1 m -93.78 126.75 39.15 Favored 'General case' 0 C--N 1.325 -0.464 0 N-CA-C 108.268 -1.012 . . . . 0.0 108.268 -179.973 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' THR . . . . . 0.405 ' O ' ' SG ' ' A' ' 10' ' ' CYS . 11.2 p -93.8 152.41 18.93 Favored 'General case' 0 C--N 1.324 -0.511 0 O-C-N 124.456 1.098 . . . . 0.0 110.393 -179.981 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 43.4 t -80.0 98.14 7.07 Favored 'General case' 0 C--N 1.325 -0.473 0 O-C-N 124.475 1.109 . . . . 0.0 108.331 179.983 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' SER . . . . . 0.519 ' O ' ' C ' ' A' ' 19' ' ' TRP . 30.0 t -105.72 64.92 0.7 Allowed 'General case' 0 C--N 1.325 -0.472 0 O-C-N 124.502 1.126 . . . . 0.0 109.986 174.242 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' TRP . . . . . 0.586 ' CG ' ' HA ' ' A' ' 20' ' ' PRO . 0.4 OUTLIER -35.42 147.0 0.17 Allowed Pre-proline 0 C--N 1.325 -0.472 0 O-C-N 124.537 1.148 . . . . 0.0 108.024 -174.284 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . 0.586 ' HA ' ' CG ' ' A' ' 19' ' ' TRP . 18.3 Cg_endo -74.98 -13.97 23.3 Favored 'Cis proline' 0 C--N 1.36 1.148 0 C-N-CA 121.013 -2.495 . . . . 0.0 111.006 -8.605 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.503 ' O ' ' C ' ' A' ' 18' ' ' SER . 3.8 t -97.94 175.31 0.82 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 O-C-N 124.478 1.111 . . . . 0.0 109.239 -173.022 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . 0.406 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 3.5 m -102.36 170.0 8.34 Favored 'General case' 0 C--N 1.325 -0.483 0 O-C-N 124.463 1.102 . . . . 0.0 108.338 179.995 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 1.9 p -147.27 163.41 36.49 Favored 'General case' 0 C--N 1.325 -0.495 0 O-C-N 124.49 1.119 . . . . 0.0 110.385 179.996 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . 0.46 ' HB3' ' CG2' ' A' ' 29' ' ' VAL . 0.3 OUTLIER -139.77 118.91 12.7 Favored 'General case' 0 C--N 1.324 -0.509 0 O-C-N 124.573 1.17 . . . . 0.0 110.33 179.937 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 18.0 t-20 57.91 22.36 8.64 Favored 'General case' 0 C--N 1.325 -0.48 0 O-C-N 124.528 1.142 . . . . 0.0 109.277 -179.988 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 84.55 23.21 51.49 Favored Glycine 0 CA--C 1.531 1.042 0 O-C-N 124.504 1.128 . . . . 0.0 110.959 179.952 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 12.1 mt -145.96 128.04 7.79 Favored Pre-proline 0 C--N 1.325 -0.491 0 O-C-N 124.515 0.773 . . . . 0.0 109.311 -179.976 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 20.3 Cg_endo -74.92 78.25 2.91 Favored 'Trans proline' 0 N--CA 1.453 -0.889 0 O-C-N 124.515 1.797 . . . . 0.0 110.966 -168.294 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.46 ' CG2' ' HB3' ' A' ' 24' ' ' ARG . 30.8 m . . . . . 0 C--N 1.324 -0.517 0 O-C-N 124.509 1.131 . . . . 0.0 109.289 179.985 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 99.7 m . . . . . 0 N--CA 1.453 -0.311 0 N-CA-C 108.319 -0.993 . . . . 0.0 108.319 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 84.61 -13.21 53.47 Favored Glycine 0 CA--C 1.53 1.004 0 O-C-N 124.475 1.109 . . . . 0.0 110.958 179.936 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . 0.403 ' HG3' ' SG ' ' A' ' 22' ' ' CYS . 23.1 pt-20 -100.42 171.72 7.57 Favored 'General case' 0 C--N 1.325 -0.495 0 O-C-N 124.504 0.767 . . . . 0.0 110.262 -179.983 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 38.4 p -129.72 143.16 50.68 Favored 'General case' 0 C--N 1.325 -0.482 0 O-C-N 124.506 1.128 . . . . 0.0 110.377 179.991 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . 0.584 ' O ' ' CD1' ' A' ' 19' ' ' TRP . 14.8 p -96.67 52.46 1.2 Allowed 'General case' 0 C--N 1.325 -0.469 0 O-C-N 124.474 1.109 . . . . 0.0 108.301 179.953 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 4.5 t -59.01 -24.9 28.13 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 O-C-N 124.428 1.08 . . . . 0.0 109.309 179.992 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -84.02 -35.09 16.28 Favored Glycine 0 CA--C 1.53 1.028 0 O-C-N 124.467 1.104 . . . . 0.0 111.021 179.996 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . 0.4 ' O ' ' SG ' ' A' ' 17' ' ' CYS . . . 133.34 -13.24 4.91 Favored Glycine 0 C--N 1.346 1.106 0 O-C-N 125.139 1.14 . . . . 0.0 110.979 178.327 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -131.1 162.93 28.78 Favored 'General case' 0 C--N 1.324 -0.502 0 O-C-N 124.517 0.775 . . . . 0.0 110.411 -179.96 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . 0.406 ' SG ' ' O ' ' A' ' 16' ' ' THR . 86.9 m -107.16 141.64 38.11 Favored 'General case' 0 C--N 1.325 -0.49 0 O-C-N 124.499 1.124 . . . . 0.0 108.268 -179.951 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 64.1 t-20 -89.59 -38.13 14.17 Favored 'General case' 0 C--N 1.325 -0.481 0 O-C-N 124.522 1.139 . . . . 0.0 109.329 179.961 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' THR . . . . . 0.494 ' CG2' ' SG ' ' A' ' 15' ' ' CYS . 16.5 m -67.44 143.11 96.97 Favored Pre-proline 0 C--N 1.326 -0.454 0 O-C-N 124.509 1.131 . . . . 0.0 110.429 -179.996 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . 0.486 ' HD2' ' CG2' ' A' ' 12' ' ' THR . 20.2 Cg_endo -74.98 129.15 12.09 Favored 'Trans proline' 0 N--CA 1.453 -0.88 0 O-C-N 124.569 1.826 . . . . 0.0 110.99 -168.27 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 76.86 14.27 82.76 Favored Glycine 0 CA--C 1.529 0.951 0 O-C-N 124.517 1.135 . . . . 0.0 111.035 -179.964 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.494 ' SG ' ' CG2' ' A' ' 12' ' ' THR . 57.7 m -96.45 129.38 43.82 Favored 'General case' 0 C--N 1.325 -0.459 0 N-CA-C 108.315 -0.994 . . . . 0.0 108.315 179.976 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' THR . . . . . 0.406 ' O ' ' SG ' ' A' ' 10' ' ' CYS . 23.4 p -93.57 148.71 21.84 Favored 'General case' 0 C--N 1.325 -0.474 0 O-C-N 124.492 1.12 . . . . 0.0 110.358 -179.977 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . 0.4 ' SG ' ' O ' ' A' ' 8' ' ' GLY . 11.9 t -81.23 95.06 6.82 Favored 'General case' 0 C--N 1.325 -0.462 0 O-C-N 124.5 1.125 . . . . 0.0 108.293 179.988 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' SER . . . . . 0.513 ' O ' ' C ' ' A' ' 19' ' ' TRP . 20.4 p -102.31 65.79 0.97 Allowed 'General case' 0 C--N 1.325 -0.497 0 O-C-N 124.493 1.121 . . . . 0.0 110.036 173.993 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' TRP . . . . . 0.584 ' CD1' ' O ' ' A' ' 5' ' ' CYS . 0.0 OUTLIER -36.02 147.23 0.18 Allowed Pre-proline 0 C--N 1.325 -0.459 0 N-CA-C 107.998 -1.112 . . . . 0.0 107.998 -174.047 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . 0.527 ' HA ' ' CG ' ' A' ' 19' ' ' TRP . 18.4 Cg_endo -74.95 -13.53 23.44 Favored 'Cis proline' 0 C--N 1.36 1.161 0 C-N-CA 120.995 -2.502 . . . . 0.0 111.01 -8.641 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.493 ' O ' ' C ' ' A' ' 18' ' ' SER . 2.3 p -96.35 173.99 0.9 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.478 0 O-C-N 124.53 1.144 . . . . 0.0 109.331 -173.224 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . 0.403 ' SG ' ' HG3' ' A' ' 3' ' ' GLU . 1.7 m -102.09 169.2 8.9 Favored 'General case' 0 C--N 1.325 -0.488 0 O-C-N 124.485 1.115 . . . . 0.0 108.324 -179.973 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' THR . . . . . 0.406 HG23 ' CB ' ' A' ' 18' ' ' SER . 1.1 p -141.99 169.1 18.22 Favored 'General case' 0 C--N 1.325 -0.488 0 O-C-N 124.494 1.121 . . . . 0.0 110.413 -179.981 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . 0.454 ' HB3' ' CG2' ' A' ' 29' ' ' VAL . 6.0 ttt180 -143.74 117.02 9.0 Favored 'General case' 0 C--N 1.325 -0.475 0 O-C-N 124.527 1.142 . . . . 0.0 110.279 -179.986 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 71.1 m-20 58.47 22.23 9.36 Favored 'General case' 0 C--N 1.325 -0.482 0 O-C-N 124.516 1.135 . . . . 0.0 109.31 179.992 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 86.48 20.64 53.99 Favored Glycine 0 CA--C 1.53 0.974 0 O-C-N 124.498 1.124 . . . . 0.0 111.009 -179.997 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 9.7 mt -144.7 128.81 8.92 Favored Pre-proline 0 C--N 1.325 -0.493 0 O-C-N 124.514 0.773 . . . . 0.0 109.29 -179.98 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 20.2 Cg_endo -74.97 84.68 1.62 Allowed 'Trans proline' 0 N--CA 1.453 -0.895 0 O-C-N 124.499 1.789 . . . . 0.0 111.014 -168.321 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.454 ' CG2' ' HB3' ' A' ' 24' ' ' ARG . 28.4 m . . . . . 0 C--N 1.324 -0.508 0 O-C-N 124.547 1.154 . . . . 0.0 109.295 -179.968 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 83.0 m . . . . . 0 N--CA 1.453 -0.296 0 N-CA-C 108.286 -1.005 . . . . 0.0 108.286 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 100.56 -25.33 28.71 Favored Glycine 0 CA--C 1.53 1.017 0 O-C-N 124.475 1.109 . . . . 0.0 110.99 -179.996 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 28.6 tt0 -78.51 150.47 32.9 Favored 'General case' 0 C--N 1.324 -0.511 0 O-C-N 124.519 0.776 . . . . 0.0 110.293 -179.969 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 75.2 p -110.21 130.94 55.45 Favored 'General case' 0 C--N 1.325 -0.476 0 O-C-N 124.453 1.095 . . . . 0.0 110.42 179.977 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . 0.416 ' SG ' ' O ' ' A' ' 5' ' ' CYS . 14.5 p -99.0 51.58 0.96 Allowed 'General case' 0 C--N 1.325 -0.46 0 O-C-N 124.452 1.095 . . . . 0.0 108.301 -179.975 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 9.6 t -59.22 -24.59 27.94 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 O-C-N 124.553 1.158 . . . . 0.0 109.334 -179.991 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -83.89 -33.42 21.31 Favored Glycine 0 CA--C 1.53 0.984 0 O-C-N 124.52 1.138 . . . . 0.0 110.972 -179.978 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 125.95 14.24 3.12 Favored Glycine 0 C--N 1.346 1.086 0 C-N-CA 119.776 -1.202 . . . . 0.0 110.982 177.846 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -150.07 166.25 30.31 Favored 'General case' 0 C--N 1.325 -0.494 0 O-C-N 124.456 0.739 . . . . 0.0 110.355 -179.997 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . 0.405 ' SG ' ' O ' ' A' ' 16' ' ' THR . 74.8 m -123.14 144.28 49.45 Favored 'General case' 0 C--N 1.326 -0.439 0 O-C-N 124.477 1.11 . . . . 0.0 108.288 -179.989 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 9.8 t-20 -91.18 -44.39 9.27 Favored 'General case' 0 C--N 1.325 -0.464 0 O-C-N 124.463 1.102 . . . . 0.0 109.313 -179.971 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' THR . . . . . 0.496 ' CG2' ' SG ' ' A' ' 15' ' ' CYS . 20.6 m -58.03 142.73 79.47 Favored Pre-proline 0 C--N 1.325 -0.48 0 O-C-N 124.487 1.117 . . . . 0.0 110.392 -179.984 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . 0.471 ' HD2' ' CG2' ' A' ' 12' ' ' THR . 20.2 Cg_endo -74.98 132.34 15.34 Favored 'Trans proline' 0 N--CA 1.453 -0.871 0 O-C-N 124.443 1.76 . . . . 0.0 110.937 -168.251 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 75.47 8.71 84.2 Favored Glycine 0 CA--C 1.53 1.014 0 O-C-N 124.472 1.107 . . . . 0.0 111.028 179.993 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.496 ' SG ' ' CG2' ' A' ' 12' ' ' THR . 81.5 m -93.29 125.43 37.89 Favored 'General case' 0 C--N 1.324 -0.509 0 N-CA-C 108.279 -1.008 . . . . 0.0 108.279 179.995 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' THR . . . . . 0.405 ' O ' ' SG ' ' A' ' 10' ' ' CYS . 2.2 p -94.0 156.07 16.8 Favored 'General case' 0 C--N 1.325 -0.483 0 O-C-N 124.524 1.14 . . . . 0.0 110.393 -179.994 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 48.5 t -81.25 91.14 6.16 Favored 'General case' 0 C--N 1.325 -0.495 0 O-C-N 124.512 1.133 . . . . 0.0 108.336 179.968 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' SER . . . . . 0.525 ' O ' ' C ' ' A' ' 19' ' ' TRP . 1.9 m -98.09 65.23 1.73 Allowed 'General case' 0 C--N 1.324 -0.502 0 O-C-N 124.503 1.127 . . . . 0.0 110.001 174.231 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' TRP . . . . . 0.549 ' CG ' ' HA ' ' A' ' 20' ' ' PRO . 0.0 OUTLIER -35.52 147.1 0.17 Allowed Pre-proline 0 C--N 1.324 -0.506 0 O-C-N 124.503 1.127 . . . . 0.0 107.993 -173.882 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . 0.549 ' HA ' ' CG ' ' A' ' 19' ' ' TRP . 18.4 Cg_endo -74.98 -13.27 23.65 Favored 'Cis proline' 0 C--N 1.36 1.143 0 C-N-CA 121.012 -2.495 . . . . 0.0 110.98 -8.386 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.508 ' O ' ' C ' ' A' ' 18' ' ' SER . 2.4 m -99.92 178.65 0.64 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.494 0 O-C-N 124.468 1.105 . . . . 0.0 109.295 -173.117 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 82.7 m -102.21 171.75 7.3 Favored 'General case' 0 C--N 1.325 -0.486 0 O-C-N 124.524 1.14 . . . . 0.0 108.281 -179.997 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -150.3 161.0 43.3 Favored 'General case' 0 C--N 1.325 -0.477 0 O-C-N 124.526 1.141 . . . . 0.0 110.396 179.991 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . 0.475 ' HB3' ' CG2' ' A' ' 29' ' ' VAL . 8.6 ttt180 -132.4 119.08 20.18 Favored 'General case' 0 C--N 1.325 -0.493 0 O-C-N 124.552 1.157 . . . . 0.0 110.289 -179.99 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . 0.404 ' OD1' ' O ' ' A' ' 25' ' ' ASN . 22.9 t-20 57.24 28.87 15.8 Favored 'General case' 0 C--N 1.325 -0.484 0 O-C-N 124.507 1.129 . . . . 0.0 109.291 179.992 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 76.05 23.3 72.04 Favored Glycine 0 CA--C 1.531 1.038 0 O-C-N 124.504 1.127 . . . . 0.0 110.989 179.988 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 7.3 mt -141.4 129.22 11.99 Favored Pre-proline 0 C--N 1.324 -0.509 0 O-C-N 124.554 0.796 . . . . 0.0 109.311 -179.971 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 20.2 Cg_endo -75.0 88.3 1.25 Allowed 'Trans proline' 0 N--CA 1.453 -0.875 0 O-C-N 124.487 1.783 . . . . 0.0 110.944 -168.261 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.475 ' CG2' ' HB3' ' A' ' 24' ' ' ARG . 27.1 m . . . . . 0 C--N 1.325 -0.468 0 O-C-N 124.476 1.11 . . . . 0.0 109.345 179.958 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 91.6 m . . . . . 0 N--CA 1.453 -0.284 0 N-CA-C 108.271 -1.011 . . . . 0.0 108.271 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 92.57 7.93 62.83 Favored Glycine 0 CA--C 1.53 1.023 0 O-C-N 124.486 1.116 . . . . 0.0 110.972 -179.985 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 89.8 mt-10 -100.23 165.01 11.7 Favored 'General case' 0 C--N 1.325 -0.495 0 O-C-N 124.493 0.761 . . . . 0.0 110.308 179.999 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 23.9 p -121.51 114.99 22.01 Favored 'General case' 0 C--N 1.325 -0.485 0 O-C-N 124.456 1.098 . . . . 0.0 110.4 -179.984 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . 0.432 ' O ' ' SG ' ' A' ' 5' ' ' CYS . 13.3 p -91.08 49.62 1.66 Allowed 'General case' 0 C--N 1.325 -0.474 0 O-C-N 124.5 1.125 . . . . 0.0 108.315 -179.976 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 17.5 t -59.19 -24.54 27.75 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 O-C-N 124.5 1.125 . . . . 0.0 109.355 -179.985 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -84.62 -34.25 16.73 Favored Glycine 0 CA--C 1.531 1.036 0 O-C-N 124.498 1.124 . . . . 0.0 110.981 -179.994 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 125.84 13.1 3.43 Favored Glycine 0 CA--C 1.53 1.006 0 O-C-N 125.1 1.118 . . . . 0.0 111.041 178.05 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 2.5 m -150.02 161.4 42.4 Favored 'General case' 0 C--N 1.326 -0.452 0 O-C-N 124.529 0.782 . . . . 0.0 110.383 -179.975 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . 0.402 ' SG ' ' O ' ' A' ' 16' ' ' THR . 72.3 m -119.11 156.37 29.88 Favored 'General case' 0 C--N 1.325 -0.489 0 O-C-N 124.468 1.105 . . . . 0.0 108.327 179.974 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 17.6 t30 -97.98 -58.17 2.05 Favored 'General case' 0 C--N 1.325 -0.475 0 O-C-N 124.518 1.136 . . . . 0.0 109.341 179.97 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' THR . . . . . 0.489 ' CG2' ' SG ' ' A' ' 15' ' ' CYS . 5.3 m -44.69 142.64 2.45 Favored Pre-proline 0 C--N 1.324 -0.501 0 O-C-N 124.558 1.161 . . . . 0.0 110.405 179.954 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . 0.434 ' HD2' ' CG2' ' A' ' 12' ' ' THR . 20.4 Cg_endo -74.94 129.53 12.49 Favored 'Trans proline' 0 N--CA 1.453 -0.871 0 O-C-N 124.493 1.786 . . . . 0.0 111.023 -168.34 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 78.88 11.57 85.08 Favored Glycine 0 CA--C 1.53 0.986 0 O-C-N 124.513 1.133 . . . . 0.0 111.034 -179.988 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.489 ' SG ' ' CG2' ' A' ' 12' ' ' THR . 57.7 m -95.29 125.71 40.11 Favored 'General case' 0 C--N 1.325 -0.461 0 N-CA-C 108.306 -0.998 . . . . 0.0 108.306 -179.943 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' THR . . . . . 0.402 ' O ' ' SG ' ' A' ' 10' ' ' CYS . 18.7 p -95.16 157.35 15.93 Favored 'General case' 0 C--N 1.326 -0.449 0 O-C-N 124.469 1.106 . . . . 0.0 110.423 -179.989 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 24.5 t -82.74 95.84 7.99 Favored 'General case' 0 C--N 1.325 -0.486 0 O-C-N 124.543 1.152 . . . . 0.0 108.291 179.989 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' SER . . . . . 0.525 ' O ' ' C ' ' A' ' 19' ' ' TRP . 11.2 t -100.45 64.56 1.15 Allowed 'General case' 0 C--N 1.325 -0.469 0 O-C-N 124.504 1.128 . . . . 0.0 110.057 173.855 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' TRP . . . . . 0.551 ' CG ' ' HA ' ' A' ' 20' ' ' PRO . 0.3 OUTLIER -35.39 145.96 0.19 Allowed Pre-proline 0 C--N 1.325 -0.496 0 O-C-N 124.549 1.155 . . . . 0.0 108.033 -174.124 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . 0.551 ' HA ' ' CG ' ' A' ' 19' ' ' TRP . 18.3 Cg_endo -75.04 -14.88 22.92 Favored 'Cis proline' 0 C--N 1.359 1.13 0 C-N-CA 121.021 -2.491 . . . . 0.0 110.973 -8.459 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.492 ' O ' ' C ' ' A' ' 18' ' ' SER . 3.1 m -95.76 177.09 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 O-C-N 124.515 1.134 . . . . 0.0 109.241 -173.101 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 43.9 m -101.85 166.71 10.51 Favored 'General case' 0 C--N 1.325 -0.487 0 O-C-N 124.537 1.148 . . . . 0.0 108.333 179.987 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -145.04 169.51 17.98 Favored 'General case' 0 C--N 1.325 -0.485 0 O-C-N 124.516 1.135 . . . . 0.0 110.384 179.991 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . 0.457 ' HB3' ' CG2' ' A' ' 29' ' ' VAL . 0.1 OUTLIER -142.18 118.22 10.65 Favored 'General case' 0 C--N 1.325 -0.474 0 O-C-N 124.524 1.14 . . . . 0.0 110.304 -179.972 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 72.0 m-20 57.77 23.37 9.51 Favored 'General case' 0 C--N 1.325 -0.466 0 O-C-N 124.557 1.16 . . . . 0.0 109.357 -179.957 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 82.17 24.14 55.41 Favored Glycine 0 CA--C 1.531 1.036 0 O-C-N 124.524 1.14 . . . . 0.0 111.039 -179.994 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 7.5 mt -143.31 129.57 10.34 Favored Pre-proline 0 C--N 1.325 -0.467 0 O-C-N 124.487 0.757 . . . . 0.0 109.317 -179.973 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 20.4 Cg_endo -74.89 82.18 2.03 Favored 'Trans proline' 0 N--CA 1.453 -0.904 0 O-C-N 124.535 1.808 . . . . 0.0 111.02 -168.348 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.457 ' CG2' ' HB3' ' A' ' 24' ' ' ARG . 32.7 m . . . . . 0 C--N 1.324 -0.51 0 O-C-N 124.526 1.141 . . . . 0.0 109.308 179.997 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 95.2 m . . . . . 0 N--CA 1.452 -0.327 0 N-CA-C 108.266 -1.013 . . . . 0.0 108.266 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 91.03 -27.22 9.35 Favored Glycine 0 CA--C 1.53 0.975 0 O-C-N 124.569 1.168 . . . . 0.0 111.041 -179.976 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 23.5 tt0 -83.53 151.88 25.18 Favored 'General case' 0 C--N 1.325 -0.495 0 O-C-N 124.503 0.767 . . . . 0.0 110.292 -179.988 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 60.2 p -112.83 137.93 50.43 Favored 'General case' 0 C--N 1.324 -0.505 0 O-C-N 124.532 1.145 . . . . 0.0 110.372 179.995 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . 0.407 ' SG ' ' O ' ' A' ' 5' ' ' CYS . 15.0 p -100.88 52.79 0.85 Allowed 'General case' 0 C--N 1.325 -0.477 0 O-C-N 124.551 1.157 . . . . 0.0 108.29 179.99 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 10.3 t -59.22 -24.14 26.74 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 O-C-N 124.508 1.13 . . . . 0.0 109.288 -179.996 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -84.75 -34.6 15.26 Favored Glycine 0 CA--C 1.53 1.006 0 O-C-N 124.524 1.14 . . . . 0.0 110.968 -179.976 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 127.19 14.78 2.64 Favored Glycine 0 CA--C 1.531 1.043 0 O-C-N 125.138 1.14 . . . . 0.0 111.029 177.62 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -150.08 166.73 28.88 Favored 'General case' 0 C--N 1.325 -0.476 0 O-C-N 124.489 0.758 . . . . 0.0 110.386 -179.971 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . 0.414 ' SG ' ' O ' ' A' ' 16' ' ' THR . 72.3 m -124.56 140.71 52.69 Favored 'General case' 0 C--N 1.325 -0.486 0 O-C-N 124.525 1.14 . . . . 0.0 108.298 180.0 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 3.0 m120 -89.58 -40.13 12.81 Favored 'General case' 0 C--N 1.325 -0.465 0 O-C-N 124.428 1.08 . . . . 0.0 109.291 -179.989 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 12' ' ' THR . . . . . 0.495 ' CG2' ' SG ' ' A' ' 15' ' ' CYS . 20.9 m -60.05 142.69 89.08 Favored Pre-proline 0 C--N 1.325 -0.467 0 O-C-N 124.465 1.103 . . . . 0.0 110.393 179.995 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . 0.478 ' HD2' ' CG2' ' A' ' 12' ' ' THR . 20.2 Cg_endo -74.97 132.08 15.05 Favored 'Trans proline' 0 N--CA 1.453 -0.877 0 O-C-N 124.485 1.781 . . . . 0.0 110.947 -168.269 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 73.34 13.35 79.85 Favored Glycine 0 CA--C 1.53 0.999 0 O-C-N 124.563 1.165 . . . . 0.0 110.999 179.974 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.495 ' SG ' ' CG2' ' A' ' 12' ' ' THR . 68.7 m -97.97 125.64 42.99 Favored 'General case' 0 C--N 1.325 -0.486 0 N-CA-C 108.306 -0.998 . . . . 0.0 108.306 -179.989 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' THR . . . . . 0.414 ' O ' ' SG ' ' A' ' 10' ' ' CYS . 44.4 p -93.73 157.56 16.1 Favored 'General case' 0 C--N 1.325 -0.498 0 O-C-N 124.479 1.112 . . . . 0.0 110.387 179.985 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 46.8 t -83.09 95.04 7.94 Favored 'General case' 0 C--N 1.326 -0.454 0 O-C-N 124.491 1.12 . . . . 0.0 108.273 -179.948 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' SER . . . . . 0.52 ' O ' ' C ' ' A' ' 19' ' ' TRP . 1.0 OUTLIER -102.79 66.92 0.96 Allowed 'General case' 0 C--N 1.325 -0.469 0 O-C-N 124.459 1.099 . . . . 0.0 110.029 173.96 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 19' ' ' TRP . . . . . 0.551 ' CG ' ' HA ' ' A' ' 20' ' ' PRO . 0.0 OUTLIER -35.7 147.46 0.17 Allowed Pre-proline 0 C--N 1.326 -0.455 0 O-C-N 124.496 1.123 . . . . 0.0 107.982 -174.009 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . 0.551 ' HA ' ' CG ' ' A' ' 19' ' ' TRP . 18.3 Cg_endo -75.01 -13.5 23.62 Favored 'Cis proline' 0 C--N 1.361 1.206 0 C-N-CA 121.001 -2.5 . . . . 0.0 111.025 -8.572 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.495 ' O ' ' C ' ' A' ' 18' ' ' SER . 4.8 p -100.05 178.84 0.63 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 O-C-N 124.547 1.154 . . . . 0.0 109.323 -173.006 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 81.4 m -102.22 174.0 6.12 Favored 'General case' 0 C--N 1.325 -0.492 0 O-C-N 124.503 1.127 . . . . 0.0 108.285 179.991 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 23' ' ' THR . . . . . 0.428 ' CG2' ' CB ' ' A' ' 18' ' ' SER . 7.2 p -147.02 159.19 43.88 Favored 'General case' 0 C--N 1.325 -0.496 0 O-C-N 124.519 1.137 . . . . 0.0 110.402 179.985 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . 0.458 ' HB3' ' CG2' ' A' ' 29' ' ' VAL . 3.4 ttt180 -130.5 116.49 18.26 Favored 'General case' 0 C--N 1.325 -0.465 0 O-C-N 124.513 1.133 . . . . 0.0 110.326 179.948 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 74.9 m-20 57.61 23.46 9.34 Favored 'General case' 0 C--N 1.325 -0.476 0 O-C-N 124.51 1.131 . . . . 0.0 109.329 -179.939 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 84.27 24.72 46.57 Favored Glycine 0 CA--C 1.53 1.002 0 O-C-N 124.522 1.139 . . . . 0.0 111.013 180.0 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 10.7 mt -144.84 130.31 9.44 Favored Pre-proline 0 C--N 1.325 -0.481 0 O-C-N 124.495 0.762 . . . . 0.0 109.262 -179.984 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 20.2 Cg_endo -74.99 88.24 1.26 Allowed 'Trans proline' 0 N--CA 1.453 -0.891 0 O-C-N 124.5 1.789 . . . . 0.0 110.986 -168.312 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.458 ' CG2' ' HB3' ' A' ' 24' ' ' ARG . 32.4 m . . . . . 0 C--N 1.325 -0.482 0 O-C-N 124.51 1.131 . . . . 0.0 109.294 -179.998 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 58.5 m . . . . . 0 N--CA 1.453 -0.307 0 N-CA-C 108.301 -1.0 . . . . 0.0 108.301 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 90.93 -15.76 60.06 Favored Glycine 0 CA--C 1.531 1.042 0 O-C-N 124.483 1.115 . . . . 0.0 110.96 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 15.6 tt0 -88.76 162.72 16.07 Favored 'General case' 0 C--N 1.325 -0.471 0 O-C-N 124.541 0.789 . . . . 0.0 110.316 179.999 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 53.0 p -120.39 134.97 55.18 Favored 'General case' 0 C--N 1.324 -0.502 0 O-C-N 124.496 1.123 . . . . 0.0 110.425 179.998 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.417 ' O ' ' CD1' ' A' ' 19' ' ' TRP . 13.8 p -105.05 49.06 0.82 Allowed 'General case' 0 C--N 1.325 -0.487 0 O-C-N 124.487 1.117 . . . . 0.0 108.334 179.982 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 37.9 t -59.12 -23.37 24.35 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 O-C-N 124.491 1.12 . . . . 0.0 109.327 179.986 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -82.89 -32.69 26.04 Favored Glycine 0 CA--C 1.531 1.033 0 O-C-N 124.477 1.111 . . . . 0.0 110.985 -179.967 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 125.64 10.8 4.3 Favored Glycine 0 CA--C 1.53 0.997 0 O-C-N 125.068 1.099 . . . . 0.0 110.959 178.183 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 83.6 m -150.19 165.38 33.08 Favored 'General case' 0 C--N 1.325 -0.495 0 O-C-N 124.493 0.761 . . . . 0.0 110.398 179.947 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 91.4 m -118.45 141.85 48.14 Favored 'General case' 0 C--N 1.325 -0.473 0 O-C-N 124.498 1.124 . . . . 0.0 108.29 -179.976 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 13.0 t-20 -89.79 -39.9 12.81 Favored 'General case' 0 C--N 1.325 -0.488 0 O-C-N 124.526 1.141 . . . . 0.0 109.342 179.959 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' THR . . . . . 0.497 ' CG2' ' SG ' ' A' ' 15' ' ' CYS . 17.6 m -62.32 142.99 95.9 Favored Pre-proline 0 C--N 1.325 -0.49 0 O-C-N 124.458 1.099 . . . . 0.0 110.383 -179.989 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . 0.481 ' HD2' ' CG2' ' A' ' 12' ' ' THR . 20.3 Cg_endo -74.9 132.06 15.12 Favored 'Trans proline' 0 N--CA 1.453 -0.875 0 O-C-N 124.524 1.802 . . . . 0.0 110.983 -168.314 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 74.37 12.46 82.04 Favored Glycine 0 CA--C 1.53 1.023 0 O-C-N 124.465 1.103 . . . . 0.0 110.962 179.935 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.497 ' SG ' ' CG2' ' A' ' 12' ' ' THR . 67.3 m -96.71 127.64 42.89 Favored 'General case' 0 C--N 1.325 -0.465 0 N-CA-C 108.307 -0.997 . . . . 0.0 108.307 179.97 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 77.5 p -95.15 152.85 17.99 Favored 'General case' 0 C--N 1.325 -0.457 0 O-C-N 124.511 1.132 . . . . 0.0 110.383 -179.986 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 54.1 t -77.72 93.86 4.35 Favored 'General case' 0 C--N 1.325 -0.493 0 O-C-N 124.487 1.117 . . . . 0.0 108.33 179.983 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' SER . . . . . 0.512 ' O ' ' C ' ' A' ' 19' ' ' TRP . 3.1 t -100.41 65.9 1.23 Allowed 'General case' 0 C--N 1.324 -0.526 0 O-C-N 124.494 1.121 . . . . 0.0 109.992 174.321 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' TRP . . . . . 0.524 ' CG ' ' HA ' ' A' ' 20' ' ' PRO . 0.0 OUTLIER -36.93 147.89 0.2 Allowed Pre-proline 0 C--N 1.325 -0.472 0 O-C-N 124.52 1.138 . . . . 0.0 108.009 -173.973 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . 0.524 ' HA ' ' CG ' ' A' ' 19' ' ' TRP . 18.5 Cg_endo -74.98 -12.11 23.98 Favored 'Cis proline' 0 C--N 1.36 1.176 0 C-N-CA 121.023 -2.49 . . . . 0.0 111.047 -8.5 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.492 ' O ' ' C ' ' A' ' 18' ' ' SER . 3.7 p -99.33 -179.55 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 O-C-N 124.5 1.125 . . . . 0.0 109.232 -173.465 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 43.2 m -101.32 168.4 9.57 Favored 'General case' 0 C--N 1.325 -0.478 0 O-C-N 124.509 1.131 . . . . 0.0 108.3 179.99 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' THR . . . . . 0.471 ' CG2' ' CB ' ' A' ' 18' ' ' SER . 0.7 OUTLIER -144.95 164.95 29.56 Favored 'General case' 0 C--N 1.325 -0.478 0 O-C-N 124.553 1.158 . . . . 0.0 110.383 -179.983 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . 0.423 ' HB3' ' CG2' ' A' ' 29' ' ' VAL . 0.0 OUTLIER -133.87 117.55 16.94 Favored 'General case' 0 C--N 1.325 -0.463 0 O-C-N 124.539 1.149 . . . . 0.0 110.298 179.969 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 74.0 m-20 57.68 23.42 9.43 Favored 'General case' 0 C--N 1.326 -0.456 0 O-C-N 124.447 1.092 . . . . 0.0 109.332 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 84.01 24.59 48.11 Favored Glycine 0 CA--C 1.53 0.993 0 O-C-N 124.52 1.137 . . . . 0.0 110.994 179.986 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 9.6 mt -143.67 130.32 10.37 Favored Pre-proline 0 C--N 1.325 -0.471 0 O-C-N 124.485 0.756 . . . . 0.0 109.339 -179.992 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 20.1 Cg_endo -74.95 89.32 1.16 Allowed 'Trans proline' 0 N--CA 1.453 -0.899 0 O-C-N 124.5 1.79 . . . . 0.0 110.981 -168.294 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.423 ' CG2' ' HB3' ' A' ' 24' ' ' ARG . 22.4 m . . . . . 0 C--N 1.325 -0.496 0 O-C-N 124.501 1.125 . . . . 0.0 109.312 179.991 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 64.8 m . . . . . 0 N--CA 1.453 -0.294 0 N-CA-C 108.305 -0.998 . . . . 0.0 108.305 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 89.63 -17.35 53.02 Favored Glycine 0 CA--C 1.53 0.979 0 O-C-N 124.507 1.129 . . . . 0.0 111.03 179.999 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 14.8 tt0 -87.94 162.62 16.78 Favored 'General case' 0 C--N 1.325 -0.499 0 O-C-N 124.491 0.759 . . . . 0.0 110.291 179.99 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 40.0 p -121.52 137.71 54.61 Favored 'General case' 0 C--N 1.326 -0.445 0 O-C-N 124.497 1.123 . . . . 0.0 110.424 179.98 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.448 ' O ' ' CD1' ' A' ' 19' ' ' TRP . 14.3 p -105.87 51.13 0.76 Allowed 'General case' 0 C--N 1.325 -0.487 0 O-C-N 124.511 1.132 . . . . 0.0 108.289 -179.967 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 6.0 t -59.1 -24.74 27.99 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 O-C-N 124.482 1.114 . . . . 0.0 109.312 179.994 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -83.91 -33.8 20.18 Favored Glycine 0 CA--C 1.53 0.969 0 O-C-N 124.45 1.093 . . . . 0.0 110.982 -179.992 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 126.27 13.96 3.09 Favored Glycine 0 CA--C 1.53 1.012 0 O-C-N 125.044 1.085 . . . . 0.0 111.031 177.78 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 28.8 m -149.91 163.64 37.54 Favored 'General case' 0 C--N 1.325 -0.483 0 O-C-N 124.509 0.77 . . . . 0.0 110.364 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . 0.409 ' SG ' ' O ' ' A' ' 16' ' ' THR . 90.2 m -120.55 143.13 48.75 Favored 'General case' 0 C--N 1.325 -0.475 0 O-C-N 124.481 1.113 . . . . 0.0 108.331 179.987 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 76.2 m-20 -89.96 -46.99 8.14 Favored 'General case' 0 C--N 1.325 -0.462 0 O-C-N 124.462 1.101 . . . . 0.0 109.287 -179.968 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' THR . . . . . 0.498 ' CG2' ' SG ' ' A' ' 15' ' ' CYS . 20.7 m -55.23 142.71 57.66 Favored Pre-proline 0 C--N 1.325 -0.489 0 O-C-N 124.524 1.14 . . . . 0.0 110.343 -179.958 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . 0.475 ' HD2' ' CG2' ' A' ' 12' ' ' THR . 20.3 Cg_endo -74.92 132.0 15.03 Favored 'Trans proline' 0 N--CA 1.453 -0.872 0 O-C-N 124.572 1.827 . . . . 0.0 111.028 -168.334 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 74.76 12.29 82.92 Favored Glycine 0 CA--C 1.53 1.011 0 O-C-N 124.478 1.111 . . . . 0.0 110.956 179.976 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.498 ' SG ' ' CG2' ' A' ' 12' ' ' THR . 69.6 m -95.52 126.02 40.52 Favored 'General case' 0 C--N 1.324 -0.507 0 N-CA-C 108.262 -1.014 . . . . 0.0 108.262 -179.986 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' THR . . . . . 0.409 ' O ' ' SG ' ' A' ' 10' ' ' CYS . 29.1 p -93.75 156.2 16.81 Favored 'General case' 0 C--N 1.325 -0.492 0 O-C-N 124.526 1.141 . . . . 0.0 110.387 179.999 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 51.6 t -81.34 94.06 6.69 Favored 'General case' 0 C--N 1.325 -0.498 0 O-C-N 124.531 1.144 . . . . 0.0 108.291 179.997 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' SER . . . . . 0.514 ' O ' ' C ' ' A' ' 19' ' ' TRP . 1.9 m -101.07 66.39 1.14 Allowed 'General case' 0 C--N 1.325 -0.488 0 O-C-N 124.552 1.157 . . . . 0.0 109.989 174.26 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' TRP . . . . . 0.531 ' CG ' ' HA ' ' A' ' 20' ' ' PRO . 0.0 OUTLIER -36.74 148.19 0.19 Allowed Pre-proline 0 C--N 1.325 -0.481 0 N-CA-C 107.964 -1.124 . . . . 0.0 107.964 -174.019 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . 0.531 ' HA ' ' CG ' ' A' ' 19' ' ' TRP . 18.2 Cg_endo -75.03 -11.87 24.19 Favored 'Cis proline' 0 C--N 1.361 1.192 0 C-N-CA 120.967 -2.514 . . . . 0.0 110.997 -8.474 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.487 ' O ' ' C ' ' A' ' 18' ' ' SER . 2.2 t -100.2 179.92 0.58 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 O-C-N 124.521 1.138 . . . . 0.0 109.285 -173.386 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 57.0 m -101.63 168.43 9.48 Favored 'General case' 0 C--N 1.325 -0.491 0 O-C-N 124.494 1.121 . . . . 0.0 108.312 179.987 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -145.25 165.06 29.47 Favored 'General case' 0 C--N 1.325 -0.476 0 O-C-N 124.558 1.161 . . . . 0.0 110.427 179.975 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . 0.462 ' HB3' ' CG2' ' A' ' 29' ' ' VAL . 1.3 ttt-85 -132.81 116.26 16.32 Favored 'General case' 0 C--N 1.324 -0.5 0 O-C-N 124.523 1.139 . . . . 0.0 110.327 -179.991 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 78.4 m-20 57.79 23.08 9.21 Favored 'General case' 0 C--N 1.324 -0.502 0 O-C-N 124.501 1.126 . . . . 0.0 109.291 179.996 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 84.78 23.51 49.54 Favored Glycine 0 CA--C 1.529 0.968 0 O-C-N 124.487 1.117 . . . . 0.0 111.012 -179.966 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 7.2 mt -142.46 129.93 11.26 Favored Pre-proline 0 C--N 1.325 -0.497 0 O-C-N 124.496 0.762 . . . . 0.0 109.288 -179.935 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 20.2 Cg_endo -74.98 89.59 1.15 Allowed 'Trans proline' 0 N--CA 1.453 -0.876 0 O-C-N 124.534 1.807 . . . . 0.0 110.987 -168.323 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.462 ' CG2' ' HB3' ' A' ' 24' ' ' ARG . 32.6 m . . . . . 0 C--N 1.325 -0.479 0 O-C-N 124.487 1.117 . . . . 0.0 109.276 179.997 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 32.9 m . . . . . 0 N--CA 1.453 -0.282 0 N-CA-C 108.28 -1.008 . . . . 0.0 108.28 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 88.54 -16.01 55.02 Favored Glycine 0 CA--C 1.531 1.044 0 O-C-N 124.503 1.127 . . . . 0.0 110.985 -179.992 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 16.4 tt0 -90.21 161.92 15.49 Favored 'General case' 0 C--N 1.325 -0.483 0 O-C-N 124.515 0.774 . . . . 0.0 110.329 179.982 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 37.3 p -122.67 135.99 54.75 Favored 'General case' 0 C--N 1.324 -0.518 0 O-C-N 124.481 1.113 . . . . 0.0 110.417 179.992 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.406 ' SG ' ' O ' ' A' ' 5' ' ' CYS . 15.3 p -102.65 53.04 0.79 Allowed 'General case' 0 C--N 1.325 -0.484 0 O-C-N 124.528 1.142 . . . . 0.0 108.281 -179.971 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 15.6 t -59.43 -24.51 28.41 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 O-C-N 124.471 1.107 . . . . 0.0 109.331 179.97 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -84.54 -30.96 25.79 Favored Glycine 0 CA--C 1.53 0.982 0 O-C-N 124.485 1.116 . . . . 0.0 110.992 179.97 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 122.6 13.26 4.74 Favored Glycine 0 CA--C 1.53 1.012 0 O-C-N 124.953 1.031 . . . . 0.0 110.979 178.611 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 5.9 m -150.14 158.76 44.5 Favored 'General case' 0 C--N 1.325 -0.497 0 O-C-N 124.512 0.772 . . . . 0.0 110.41 179.973 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . 0.403 ' SG ' ' O ' ' A' ' 16' ' ' THR . 97.2 m -114.3 141.58 47.41 Favored 'General case' 0 C--N 1.325 -0.461 0 O-C-N 124.491 1.12 . . . . 0.0 108.307 -179.971 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 64.3 t30 -89.83 -44.5 9.91 Favored 'General case' 0 C--N 1.325 -0.48 0 O-C-N 124.518 1.136 . . . . 0.0 109.284 -179.965 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' THR . . . . . 0.5 ' CG2' ' SG ' ' A' ' 15' ' ' CYS . 18.9 m -57.65 142.85 77.07 Favored Pre-proline 0 C--N 1.325 -0.472 0 O-C-N 124.487 1.117 . . . . 0.0 110.348 -179.987 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . 0.478 ' HD2' ' CG2' ' A' ' 12' ' ' THR . 20.3 Cg_endo -75.01 130.57 13.38 Favored 'Trans proline' 0 N--CA 1.452 -0.925 0 O-C-N 124.488 1.783 . . . . 0.0 111.026 -168.328 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 75.59 14.09 82.36 Favored Glycine 0 CA--C 1.531 1.034 0 O-C-N 124.518 1.136 . . . . 0.0 110.975 -179.989 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.5 ' SG ' ' CG2' ' A' ' 12' ' ' THR . 62.3 m -95.69 129.54 42.86 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 108.274 -1.01 . . . . 0.0 108.274 -179.971 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' THR . . . . . 0.403 ' O ' ' SG ' ' A' ' 10' ' ' CYS . 7.7 p -95.54 152.35 18.5 Favored 'General case' 0 C--N 1.325 -0.481 0 O-C-N 124.491 1.12 . . . . 0.0 110.388 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 45.6 t -81.67 94.92 7.06 Favored 'General case' 0 C--N 1.325 -0.497 0 O-C-N 124.515 1.134 . . . . 0.0 108.328 179.999 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' SER . . . . . 0.514 ' O ' ' C ' ' A' ' 19' ' ' TRP . 1.2 t -104.13 67.05 0.84 Allowed 'General case' 0 C--N 1.324 -0.504 0 O-C-N 124.551 1.157 . . . . 0.0 109.98 174.221 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' TRP . . . . . 0.564 ' CG ' ' HA ' ' A' ' 20' ' ' PRO . 0.1 OUTLIER -36.1 147.23 0.19 Allowed Pre-proline 0 C--N 1.325 -0.485 0 O-C-N 124.502 1.127 . . . . 0.0 108.011 -174.257 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . 0.564 ' HA ' ' CG ' ' A' ' 19' ' ' TRP . 18.1 Cg_endo -74.98 -14.0 23.26 Favored 'Cis proline' 0 C--N 1.36 1.136 0 C-N-CA 121.014 -2.494 . . . . 0.0 110.996 -8.659 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.484 ' O ' ' C ' ' A' ' 18' ' ' SER . 3.0 m -97.67 177.83 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.478 0 O-C-N 124.496 1.123 . . . . 0.0 109.294 -173.075 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 52.9 m -102.18 172.5 6.86 Favored 'General case' 0 C--N 1.325 -0.485 0 O-C-N 124.477 1.111 . . . . 0.0 108.317 179.98 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' THR . . . . . 0.486 ' CG2' ' CB ' ' A' ' 18' ' ' SER . 6.5 p -145.56 165.1 29.64 Favored 'General case' 0 C--N 1.324 -0.504 0 O-C-N 124.539 1.149 . . . . 0.0 110.416 -179.982 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . 0.463 ' HB3' ' CG2' ' A' ' 29' ' ' VAL . 0.1 OUTLIER -131.89 112.97 12.9 Favored 'General case' 0 C--N 1.325 -0.464 0 O-C-N 124.459 1.099 . . . . 0.0 110.293 179.986 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 2.6 m-80 57.12 22.96 7.99 Favored 'General case' 0 C--N 1.326 -0.451 0 O-C-N 124.498 1.124 . . . . 0.0 109.319 -179.986 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 86.15 25.3 37.56 Favored Glycine 0 CA--C 1.53 0.985 0 O-C-N 124.522 1.139 . . . . 0.0 111.016 -179.986 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 7.9 mt -143.37 130.01 10.48 Favored Pre-proline 0 C--N 1.325 -0.477 0 O-C-N 124.511 0.771 . . . . 0.0 109.3 179.983 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 20.2 Cg_endo -74.97 85.99 1.46 Allowed 'Trans proline' 0 N--CA 1.453 -0.891 0 O-C-N 124.55 1.816 . . . . 0.0 111.043 -168.34 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.463 ' CG2' ' HB3' ' A' ' 24' ' ' ARG . 21.6 m . . . . . 0 C--N 1.325 -0.469 0 O-C-N 124.512 1.133 . . . . 0.0 109.3 179.995 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 37.6 m . . . . . 0 N--CA 1.453 -0.304 0 N-CA-C 108.294 -1.002 . . . . 0.0 108.294 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 91.42 -21.64 34.21 Favored Glycine 0 CA--C 1.531 1.06 0 O-C-N 124.505 1.128 . . . . 0.0 110.999 179.989 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 16.0 tt0 -85.23 161.1 19.71 Favored 'General case' 0 C--N 1.325 -0.466 0 O-C-N 124.541 0.789 . . . . 0.0 110.274 -179.987 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 72.5 p -121.94 136.2 54.91 Favored 'General case' 0 C--N 1.325 -0.457 0 O-C-N 124.445 1.09 . . . . 0.0 110.455 179.996 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.426 ' O ' ' CD1' ' A' ' 19' ' ' TRP . 15.2 p -102.1 53.78 0.8 Allowed 'General case' 0 C--N 1.325 -0.493 0 O-C-N 124.573 1.17 . . . . 0.0 108.283 -179.978 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 4.7 t -59.5 -24.85 29.54 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 O-C-N 124.515 1.135 . . . . 0.0 109.302 -179.993 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -85.42 -32.97 18.11 Favored Glycine 0 CA--C 1.53 0.991 0 O-C-N 124.524 1.14 . . . . 0.0 110.978 -179.979 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 124.31 15.34 3.4 Favored Glycine 0 CA--C 1.53 0.983 0 O-C-N 125.021 1.071 . . . . 0.0 110.977 178.057 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 6.0 m -150.17 158.95 44.7 Favored 'General case' 0 C--N 1.325 -0.48 0 O-C-N 124.494 0.761 . . . . 0.0 110.397 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 74.9 m -117.8 141.75 48.07 Favored 'General case' 0 C--N 1.325 -0.476 0 O-C-N 124.496 1.123 . . . . 0.0 108.302 179.975 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 4.6 m120 -89.7 -47.62 7.81 Favored 'General case' 0 C--N 1.325 -0.475 0 O-C-N 124.498 1.124 . . . . 0.0 109.294 179.997 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' THR . . . . . 0.498 ' CG2' ' SG ' ' A' ' 15' ' ' CYS . 20.8 m -53.87 142.75 43.57 Favored Pre-proline 0 C--N 1.325 -0.479 0 O-C-N 124.442 1.089 . . . . 0.0 110.392 -179.975 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . 0.472 ' HD2' ' CG2' ' A' ' 12' ' ' THR . 20.2 Cg_endo -75.04 130.78 13.54 Favored 'Trans proline' 0 N--CA 1.453 -0.866 0 O-C-N 124.443 1.759 . . . . 0.0 110.928 -168.237 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 75.36 13.55 82.75 Favored Glycine 0 CA--C 1.53 0.986 0 O-C-N 124.497 1.123 . . . . 0.0 111.022 -179.978 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.498 ' SG ' ' CG2' ' A' ' 12' ' ' THR . 64.2 m -95.54 126.65 40.97 Favored 'General case' 0 C--N 1.325 -0.476 0 N-CA-C 108.316 -0.994 . . . . 0.0 108.316 -179.967 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 17.6 p -94.0 155.23 17.24 Favored 'General case' 0 C--N 1.325 -0.485 0 O-C-N 124.48 1.112 . . . . 0.0 110.437 179.991 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 43.4 t -83.4 94.27 7.94 Favored 'General case' 0 C--N 1.325 -0.48 0 O-C-N 124.482 1.114 . . . . 0.0 108.325 -179.965 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' SER . . . . . 0.518 ' O ' ' C ' ' A' ' 19' ' ' TRP . 47.9 t -102.53 66.67 0.98 Allowed 'General case' 0 C--N 1.325 -0.497 0 O-C-N 124.486 1.116 . . . . 0.0 109.971 174.166 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' TRP . . . . . 0.545 ' CG ' ' HA ' ' A' ' 20' ' ' PRO . 0.0 OUTLIER -36.0 147.3 0.18 Allowed Pre-proline 0 C--N 1.325 -0.485 0 O-C-N 124.483 1.114 . . . . 0.0 108.022 -174.167 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . 0.545 ' HA ' ' CG ' ' A' ' 19' ' ' TRP . 18.3 Cg_endo -74.94 -13.69 23.34 Favored 'Cis proline' 0 C--N 1.36 1.159 0 C-N-CA 121.006 -2.498 . . . . 0.0 111.038 -8.513 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.49 ' O ' ' C ' ' A' ' 18' ' ' SER . 1.1 p -98.42 177.75 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 O-C-N 124.512 1.132 . . . . 0.0 109.305 -173.083 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 56.6 m -102.1 170.52 8.05 Favored 'General case' 0 C--N 1.325 -0.472 0 O-C-N 124.502 1.126 . . . . 0.0 108.271 -179.983 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 1.1 p -144.98 164.86 29.86 Favored 'General case' 0 C--N 1.325 -0.466 0 O-C-N 124.561 1.163 . . . . 0.0 110.423 179.974 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . 0.463 ' HB3' ' CG2' ' A' ' 29' ' ' VAL . 7.5 ttt180 -132.87 116.91 17.08 Favored 'General case' 0 C--N 1.325 -0.488 0 O-C-N 124.476 1.11 . . . . 0.0 110.341 179.966 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 75.7 m-20 57.39 23.37 8.89 Favored 'General case' 0 C--N 1.325 -0.48 0 O-C-N 124.452 1.095 . . . . 0.0 109.278 -179.991 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 83.89 25.22 46.26 Favored Glycine 0 CA--C 1.53 1.004 0 O-C-N 124.453 1.096 . . . . 0.0 110.995 -179.982 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 10.0 mt -144.22 131.19 10.31 Favored Pre-proline 0 C--N 1.325 -0.492 0 O-C-N 124.516 0.774 . . . . 0.0 109.268 179.995 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 20.1 Cg_endo -74.97 89.08 1.18 Allowed 'Trans proline' 0 N--CA 1.453 -0.872 0 O-C-N 124.462 1.77 . . . . 0.0 110.986 -168.308 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.463 ' CG2' ' HB3' ' A' ' 24' ' ' ARG . 33.5 m . . . . . 0 C--N 1.325 -0.485 0 O-C-N 124.443 1.09 . . . . 0.0 109.327 179.99 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 52.7 m . . . . . 0 N--CA 1.453 -0.279 0 N-CA-C 108.32 -0.993 . . . . 0.0 108.32 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 100.81 -10.16 58.75 Favored Glycine 0 CA--C 1.53 0.995 0 O-C-N 124.527 1.142 . . . . 0.0 110.997 -179.976 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 14.6 tt0 -99.17 162.77 12.87 Favored 'General case' 0 C--N 1.325 -0.484 0 O-C-N 124.51 0.77 . . . . 0.0 110.262 -179.96 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 80.9 p -120.12 138.09 53.77 Favored 'General case' 0 C--N 1.326 -0.446 0 O-C-N 124.541 1.151 . . . . 0.0 110.395 179.945 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.431 ' O ' ' CD1' ' A' ' 19' ' ' TRP . 14.5 p -107.72 51.26 0.75 Allowed 'General case' 0 C--N 1.325 -0.482 0 O-C-N 124.515 1.134 . . . . 0.0 108.301 179.999 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 15.0 t -59.15 -23.89 25.86 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.468 0 O-C-N 124.461 1.101 . . . . 0.0 109.28 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -85.68 -34.07 14.5 Favored Glycine 0 CA--C 1.53 1.025 0 O-C-N 124.523 1.139 . . . . 0.0 111.019 179.981 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 126.19 17.57 2.44 Favored Glycine 0 C--N 1.344 0.993 0 O-C-N 125.223 1.19 . . . . 0.0 111.003 177.32 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -150.34 166.02 31.29 Favored 'General case' 0 C--N 1.325 -0.488 0 O-C-N 124.534 0.785 . . . . 0.0 110.377 -179.987 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . 0.41 ' SG ' ' O ' ' A' ' 16' ' ' THR . 80.1 m -125.97 142.76 51.38 Favored 'General case' 0 C--N 1.325 -0.468 0 O-C-N 124.485 1.116 . . . . 0.0 108.285 179.996 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 4.3 m-20 -89.99 -48.3 7.3 Favored 'General case' 0 C--N 1.324 -0.514 0 O-C-N 124.489 1.118 . . . . 0.0 109.286 -179.992 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' THR . . . . . 0.504 ' CG2' ' SG ' ' A' ' 15' ' ' CYS . 18.9 m -53.04 142.78 34.79 Favored Pre-proline 0 C--N 1.326 -0.453 0 O-C-N 124.497 1.123 . . . . 0.0 110.417 179.971 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . 0.476 ' HD2' ' CG2' ' A' ' 12' ' ' THR . 20.1 Cg_endo -75.01 131.39 14.22 Favored 'Trans proline' 0 N--CA 1.453 -0.906 0 O-C-N 124.495 1.787 . . . . 0.0 110.969 -168.3 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 74.2 15.11 80.15 Favored Glycine 0 CA--C 1.53 0.999 0 O-C-N 124.46 1.1 . . . . 0.0 110.984 179.965 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.504 ' SG ' ' CG2' ' A' ' 12' ' ' THR . 63.7 m -97.47 125.93 42.44 Favored 'General case' 0 C--N 1.325 -0.483 0 N-CA-C 108.285 -1.006 . . . . 0.0 108.285 179.996 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' THR . . . . . 0.41 ' O ' ' SG ' ' A' ' 10' ' ' CYS . 18.6 p -94.11 158.61 15.53 Favored 'General case' 0 C--N 1.324 -0.504 0 O-C-N 124.489 1.118 . . . . 0.0 110.393 -179.993 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 42.4 t -81.72 94.11 6.93 Favored 'General case' 0 C--N 1.325 -0.473 0 O-C-N 124.467 1.104 . . . . 0.0 108.334 179.951 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' SER . . . . . 0.517 ' O ' ' C ' ' A' ' 19' ' ' TRP . 2.5 t -100.98 65.57 1.11 Allowed 'General case' 0 C--N 1.325 -0.457 0 O-C-N 124.475 1.109 . . . . 0.0 109.989 174.214 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' TRP . . . . . 0.525 ' CG ' ' HA ' ' A' ' 20' ' ' PRO . 0.0 OUTLIER -36.64 148.04 0.19 Allowed Pre-proline 0 C--N 1.324 -0.507 0 O-C-N 124.489 1.118 . . . . 0.0 108.0 -174.067 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . 0.525 ' HA ' ' CG ' ' A' ' 19' ' ' TRP . 18.1 Cg_endo -75.02 -11.49 24.25 Favored 'Cis proline' 0 C--N 1.361 1.186 0 C-N-CA 121.017 -2.493 . . . . 0.0 110.97 -8.309 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.502 ' O ' ' C ' ' A' ' 18' ' ' SER . 3.2 p -100.5 -179.6 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 O-C-N 124.499 1.124 . . . . 0.0 109.291 -173.528 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 60.4 m -101.67 167.01 10.39 Favored 'General case' 0 C--N 1.326 -0.456 0 O-C-N 124.526 1.141 . . . . 0.0 108.316 179.999 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' THR . . . . . 0.466 ' CG2' ' CB ' ' A' ' 18' ' ' SER . 0.8 OUTLIER -144.45 165.7 27.22 Favored 'General case' 0 C--N 1.324 -0.517 0 O-C-N 124.487 1.117 . . . . 0.0 110.412 179.958 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . 0.426 ' HB3' ' CG2' ' A' ' 29' ' ' VAL . 15.0 ttt180 -135.18 120.2 18.67 Favored 'General case' 0 C--N 1.325 -0.495 0 O-C-N 124.542 1.151 . . . . 0.0 110.293 -179.958 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 28.5 t-20 56.46 25.42 9.64 Favored 'General case' 0 C--N 1.324 -0.5 0 O-C-N 124.493 1.121 . . . . 0.0 109.296 179.977 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 79.41 27.93 53.78 Favored Glycine 0 CA--C 1.529 0.966 0 O-C-N 124.457 1.098 . . . . 0.0 111.021 179.999 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 40.1 mt -146.8 132.49 9.32 Favored Pre-proline 0 C--N 1.325 -0.469 0 O-C-N 124.47 0.747 . . . . 0.0 109.26 -179.986 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 20.1 Cg_endo -74.99 87.52 1.32 Allowed 'Trans proline' 0 N--CA 1.453 -0.895 0 O-C-N 124.543 1.812 . . . . 0.0 110.968 -168.319 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.426 ' CG2' ' HB3' ' A' ' 24' ' ' ARG . 18.2 m . . . . . 0 C--N 1.325 -0.465 0 O-C-N 124.532 1.145 . . . . 0.0 109.287 179.993 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 72.9 m . . . . . 0 N--CA 1.452 -0.336 0 N-CA-C 108.332 -0.988 . . . . 0.0 108.332 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 83.42 -10.96 57.67 Favored Glycine 0 CA--C 1.53 0.981 0 O-C-N 124.551 1.157 . . . . 0.0 110.988 179.981 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 7.7 pt-20 -100.28 171.59 7.68 Favored 'General case' 0 C--N 1.325 -0.46 0 O-C-N 124.493 0.76 . . . . 0.0 110.346 179.994 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.45 ' CG2' HG23 ' A' ' 21' ' ' VAL . 67.8 p -129.62 145.1 51.52 Favored 'General case' 0 C--N 1.325 -0.486 0 O-C-N 124.469 1.106 . . . . 0.0 110.455 179.997 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.429 ' O ' ' CD1' ' A' ' 19' ' ' TRP . 22.6 p -107.35 56.41 0.64 Allowed 'General case' 0 C--N 1.324 -0.524 0 O-C-N 124.52 1.138 . . . . 0.0 108.292 -179.95 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.4 t -59.45 -24.87 29.46 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 O-C-N 124.508 1.13 . . . . 0.0 109.284 -179.956 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -84.85 -35.1 13.55 Favored Glycine 0 CA--C 1.53 1.009 0 O-C-N 124.509 1.13 . . . . 0.0 110.981 -179.986 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 125.48 17.22 2.67 Favored Glycine 0 C--N 1.344 1.025 0 O-C-N 125.055 1.091 . . . . 0.0 111.047 177.698 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 2.4 m -150.33 155.62 39.99 Favored 'General case' 0 C--N 1.326 -0.45 0 O-C-N 124.484 0.755 . . . . 0.0 110.436 179.969 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 94.5 m -110.89 140.56 45.26 Favored 'General case' 0 C--N 1.325 -0.477 0 O-C-N 124.501 1.126 . . . . 0.0 108.268 -179.969 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 30.5 m-20 -90.01 -38.74 13.41 Favored 'General case' 0 C--N 1.325 -0.477 0 O-C-N 124.47 1.106 . . . . 0.0 109.306 -179.999 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' THR . . . . . 0.491 ' CG2' ' SG ' ' A' ' 15' ' ' CYS . 15.6 m -65.58 143.25 98.58 Favored Pre-proline 0 C--N 1.325 -0.474 0 O-C-N 124.521 1.138 . . . . 0.0 110.43 179.988 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . 0.483 ' HD2' ' CG2' ' A' ' 12' ' ' THR . 20.3 Cg_endo -74.92 131.05 13.96 Favored 'Trans proline' 0 N--CA 1.453 -0.894 0 O-C-N 124.496 1.787 . . . . 0.0 110.976 -168.302 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 75.04 15.13 81.25 Favored Glycine 0 CA--C 1.53 1.02 0 O-C-N 124.504 1.128 . . . . 0.0 110.97 179.963 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.491 ' SG ' ' CG2' ' A' ' 12' ' ' THR . 64.3 m -98.1 127.61 44.14 Favored 'General case' 0 C--N 1.325 -0.464 0 N-CA-C 108.308 -0.997 . . . . 0.0 108.308 179.971 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 71.0 p -94.28 152.25 18.81 Favored 'General case' 0 C--N 1.325 -0.484 0 O-C-N 124.48 1.112 . . . . 0.0 110.44 179.97 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 47.4 t -78.18 98.09 5.72 Favored 'General case' 0 C--N 1.325 -0.492 0 O-C-N 124.479 1.112 . . . . 0.0 108.243 -179.951 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' SER . . . . . 0.509 ' O ' ' C ' ' A' ' 19' ' ' TRP . 10.8 t -104.78 65.89 0.76 Allowed 'General case' 0 C--N 1.324 -0.51 0 O-C-N 124.553 1.158 . . . . 0.0 109.958 174.442 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' TRP . . . . . 0.542 ' CG ' ' HA ' ' A' ' 20' ' ' PRO . 0.0 OUTLIER -36.88 147.87 0.2 Allowed Pre-proline 0 C--N 1.325 -0.489 0 O-C-N 124.505 1.128 . . . . 0.0 107.99 -174.18 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . 0.542 ' HA ' ' CG ' ' A' ' 19' ' ' TRP . 18.1 Cg_endo -75.04 -12.57 24.07 Favored 'Cis proline' 0 C--N 1.36 1.144 0 C-N-CA 120.974 -2.511 . . . . 0.0 110.957 -8.505 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.488 ' O ' ' C ' ' A' ' 18' ' ' SER . 4.4 p -98.09 178.85 0.6 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 O-C-N 124.521 1.138 . . . . 0.0 109.289 -173.628 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . 0.402 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 1.7 m -101.95 168.51 9.36 Favored 'General case' 0 C--N 1.325 -0.477 0 O-C-N 124.49 1.119 . . . . 0.0 108.348 -179.993 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -145.34 168.31 20.8 Favored 'General case' 0 C--N 1.325 -0.488 0 O-C-N 124.486 1.116 . . . . 0.0 110.399 -179.976 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . 0.468 ' HB3' ' CG2' ' A' ' 29' ' ' VAL . 29.3 ttt-85 -144.64 119.39 9.85 Favored 'General case' 0 C--N 1.324 -0.506 0 O-C-N 124.514 1.133 . . . . 0.0 110.332 -179.979 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 17.9 t-20 57.42 23.28 8.84 Favored 'General case' 0 C--N 1.325 -0.491 0 O-C-N 124.506 1.129 . . . . 0.0 109.293 -179.997 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 83.44 24.27 51.37 Favored Glycine 0 CA--C 1.53 0.974 0 O-C-N 124.514 1.134 . . . . 0.0 111.027 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 19.1 mt -147.3 128.27 7.09 Favored Pre-proline 0 C--N 1.325 -0.463 0 O-C-N 124.464 0.744 . . . . 0.0 109.325 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 20.2 Cg_endo -74.97 80.96 2.31 Favored 'Trans proline' 0 N--CA 1.453 -0.891 0 O-C-N 124.474 1.776 . . . . 0.0 110.972 -168.271 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.468 ' CG2' ' HB3' ' A' ' 24' ' ' ARG . 17.6 m . . . . . 0 C--N 1.325 -0.46 0 O-C-N 124.482 1.114 . . . . 0.0 109.289 -179.982 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 80.8 m . . . . . 0 N--CA 1.453 -0.319 0 N-CA-C 108.317 -0.994 . . . . 0.0 108.317 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 82.75 -10.69 55.96 Favored Glycine 0 CA--C 1.53 0.992 0 O-C-N 124.525 1.141 . . . . 0.0 111.042 -179.993 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 7.6 pt-20 -100.28 171.87 7.51 Favored 'General case' 0 C--N 1.325 -0.478 0 O-C-N 124.497 0.763 . . . . 0.0 110.288 179.98 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 46.1 p -128.92 144.36 51.16 Favored 'General case' 0 C--N 1.326 -0.452 0 O-C-N 124.463 1.102 . . . . 0.0 110.394 179.965 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.526 ' O ' ' CD1' ' A' ' 19' ' ' TRP . 15.1 p -103.08 52.39 0.78 Allowed 'General case' 0 C--N 1.325 -0.472 0 O-C-N 124.505 1.128 . . . . 0.0 108.291 -179.984 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.8 t -59.26 -25.01 29.26 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 O-C-N 124.502 1.127 . . . . 0.0 109.328 -179.986 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -84.63 -32.91 20.68 Favored Glycine 0 CA--C 1.529 0.966 0 O-C-N 124.522 1.138 . . . . 0.0 110.982 179.988 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 124.4 14.63 3.55 Favored Glycine 0 CA--C 1.531 1.049 0 O-C-N 124.892 0.995 . . . . 0.0 110.97 177.996 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 49.1 m -150.29 165.15 33.88 Favored 'General case' 0 C--N 1.325 -0.468 0 O-C-N 124.483 0.755 . . . . 0.0 110.374 -180.0 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 98.4 m -118.37 141.4 48.57 Favored 'General case' 0 C--N 1.326 -0.449 0 O-C-N 124.458 1.099 . . . . 0.0 108.272 -179.989 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 47.2 t30 -89.89 -39.84 12.79 Favored 'General case' 0 C--N 1.325 -0.467 0 O-C-N 124.51 1.131 . . . . 0.0 109.33 179.973 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' THR . . . . . 0.498 ' CG2' ' SG ' ' A' ' 15' ' ' CYS . 16.9 m -64.68 143.02 98.64 Favored Pre-proline 0 C--N 1.325 -0.472 0 O-C-N 124.495 1.122 . . . . 0.0 110.377 -179.993 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . 0.48 ' HD2' ' CG2' ' A' ' 12' ' ' THR . 20.1 Cg_endo -75.01 130.65 13.46 Favored 'Trans proline' 0 N--CA 1.453 -0.875 0 O-C-N 124.502 1.791 . . . . 0.0 110.955 -168.298 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 76.22 12.82 83.85 Favored Glycine 0 CA--C 1.53 0.979 0 O-C-N 124.514 1.134 . . . . 0.0 111.02 -179.987 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.498 ' SG ' ' CG2' ' A' ' 12' ' ' THR . 64.9 m -95.7 127.48 41.76 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 108.318 -0.993 . . . . 0.0 108.318 179.964 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 29.9 p -94.5 150.16 20.53 Favored 'General case' 0 C--N 1.325 -0.472 0 O-C-N 124.456 1.098 . . . . 0.0 110.466 179.958 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 37.5 t -76.96 96.18 4.31 Favored 'General case' 0 C--N 1.324 -0.523 0 O-C-N 124.557 1.161 . . . . 0.0 108.283 179.988 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' SER . . . . . 0.51 ' O ' ' C ' ' A' ' 19' ' ' TRP . 1.8 m -102.31 65.51 0.95 Allowed 'General case' 0 C--N 1.325 -0.482 0 O-C-N 124.506 1.128 . . . . 0.0 110.003 174.326 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' TRP . . . . . 0.54 ' CG ' ' HA ' ' A' ' 20' ' ' PRO . 0.0 OUTLIER -36.71 148.05 0.19 Allowed Pre-proline 0 C--N 1.325 -0.498 0 O-C-N 124.525 1.141 . . . . 0.0 108.008 -173.995 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . 0.54 ' HA ' ' CG ' ' A' ' 19' ' ' TRP . 18.5 Cg_endo -74.93 -12.53 23.78 Favored 'Cis proline' 0 C--N 1.36 1.149 0 C-N-CA 121.03 -2.487 . . . . 0.0 111.015 -8.509 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.487 ' O ' ' C ' ' A' ' 18' ' ' SER . 5.8 p -98.87 177.38 0.69 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 O-C-N 124.475 1.11 . . . . 0.0 109.324 -173.279 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . 0.404 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 1.8 m -102.07 169.74 8.56 Favored 'General case' 0 C--N 1.324 -0.507 0 O-C-N 124.521 1.138 . . . . 0.0 108.314 179.973 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -149.5 165.05 33.35 Favored 'General case' 0 C--N 1.324 -0.518 0 O-C-N 124.49 1.119 . . . . 0.0 110.429 -179.931 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . 0.461 ' HB3' ' CG2' ' A' ' 29' ' ' VAL . 10.9 ttt85 -141.22 119.68 12.32 Favored 'General case' 0 C--N 1.325 -0.488 0 O-C-N 124.49 1.119 . . . . 0.0 110.289 179.952 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . 0.405 ' O ' ' OD1' ' A' ' 25' ' ' ASN . 16.5 t-20 57.58 22.71 8.47 Favored 'General case' 0 C--N 1.325 -0.488 0 O-C-N 124.534 1.146 . . . . 0.0 109.329 -179.965 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 83.9 23.93 50.85 Favored Glycine 0 CA--C 1.53 0.997 0 O-C-N 124.533 1.146 . . . . 0.0 110.975 179.978 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 13.8 mt -145.93 128.37 7.94 Favored Pre-proline 0 C--N 1.325 -0.48 0 O-C-N 124.551 0.795 . . . . 0.0 109.281 179.976 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 20.3 Cg_endo -74.98 77.42 3.13 Favored 'Trans proline' 0 N--CA 1.453 -0.892 0 O-C-N 124.503 1.791 . . . . 0.0 111.014 -168.327 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.461 ' CG2' ' HB3' ' A' ' 24' ' ' ARG . 36.0 m . . . . . 0 C--N 1.325 -0.458 0 O-C-N 124.527 1.142 . . . . 0.0 109.259 -179.994 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 87.2 m . . . . . 0 N--CA 1.452 -0.33 0 N-CA-C 108.322 -0.992 . . . . 0.0 108.322 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 91.31 -15.27 61.6 Favored Glycine 0 CA--C 1.53 1.023 0 O-C-N 124.504 1.127 . . . . 0.0 110.98 179.996 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 15.2 tt0 -88.3 162.25 16.7 Favored 'General case' 0 C--N 1.324 -0.509 0 O-C-N 124.534 0.785 . . . . 0.0 110.291 179.98 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 47.7 p -120.73 131.83 54.73 Favored 'General case' 0 C--N 1.325 -0.484 0 O-C-N 124.456 1.098 . . . . 0.0 110.389 -179.993 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.417 ' SG ' ' O ' ' A' ' 5' ' ' CYS . 14.6 p -100.11 52.08 0.9 Allowed 'General case' 0 C--N 1.325 -0.46 0 O-C-N 124.502 1.126 . . . . 0.0 108.316 179.963 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 11.9 t -59.27 -24.84 28.8 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 O-C-N 124.496 1.123 . . . . 0.0 109.318 179.951 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -84.54 -32.0 23.19 Favored Glycine 0 CA--C 1.53 0.983 0 O-C-N 124.503 1.127 . . . . 0.0 111.008 -179.945 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 123.84 15.91 3.44 Favored Glycine 0 CA--C 1.53 0.992 0 O-C-N 124.896 0.998 . . . . 0.0 110.996 178.112 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 62.2 m -150.11 165.57 32.41 Favored 'General case' 0 C--N 1.325 -0.476 0 O-C-N 124.508 0.769 . . . . 0.0 110.413 179.975 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . 0.405 ' SG ' ' O ' ' A' ' 16' ' ' THR . 96.9 m -122.15 143.45 49.55 Favored 'General case' 0 C--N 1.325 -0.464 0 O-C-N 124.512 1.133 . . . . 0.0 108.295 179.999 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 12.0 m-20 -90.11 -47.03 8.07 Favored 'General case' 0 C--N 1.324 -0.511 0 O-C-N 124.505 1.128 . . . . 0.0 109.26 -179.984 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' THR . . . . . 0.504 ' CG2' ' SG ' ' A' ' 15' ' ' CYS . 20.9 m -54.6 142.68 51.54 Favored Pre-proline 0 C--N 1.325 -0.461 0 O-C-N 124.462 1.101 . . . . 0.0 110.431 179.985 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . 0.476 ' HD2' ' CG2' ' A' ' 12' ' ' THR . 20.1 Cg_endo -74.99 131.36 14.21 Favored 'Trans proline' 0 N--CA 1.453 -0.867 0 O-C-N 124.531 1.806 . . . . 0.0 110.977 -168.295 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 74.69 14.91 80.94 Favored Glycine 0 CA--C 1.53 1.028 0 O-C-N 124.495 1.122 . . . . 0.0 111.024 179.989 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.504 ' SG ' ' CG2' ' A' ' 12' ' ' THR . 63.9 m -96.08 134.58 38.95 Favored 'General case' 0 C--N 1.325 -0.483 0 N-CA-C 108.297 -1.001 . . . . 0.0 108.297 179.987 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' THR . . . . . 0.405 ' O ' ' SG ' ' A' ' 10' ' ' CYS . 82.7 p -101.11 152.97 19.98 Favored 'General case' 0 C--N 1.325 -0.466 0 O-C-N 124.445 1.091 . . . . 0.0 110.401 179.975 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 41.3 t -79.71 94.41 5.72 Favored 'General case' 0 C--N 1.325 -0.481 0 O-C-N 124.52 1.138 . . . . 0.0 108.363 179.942 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' SER . . . . . 0.517 ' O ' ' C ' ' A' ' 19' ' ' TRP . 17.5 t -101.45 65.48 1.05 Allowed 'General case' 0 C--N 1.325 -0.488 0 O-C-N 124.456 1.097 . . . . 0.0 110.002 174.236 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' TRP . . . . . 0.563 ' CG ' ' HA ' ' A' ' 20' ' ' PRO . 0.1 OUTLIER -36.14 147.01 0.19 Allowed Pre-proline 0 C--N 1.325 -0.477 0 O-C-N 124.515 1.134 . . . . 0.0 107.997 -174.129 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . 0.563 ' HA ' ' CG ' ' A' ' 19' ' ' TRP . 18.2 Cg_endo -74.97 -13.76 23.37 Favored 'Cis proline' 0 C--N 1.36 1.166 0 C-N-CA 121.009 -2.496 . . . . 0.0 111.003 -8.557 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.485 ' O ' ' C ' ' A' ' 18' ' ' SER . 0.9 OUTLIER -97.35 178.04 0.63 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 O-C-N 124.449 1.093 . . . . 0.0 109.29 -173.148 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 36.8 m -101.72 170.48 8.14 Favored 'General case' 0 C--N 1.325 -0.461 0 O-C-N 124.549 1.156 . . . . 0.0 108.289 -179.991 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -146.88 166.81 25.61 Favored 'General case' 0 C--N 1.325 -0.487 0 O-C-N 124.483 1.115 . . . . 0.0 110.404 179.985 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . 0.462 ' HB3' ' CG2' ' A' ' 29' ' ' VAL . 2.5 ttt180 -139.05 119.28 13.61 Favored 'General case' 0 C--N 1.325 -0.487 0 O-C-N 124.514 1.134 . . . . 0.0 110.327 179.995 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 81.1 m-20 57.16 22.99 8.08 Favored 'General case' 0 C--N 1.325 -0.478 0 O-C-N 124.515 1.134 . . . . 0.0 109.333 -179.973 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 83.7 25.58 45.64 Favored Glycine 0 CA--C 1.53 0.997 0 O-C-N 124.519 1.137 . . . . 0.0 110.968 179.949 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 12.9 mt -145.57 130.38 9.01 Favored Pre-proline 0 C--N 1.325 -0.488 0 O-C-N 124.457 0.739 . . . . 0.0 109.309 179.991 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 20.1 Cg_endo -75.01 82.48 2.0 Allowed 'Trans proline' 0 N--CA 1.453 -0.91 0 O-C-N 124.505 1.792 . . . . 0.0 110.955 -168.309 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.462 ' CG2' ' HB3' ' A' ' 24' ' ' ARG . 28.2 m . . . . . 0 C--N 1.325 -0.465 0 O-C-N 124.528 1.142 . . . . 0.0 109.346 179.951 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 93.5 m . . . . . 0 N--CA 1.453 -0.287 0 N-CA-C 108.32 -0.993 . . . . 0.0 108.32 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 95.54 -15.2 63.66 Favored Glycine 0 CA--C 1.53 1.03 0 O-C-N 124.486 1.116 . . . . 0.0 110.995 179.987 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 15.1 tt0 -86.4 161.82 18.47 Favored 'General case' 0 C--N 1.325 -0.459 0 O-C-N 124.504 0.767 . . . . 0.0 110.287 -179.992 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 48.0 p -119.03 132.23 56.03 Favored 'General case' 0 C--N 1.324 -0.508 0 O-C-N 124.505 1.128 . . . . 0.0 110.406 179.987 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.427 ' O ' ' CD1' ' A' ' 19' ' ' TRP . 14.3 p -102.18 51.29 0.82 Allowed 'General case' 0 C--N 1.324 -0.509 0 O-C-N 124.531 1.144 . . . . 0.0 108.295 -179.965 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 6.6 t -59.27 -24.5 27.89 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 O-C-N 124.458 1.099 . . . . 0.0 109.289 -179.97 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -85.52 -34.31 14.25 Favored Glycine 0 CA--C 1.53 0.976 0 O-C-N 124.503 1.127 . . . . 0.0 111.041 -180.0 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 125.1 16.75 2.86 Favored Glycine 0 CA--C 1.53 1.0 0 O-C-N 124.945 1.026 . . . . 0.0 111.043 177.818 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 2.6 m -150.21 157.92 43.6 Favored 'General case' 0 C--N 1.325 -0.473 0 O-C-N 124.533 0.784 . . . . 0.0 110.414 -179.963 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . 0.411 ' SG ' ' O ' ' A' ' 16' ' ' THR . 84.0 m -118.59 144.56 46.03 Favored 'General case' 0 C--N 1.325 -0.471 0 O-C-N 124.487 1.117 . . . . 0.0 108.313 179.989 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 76.1 m-20 -89.86 -51.78 5.32 Favored 'General case' 0 C--N 1.325 -0.481 0 O-C-N 124.512 1.133 . . . . 0.0 109.314 179.977 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' THR . . . . . 0.505 ' CG2' ' SG ' ' A' ' 15' ' ' CYS . 22.0 m -49.72 142.58 12.19 Favored Pre-proline 0 C--N 1.325 -0.49 0 O-C-N 124.551 1.157 . . . . 0.0 110.405 179.982 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . 0.473 ' HD2' ' CG2' ' A' ' 12' ' ' THR . 20.2 Cg_endo -74.99 131.7 14.59 Favored 'Trans proline' 0 N--CA 1.452 -0.947 0 O-C-N 124.45 1.763 . . . . 0.0 111.011 -168.267 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 74.36 13.78 81.31 Favored Glycine 0 CA--C 1.53 1.022 0 O-C-N 124.49 1.118 . . . . 0.0 111.009 -179.978 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.505 ' SG ' ' CG2' ' A' ' 12' ' ' THR . 67.4 m -96.31 126.18 41.34 Favored 'General case' 0 C--N 1.324 -0.504 0 N-CA-C 108.336 -0.987 . . . . 0.0 108.336 179.971 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' THR . . . . . 0.411 ' O ' ' SG ' ' A' ' 10' ' ' CYS . 30.8 p -94.24 158.32 15.65 Favored 'General case' 0 C--N 1.325 -0.481 0 O-C-N 124.482 1.114 . . . . 0.0 110.387 -180.0 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 42.4 t -82.37 94.99 7.5 Favored 'General case' 0 C--N 1.325 -0.484 0 O-C-N 124.524 1.14 . . . . 0.0 108.339 179.968 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' SER . . . . . 0.515 ' O ' ' C ' ' A' ' 19' ' ' TRP . 3.0 t -100.54 65.57 1.19 Allowed 'General case' 0 C--N 1.325 -0.463 0 O-C-N 124.526 1.141 . . . . 0.0 109.993 174.198 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' TRP . . . . . 0.532 ' CG ' ' HA ' ' A' ' 20' ' ' PRO . 0.0 OUTLIER -36.73 147.47 0.2 Allowed Pre-proline 0 C--N 1.325 -0.484 0 N-CA-C 107.958 -1.127 . . . . 0.0 107.958 -173.93 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . 0.532 ' HA ' ' CG ' ' A' ' 19' ' ' TRP . 18.2 Cg_endo -75.04 -12.83 23.99 Favored 'Cis proline' 0 C--N 1.36 1.184 0 C-N-CA 120.968 -2.513 . . . . 0.0 111.003 -8.478 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.492 ' O ' ' C ' ' A' ' 18' ' ' SER . 16.3 m -98.05 179.24 0.58 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.494 0 O-C-N 124.514 1.134 . . . . 0.0 109.293 -173.478 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 51.9 m -101.77 168.08 9.68 Favored 'General case' 0 C--N 1.325 -0.488 0 O-C-N 124.54 1.15 . . . . 0.0 108.311 179.979 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' THR . . . . . 0.447 ' OG1' ' CB ' ' A' ' 18' ' ' SER . 0.8 OUTLIER -146.97 168.06 22.44 Favored 'General case' 0 C--N 1.325 -0.458 0 O-C-N 124.515 1.135 . . . . 0.0 110.382 179.999 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . 0.465 ' HB3' ' CG2' ' A' ' 29' ' ' VAL . 0.3 OUTLIER -141.54 119.69 12.12 Favored 'General case' 0 C--N 1.325 -0.468 0 O-C-N 124.506 1.128 . . . . 0.0 110.279 179.993 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 17.5 t-20 57.84 23.07 9.27 Favored 'General case' 0 C--N 1.326 -0.455 0 O-C-N 124.479 1.112 . . . . 0.0 109.303 179.967 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 82.43 23.34 56.78 Favored Glycine 0 CA--C 1.53 1.019 0 O-C-N 124.467 1.104 . . . . 0.0 110.976 179.992 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 11.9 mt -143.53 129.62 10.19 Favored Pre-proline 0 C--N 1.325 -0.498 0 O-C-N 124.461 0.742 . . . . 0.0 109.331 -179.997 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 20.5 Cg_endo -74.92 82.53 1.97 Allowed 'Trans proline' 0 N--CA 1.453 -0.861 0 O-C-N 124.516 1.798 . . . . 0.0 111.031 -168.343 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.465 ' CG2' ' HB3' ' A' ' 24' ' ' ARG . 27.4 m . . . . . 0 C--N 1.325 -0.484 0 O-C-N 124.489 1.118 . . . . 0.0 109.343 179.982 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 69.1 m . . . . . 0 N--CA 1.452 -0.328 0 N-CA-C 108.276 -1.009 . . . . 0.0 108.276 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 93.89 -15.7 62.51 Favored Glycine 0 CA--C 1.53 1.004 0 O-C-N 124.524 1.14 . . . . 0.0 110.995 179.97 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 15.5 tt0 -86.75 162.53 17.8 Favored 'General case' 0 C--N 1.326 -0.446 0 O-C-N 124.474 0.749 . . . . 0.0 110.322 -179.971 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 65.9 p -120.16 132.97 55.59 Favored 'General case' 0 C--N 1.325 -0.486 0 O-C-N 124.452 1.095 . . . . 0.0 110.398 179.961 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.425 ' SG ' ' O ' ' A' ' 5' ' ' CYS . 13.8 p -102.44 49.96 0.84 Allowed 'General case' 0 C--N 1.325 -0.457 0 O-C-N 124.449 1.093 . . . . 0.0 108.279 -179.981 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 15.1 t -59.09 -24.0 25.97 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 O-C-N 124.562 1.164 . . . . 0.0 109.351 179.947 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -83.61 -33.67 21.45 Favored Glycine 0 CA--C 1.53 1.0 0 O-C-N 124.488 1.118 . . . . 0.0 111.033 179.972 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 126.88 10.85 3.74 Favored Glycine 0 C--N 1.345 1.074 0 C-N-CA 119.774 -1.203 . . . . 0.0 110.989 177.917 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -149.92 166.96 28.0 Favored 'General case' 0 C--N 1.325 -0.496 0 O-C-N 124.522 0.778 . . . . 0.0 110.416 -179.994 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . 0.412 ' SG ' ' O ' ' A' ' 16' ' ' THR . 80.2 m -121.8 146.37 47.14 Favored 'General case' 0 C--N 1.325 -0.469 0 O-C-N 124.484 1.115 . . . . 0.0 108.293 179.996 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 22.2 t30 -92.41 -44.17 8.83 Favored 'General case' 0 C--N 1.325 -0.479 0 O-C-N 124.518 1.136 . . . . 0.0 109.306 -179.995 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' THR . . . . . 0.5 ' CG2' ' SG ' ' A' ' 15' ' ' CYS . 18.4 m -57.75 142.89 77.62 Favored Pre-proline 0 C--N 1.324 -0.506 0 O-C-N 124.495 1.122 . . . . 0.0 110.391 179.976 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . 0.475 ' HD2' ' CG2' ' A' ' 12' ' ' THR . 20.3 Cg_endo -74.96 131.68 14.62 Favored 'Trans proline' 0 N--CA 1.453 -0.879 0 O-C-N 124.533 1.807 . . . . 0.0 111.003 -168.335 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 76.42 7.23 85.08 Favored Glycine 0 CA--C 1.53 0.985 0 O-C-N 124.428 1.08 . . . . 0.0 111.007 179.985 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.5 ' SG ' ' CG2' ' A' ' 12' ' ' THR . 69.2 m -92.14 126.28 37.16 Favored 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 108.283 -1.006 . . . . 0.0 108.283 -179.998 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' THR . . . . . 0.412 ' O ' ' SG ' ' A' ' 10' ' ' CYS . 34.3 p -95.28 156.52 16.29 Favored 'General case' 0 C--N 1.325 -0.484 0 O-C-N 124.543 1.152 . . . . 0.0 110.378 179.997 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 42.7 t -80.99 94.12 6.49 Favored 'General case' 0 C--N 1.325 -0.478 0 O-C-N 124.532 1.145 . . . . 0.0 108.276 -179.964 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' SER . . . . . 0.518 ' O ' ' C ' ' A' ' 19' ' ' TRP . 3.6 t -100.36 65.51 1.22 Allowed 'General case' 0 C--N 1.325 -0.484 0 O-C-N 124.506 1.128 . . . . 0.0 110.006 174.172 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' TRP . . . . . 0.544 ' CG ' ' HA ' ' A' ' 20' ' ' PRO . 0.0 OUTLIER -36.3 147.42 0.19 Allowed Pre-proline 0 C--N 1.325 -0.465 0 N-CA-C 107.992 -1.114 . . . . 0.0 107.992 -173.981 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . 0.544 ' HA ' ' CG ' ' A' ' 19' ' ' TRP . 18.3 Cg_endo -75.03 -12.92 23.97 Favored 'Cis proline' 0 C--N 1.36 1.166 0 C-N-CA 121.035 -2.485 . . . . 0.0 110.981 -8.374 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.494 ' O ' ' C ' ' A' ' 18' ' ' SER . 4.6 p -99.02 179.16 0.6 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.5 0 O-C-N 124.502 1.126 . . . . 0.0 109.292 -173.284 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 53.3 m -101.63 168.9 9.18 Favored 'General case' 0 C--N 1.325 -0.473 0 O-C-N 124.476 1.11 . . . . 0.0 108.358 179.986 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' THR . . . . . 0.441 ' OG1' ' CB ' ' A' ' 18' ' ' SER . 0.8 OUTLIER -148.36 167.54 24.97 Favored 'General case' 0 C--N 1.325 -0.488 0 O-C-N 124.5 1.125 . . . . 0.0 110.389 -179.986 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . 0.446 ' HB3' ' CG2' ' A' ' 29' ' ' VAL . 1.4 ttt85 -137.72 120.04 15.8 Favored 'General case' 0 C--N 1.325 -0.472 0 O-C-N 124.493 1.121 . . . . 0.0 110.263 -179.961 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 58.4 t30 56.3 23.33 7.11 Favored 'General case' 0 C--N 1.325 -0.48 0 O-C-N 124.521 1.138 . . . . 0.0 109.288 179.972 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 81.99 28.85 40.08 Favored Glycine 0 CA--C 1.53 0.992 0 O-C-N 124.513 1.133 . . . . 0.0 111.014 -179.988 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 22.9 mt -147.27 130.2 7.96 Favored Pre-proline 0 C--N 1.325 -0.461 0 O-C-N 124.513 0.772 . . . . 0.0 109.284 179.957 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 20.2 Cg_endo -75.0 84.28 1.69 Allowed 'Trans proline' 0 N--CA 1.453 -0.881 0 O-C-N 124.488 1.783 . . . . 0.0 110.995 -168.332 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.446 ' CG2' ' HB3' ' A' ' 24' ' ' ARG . 30.4 m . . . . . 0 C--N 1.326 -0.447 0 O-C-N 124.482 1.114 . . . . 0.0 109.308 179.962 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 16.7 m . . . . . 0 N--CA 1.453 -0.303 0 N-CA-C 108.314 -0.995 . . . . 0.0 108.314 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 92.96 -20.03 48.24 Favored Glycine 0 CA--C 1.53 1.021 0 O-C-N 124.49 1.119 . . . . 0.0 111.001 179.97 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 15.6 tt0 -83.86 162.07 20.67 Favored 'General case' 0 C--N 1.325 -0.475 0 O-C-N 124.487 0.757 . . . . 0.0 110.353 179.976 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 53.3 p -123.13 132.84 54.24 Favored 'General case' 0 C--N 1.325 -0.478 0 O-C-N 124.455 1.097 . . . . 0.0 110.371 -179.98 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.404 ' SG ' ' O ' ' A' ' 5' ' ' CYS . 16.4 p -100.34 55.22 0.9 Allowed 'General case' 0 C--N 1.326 -0.447 0 O-C-N 124.508 1.13 . . . . 0.0 108.337 179.94 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 9.6 t -59.33 -25.35 30.52 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 O-C-N 124.45 1.094 . . . . 0.0 109.245 -179.944 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -83.79 -30.68 28.68 Favored Glycine 0 CA--C 1.529 0.964 0 O-C-N 124.52 1.138 . . . . 0.0 111.006 179.991 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 122.3 14.23 4.55 Favored Glycine 0 CA--C 1.53 1.013 0 O-C-N 125.006 1.062 . . . . 0.0 110.988 178.694 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 42.5 m -149.95 164.15 36.2 Favored 'General case' 0 C--N 1.325 -0.484 0 O-C-N 124.54 0.788 . . . . 0.0 110.362 -180.0 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . 0.401 ' SG ' ' O ' ' A' ' 16' ' ' THR . 97.2 m -120.45 140.98 50.59 Favored 'General case' 0 C--N 1.326 -0.447 0 O-C-N 124.467 1.104 . . . . 0.0 108.292 179.991 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 37.6 t30 -89.74 -45.02 9.59 Favored 'General case' 0 C--N 1.325 -0.463 0 O-C-N 124.493 1.121 . . . . 0.0 109.298 179.977 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' THR . . . . . 0.5 ' CG2' ' SG ' ' A' ' 15' ' ' CYS . 18.3 m -56.02 143.05 63.9 Favored Pre-proline 0 C--N 1.326 -0.453 0 O-C-N 124.462 1.101 . . . . 0.0 110.417 179.973 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . 0.481 ' HD2' ' CG2' ' A' ' 12' ' ' THR . 20.2 Cg_endo -74.97 130.3 13.18 Favored 'Trans proline' 0 N--CA 1.452 -0.917 0 O-C-N 124.508 1.793 . . . . 0.0 110.987 -168.329 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 75.12 15.29 81.19 Favored Glycine 0 CA--C 1.53 0.995 0 O-C-N 124.442 1.089 . . . . 0.0 111.035 -179.999 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.5 ' SG ' ' CG2' ' A' ' 12' ' ' THR . 57.6 m -96.62 129.88 43.92 Favored 'General case' 0 C--N 1.325 -0.489 0 N-CA-C 108.323 -0.991 . . . . 0.0 108.323 179.999 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' THR . . . . . 0.401 ' O ' ' SG ' ' A' ' 10' ' ' CYS . 21.6 p -95.99 152.7 18.28 Favored 'General case' 0 C--N 1.325 -0.472 0 O-C-N 124.497 1.123 . . . . 0.0 110.366 -179.965 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 45.0 t -82.99 95.86 8.14 Favored 'General case' 0 C--N 1.325 -0.498 0 O-C-N 124.483 1.115 . . . . 0.0 108.285 179.973 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' SER . . . . . 0.514 ' O ' ' C ' ' A' ' 19' ' ' TRP . 34.6 p -105.88 66.39 0.72 Allowed 'General case' 0 C--N 1.326 -0.453 0 O-C-N 124.464 1.102 . . . . 0.0 110.023 174.144 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' TRP . . . . . 0.588 ' CG ' ' HA ' ' A' ' 20' ' ' PRO . 0.8 OUTLIER -35.79 146.7 0.19 Allowed Pre-proline 0 C--N 1.324 -0.51 0 O-C-N 124.552 1.158 . . . . 0.0 107.975 -174.399 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . 0.588 ' HA ' ' CG ' ' A' ' 19' ' ' TRP . 18.2 Cg_endo -75.04 -14.83 22.94 Favored 'Cis proline' 0 C--N 1.36 1.159 0 C-N-CA 120.954 -2.519 . . . . 0.0 111.005 -8.67 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.491 ' O ' ' C ' ' A' ' 18' ' ' SER . 2.2 t -96.38 175.97 0.74 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.479 0 O-C-N 124.496 1.122 . . . . 0.0 109.31 -172.992 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 33.4 m -102.47 170.13 8.24 Favored 'General case' 0 C--N 1.325 -0.481 0 O-C-N 124.465 1.103 . . . . 0.0 108.298 179.977 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' THR . . . . . 0.44 HG23 ' CB ' ' A' ' 18' ' ' SER . 1.0 OUTLIER -141.7 168.4 19.85 Favored 'General case' 0 C--N 1.325 -0.469 0 O-C-N 124.483 1.115 . . . . 0.0 110.427 179.949 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . 0.447 ' HB3' ' CG2' ' A' ' 29' ' ' VAL . 0.1 OUTLIER -137.0 115.33 11.77 Favored 'General case' 0 C--N 1.325 -0.478 0 O-C-N 124.514 1.133 . . . . 0.0 110.297 -179.984 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 86.9 m-20 57.2 21.84 6.98 Favored 'General case' 0 C--N 1.325 -0.47 0 O-C-N 124.48 1.113 . . . . 0.0 109.295 -179.986 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 87.15 25.52 33.73 Favored Glycine 0 CA--C 1.531 1.049 0 O-C-N 124.464 1.102 . . . . 0.0 110.966 179.975 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 12.8 mt -145.03 130.29 9.3 Favored Pre-proline 0 C--N 1.325 -0.485 0 O-C-N 124.535 0.785 . . . . 0.0 109.289 -179.961 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 20.1 Cg_endo -74.97 79.99 2.53 Favored 'Trans proline' 0 N--CA 1.452 -0.927 0 O-C-N 124.515 1.797 . . . . 0.0 111.008 -168.285 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.447 ' CG2' ' HB3' ' A' ' 24' ' ' ARG . 18.0 m . . . . . 0 C--N 1.325 -0.482 0 O-C-N 124.51 1.131 . . . . 0.0 109.307 -179.99 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 83.6 m . . . . . 0 N--CA 1.454 -0.266 0 N-CA-C 108.297 -1.001 . . . . 0.0 108.297 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 103.53 -21.09 40.1 Favored Glycine 0 CA--C 1.53 1.01 0 O-C-N 124.515 1.135 . . . . 0.0 110.989 179.981 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 28.5 tt0 -84.4 150.45 25.33 Favored 'General case' 0 C--N 1.324 -0.5 0 O-C-N 124.456 0.739 . . . . 0.0 110.333 179.977 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 66.0 p -109.74 129.91 55.57 Favored 'General case' 0 C--N 1.325 -0.499 0 O-C-N 124.508 1.13 . . . . 0.0 110.429 -179.983 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.42 ' SG ' ' O ' ' A' ' 5' ' ' CYS . 14.2 p -97.16 51.06 1.09 Allowed 'General case' 0 C--N 1.325 -0.474 0 O-C-N 124.523 1.14 . . . . 0.0 108.292 -179.988 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 9.4 t -59.03 -24.74 27.78 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 O-C-N 124.481 1.113 . . . . 0.0 109.317 179.966 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -83.96 -32.6 23.3 Favored Glycine 0 CA--C 1.53 1.028 0 O-C-N 124.512 1.132 . . . . 0.0 110.989 179.999 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 124.73 14.21 3.54 Favored Glycine 0 C--N 1.344 1.004 0 O-C-N 125.103 1.12 . . . . 0.0 111.013 177.972 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -149.6 166.73 28.39 Favored 'General case' 0 C--N 1.325 -0.476 0 O-C-N 124.501 0.765 . . . . 0.0 110.384 179.95 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . 0.406 ' SG ' ' O ' ' A' ' 16' ' ' THR . 75.9 m -123.78 141.96 51.54 Favored 'General case' 0 C--N 1.326 -0.449 0 O-C-N 124.466 1.104 . . . . 0.0 108.279 -179.981 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 34.0 t-20 -89.87 -43.07 10.86 Favored 'General case' 0 C--N 1.325 -0.457 0 O-C-N 124.492 1.12 . . . . 0.0 109.29 -179.998 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' THR . . . . . 0.496 ' CG2' ' SG ' ' A' ' 15' ' ' CYS . 20.2 m -58.35 142.8 81.17 Favored Pre-proline 0 C--N 1.325 -0.485 0 O-C-N 124.427 1.079 . . . . 0.0 110.355 -179.981 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . 0.478 ' HD2' ' CG2' ' A' ' 12' ' ' THR . 20.2 Cg_endo -74.99 131.59 14.48 Favored 'Trans proline' 0 N--CA 1.453 -0.868 0 O-C-N 124.501 1.79 . . . . 0.0 110.997 -168.322 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 74.1 13.73 80.91 Favored Glycine 0 CA--C 1.53 1.025 0 O-C-N 124.482 1.114 . . . . 0.0 110.985 179.975 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.496 ' SG ' ' CG2' ' A' ' 12' ' ' THR . 66.8 m -97.29 125.93 42.19 Favored 'General case' 0 C--N 1.325 -0.469 0 N-CA-C 108.313 -0.995 . . . . 0.0 108.313 179.97 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' THR . . . . . 0.406 ' O ' ' SG ' ' A' ' 10' ' ' CYS . 68.9 p -93.48 156.07 16.97 Favored 'General case' 0 C--N 1.325 -0.483 0 O-C-N 124.481 1.113 . . . . 0.0 110.383 -179.969 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 43.1 t -82.26 91.53 6.78 Favored 'General case' 0 C--N 1.325 -0.486 0 O-C-N 124.535 1.147 . . . . 0.0 108.301 -179.985 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' SER . . . . . 0.522 ' O ' ' C ' ' A' ' 19' ' ' TRP . 3.8 m -98.87 65.81 1.54 Allowed 'General case' 0 C--N 1.325 -0.488 0 O-C-N 124.477 1.111 . . . . 0.0 110.008 174.052 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' TRP . . . . . 0.55 ' CG ' ' HA ' ' A' ' 20' ' ' PRO . 0.1 OUTLIER -35.63 147.12 0.17 Allowed Pre-proline 0 C--N 1.325 -0.5 0 O-C-N 124.556 1.16 . . . . 0.0 107.971 -173.996 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . 0.55 ' HA ' ' CG ' ' A' ' 19' ' ' TRP . 18.4 Cg_endo -74.91 -13.48 23.37 Favored 'Cis proline' 0 C--N 1.36 1.16 0 C-N-CA 121.01 -2.496 . . . . 0.0 111.037 -8.647 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.503 ' O ' ' C ' ' A' ' 18' ' ' SER . 2.2 t -99.11 177.91 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 O-C-N 124.472 1.108 . . . . 0.0 109.288 -173.032 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 69.3 m -101.98 169.1 8.98 Favored 'General case' 0 C--N 1.325 -0.485 0 O-C-N 124.501 1.126 . . . . 0.0 108.288 -179.957 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 1.1 p -144.26 160.54 40.82 Favored 'General case' 0 C--N 1.325 -0.484 0 O-C-N 124.458 1.099 . . . . 0.0 110.398 179.982 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . 0.458 ' HB3' ' CG2' ' A' ' 29' ' ' VAL . 1.1 ttt85 -132.23 118.33 19.37 Favored 'General case' 0 C--N 1.325 -0.471 0 O-C-N 124.537 1.148 . . . . 0.0 110.292 -179.985 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 76.2 m-20 57.47 24.55 10.37 Favored 'General case' 0 C--N 1.324 -0.514 0 O-C-N 124.535 1.147 . . . . 0.0 109.289 -179.973 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 82.59 23.36 56.43 Favored Glycine 0 CA--C 1.53 1.024 0 O-C-N 124.586 1.179 . . . . 0.0 111.002 179.982 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 8.0 mt -143.26 129.91 10.52 Favored Pre-proline 0 C--N 1.325 -0.499 0 O-C-N 124.548 0.793 . . . . 0.0 109.337 179.978 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 20.1 Cg_endo -74.99 81.95 2.1 Favored 'Trans proline' 0 N--CA 1.453 -0.87 0 O-C-N 124.511 1.795 . . . . 0.0 110.997 -168.279 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.458 ' CG2' ' HB3' ' A' ' 24' ' ' ARG . 21.9 m . . . . . 0 C--N 1.325 -0.477 0 O-C-N 124.517 1.136 . . . . 0.0 109.312 179.991 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 83.5 m . . . . . 0 N--CA 1.453 -0.301 0 N-CA-C 108.28 -1.007 . . . . 0.0 108.28 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 91.62 -17.58 55.75 Favored Glycine 0 CA--C 1.53 1.006 0 O-C-N 124.431 1.082 . . . . 0.0 110.994 -179.961 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 15.5 tt0 -85.59 161.72 19.17 Favored 'General case' 0 C--N 1.325 -0.471 0 O-C-N 124.47 0.747 . . . . 0.0 110.314 179.976 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 47.5 p -120.54 132.0 54.96 Favored 'General case' 0 C--N 1.325 -0.498 0 O-C-N 124.52 1.138 . . . . 0.0 110.456 179.978 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.417 ' SG ' ' O ' ' A' ' 5' ' ' CYS . 14.5 p -98.97 51.64 0.96 Allowed 'General case' 0 C--N 1.325 -0.475 0 O-C-N 124.475 1.109 . . . . 0.0 108.286 -179.977 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 9.0 t -59.22 -24.99 29.07 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 O-C-N 124.497 1.123 . . . . 0.0 109.288 -179.988 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -84.32 -32.25 23.18 Favored Glycine 0 CA--C 1.53 0.979 0 O-C-N 124.507 1.129 . . . . 0.0 111.062 179.961 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 124.37 13.98 3.75 Favored Glycine 0 CA--C 1.529 0.969 0 O-C-N 125.024 1.073 . . . . 0.0 111.036 178.176 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 45.8 m -149.93 164.76 34.58 Favored 'General case' 0 C--N 1.325 -0.47 0 O-C-N 124.514 0.773 . . . . 0.0 110.427 179.995 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . 0.405 ' SG ' ' O ' ' A' ' 16' ' ' THR . 94.2 m -121.67 143.16 49.5 Favored 'General case' 0 C--N 1.325 -0.491 0 O-C-N 124.469 1.106 . . . . 0.0 108.254 -179.955 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 76.1 m-20 -90.26 -47.84 7.53 Favored 'General case' 0 C--N 1.325 -0.458 0 O-C-N 124.439 1.087 . . . . 0.0 109.273 -179.982 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' THR . . . . . 0.503 ' CG2' ' SG ' ' A' ' 15' ' ' CYS . 19.5 m -53.16 142.7 36.3 Favored Pre-proline 0 C--N 1.325 -0.474 0 O-C-N 124.495 1.122 . . . . 0.0 110.397 180.0 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . 0.473 ' HD2' ' CG2' ' A' ' 12' ' ' THR . 20.4 Cg_endo -74.94 131.63 14.59 Favored 'Trans proline' 0 N--CA 1.453 -0.856 0 O-C-N 124.495 1.787 . . . . 0.0 110.975 -168.328 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 73.97 15.81 79.64 Favored Glycine 0 CA--C 1.53 0.977 0 O-C-N 124.524 1.14 . . . . 0.0 110.984 179.953 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.503 ' SG ' ' CG2' ' A' ' 12' ' ' THR . 63.8 m -97.64 131.5 44.15 Favored 'General case' 0 C--N 1.325 -0.47 0 N-CA-C 108.265 -1.013 . . . . 0.0 108.265 -179.991 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' THR . . . . . 0.405 ' O ' ' SG ' ' A' ' 10' ' ' CYS . 73.1 p -98.37 154.68 17.67 Favored 'General case' 0 C--N 1.325 -0.494 0 O-C-N 124.533 1.145 . . . . 0.0 110.405 -180.0 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 44.4 t -82.19 94.69 7.33 Favored 'General case' 0 C--N 1.325 -0.478 0 O-C-N 124.461 1.101 . . . . 0.0 108.261 -179.976 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' SER . . . . . 0.517 ' O ' ' C ' ' A' ' 19' ' ' TRP . 40.8 t -102.23 66.02 0.98 Allowed 'General case' 0 C--N 1.325 -0.494 0 O-C-N 124.506 1.129 . . . . 0.0 109.964 174.045 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' TRP . . . . . 0.561 ' CG ' ' HA ' ' A' ' 20' ' ' PRO . 0.1 OUTLIER -35.92 147.13 0.18 Allowed Pre-proline 0 C--N 1.325 -0.464 0 O-C-N 124.48 1.112 . . . . 0.0 108.02 -174.211 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . 0.561 ' HA ' ' CG ' ' A' ' 19' ' ' TRP . 18.3 Cg_endo -75.03 -13.9 23.44 Favored 'Cis proline' 0 C--N 1.36 1.148 0 C-N-CA 120.991 -2.504 . . . . 0.0 110.972 -8.69 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.484 ' O ' ' C ' ' A' ' 18' ' ' SER . 0.8 OUTLIER -97.63 177.0 0.69 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 O-C-N 124.512 1.132 . . . . 0.0 109.301 -172.977 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 52.7 m -102.0 171.19 7.65 Favored 'General case' 0 C--N 1.325 -0.493 0 O-C-N 124.508 1.13 . . . . 0.0 108.292 -179.995 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -148.83 168.09 23.92 Favored 'General case' 0 C--N 1.325 -0.486 0 O-C-N 124.543 1.152 . . . . 0.0 110.342 179.993 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . 0.468 ' HB3' ' CG2' ' A' ' 29' ' ' VAL . 8.6 ttt180 -140.57 118.67 11.94 Favored 'General case' 0 C--N 1.326 -0.451 0 O-C-N 124.459 1.099 . . . . 0.0 110.335 179.982 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 14.6 t-20 58.2 22.75 9.51 Favored 'General case' 0 C--N 1.325 -0.465 0 O-C-N 124.494 1.121 . . . . 0.0 109.319 -179.967 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 82.72 22.67 57.69 Favored Glycine 0 CA--C 1.53 0.982 0 O-C-N 124.435 1.085 . . . . 0.0 111.012 -179.997 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 6.2 mt -141.68 130.56 12.28 Favored Pre-proline 0 C--N 1.325 -0.467 0 O-C-N 124.478 0.752 . . . . 0.0 109.286 -179.985 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 20.1 Cg_endo -74.98 83.82 1.75 Allowed 'Trans proline' 0 N--CA 1.453 -0.904 0 O-C-N 124.468 1.773 . . . . 0.0 110.975 -168.258 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.468 ' CG2' ' HB3' ' A' ' 24' ' ' ARG . 35.5 m . . . . . 0 C--N 1.325 -0.477 0 O-C-N 124.507 1.13 . . . . 0.0 109.29 179.982 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 99.6 m . . . . . 0 N--CA 1.453 -0.286 0 N-CA-C 108.316 -0.994 . . . . 0.0 108.316 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 91.78 -26.92 10.83 Favored Glycine 0 CA--C 1.53 1.015 0 O-C-N 124.477 1.11 . . . . 0.0 111.005 179.98 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 25.3 tt0 -81.46 152.73 27.22 Favored 'General case' 0 C--N 1.326 -0.453 0 O-C-N 124.49 0.759 . . . . 0.0 110.258 -179.959 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 76.2 p -113.26 134.88 54.38 Favored 'General case' 0 C--N 1.325 -0.495 0 O-C-N 124.519 1.137 . . . . 0.0 110.394 179.962 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.41 ' SG ' ' O ' ' A' ' 5' ' ' CYS . 15.0 p -98.79 52.65 0.99 Allowed 'General case' 0 C--N 1.326 -0.454 0 O-C-N 124.495 1.122 . . . . 0.0 108.332 179.965 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 8.6 t -59.32 -24.73 28.68 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 O-C-N 124.492 1.12 . . . . 0.0 109.301 -179.97 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -84.13 -34.06 18.79 Favored Glycine 0 CA--C 1.529 0.968 0 O-C-N 124.505 1.128 . . . . 0.0 110.975 -179.984 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 126.54 14.63 2.85 Favored Glycine 0 C--N 1.345 1.047 0 O-C-N 125.13 1.135 . . . . 0.0 110.998 177.776 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -150.0 166.94 28.15 Favored 'General case' 0 C--N 1.325 -0.488 0 O-C-N 124.53 0.782 . . . . 0.0 110.413 179.981 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . 0.408 ' SG ' ' O ' ' A' ' 16' ' ' THR . 72.8 m -124.22 141.78 51.78 Favored 'General case' 0 C--N 1.324 -0.52 0 O-C-N 124.54 1.15 . . . . 0.0 108.343 179.946 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 32.4 t-20 -89.65 -43.29 10.84 Favored 'General case' 0 C--N 1.325 -0.474 0 O-C-N 124.527 1.142 . . . . 0.0 109.335 -180.0 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' THR . . . . . 0.498 ' CG2' ' SG ' ' A' ' 15' ' ' CYS . 20.0 m -57.67 142.71 77.41 Favored Pre-proline 0 C--N 1.326 -0.448 0 O-C-N 124.505 1.128 . . . . 0.0 110.399 179.989 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . 0.472 ' HD2' ' CG2' ' A' ' 12' ' ' THR . 20.1 Cg_endo -75.01 132.33 15.28 Favored 'Trans proline' 0 N--CA 1.453 -0.895 0 O-C-N 124.506 1.793 . . . . 0.0 110.99 -168.306 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 73.62 13.28 80.37 Favored Glycine 0 CA--C 1.529 0.969 0 O-C-N 124.476 1.11 . . . . 0.0 111.016 -179.98 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.498 ' SG ' ' CG2' ' A' ' 12' ' ' THR . 68.7 m -97.49 125.65 42.3 Favored 'General case' 0 C--N 1.325 -0.479 0 N-CA-C 108.29 -1.004 . . . . 0.0 108.29 -179.983 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' THR . . . . . 0.408 ' O ' ' SG ' ' A' ' 10' ' ' CYS . 70.7 p -93.61 156.82 16.5 Favored 'General case' 0 C--N 1.325 -0.491 0 O-C-N 124.558 1.161 . . . . 0.0 110.437 179.977 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 42.7 t -82.86 94.98 7.8 Favored 'General case' 0 C--N 1.325 -0.482 0 O-C-N 124.447 1.092 . . . . 0.0 108.315 -179.993 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' SER . . . . . 0.52 ' O ' ' C ' ' A' ' 19' ' ' TRP . 1.0 OUTLIER -102.48 66.39 0.97 Allowed 'General case' 0 C--N 1.325 -0.486 0 O-C-N 124.494 1.121 . . . . 0.0 109.968 173.987 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' TRP . . . . . 0.554 ' CG ' ' HA ' ' A' ' 20' ' ' PRO . 0.1 OUTLIER -35.51 147.15 0.17 Allowed Pre-proline 0 C--N 1.326 -0.453 0 O-C-N 124.497 1.123 . . . . 0.0 108.0 -174.085 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . 0.554 ' HA ' ' CG ' ' A' ' 19' ' ' TRP . 18.3 Cg_endo -75.0 -13.85 23.39 Favored 'Cis proline' 0 C--N 1.36 1.135 0 C-N-CA 120.967 -2.514 . . . . 0.0 111.013 -8.645 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.495 ' O ' ' C ' ' A' ' 18' ' ' SER . 2.8 p -99.13 178.08 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 O-C-N 124.512 1.132 . . . . 0.0 109.34 -172.964 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 66.7 m -102.29 172.75 6.71 Favored 'General case' 0 C--N 1.325 -0.471 0 O-C-N 124.486 1.116 . . . . 0.0 108.301 179.993 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' THR . . . . . 0.441 ' CG2' ' CB ' ' A' ' 18' ' ' SER . 8.4 p -146.59 159.31 43.61 Favored 'General case' 0 C--N 1.325 -0.467 0 O-C-N 124.486 1.117 . . . . 0.0 110.391 -179.985 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . 0.462 ' HB3' ' CG2' ' A' ' 29' ' ' VAL . 0.5 OUTLIER -131.81 117.68 18.87 Favored 'General case' 0 C--N 1.325 -0.483 0 O-C-N 124.498 1.124 . . . . 0.0 110.291 179.965 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 78.8 m-20 57.52 23.4 9.14 Favored 'General case' 0 C--N 1.325 -0.469 0 O-C-N 124.491 1.119 . . . . 0.0 109.298 -179.987 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 84.04 23.01 53.71 Favored Glycine 0 CA--C 1.53 0.99 0 O-C-N 124.428 1.08 . . . . 0.0 110.983 179.988 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 8.1 mt -143.06 129.99 10.71 Favored Pre-proline 0 C--N 1.325 -0.481 0 O-C-N 124.476 0.751 . . . . 0.0 109.29 179.972 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 20.2 Cg_endo -74.99 85.66 1.5 Allowed 'Trans proline' 0 N--CA 1.453 -0.88 0 O-C-N 124.508 1.794 . . . . 0.0 110.965 -168.287 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.462 ' CG2' ' HB3' ' A' ' 24' ' ' ARG . 33.5 m . . . . . 0 C--N 1.325 -0.472 0 O-C-N 124.542 1.151 . . . . 0.0 109.324 179.968 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . 0.406 ' SG ' ' O ' ' A' ' 23' ' ' THR . 20.0 m . . . . . 0 N--CA 1.452 -0.333 0 N-CA-C 108.302 -0.999 . . . . 0.0 108.302 . . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 108.48 -11.0 36.03 Favored Glycine 0 CA--C 1.53 0.985 0 O-C-N 124.524 1.14 . . . . 0.0 111.011 179.982 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 15.4 mt-10 -99.99 164.4 12.01 Favored 'General case' 0 C--N 1.326 -0.449 0 O-C-N 124.465 0.744 . . . . 0.0 110.282 -179.975 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 76.5 p -122.22 134.81 54.7 Favored 'General case' 0 C--N 1.325 -0.499 0 O-C-N 124.455 1.097 . . . . 0.0 110.44 179.99 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.441 ' SG ' ' O ' ' A' ' 5' ' ' CYS . 11.8 p -101.7 48.23 0.89 Allowed 'General case' 0 C--N 1.325 -0.475 0 O-C-N 124.493 1.121 . . . . 0.0 108.295 -179.965 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 27.0 t -59.06 -23.61 24.82 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 O-C-N 124.511 1.132 . . . . 0.0 109.266 -179.992 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -87.82 -29.14 21.78 Favored Glycine 0 CA--C 1.53 1.027 0 O-C-N 124.51 1.132 . . . . 0.0 111.002 179.986 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 121.7 16.1 4.24 Favored Glycine 0 CA--C 1.531 1.036 0 O-C-N 124.964 1.038 . . . . 0.0 111.015 178.398 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 89.8 m -150.18 166.29 30.3 Favored 'General case' 0 C--N 1.325 -0.493 0 O-C-N 124.513 0.772 . . . . 0.0 110.415 179.942 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . 0.407 ' SG ' ' O ' ' A' ' 16' ' ' THR . 87.9 m -124.38 143.95 50.31 Favored 'General case' 0 C--N 1.325 -0.476 0 O-C-N 124.526 1.141 . . . . 0.0 108.306 179.979 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 18.9 t30 -89.78 -50.44 6.05 Favored 'General case' 0 C--N 1.325 -0.486 0 O-C-N 124.489 1.118 . . . . 0.0 109.353 179.978 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' THR . . . . . 0.505 ' CG2' ' SG ' ' A' ' 15' ' ' CYS . 18.5 m -52.32 142.77 28.4 Favored Pre-proline 0 C--N 1.325 -0.479 0 O-C-N 124.464 1.102 . . . . 0.0 110.406 -179.999 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . 0.473 ' HD2' ' CG2' ' A' ' 12' ' ' THR . 20.1 Cg_endo -74.95 129.52 12.47 Favored 'Trans proline' 0 N--CA 1.453 -0.892 0 O-C-N 124.504 1.792 . . . . 0.0 110.991 -168.284 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.415 ' HA3' ' NH1' ' A' ' 24' ' ' ARG . . . 76.01 15.15 81.58 Favored Glycine 0 CA--C 1.53 0.997 0 O-C-N 124.497 1.123 . . . . 0.0 110.999 179.988 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.505 ' SG ' ' CG2' ' A' ' 12' ' ' THR . 55.9 m -95.78 126.33 40.97 Favored 'General case' 0 C--N 1.325 -0.481 0 N-CA-C 108.282 -1.007 . . . . 0.0 108.282 -179.952 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' THR . . . . . 0.407 ' O ' ' SG ' ' A' ' 10' ' ' CYS . 12.3 p -92.45 154.36 18.54 Favored 'General case' 0 C--N 1.325 -0.497 0 O-C-N 124.51 1.131 . . . . 0.0 110.408 -179.998 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 21.9 t -83.59 94.81 8.16 Favored 'General case' 0 C--N 1.324 -0.508 0 O-C-N 124.497 1.123 . . . . 0.0 108.3 -179.996 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' SER . . . . . 0.517 ' O ' ' C ' ' A' ' 19' ' ' TRP . 1.1 t -102.68 68.06 1.02 Allowed 'General case' 0 C--N 1.325 -0.474 0 O-C-N 124.501 1.126 . . . . 0.0 110.011 174.02 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' TRP . . . . . 0.544 ' CG ' ' HA ' ' A' ' 20' ' ' PRO . 0.0 OUTLIER -36.03 147.02 0.19 Allowed Pre-proline 0 C--N 1.325 -0.5 0 O-C-N 124.501 1.125 . . . . 0.0 107.972 -174.213 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . 0.544 ' HA ' ' CG ' ' A' ' 19' ' ' TRP . 18.2 Cg_endo -75.04 -14.34 23.23 Favored 'Cis proline' 0 C--N 1.361 1.194 0 C-N-CA 120.988 -2.505 . . . . 0.0 110.998 -8.67 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.478 ' O ' ' C ' ' A' ' 18' ' ' SER . 3.8 p -97.61 178.46 0.61 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 O-C-N 124.508 1.13 . . . . 0.0 109.277 -172.984 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 35.3 m -102.14 172.76 6.71 Favored 'General case' 0 C--N 1.326 -0.439 0 O-C-N 124.497 1.123 . . . . 0.0 108.279 -179.97 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' THR . . . . . 0.488 ' CG2' ' CB ' ' A' ' 18' ' ' SER . 5.9 p -145.53 160.57 41.42 Favored 'General case' 0 C--N 1.325 -0.497 0 O-C-N 124.51 1.131 . . . . 0.0 110.446 179.965 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . 0.415 ' NH1' ' HA3' ' A' ' 14' ' ' GLY . 15.1 tpt180 -127.92 114.69 17.5 Favored 'General case' 0 C--N 1.325 -0.485 0 O-C-N 124.515 1.134 . . . . 0.0 110.304 -179.984 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 66.1 t30 57.07 25.55 10.94 Favored 'General case' 0 C--N 1.325 -0.49 0 O-C-N 124.496 1.123 . . . . 0.0 109.281 -179.997 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 82.74 22.18 58.46 Favored Glycine 0 CA--C 1.53 1.019 0 O-C-N 124.487 1.117 . . . . 0.0 110.999 -179.999 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 52.3 mt -140.35 132.23 14.37 Favored Pre-proline 0 C--N 1.325 -0.475 0 O-C-N 124.512 0.772 . . . . 0.0 109.261 179.996 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 20.2 Cg_endo -75.0 86.29 1.44 Allowed 'Trans proline' 0 N--CA 1.453 -0.89 0 O-C-N 124.465 1.771 . . . . 0.0 110.967 -168.321 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.408 ' CG2' ' HB3' ' A' ' 24' ' ' ARG . 19.0 m . . . . . 0 C--N 1.325 -0.477 0 O-C-N 124.467 1.104 . . . . 0.0 109.311 179.983 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 79.0 m . . . . . 0 N--CA 1.453 -0.306 0 N-CA-C 108.295 -1.002 . . . . 0.0 108.295 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 82.82 -9.74 58.93 Favored Glycine 0 CA--C 1.53 0.994 0 O-C-N 124.501 1.126 . . . . 0.0 111.057 -179.966 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 11.4 pt-20 -100.24 167.85 10.17 Favored 'General case' 0 C--N 1.326 -0.446 0 O-C-N 124.495 0.762 . . . . 0.0 110.272 -179.99 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 50.9 p -127.07 143.94 51.15 Favored 'General case' 0 C--N 1.325 -0.481 0 O-C-N 124.52 1.138 . . . . 0.0 110.392 179.998 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.418 ' HB2' ' N ' ' A' ' 9' ' ' THR . 20.5 p -104.26 56.98 0.71 Allowed 'General case' 0 C--N 1.324 -0.5 0 O-C-N 124.494 1.121 . . . . 0.0 108.324 179.976 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 4.9 t -59.48 -24.74 29.18 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 O-C-N 124.493 1.121 . . . . 0.0 109.319 179.981 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -85.23 -33.94 15.95 Favored Glycine 0 CA--C 1.53 1.016 0 O-C-N 124.527 1.142 . . . . 0.0 110.952 -179.932 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 125.14 17.3 2.75 Favored Glycine 0 CA--C 1.53 1.023 0 O-C-N 124.889 0.994 . . . . 0.0 111.005 177.766 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' THR . . . . . 0.418 ' N ' ' HB2' ' A' ' 5' ' ' CYS . 32.1 m -150.38 164.01 36.92 Favored 'General case' 0 C--N 1.325 -0.485 0 O-C-N 124.495 0.762 . . . . 0.0 110.397 179.978 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . 0.405 ' SG ' ' O ' ' A' ' 16' ' ' THR . 74.9 m -118.55 142.41 47.63 Favored 'General case' 0 C--N 1.325 -0.485 0 O-C-N 124.505 1.128 . . . . 0.0 108.312 -179.998 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 3.9 m120 -90.87 -40.9 11.49 Favored 'General case' 0 C--N 1.325 -0.469 0 O-C-N 124.485 1.115 . . . . 0.0 109.275 -179.998 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' THR . . . . . 0.5 ' CG2' ' SG ' ' A' ' 15' ' ' CYS . 17.5 m -63.76 142.82 98.09 Favored Pre-proline 0 C--N 1.325 -0.484 0 O-C-N 124.483 1.115 . . . . 0.0 110.426 -179.993 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . 0.475 ' HD2' ' CG2' ' A' ' 12' ' ' THR . 20.1 Cg_endo -74.97 130.73 13.58 Favored 'Trans proline' 0 N--CA 1.453 -0.876 0 O-C-N 124.481 1.779 . . . . 0.0 110.969 -168.246 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 77.16 10.37 86.29 Favored Glycine 0 CA--C 1.53 1.022 0 O-C-N 124.511 1.132 . . . . 0.0 111.001 179.985 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.5 ' SG ' ' CG2' ' A' ' 12' ' ' THR . 68.1 m -93.78 126.75 39.15 Favored 'General case' 0 C--N 1.325 -0.464 0 N-CA-C 108.268 -1.012 . . . . 0.0 108.268 -179.973 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' THR . . . . . 0.405 ' O ' ' SG ' ' A' ' 10' ' ' CYS . 11.2 p -93.8 152.41 18.93 Favored 'General case' 0 C--N 1.324 -0.511 0 O-C-N 124.456 1.098 . . . . 0.0 110.393 -179.981 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 43.4 t -80.0 98.14 7.07 Favored 'General case' 0 C--N 1.325 -0.473 0 O-C-N 124.475 1.109 . . . . 0.0 108.331 179.983 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' SER . . . . . 0.519 ' O ' ' C ' ' A' ' 19' ' ' TRP . 30.0 t -105.72 64.92 0.7 Allowed 'General case' 0 C--N 1.325 -0.472 0 O-C-N 124.502 1.126 . . . . 0.0 109.986 174.242 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' TRP . . . . . 0.586 ' CG ' ' HA ' ' A' ' 20' ' ' PRO . 0.4 OUTLIER -35.42 147.0 0.17 Allowed Pre-proline 0 C--N 1.325 -0.472 0 O-C-N 124.537 1.148 . . . . 0.0 108.024 -174.284 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . 0.586 ' HA ' ' CG ' ' A' ' 19' ' ' TRP . 18.3 Cg_endo -74.98 -13.97 23.3 Favored 'Cis proline' 0 C--N 1.36 1.148 0 C-N-CA 121.013 -2.495 . . . . 0.0 111.006 -8.605 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.503 ' O ' ' C ' ' A' ' 18' ' ' SER . 3.8 t -97.94 175.31 0.82 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 O-C-N 124.478 1.111 . . . . 0.0 109.239 -173.022 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . 0.406 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 3.5 m -102.36 170.0 8.34 Favored 'General case' 0 C--N 1.325 -0.483 0 O-C-N 124.463 1.102 . . . . 0.0 108.338 179.995 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 1.9 p -147.27 163.41 36.49 Favored 'General case' 0 C--N 1.325 -0.495 0 O-C-N 124.49 1.119 . . . . 0.0 110.385 179.996 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . 0.46 ' HB3' ' CG2' ' A' ' 29' ' ' VAL . 0.3 OUTLIER -139.77 118.91 12.7 Favored 'General case' 0 C--N 1.324 -0.509 0 O-C-N 124.573 1.17 . . . . 0.0 110.33 179.937 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 18.0 t-20 57.91 22.36 8.64 Favored 'General case' 0 C--N 1.325 -0.48 0 O-C-N 124.528 1.142 . . . . 0.0 109.277 -179.988 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 84.55 23.21 51.49 Favored Glycine 0 CA--C 1.531 1.042 0 O-C-N 124.504 1.128 . . . . 0.0 110.959 179.952 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 12.1 mt -145.96 128.04 7.79 Favored Pre-proline 0 C--N 1.325 -0.491 0 O-C-N 124.515 0.773 . . . . 0.0 109.311 -179.976 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 20.3 Cg_endo -74.92 78.25 2.91 Favored 'Trans proline' 0 N--CA 1.453 -0.889 0 O-C-N 124.515 1.797 . . . . 0.0 110.966 -168.294 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.46 ' CG2' ' HB3' ' A' ' 24' ' ' ARG . 30.8 m . . . . . 0 C--N 1.324 -0.517 0 O-C-N 124.509 1.131 . . . . 0.0 109.289 179.985 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 99.7 m . . . . . 0 N--CA 1.453 -0.311 0 N-CA-C 108.319 -0.993 . . . . 0.0 108.319 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 84.61 -13.21 53.47 Favored Glycine 0 CA--C 1.53 1.004 0 O-C-N 124.475 1.109 . . . . 0.0 110.958 179.936 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . 0.403 ' HG3' ' SG ' ' A' ' 22' ' ' CYS . 23.1 pt-20 -100.42 171.72 7.57 Favored 'General case' 0 C--N 1.325 -0.495 0 O-C-N 124.504 0.767 . . . . 0.0 110.262 -179.983 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 38.4 p -129.72 143.16 50.68 Favored 'General case' 0 C--N 1.325 -0.482 0 O-C-N 124.506 1.128 . . . . 0.0 110.377 179.991 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.584 ' O ' ' CD1' ' A' ' 19' ' ' TRP . 14.8 p -96.67 52.46 1.2 Allowed 'General case' 0 C--N 1.325 -0.469 0 O-C-N 124.474 1.109 . . . . 0.0 108.301 179.953 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 4.5 t -59.01 -24.9 28.13 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 O-C-N 124.428 1.08 . . . . 0.0 109.309 179.992 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -84.02 -35.09 16.28 Favored Glycine 0 CA--C 1.53 1.028 0 O-C-N 124.467 1.104 . . . . 0.0 111.021 179.996 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . 0.4 ' O ' ' SG ' ' A' ' 17' ' ' CYS . . . 133.34 -13.24 4.91 Favored Glycine 0 C--N 1.346 1.106 0 O-C-N 125.139 1.14 . . . . 0.0 110.979 178.327 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -131.1 162.93 28.78 Favored 'General case' 0 C--N 1.324 -0.502 0 O-C-N 124.517 0.775 . . . . 0.0 110.411 -179.96 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . 0.406 ' SG ' ' O ' ' A' ' 16' ' ' THR . 86.9 m -107.16 141.64 38.11 Favored 'General case' 0 C--N 1.325 -0.49 0 O-C-N 124.499 1.124 . . . . 0.0 108.268 -179.951 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 64.1 t-20 -89.59 -38.13 14.17 Favored 'General case' 0 C--N 1.325 -0.481 0 O-C-N 124.522 1.139 . . . . 0.0 109.329 179.961 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' THR . . . . . 0.494 ' CG2' ' SG ' ' A' ' 15' ' ' CYS . 16.5 m -67.44 143.11 96.97 Favored Pre-proline 0 C--N 1.326 -0.454 0 O-C-N 124.509 1.131 . . . . 0.0 110.429 -179.996 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . 0.486 ' HD2' ' CG2' ' A' ' 12' ' ' THR . 20.2 Cg_endo -74.98 129.15 12.09 Favored 'Trans proline' 0 N--CA 1.453 -0.88 0 O-C-N 124.569 1.826 . . . . 0.0 110.99 -168.27 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 76.86 14.27 82.76 Favored Glycine 0 CA--C 1.529 0.951 0 O-C-N 124.517 1.135 . . . . 0.0 111.035 -179.964 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.494 ' SG ' ' CG2' ' A' ' 12' ' ' THR . 57.7 m -96.45 129.38 43.82 Favored 'General case' 0 C--N 1.325 -0.459 0 N-CA-C 108.315 -0.994 . . . . 0.0 108.315 179.976 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' THR . . . . . 0.406 ' O ' ' SG ' ' A' ' 10' ' ' CYS . 23.4 p -93.57 148.71 21.84 Favored 'General case' 0 C--N 1.325 -0.474 0 O-C-N 124.492 1.12 . . . . 0.0 110.358 -179.977 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . 0.4 ' SG ' ' O ' ' A' ' 8' ' ' GLY . 11.9 t -81.23 95.06 6.82 Favored 'General case' 0 C--N 1.325 -0.462 0 O-C-N 124.5 1.125 . . . . 0.0 108.293 179.988 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' SER . . . . . 0.513 ' O ' ' C ' ' A' ' 19' ' ' TRP . 20.4 p -102.31 65.79 0.97 Allowed 'General case' 0 C--N 1.325 -0.497 0 O-C-N 124.493 1.121 . . . . 0.0 110.036 173.993 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' TRP . . . . . 0.584 ' CD1' ' O ' ' A' ' 5' ' ' CYS . 0.0 OUTLIER -36.02 147.23 0.18 Allowed Pre-proline 0 C--N 1.325 -0.459 0 N-CA-C 107.998 -1.112 . . . . 0.0 107.998 -174.047 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . 0.527 ' HA ' ' CG ' ' A' ' 19' ' ' TRP . 18.4 Cg_endo -74.95 -13.53 23.44 Favored 'Cis proline' 0 C--N 1.36 1.161 0 C-N-CA 120.995 -2.502 . . . . 0.0 111.01 -8.641 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.493 ' O ' ' C ' ' A' ' 18' ' ' SER . 2.3 p -96.35 173.99 0.9 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.478 0 O-C-N 124.53 1.144 . . . . 0.0 109.331 -173.224 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . 0.403 ' SG ' ' HG3' ' A' ' 3' ' ' GLU . 1.7 m -102.09 169.2 8.9 Favored 'General case' 0 C--N 1.325 -0.488 0 O-C-N 124.485 1.115 . . . . 0.0 108.324 -179.973 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' THR . . . . . 0.406 HG23 ' CB ' ' A' ' 18' ' ' SER . 1.1 p -141.99 169.1 18.22 Favored 'General case' 0 C--N 1.325 -0.488 0 O-C-N 124.494 1.121 . . . . 0.0 110.413 -179.981 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . 0.454 ' HB3' ' CG2' ' A' ' 29' ' ' VAL . 6.0 ttt180 -143.74 117.02 9.0 Favored 'General case' 0 C--N 1.325 -0.475 0 O-C-N 124.527 1.142 . . . . 0.0 110.279 -179.986 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 71.1 m-20 58.47 22.23 9.36 Favored 'General case' 0 C--N 1.325 -0.482 0 O-C-N 124.516 1.135 . . . . 0.0 109.31 179.992 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 86.48 20.64 53.99 Favored Glycine 0 CA--C 1.53 0.974 0 O-C-N 124.498 1.124 . . . . 0.0 111.009 -179.997 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 9.7 mt -144.7 128.81 8.92 Favored Pre-proline 0 C--N 1.325 -0.493 0 O-C-N 124.514 0.773 . . . . 0.0 109.29 -179.98 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 20.2 Cg_endo -74.97 84.68 1.62 Allowed 'Trans proline' 0 N--CA 1.453 -0.895 0 O-C-N 124.499 1.789 . . . . 0.0 111.014 -168.321 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.454 ' CG2' ' HB3' ' A' ' 24' ' ' ARG . 28.4 m . . . . . 0 C--N 1.324 -0.508 0 O-C-N 124.547 1.154 . . . . 0.0 109.295 -179.968 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 83.0 m . . . . . 0 N--CA 1.453 -0.296 0 N-CA-C 108.286 -1.005 . . . . 0.0 108.286 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 100.56 -25.33 28.71 Favored Glycine 0 CA--C 1.53 1.017 0 O-C-N 124.475 1.109 . . . . 0.0 110.99 -179.996 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 28.6 tt0 -78.51 150.47 32.9 Favored 'General case' 0 C--N 1.324 -0.511 0 O-C-N 124.519 0.776 . . . . 0.0 110.293 -179.969 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 75.2 p -110.21 130.94 55.45 Favored 'General case' 0 C--N 1.325 -0.476 0 O-C-N 124.453 1.095 . . . . 0.0 110.42 179.977 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.416 ' SG ' ' O ' ' A' ' 5' ' ' CYS . 14.5 p -99.0 51.58 0.96 Allowed 'General case' 0 C--N 1.325 -0.46 0 O-C-N 124.452 1.095 . . . . 0.0 108.301 -179.975 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 9.6 t -59.22 -24.59 27.94 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 O-C-N 124.553 1.158 . . . . 0.0 109.334 -179.991 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -83.89 -33.42 21.31 Favored Glycine 0 CA--C 1.53 0.984 0 O-C-N 124.52 1.138 . . . . 0.0 110.972 -179.978 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 125.95 14.24 3.12 Favored Glycine 0 C--N 1.346 1.086 0 C-N-CA 119.776 -1.202 . . . . 0.0 110.982 177.846 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -150.07 166.25 30.31 Favored 'General case' 0 C--N 1.325 -0.494 0 O-C-N 124.456 0.739 . . . . 0.0 110.355 -179.997 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . 0.405 ' SG ' ' O ' ' A' ' 16' ' ' THR . 74.8 m -123.14 144.28 49.45 Favored 'General case' 0 C--N 1.326 -0.439 0 O-C-N 124.477 1.11 . . . . 0.0 108.288 -179.989 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 9.8 t-20 -91.18 -44.39 9.27 Favored 'General case' 0 C--N 1.325 -0.464 0 O-C-N 124.463 1.102 . . . . 0.0 109.313 -179.971 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' THR . . . . . 0.496 ' CG2' ' SG ' ' A' ' 15' ' ' CYS . 20.6 m -58.03 142.73 79.47 Favored Pre-proline 0 C--N 1.325 -0.48 0 O-C-N 124.487 1.117 . . . . 0.0 110.392 -179.984 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . 0.471 ' HD2' ' CG2' ' A' ' 12' ' ' THR . 20.2 Cg_endo -74.98 132.34 15.34 Favored 'Trans proline' 0 N--CA 1.453 -0.871 0 O-C-N 124.443 1.76 . . . . 0.0 110.937 -168.251 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 75.47 8.71 84.2 Favored Glycine 0 CA--C 1.53 1.014 0 O-C-N 124.472 1.107 . . . . 0.0 111.028 179.993 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.496 ' SG ' ' CG2' ' A' ' 12' ' ' THR . 81.5 m -93.29 125.43 37.89 Favored 'General case' 0 C--N 1.324 -0.509 0 N-CA-C 108.279 -1.008 . . . . 0.0 108.279 179.995 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' THR . . . . . 0.405 ' O ' ' SG ' ' A' ' 10' ' ' CYS . 2.2 p -94.0 156.07 16.8 Favored 'General case' 0 C--N 1.325 -0.483 0 O-C-N 124.524 1.14 . . . . 0.0 110.393 -179.994 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 48.5 t -81.25 91.14 6.16 Favored 'General case' 0 C--N 1.325 -0.495 0 O-C-N 124.512 1.133 . . . . 0.0 108.336 179.968 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' SER . . . . . 0.525 ' O ' ' C ' ' A' ' 19' ' ' TRP . 1.9 m -98.09 65.23 1.73 Allowed 'General case' 0 C--N 1.324 -0.502 0 O-C-N 124.503 1.127 . . . . 0.0 110.001 174.231 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' TRP . . . . . 0.549 ' CG ' ' HA ' ' A' ' 20' ' ' PRO . 0.0 OUTLIER -35.52 147.1 0.17 Allowed Pre-proline 0 C--N 1.324 -0.506 0 O-C-N 124.503 1.127 . . . . 0.0 107.993 -173.882 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . 0.549 ' HA ' ' CG ' ' A' ' 19' ' ' TRP . 18.4 Cg_endo -74.98 -13.27 23.65 Favored 'Cis proline' 0 C--N 1.36 1.143 0 C-N-CA 121.012 -2.495 . . . . 0.0 110.98 -8.386 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.508 ' O ' ' C ' ' A' ' 18' ' ' SER . 2.4 m -99.92 178.65 0.64 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.494 0 O-C-N 124.468 1.105 . . . . 0.0 109.295 -173.117 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 82.7 m -102.21 171.75 7.3 Favored 'General case' 0 C--N 1.325 -0.486 0 O-C-N 124.524 1.14 . . . . 0.0 108.281 -179.997 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -150.3 161.0 43.3 Favored 'General case' 0 C--N 1.325 -0.477 0 O-C-N 124.526 1.141 . . . . 0.0 110.396 179.991 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . 0.475 ' HB3' ' CG2' ' A' ' 29' ' ' VAL . 8.6 ttt180 -132.4 119.08 20.18 Favored 'General case' 0 C--N 1.325 -0.493 0 O-C-N 124.552 1.157 . . . . 0.0 110.289 -179.99 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . 0.404 ' OD1' ' O ' ' A' ' 25' ' ' ASN . 22.9 t-20 57.24 28.87 15.8 Favored 'General case' 0 C--N 1.325 -0.484 0 O-C-N 124.507 1.129 . . . . 0.0 109.291 179.992 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 76.05 23.3 72.04 Favored Glycine 0 CA--C 1.531 1.038 0 O-C-N 124.504 1.127 . . . . 0.0 110.989 179.988 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 7.3 mt -141.4 129.22 11.99 Favored Pre-proline 0 C--N 1.324 -0.509 0 O-C-N 124.554 0.796 . . . . 0.0 109.311 -179.971 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 20.2 Cg_endo -75.0 88.3 1.25 Allowed 'Trans proline' 0 N--CA 1.453 -0.875 0 O-C-N 124.487 1.783 . . . . 0.0 110.944 -168.261 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.475 ' CG2' ' HB3' ' A' ' 24' ' ' ARG . 27.1 m . . . . . 0 C--N 1.325 -0.468 0 O-C-N 124.476 1.11 . . . . 0.0 109.345 179.958 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 91.6 m . . . . . 0 N--CA 1.453 -0.284 0 N-CA-C 108.271 -1.011 . . . . 0.0 108.271 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 92.57 7.93 62.83 Favored Glycine 0 CA--C 1.53 1.023 0 O-C-N 124.486 1.116 . . . . 0.0 110.972 -179.985 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 89.8 mt-10 -100.23 165.01 11.7 Favored 'General case' 0 C--N 1.325 -0.495 0 O-C-N 124.493 0.761 . . . . 0.0 110.308 179.999 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 23.9 p -121.51 114.99 22.01 Favored 'General case' 0 C--N 1.325 -0.485 0 O-C-N 124.456 1.098 . . . . 0.0 110.4 -179.984 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.432 ' O ' ' SG ' ' A' ' 5' ' ' CYS . 13.3 p -91.08 49.62 1.66 Allowed 'General case' 0 C--N 1.325 -0.474 0 O-C-N 124.5 1.125 . . . . 0.0 108.315 -179.976 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 17.5 t -59.19 -24.54 27.75 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 O-C-N 124.5 1.125 . . . . 0.0 109.355 -179.985 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -84.62 -34.25 16.73 Favored Glycine 0 CA--C 1.531 1.036 0 O-C-N 124.498 1.124 . . . . 0.0 110.981 -179.994 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 125.84 13.1 3.43 Favored Glycine 0 CA--C 1.53 1.006 0 O-C-N 125.1 1.118 . . . . 0.0 111.041 178.05 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 2.5 m -150.02 161.4 42.4 Favored 'General case' 0 C--N 1.326 -0.452 0 O-C-N 124.529 0.782 . . . . 0.0 110.383 -179.975 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . 0.402 ' SG ' ' O ' ' A' ' 16' ' ' THR . 72.3 m -119.11 156.37 29.88 Favored 'General case' 0 C--N 1.325 -0.489 0 O-C-N 124.468 1.105 . . . . 0.0 108.327 179.974 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 17.6 t30 -97.98 -58.17 2.05 Favored 'General case' 0 C--N 1.325 -0.475 0 O-C-N 124.518 1.136 . . . . 0.0 109.341 179.97 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' THR . . . . . 0.489 ' CG2' ' SG ' ' A' ' 15' ' ' CYS . 5.3 m -44.69 142.64 2.45 Favored Pre-proline 0 C--N 1.324 -0.501 0 O-C-N 124.558 1.161 . . . . 0.0 110.405 179.954 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . 0.434 ' HD2' ' CG2' ' A' ' 12' ' ' THR . 20.4 Cg_endo -74.94 129.53 12.49 Favored 'Trans proline' 0 N--CA 1.453 -0.871 0 O-C-N 124.493 1.786 . . . . 0.0 111.023 -168.34 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 78.88 11.57 85.08 Favored Glycine 0 CA--C 1.53 0.986 0 O-C-N 124.513 1.133 . . . . 0.0 111.034 -179.988 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.489 ' SG ' ' CG2' ' A' ' 12' ' ' THR . 57.7 m -95.29 125.71 40.11 Favored 'General case' 0 C--N 1.325 -0.461 0 N-CA-C 108.306 -0.998 . . . . 0.0 108.306 -179.943 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' THR . . . . . 0.402 ' O ' ' SG ' ' A' ' 10' ' ' CYS . 18.7 p -95.16 157.35 15.93 Favored 'General case' 0 C--N 1.326 -0.449 0 O-C-N 124.469 1.106 . . . . 0.0 110.423 -179.989 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 24.5 t -82.74 95.84 7.99 Favored 'General case' 0 C--N 1.325 -0.486 0 O-C-N 124.543 1.152 . . . . 0.0 108.291 179.989 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' SER . . . . . 0.525 ' O ' ' C ' ' A' ' 19' ' ' TRP . 11.2 t -100.45 64.56 1.15 Allowed 'General case' 0 C--N 1.325 -0.469 0 O-C-N 124.504 1.128 . . . . 0.0 110.057 173.855 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' TRP . . . . . 0.551 ' CG ' ' HA ' ' A' ' 20' ' ' PRO . 0.3 OUTLIER -35.39 145.96 0.19 Allowed Pre-proline 0 C--N 1.325 -0.496 0 O-C-N 124.549 1.155 . . . . 0.0 108.033 -174.124 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . 0.551 ' HA ' ' CG ' ' A' ' 19' ' ' TRP . 18.3 Cg_endo -75.04 -14.88 22.92 Favored 'Cis proline' 0 C--N 1.359 1.13 0 C-N-CA 121.021 -2.491 . . . . 0.0 110.973 -8.459 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.492 ' O ' ' C ' ' A' ' 18' ' ' SER . 3.1 m -95.76 177.09 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 O-C-N 124.515 1.134 . . . . 0.0 109.241 -173.101 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 43.9 m -101.85 166.71 10.51 Favored 'General case' 0 C--N 1.325 -0.487 0 O-C-N 124.537 1.148 . . . . 0.0 108.333 179.987 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -145.04 169.51 17.98 Favored 'General case' 0 C--N 1.325 -0.485 0 O-C-N 124.516 1.135 . . . . 0.0 110.384 179.991 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . 0.457 ' HB3' ' CG2' ' A' ' 29' ' ' VAL . 0.1 OUTLIER -142.18 118.22 10.65 Favored 'General case' 0 C--N 1.325 -0.474 0 O-C-N 124.524 1.14 . . . . 0.0 110.304 -179.972 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 72.0 m-20 57.77 23.37 9.51 Favored 'General case' 0 C--N 1.325 -0.466 0 O-C-N 124.557 1.16 . . . . 0.0 109.357 -179.957 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 82.17 24.14 55.41 Favored Glycine 0 CA--C 1.531 1.036 0 O-C-N 124.524 1.14 . . . . 0.0 111.039 -179.994 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 7.5 mt -143.31 129.57 10.34 Favored Pre-proline 0 C--N 1.325 -0.467 0 O-C-N 124.487 0.757 . . . . 0.0 109.317 -179.973 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 20.4 Cg_endo -74.89 82.18 2.03 Favored 'Trans proline' 0 N--CA 1.453 -0.904 0 O-C-N 124.535 1.808 . . . . 0.0 111.02 -168.348 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.457 ' CG2' ' HB3' ' A' ' 24' ' ' ARG . 32.7 m . . . . . 0 C--N 1.324 -0.51 0 O-C-N 124.526 1.141 . . . . 0.0 109.308 179.997 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 95.2 m . . . . . 0 N--CA 1.452 -0.327 0 N-CA-C 108.266 -1.013 . . . . 0.0 108.266 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 91.03 -27.22 9.35 Favored Glycine 0 CA--C 1.53 0.975 0 O-C-N 124.569 1.168 . . . . 0.0 111.041 -179.976 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 23.5 tt0 -83.53 151.88 25.18 Favored 'General case' 0 C--N 1.325 -0.495 0 O-C-N 124.503 0.767 . . . . 0.0 110.292 -179.988 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 60.2 p -112.83 137.93 50.43 Favored 'General case' 0 C--N 1.324 -0.505 0 O-C-N 124.532 1.145 . . . . 0.0 110.372 179.995 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.407 ' SG ' ' O ' ' A' ' 5' ' ' CYS . 15.0 p -100.88 52.79 0.85 Allowed 'General case' 0 C--N 1.325 -0.477 0 O-C-N 124.551 1.157 . . . . 0.0 108.29 179.99 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 10.3 t -59.22 -24.14 26.74 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 O-C-N 124.508 1.13 . . . . 0.0 109.288 -179.996 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -84.75 -34.6 15.26 Favored Glycine 0 CA--C 1.53 1.006 0 O-C-N 124.524 1.14 . . . . 0.0 110.968 -179.976 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 127.19 14.78 2.64 Favored Glycine 0 CA--C 1.531 1.043 0 O-C-N 125.138 1.14 . . . . 0.0 111.029 177.62 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -150.08 166.73 28.88 Favored 'General case' 0 C--N 1.325 -0.476 0 O-C-N 124.489 0.758 . . . . 0.0 110.386 -179.971 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . 0.414 ' SG ' ' O ' ' A' ' 16' ' ' THR . 72.3 m -124.56 140.71 52.69 Favored 'General case' 0 C--N 1.325 -0.486 0 O-C-N 124.525 1.14 . . . . 0.0 108.298 180.0 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 3.0 m120 -89.58 -40.13 12.81 Favored 'General case' 0 C--N 1.325 -0.465 0 O-C-N 124.428 1.08 . . . . 0.0 109.291 -179.989 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' THR . . . . . 0.495 ' CG2' ' SG ' ' A' ' 15' ' ' CYS . 20.9 m -60.05 142.69 89.08 Favored Pre-proline 0 C--N 1.325 -0.467 0 O-C-N 124.465 1.103 . . . . 0.0 110.393 179.995 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . 0.478 ' HD2' ' CG2' ' A' ' 12' ' ' THR . 20.2 Cg_endo -74.97 132.08 15.05 Favored 'Trans proline' 0 N--CA 1.453 -0.877 0 O-C-N 124.485 1.781 . . . . 0.0 110.947 -168.269 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 73.34 13.35 79.85 Favored Glycine 0 CA--C 1.53 0.999 0 O-C-N 124.563 1.165 . . . . 0.0 110.999 179.974 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.495 ' SG ' ' CG2' ' A' ' 12' ' ' THR . 68.7 m -97.97 125.64 42.99 Favored 'General case' 0 C--N 1.325 -0.486 0 N-CA-C 108.306 -0.998 . . . . 0.0 108.306 -179.989 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' THR . . . . . 0.414 ' O ' ' SG ' ' A' ' 10' ' ' CYS . 44.4 p -93.73 157.56 16.1 Favored 'General case' 0 C--N 1.325 -0.498 0 O-C-N 124.479 1.112 . . . . 0.0 110.387 179.985 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 46.8 t -83.09 95.04 7.94 Favored 'General case' 0 C--N 1.326 -0.454 0 O-C-N 124.491 1.12 . . . . 0.0 108.273 -179.948 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' SER . . . . . 0.52 ' O ' ' C ' ' A' ' 19' ' ' TRP . 1.0 OUTLIER -102.79 66.92 0.96 Allowed 'General case' 0 C--N 1.325 -0.469 0 O-C-N 124.459 1.099 . . . . 0.0 110.029 173.96 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' TRP . . . . . 0.551 ' CG ' ' HA ' ' A' ' 20' ' ' PRO . 0.0 OUTLIER -35.7 147.46 0.17 Allowed Pre-proline 0 C--N 1.326 -0.455 0 O-C-N 124.496 1.123 . . . . 0.0 107.982 -174.009 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . 0.551 ' HA ' ' CG ' ' A' ' 19' ' ' TRP . 18.3 Cg_endo -75.01 -13.5 23.62 Favored 'Cis proline' 0 C--N 1.361 1.206 0 C-N-CA 121.001 -2.5 . . . . 0.0 111.025 -8.572 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.495 ' O ' ' C ' ' A' ' 18' ' ' SER . 4.8 p -100.05 178.84 0.63 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 O-C-N 124.547 1.154 . . . . 0.0 109.323 -173.006 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 81.4 m -102.22 174.0 6.12 Favored 'General case' 0 C--N 1.325 -0.492 0 O-C-N 124.503 1.127 . . . . 0.0 108.285 179.991 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' THR . . . . . 0.428 ' CG2' ' CB ' ' A' ' 18' ' ' SER . 7.2 p -147.02 159.19 43.88 Favored 'General case' 0 C--N 1.325 -0.496 0 O-C-N 124.519 1.137 . . . . 0.0 110.402 179.985 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . 0.458 ' HB3' ' CG2' ' A' ' 29' ' ' VAL . 3.4 ttt180 -130.5 116.49 18.26 Favored 'General case' 0 C--N 1.325 -0.465 0 O-C-N 124.513 1.133 . . . . 0.0 110.326 179.948 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 74.9 m-20 57.61 23.46 9.34 Favored 'General case' 0 C--N 1.325 -0.476 0 O-C-N 124.51 1.131 . . . . 0.0 109.329 -179.939 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 84.27 24.72 46.57 Favored Glycine 0 CA--C 1.53 1.002 0 O-C-N 124.522 1.139 . . . . 0.0 111.013 180.0 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 10.7 mt -144.84 130.31 9.44 Favored Pre-proline 0 C--N 1.325 -0.481 0 O-C-N 124.495 0.762 . . . . 0.0 109.262 -179.984 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 20.2 Cg_endo -74.99 88.24 1.26 Allowed 'Trans proline' 0 N--CA 1.453 -0.891 0 O-C-N 124.5 1.789 . . . . 0.0 110.986 -168.312 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.458 ' CG2' ' HB3' ' A' ' 24' ' ' ARG . 32.4 m . . . . . 0 C--N 1.325 -0.482 0 O-C-N 124.51 1.131 . . . . 0.0 109.294 -179.998 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 58.5 m . . . . . 0 N--CA 1.453 -0.307 0 N-CA-C 108.301 -1.0 . . . . 0.0 108.301 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 90.93 -15.76 60.06 Favored Glycine 0 CA--C 1.531 1.042 0 O-C-N 124.483 1.115 . . . . 0.0 110.96 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 15.6 tt0 -88.76 162.72 16.07 Favored 'General case' 0 C--N 1.325 -0.471 0 O-C-N 124.541 0.789 . . . . 0.0 110.316 179.999 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.604 HG22 HG23 ' A' ' 21' ' ' VAL . 53.0 p -120.39 134.97 55.18 Favored 'General case' 0 C--N 1.324 -0.502 0 O-C-N 124.496 1.123 . . . . 0.0 110.425 179.998 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 5' ' ' CYS . . . . . 0.417 ' O ' ' CD1' ' A' ' 19' ' ' TRP . 13.8 p -105.05 49.06 0.82 Allowed 'General case' 0 C--N 1.325 -0.487 0 O-C-N 124.487 1.117 . . . . 0.0 108.334 179.982 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 37.9 t -59.12 -23.37 24.35 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 O-C-N 124.491 1.12 . . . . 0.0 109.327 179.986 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -82.89 -32.69 26.04 Favored Glycine 0 CA--C 1.531 1.033 0 O-C-N 124.477 1.111 . . . . 0.0 110.985 -179.967 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 125.64 10.8 4.3 Favored Glycine 0 CA--C 1.53 0.997 0 O-C-N 125.068 1.099 . . . . 0.0 110.959 178.183 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 83.6 m -150.19 165.38 33.08 Favored 'General case' 0 C--N 1.325 -0.495 0 O-C-N 124.493 0.761 . . . . 0.0 110.398 179.947 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 91.4 m -118.45 141.85 48.14 Favored 'General case' 0 C--N 1.325 -0.473 0 O-C-N 124.498 1.124 . . . . 0.0 108.29 -179.976 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 13.0 t-20 -89.79 -39.9 12.81 Favored 'General case' 0 C--N 1.325 -0.488 0 O-C-N 124.526 1.141 . . . . 0.0 109.342 179.959 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.642 HG23 ' HD2' ' A' ' 13' ' ' PRO . 17.6 m -62.32 142.99 95.9 Favored Pre-proline 0 C--N 1.325 -0.49 0 O-C-N 124.458 1.099 . . . . 0.0 110.383 -179.989 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.642 ' HD2' HG23 ' A' ' 12' ' ' THR . 20.3 Cg_endo -74.9 132.06 15.12 Favored 'Trans proline' 0 N--CA 1.453 -0.875 0 O-C-N 124.524 1.802 . . . . 0.0 110.983 -168.314 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 74.37 12.46 82.04 Favored Glycine 0 CA--C 1.53 1.023 0 O-C-N 124.465 1.103 . . . . 0.0 110.962 179.935 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.503 ' SG ' HG22 ' A' ' 12' ' ' THR . 67.3 m -96.71 127.64 42.89 Favored 'General case' 0 C--N 1.325 -0.465 0 N-CA-C 108.307 -0.997 . . . . 0.0 108.307 179.97 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 77.5 p -95.15 152.85 17.99 Favored 'General case' 0 C--N 1.325 -0.457 0 O-C-N 124.511 1.132 . . . . 0.0 110.383 -179.986 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 54.1 t -77.72 93.86 4.35 Favored 'General case' 0 C--N 1.325 -0.493 0 O-C-N 124.487 1.117 . . . . 0.0 108.33 179.983 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 18' ' ' SER . . . . . 0.609 ' HB3' HG23 ' A' ' 23' ' ' THR . 3.1 t -100.41 65.9 1.23 Allowed 'General case' 0 C--N 1.324 -0.526 0 O-C-N 124.494 1.121 . . . . 0.0 109.992 174.321 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 19' ' ' TRP . . . . . 0.583 ' CG ' ' HA ' ' A' ' 20' ' ' PRO . 0.0 OUTLIER -36.93 147.89 0.2 Allowed Pre-proline 0 C--N 1.325 -0.472 0 O-C-N 124.52 1.138 . . . . 0.0 108.009 -173.973 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 20' ' ' PRO . . . . . 0.583 ' HA ' ' CG ' ' A' ' 19' ' ' TRP . 18.5 Cg_endo -74.98 -12.11 23.98 Favored 'Cis proline' 0 C--N 1.36 1.176 0 C-N-CA 121.023 -2.49 . . . . 0.0 111.047 -8.5 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.675 HG22 ' H ' ' A' ' 22' ' ' CYS . 3.7 p -99.33 -179.55 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 O-C-N 124.5 1.125 . . . . 0.0 109.232 -173.465 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.675 ' H ' HG22 ' A' ' 21' ' ' VAL . 43.2 m -101.32 168.4 9.57 Favored 'General case' 0 C--N 1.325 -0.478 0 O-C-N 124.509 1.131 . . . . 0.0 108.3 179.99 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 23' ' ' THR . . . . . 0.609 HG23 ' HB3' ' A' ' 18' ' ' SER . 0.7 OUTLIER -144.95 164.95 29.56 Favored 'General case' 0 C--N 1.325 -0.478 0 O-C-N 124.553 1.158 . . . . 0.0 110.383 -179.983 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.574 ' HB3' HG22 ' A' ' 29' ' ' VAL . 0.0 OUTLIER -133.87 117.55 16.94 Favored 'General case' 0 C--N 1.325 -0.463 0 O-C-N 124.539 1.149 . . . . 0.0 110.298 179.969 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 74.0 m-20 57.68 23.42 9.43 Favored 'General case' 0 C--N 1.326 -0.456 0 O-C-N 124.447 1.092 . . . . 0.0 109.332 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 84.01 24.59 48.11 Favored Glycine 0 CA--C 1.53 0.993 0 O-C-N 124.52 1.137 . . . . 0.0 110.994 179.986 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 9.6 mt -143.67 130.32 10.37 Favored Pre-proline 0 C--N 1.325 -0.471 0 O-C-N 124.485 0.756 . . . . 0.0 109.339 -179.992 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 20.1 Cg_endo -74.95 89.32 1.16 Allowed 'Trans proline' 0 N--CA 1.453 -0.899 0 O-C-N 124.5 1.79 . . . . 0.0 110.981 -168.294 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.574 HG22 ' HB3' ' A' ' 24' ' ' ARG . 22.4 m . . . . . 0 C--N 1.325 -0.496 0 O-C-N 124.501 1.125 . . . . 0.0 109.312 179.991 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 64.8 m . . . . . 0 N--CA 1.453 -0.294 0 N-CA-C 108.305 -0.998 . . . . 0.0 108.305 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 89.63 -17.35 53.02 Favored Glycine 0 CA--C 1.53 0.979 0 O-C-N 124.507 1.129 . . . . 0.0 111.03 179.999 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 14.8 tt0 -87.94 162.62 16.78 Favored 'General case' 0 C--N 1.325 -0.499 0 O-C-N 124.491 0.759 . . . . 0.0 110.291 179.99 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.791 HG22 HG13 ' A' ' 21' ' ' VAL . 40.0 p -121.52 137.71 54.61 Favored 'General case' 0 C--N 1.326 -0.445 0 O-C-N 124.497 1.123 . . . . 0.0 110.424 179.98 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 5' ' ' CYS . . . . . 0.448 ' O ' ' CD1' ' A' ' 19' ' ' TRP . 14.3 p -105.87 51.13 0.76 Allowed 'General case' 0 C--N 1.325 -0.487 0 O-C-N 124.511 1.132 . . . . 0.0 108.289 -179.967 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 6.0 t -59.1 -24.74 27.99 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 O-C-N 124.482 1.114 . . . . 0.0 109.312 179.994 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -83.91 -33.8 20.18 Favored Glycine 0 CA--C 1.53 0.969 0 O-C-N 124.45 1.093 . . . . 0.0 110.982 -179.992 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 126.27 13.96 3.09 Favored Glycine 0 CA--C 1.53 1.012 0 O-C-N 125.044 1.085 . . . . 0.0 111.031 177.78 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 28.8 m -149.91 163.64 37.54 Favored 'General case' 0 C--N 1.325 -0.483 0 O-C-N 124.509 0.77 . . . . 0.0 110.364 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 10' ' ' CYS . . . . . 0.409 ' SG ' ' O ' ' A' ' 16' ' ' THR . 90.2 m -120.55 143.13 48.75 Favored 'General case' 0 C--N 1.325 -0.475 0 O-C-N 124.481 1.113 . . . . 0.0 108.331 179.987 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 76.2 m-20 -89.96 -46.99 8.14 Favored 'General case' 0 C--N 1.325 -0.462 0 O-C-N 124.462 1.101 . . . . 0.0 109.287 -179.968 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.613 HG23 ' HD2' ' A' ' 13' ' ' PRO . 20.7 m -55.23 142.71 57.66 Favored Pre-proline 0 C--N 1.325 -0.489 0 O-C-N 124.524 1.14 . . . . 0.0 110.343 -179.958 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.613 ' HD2' HG23 ' A' ' 12' ' ' THR . 20.3 Cg_endo -74.92 132.0 15.03 Favored 'Trans proline' 0 N--CA 1.453 -0.872 0 O-C-N 124.572 1.827 . . . . 0.0 111.028 -168.334 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 74.76 12.29 82.92 Favored Glycine 0 CA--C 1.53 1.011 0 O-C-N 124.478 1.111 . . . . 0.0 110.956 179.976 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.498 ' SG ' ' CG2' ' A' ' 12' ' ' THR . 69.6 m -95.52 126.02 40.52 Favored 'General case' 0 C--N 1.324 -0.507 0 N-CA-C 108.262 -1.014 . . . . 0.0 108.262 -179.986 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 16' ' ' THR . . . . . 0.409 ' O ' ' SG ' ' A' ' 10' ' ' CYS . 29.1 p -93.75 156.2 16.81 Favored 'General case' 0 C--N 1.325 -0.492 0 O-C-N 124.526 1.141 . . . . 0.0 110.387 179.999 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 51.6 t -81.34 94.06 6.69 Favored 'General case' 0 C--N 1.325 -0.498 0 O-C-N 124.531 1.144 . . . . 0.0 108.291 179.997 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 18' ' ' SER . . . . . 0.567 ' HB2' HG23 ' A' ' 23' ' ' THR . 1.9 m -101.07 66.39 1.14 Allowed 'General case' 0 C--N 1.325 -0.488 0 O-C-N 124.552 1.157 . . . . 0.0 109.989 174.26 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 19' ' ' TRP . . . . . 0.592 ' CG ' ' HA ' ' A' ' 20' ' ' PRO . 0.0 OUTLIER -36.74 148.19 0.19 Allowed Pre-proline 0 C--N 1.325 -0.481 0 N-CA-C 107.964 -1.124 . . . . 0.0 107.964 -174.019 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 20' ' ' PRO . . . . . 0.592 ' HA ' ' CG ' ' A' ' 19' ' ' TRP . 18.2 Cg_endo -75.03 -11.87 24.19 Favored 'Cis proline' 0 C--N 1.361 1.192 0 C-N-CA 120.967 -2.514 . . . . 0.0 110.997 -8.474 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.791 HG13 HG22 ' A' ' 4' ' ' THR . 2.2 t -100.2 179.92 0.58 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 O-C-N 124.521 1.138 . . . . 0.0 109.285 -173.386 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.663 ' H ' HG12 ' A' ' 21' ' ' VAL . 57.0 m -101.63 168.43 9.48 Favored 'General case' 0 C--N 1.325 -0.491 0 O-C-N 124.494 1.121 . . . . 0.0 108.312 179.987 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 23' ' ' THR . . . . . 0.567 HG23 ' HB2' ' A' ' 18' ' ' SER . 0.8 OUTLIER -145.25 165.06 29.47 Favored 'General case' 0 C--N 1.325 -0.476 0 O-C-N 124.558 1.161 . . . . 0.0 110.427 179.975 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.58 ' HB3' HG22 ' A' ' 29' ' ' VAL . 1.3 ttt-85 -132.81 116.26 16.32 Favored 'General case' 0 C--N 1.324 -0.5 0 O-C-N 124.523 1.139 . . . . 0.0 110.327 -179.991 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 78.4 m-20 57.79 23.08 9.21 Favored 'General case' 0 C--N 1.324 -0.502 0 O-C-N 124.501 1.126 . . . . 0.0 109.291 179.996 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 84.78 23.51 49.54 Favored Glycine 0 CA--C 1.529 0.968 0 O-C-N 124.487 1.117 . . . . 0.0 111.012 -179.966 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 7.2 mt -142.46 129.93 11.26 Favored Pre-proline 0 C--N 1.325 -0.497 0 O-C-N 124.496 0.762 . . . . 0.0 109.288 -179.935 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 20.2 Cg_endo -74.98 89.59 1.15 Allowed 'Trans proline' 0 N--CA 1.453 -0.876 0 O-C-N 124.534 1.807 . . . . 0.0 110.987 -168.323 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.58 HG22 ' HB3' ' A' ' 24' ' ' ARG . 32.6 m . . . . . 0 C--N 1.325 -0.479 0 O-C-N 124.487 1.117 . . . . 0.0 109.276 179.997 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 32.9 m . . . . . 0 N--CA 1.453 -0.282 0 N-CA-C 108.28 -1.008 . . . . 0.0 108.28 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 88.54 -16.01 55.02 Favored Glycine 0 CA--C 1.531 1.044 0 O-C-N 124.503 1.127 . . . . 0.0 110.985 -179.992 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 16.4 tt0 -90.21 161.92 15.49 Favored 'General case' 0 C--N 1.325 -0.483 0 O-C-N 124.515 0.774 . . . . 0.0 110.329 179.982 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.787 HG22 HG12 ' A' ' 21' ' ' VAL . 37.3 p -122.67 135.99 54.75 Favored 'General case' 0 C--N 1.324 -0.518 0 O-C-N 124.481 1.113 . . . . 0.0 110.417 179.992 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 5' ' ' CYS . . . . . 0.406 ' SG ' ' O ' ' A' ' 5' ' ' CYS . 15.3 p -102.65 53.04 0.79 Allowed 'General case' 0 C--N 1.325 -0.484 0 O-C-N 124.528 1.142 . . . . 0.0 108.281 -179.971 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 15.6 t -59.43 -24.51 28.41 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 O-C-N 124.471 1.107 . . . . 0.0 109.331 179.97 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -84.54 -30.96 25.79 Favored Glycine 0 CA--C 1.53 0.982 0 O-C-N 124.485 1.116 . . . . 0.0 110.992 179.97 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 122.6 13.26 4.74 Favored Glycine 0 CA--C 1.53 1.012 0 O-C-N 124.953 1.031 . . . . 0.0 110.979 178.611 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 5.9 m -150.14 158.76 44.5 Favored 'General case' 0 C--N 1.325 -0.497 0 O-C-N 124.512 0.772 . . . . 0.0 110.41 179.973 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 10' ' ' CYS . . . . . 0.403 ' SG ' ' O ' ' A' ' 16' ' ' THR . 97.2 m -114.3 141.58 47.41 Favored 'General case' 0 C--N 1.325 -0.461 0 O-C-N 124.491 1.12 . . . . 0.0 108.307 -179.971 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 64.3 t30 -89.83 -44.5 9.91 Favored 'General case' 0 C--N 1.325 -0.48 0 O-C-N 124.518 1.136 . . . . 0.0 109.284 -179.965 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.625 HG23 ' HD2' ' A' ' 13' ' ' PRO . 18.9 m -57.65 142.85 77.07 Favored Pre-proline 0 C--N 1.325 -0.472 0 O-C-N 124.487 1.117 . . . . 0.0 110.348 -179.987 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.625 ' HD2' HG23 ' A' ' 12' ' ' THR . 20.3 Cg_endo -75.01 130.57 13.38 Favored 'Trans proline' 0 N--CA 1.452 -0.925 0 O-C-N 124.488 1.783 . . . . 0.0 111.026 -168.328 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 75.59 14.09 82.36 Favored Glycine 0 CA--C 1.531 1.034 0 O-C-N 124.518 1.136 . . . . 0.0 110.975 -179.989 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.5 ' SG ' ' CG2' ' A' ' 12' ' ' THR . 62.3 m -95.69 129.54 42.86 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 108.274 -1.01 . . . . 0.0 108.274 -179.971 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 16' ' ' THR . . . . . 0.403 ' O ' ' SG ' ' A' ' 10' ' ' CYS . 7.7 p -95.54 152.35 18.5 Favored 'General case' 0 C--N 1.325 -0.481 0 O-C-N 124.491 1.12 . . . . 0.0 110.388 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 45.6 t -81.67 94.92 7.06 Favored 'General case' 0 C--N 1.325 -0.497 0 O-C-N 124.515 1.134 . . . . 0.0 108.328 179.999 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 18' ' ' SER . . . . . 0.566 ' CB ' HG23 ' A' ' 23' ' ' THR . 1.2 t -104.13 67.05 0.84 Allowed 'General case' 0 C--N 1.324 -0.504 0 O-C-N 124.551 1.157 . . . . 0.0 109.98 174.221 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 19' ' ' TRP . . . . . 0.623 ' CG ' ' HA ' ' A' ' 20' ' ' PRO . 0.1 OUTLIER -36.1 147.23 0.19 Allowed Pre-proline 0 C--N 1.325 -0.485 0 O-C-N 124.502 1.127 . . . . 0.0 108.011 -174.257 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 20' ' ' PRO . . . . . 0.623 ' HA ' ' CG ' ' A' ' 19' ' ' TRP . 18.1 Cg_endo -74.98 -14.0 23.26 Favored 'Cis proline' 0 C--N 1.36 1.136 0 C-N-CA 121.014 -2.494 . . . . 0.0 110.996 -8.659 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.787 HG12 HG22 ' A' ' 4' ' ' THR . 3.0 m -97.67 177.83 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.478 0 O-C-N 124.496 1.123 . . . . 0.0 109.294 -173.075 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 52.9 m -102.18 172.5 6.86 Favored 'General case' 0 C--N 1.325 -0.485 0 O-C-N 124.477 1.111 . . . . 0.0 108.317 179.98 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 23' ' ' THR . . . . . 0.566 HG23 ' CB ' ' A' ' 18' ' ' SER . 6.5 p -145.56 165.1 29.64 Favored 'General case' 0 C--N 1.324 -0.504 0 O-C-N 124.539 1.149 . . . . 0.0 110.416 -179.982 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.666 ' HB3' HG22 ' A' ' 29' ' ' VAL . 0.1 OUTLIER -131.89 112.97 12.9 Favored 'General case' 0 C--N 1.325 -0.464 0 O-C-N 124.459 1.099 . . . . 0.0 110.293 179.986 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 3.6 m120 57.12 22.96 7.99 Favored 'General case' 0 C--N 1.326 -0.451 0 O-C-N 124.498 1.124 . . . . 0.0 109.319 -179.986 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 86.15 25.3 37.56 Favored Glycine 0 CA--C 1.53 0.985 0 O-C-N 124.522 1.139 . . . . 0.0 111.016 -179.986 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 7.9 mt -143.37 130.01 10.48 Favored Pre-proline 0 C--N 1.325 -0.477 0 O-C-N 124.511 0.771 . . . . 0.0 109.3 179.983 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 20.2 Cg_endo -74.97 85.99 1.46 Allowed 'Trans proline' 0 N--CA 1.453 -0.891 0 O-C-N 124.55 1.816 . . . . 0.0 111.043 -168.34 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.666 HG22 ' HB3' ' A' ' 24' ' ' ARG . 21.6 m . . . . . 0 C--N 1.325 -0.469 0 O-C-N 124.512 1.133 . . . . 0.0 109.3 179.995 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 37.6 m . . . . . 0 N--CA 1.453 -0.304 0 N-CA-C 108.294 -1.002 . . . . 0.0 108.294 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 91.42 -21.64 34.21 Favored Glycine 0 CA--C 1.531 1.06 0 O-C-N 124.505 1.128 . . . . 0.0 110.999 179.989 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 16.0 tt0 -85.23 161.1 19.71 Favored 'General case' 0 C--N 1.325 -0.466 0 O-C-N 124.541 0.789 . . . . 0.0 110.274 -179.987 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.866 HG22 HG23 ' A' ' 21' ' ' VAL . 72.5 p -121.94 136.2 54.91 Favored 'General case' 0 C--N 1.325 -0.457 0 O-C-N 124.445 1.09 . . . . 0.0 110.455 179.996 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 5' ' ' CYS . . . . . 0.426 ' O ' ' CD1' ' A' ' 19' ' ' TRP . 15.2 p -102.1 53.78 0.8 Allowed 'General case' 0 C--N 1.325 -0.493 0 O-C-N 124.573 1.17 . . . . 0.0 108.283 -179.978 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 4.7 t -59.5 -24.85 29.54 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 O-C-N 124.515 1.135 . . . . 0.0 109.302 -179.993 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -85.42 -32.97 18.11 Favored Glycine 0 CA--C 1.53 0.991 0 O-C-N 124.524 1.14 . . . . 0.0 110.978 -179.979 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 124.31 15.34 3.4 Favored Glycine 0 CA--C 1.53 0.983 0 O-C-N 125.021 1.071 . . . . 0.0 110.977 178.057 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 6.0 m -150.17 158.95 44.7 Favored 'General case' 0 C--N 1.325 -0.48 0 O-C-N 124.494 0.761 . . . . 0.0 110.397 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 74.9 m -117.8 141.75 48.07 Favored 'General case' 0 C--N 1.325 -0.476 0 O-C-N 124.496 1.123 . . . . 0.0 108.302 179.975 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 4.6 m120 -89.7 -47.62 7.81 Favored 'General case' 0 C--N 1.325 -0.475 0 O-C-N 124.498 1.124 . . . . 0.0 109.294 179.997 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.607 HG23 ' HD2' ' A' ' 13' ' ' PRO . 20.8 m -53.87 142.75 43.57 Favored Pre-proline 0 C--N 1.325 -0.479 0 O-C-N 124.442 1.089 . . . . 0.0 110.392 -179.975 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.607 ' HD2' HG23 ' A' ' 12' ' ' THR . 20.2 Cg_endo -75.04 130.78 13.54 Favored 'Trans proline' 0 N--CA 1.453 -0.866 0 O-C-N 124.443 1.759 . . . . 0.0 110.928 -168.237 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 75.36 13.55 82.75 Favored Glycine 0 CA--C 1.53 0.986 0 O-C-N 124.497 1.123 . . . . 0.0 111.022 -179.978 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.498 ' SG ' ' CG2' ' A' ' 12' ' ' THR . 64.2 m -95.54 126.65 40.97 Favored 'General case' 0 C--N 1.325 -0.476 0 N-CA-C 108.316 -0.994 . . . . 0.0 108.316 -179.967 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 17.6 p -94.0 155.23 17.24 Favored 'General case' 0 C--N 1.325 -0.485 0 O-C-N 124.48 1.112 . . . . 0.0 110.437 179.991 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 43.4 t -83.4 94.27 7.94 Favored 'General case' 0 C--N 1.325 -0.48 0 O-C-N 124.482 1.114 . . . . 0.0 108.325 -179.965 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 18' ' ' SER . . . . . 0.564 ' HB3' HG23 ' A' ' 23' ' ' THR . 47.9 t -102.53 66.67 0.98 Allowed 'General case' 0 C--N 1.325 -0.497 0 O-C-N 124.486 1.116 . . . . 0.0 109.971 174.166 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 19' ' ' TRP . . . . . 0.603 ' CG ' ' HA ' ' A' ' 20' ' ' PRO . 0.0 OUTLIER -36.0 147.3 0.18 Allowed Pre-proline 0 C--N 1.325 -0.485 0 O-C-N 124.483 1.114 . . . . 0.0 108.022 -174.167 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 20' ' ' PRO . . . . . 0.603 ' HA ' ' CG ' ' A' ' 19' ' ' TRP . 18.3 Cg_endo -74.94 -13.69 23.34 Favored 'Cis proline' 0 C--N 1.36 1.159 0 C-N-CA 121.006 -2.498 . . . . 0.0 111.038 -8.513 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.866 HG23 HG22 ' A' ' 4' ' ' THR . 1.1 p -98.42 177.75 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 O-C-N 124.512 1.132 . . . . 0.0 109.305 -173.083 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.505 ' H ' HG22 ' A' ' 21' ' ' VAL . 56.6 m -102.1 170.52 8.05 Favored 'General case' 0 C--N 1.325 -0.472 0 O-C-N 124.502 1.126 . . . . 0.0 108.271 -179.983 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 23' ' ' THR . . . . . 0.564 HG23 ' HB3' ' A' ' 18' ' ' SER . 1.1 p -144.98 164.86 29.86 Favored 'General case' 0 C--N 1.325 -0.466 0 O-C-N 124.561 1.163 . . . . 0.0 110.423 179.974 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.53 ' HB3' HG22 ' A' ' 29' ' ' VAL . 7.5 ttt180 -132.87 116.91 17.08 Favored 'General case' 0 C--N 1.325 -0.488 0 O-C-N 124.476 1.11 . . . . 0.0 110.341 179.966 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 75.7 m-20 57.39 23.37 8.89 Favored 'General case' 0 C--N 1.325 -0.48 0 O-C-N 124.452 1.095 . . . . 0.0 109.278 -179.991 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 83.89 25.22 46.26 Favored Glycine 0 CA--C 1.53 1.004 0 O-C-N 124.453 1.096 . . . . 0.0 110.995 -179.982 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 10.0 mt -144.22 131.19 10.31 Favored Pre-proline 0 C--N 1.325 -0.492 0 O-C-N 124.516 0.774 . . . . 0.0 109.268 179.995 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 20.1 Cg_endo -74.97 89.08 1.18 Allowed 'Trans proline' 0 N--CA 1.453 -0.872 0 O-C-N 124.462 1.77 . . . . 0.0 110.986 -168.308 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.53 HG22 ' HB3' ' A' ' 24' ' ' ARG . 33.5 m . . . . . 0 C--N 1.325 -0.485 0 O-C-N 124.443 1.09 . . . . 0.0 109.327 179.99 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 52.7 m . . . . . 0 N--CA 1.453 -0.279 0 N-CA-C 108.32 -0.993 . . . . 0.0 108.32 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 100.81 -10.16 58.75 Favored Glycine 0 CA--C 1.53 0.995 0 O-C-N 124.527 1.142 . . . . 0.0 110.997 -179.976 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 14.6 tt0 -99.17 162.77 12.87 Favored 'General case' 0 C--N 1.325 -0.484 0 O-C-N 124.51 0.77 . . . . 0.0 110.262 -179.96 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.674 HG22 HG23 ' A' ' 21' ' ' VAL . 80.9 p -120.12 138.09 53.77 Favored 'General case' 0 C--N 1.326 -0.446 0 O-C-N 124.541 1.151 . . . . 0.0 110.395 179.945 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 5' ' ' CYS . . . . . 0.431 ' O ' ' CD1' ' A' ' 19' ' ' TRP . 14.5 p -107.72 51.26 0.75 Allowed 'General case' 0 C--N 1.325 -0.482 0 O-C-N 124.515 1.134 . . . . 0.0 108.301 179.999 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 15.0 t -59.15 -23.89 25.86 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.468 0 O-C-N 124.461 1.101 . . . . 0.0 109.28 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -85.68 -34.07 14.5 Favored Glycine 0 CA--C 1.53 1.025 0 O-C-N 124.523 1.139 . . . . 0.0 111.019 179.981 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 126.19 17.57 2.44 Favored Glycine 0 C--N 1.344 0.993 0 O-C-N 125.223 1.19 . . . . 0.0 111.003 177.32 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -150.34 166.02 31.29 Favored 'General case' 0 C--N 1.325 -0.488 0 O-C-N 124.534 0.785 . . . . 0.0 110.377 -179.987 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 10' ' ' CYS . . . . . 0.41 ' SG ' ' O ' ' A' ' 16' ' ' THR . 80.1 m -125.97 142.76 51.38 Favored 'General case' 0 C--N 1.325 -0.468 0 O-C-N 124.485 1.116 . . . . 0.0 108.285 179.996 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 4.3 m-20 -89.99 -48.3 7.3 Favored 'General case' 0 C--N 1.324 -0.514 0 O-C-N 124.489 1.118 . . . . 0.0 109.286 -179.992 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.623 HG23 ' HD2' ' A' ' 13' ' ' PRO . 18.9 m -53.04 142.78 34.79 Favored Pre-proline 0 C--N 1.326 -0.453 0 O-C-N 124.497 1.123 . . . . 0.0 110.417 179.971 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.623 ' HD2' HG23 ' A' ' 12' ' ' THR . 20.1 Cg_endo -75.01 131.39 14.22 Favored 'Trans proline' 0 N--CA 1.453 -0.906 0 O-C-N 124.495 1.787 . . . . 0.0 110.969 -168.3 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 74.2 15.11 80.15 Favored Glycine 0 CA--C 1.53 0.999 0 O-C-N 124.46 1.1 . . . . 0.0 110.984 179.965 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.504 ' SG ' ' CG2' ' A' ' 12' ' ' THR . 63.7 m -97.47 125.93 42.44 Favored 'General case' 0 C--N 1.325 -0.483 0 N-CA-C 108.285 -1.006 . . . . 0.0 108.285 179.996 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 16' ' ' THR . . . . . 0.41 ' O ' ' SG ' ' A' ' 10' ' ' CYS . 18.6 p -94.11 158.61 15.53 Favored 'General case' 0 C--N 1.324 -0.504 0 O-C-N 124.489 1.118 . . . . 0.0 110.393 -179.993 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 42.4 t -81.72 94.11 6.93 Favored 'General case' 0 C--N 1.325 -0.473 0 O-C-N 124.467 1.104 . . . . 0.0 108.334 179.951 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 18' ' ' SER . . . . . 0.606 ' HB3' HG23 ' A' ' 23' ' ' THR . 2.5 t -100.98 65.57 1.11 Allowed 'General case' 0 C--N 1.325 -0.457 0 O-C-N 124.475 1.109 . . . . 0.0 109.989 174.214 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 19' ' ' TRP . . . . . 0.585 ' CG ' ' HA ' ' A' ' 20' ' ' PRO . 0.0 OUTLIER -36.64 148.04 0.19 Allowed Pre-proline 0 C--N 1.324 -0.507 0 O-C-N 124.489 1.118 . . . . 0.0 108.0 -174.067 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 20' ' ' PRO . . . . . 0.585 ' HA ' ' CG ' ' A' ' 19' ' ' TRP . 18.1 Cg_endo -75.02 -11.49 24.25 Favored 'Cis proline' 0 C--N 1.361 1.186 0 C-N-CA 121.017 -2.493 . . . . 0.0 110.97 -8.309 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.674 HG23 HG22 ' A' ' 4' ' ' THR . 3.2 p -100.5 -179.6 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 O-C-N 124.499 1.124 . . . . 0.0 109.291 -173.528 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.661 ' H ' HG22 ' A' ' 21' ' ' VAL . 60.4 m -101.67 167.01 10.39 Favored 'General case' 0 C--N 1.326 -0.456 0 O-C-N 124.526 1.141 . . . . 0.0 108.316 179.999 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 23' ' ' THR . . . . . 0.606 HG23 ' HB3' ' A' ' 18' ' ' SER . 0.8 OUTLIER -144.45 165.7 27.22 Favored 'General case' 0 C--N 1.324 -0.517 0 O-C-N 124.487 1.117 . . . . 0.0 110.412 179.958 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.425 ' HB3' ' CG2' ' A' ' 29' ' ' VAL . 15.0 ttt180 -135.18 120.2 18.67 Favored 'General case' 0 C--N 1.325 -0.495 0 O-C-N 124.542 1.151 . . . . 0.0 110.293 -179.958 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 25' ' ' ASN . . . . . 0.527 ' O ' ' ND2' ' A' ' 25' ' ' ASN . 0.2 OUTLIER 56.46 25.42 9.64 Favored 'General case' 0 C--N 1.324 -0.5 0 O-C-N 124.493 1.121 . . . . 0.0 109.296 179.977 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 79.41 27.93 53.78 Favored Glycine 0 CA--C 1.529 0.966 0 O-C-N 124.457 1.098 . . . . 0.0 111.021 179.999 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 40.1 mt -146.8 132.49 9.32 Favored Pre-proline 0 C--N 1.325 -0.469 0 O-C-N 124.47 0.747 . . . . 0.0 109.26 -179.986 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 20.1 Cg_endo -74.99 87.52 1.32 Allowed 'Trans proline' 0 N--CA 1.453 -0.895 0 O-C-N 124.543 1.812 . . . . 0.0 110.968 -168.319 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.425 ' CG2' ' HB3' ' A' ' 24' ' ' ARG . 18.2 m . . . . . 0 C--N 1.325 -0.465 0 O-C-N 124.532 1.145 . . . . 0.0 109.287 179.993 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 72.9 m . . . . . 0 N--CA 1.452 -0.336 0 N-CA-C 108.332 -0.988 . . . . 0.0 108.332 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 83.42 -10.96 57.67 Favored Glycine 0 CA--C 1.53 0.981 0 O-C-N 124.551 1.157 . . . . 0.0 110.988 179.981 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 7.7 pt-20 -100.28 171.59 7.68 Favored 'General case' 0 C--N 1.325 -0.46 0 O-C-N 124.493 0.76 . . . . 0.0 110.346 179.994 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 4' ' ' THR . . . . . 1.039 HG22 HG23 ' A' ' 21' ' ' VAL . 67.8 p -129.62 145.1 51.52 Favored 'General case' 0 C--N 1.325 -0.486 0 O-C-N 124.469 1.106 . . . . 0.0 110.455 179.997 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 5' ' ' CYS . . . . . 0.429 ' O ' ' CD1' ' A' ' 19' ' ' TRP . 22.6 p -107.35 56.41 0.64 Allowed 'General case' 0 C--N 1.324 -0.524 0 O-C-N 124.52 1.138 . . . . 0.0 108.292 -179.95 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.4 t -59.45 -24.87 29.46 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 O-C-N 124.508 1.13 . . . . 0.0 109.284 -179.956 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -84.85 -35.1 13.55 Favored Glycine 0 CA--C 1.53 1.009 0 O-C-N 124.509 1.13 . . . . 0.0 110.981 -179.986 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 125.48 17.22 2.67 Favored Glycine 0 C--N 1.344 1.025 0 O-C-N 125.055 1.091 . . . . 0.0 111.047 177.698 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 2.4 m -150.33 155.62 39.99 Favored 'General case' 0 C--N 1.326 -0.45 0 O-C-N 124.484 0.755 . . . . 0.0 110.436 179.969 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 94.5 m -110.89 140.56 45.26 Favored 'General case' 0 C--N 1.325 -0.477 0 O-C-N 124.501 1.126 . . . . 0.0 108.268 -179.969 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 30.5 m-20 -90.01 -38.74 13.41 Favored 'General case' 0 C--N 1.325 -0.477 0 O-C-N 124.47 1.106 . . . . 0.0 109.306 -179.999 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.667 HG23 ' HD2' ' A' ' 13' ' ' PRO . 15.6 m -65.58 143.25 98.58 Favored Pre-proline 0 C--N 1.325 -0.474 0 O-C-N 124.521 1.138 . . . . 0.0 110.43 179.988 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.667 ' HD2' HG23 ' A' ' 12' ' ' THR . 20.3 Cg_endo -74.92 131.05 13.96 Favored 'Trans proline' 0 N--CA 1.453 -0.894 0 O-C-N 124.496 1.787 . . . . 0.0 110.976 -168.302 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 75.04 15.13 81.25 Favored Glycine 0 CA--C 1.53 1.02 0 O-C-N 124.504 1.128 . . . . 0.0 110.97 179.963 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.494 ' SG ' HG22 ' A' ' 12' ' ' THR . 64.3 m -98.1 127.61 44.14 Favored 'General case' 0 C--N 1.325 -0.464 0 N-CA-C 108.308 -0.997 . . . . 0.0 108.308 179.971 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 71.0 p -94.28 152.25 18.81 Favored 'General case' 0 C--N 1.325 -0.484 0 O-C-N 124.48 1.112 . . . . 0.0 110.44 179.97 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 47.4 t -78.18 98.09 5.72 Favored 'General case' 0 C--N 1.325 -0.492 0 O-C-N 124.479 1.112 . . . . 0.0 108.243 -179.951 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 18' ' ' SER . . . . . 0.567 ' HB3' HG23 ' A' ' 23' ' ' THR . 10.8 t -104.78 65.89 0.76 Allowed 'General case' 0 C--N 1.324 -0.51 0 O-C-N 124.553 1.158 . . . . 0.0 109.958 174.442 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 19' ' ' TRP . . . . . 0.604 ' CG ' ' HA ' ' A' ' 20' ' ' PRO . 0.0 OUTLIER -36.88 147.87 0.2 Allowed Pre-proline 0 C--N 1.325 -0.489 0 O-C-N 124.505 1.128 . . . . 0.0 107.99 -174.18 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 20' ' ' PRO . . . . . 0.604 ' HA ' ' CG ' ' A' ' 19' ' ' TRP . 18.1 Cg_endo -75.04 -12.57 24.07 Favored 'Cis proline' 0 C--N 1.36 1.144 0 C-N-CA 120.974 -2.511 . . . . 0.0 110.957 -8.505 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 1.039 HG23 HG22 ' A' ' 4' ' ' THR . 4.4 p -98.09 178.85 0.6 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 O-C-N 124.521 1.138 . . . . 0.0 109.289 -173.628 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.683 ' H ' HG22 ' A' ' 21' ' ' VAL . 1.7 m -101.95 168.51 9.36 Favored 'General case' 0 C--N 1.325 -0.477 0 O-C-N 124.49 1.119 . . . . 0.0 108.348 -179.993 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 23' ' ' THR . . . . . 0.567 HG23 ' HB3' ' A' ' 18' ' ' SER . 0.8 OUTLIER -145.34 168.31 20.8 Favored 'General case' 0 C--N 1.325 -0.488 0 O-C-N 124.486 1.116 . . . . 0.0 110.399 -179.976 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.468 ' HB3' ' CG2' ' A' ' 29' ' ' VAL . 29.3 ttt-85 -144.64 119.39 9.85 Favored 'General case' 0 C--N 1.324 -0.506 0 O-C-N 124.514 1.133 . . . . 0.0 110.332 -179.979 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 25' ' ' ASN . . . . . 0.558 ' O ' ' ND2' ' A' ' 25' ' ' ASN . 2.5 t30 57.42 23.28 8.84 Favored 'General case' 0 C--N 1.325 -0.491 0 O-C-N 124.506 1.129 . . . . 0.0 109.293 -179.997 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 83.44 24.27 51.37 Favored Glycine 0 CA--C 1.53 0.974 0 O-C-N 124.514 1.134 . . . . 0.0 111.027 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 19.1 mt -147.3 128.27 7.09 Favored Pre-proline 0 C--N 1.325 -0.463 0 O-C-N 124.464 0.744 . . . . 0.0 109.325 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 20.2 Cg_endo -74.97 80.96 2.31 Favored 'Trans proline' 0 N--CA 1.453 -0.891 0 O-C-N 124.474 1.776 . . . . 0.0 110.972 -168.271 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.468 ' CG2' ' HB3' ' A' ' 24' ' ' ARG . 17.6 m . . . . . 0 C--N 1.325 -0.46 0 O-C-N 124.482 1.114 . . . . 0.0 109.289 -179.982 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 80.8 m . . . . . 0 N--CA 1.453 -0.319 0 N-CA-C 108.317 -0.994 . . . . 0.0 108.317 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 82.75 -10.69 55.96 Favored Glycine 0 CA--C 1.53 0.992 0 O-C-N 124.525 1.141 . . . . 0.0 111.042 -179.993 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 7.6 pt-20 -100.28 171.87 7.51 Favored 'General case' 0 C--N 1.325 -0.478 0 O-C-N 124.497 0.763 . . . . 0.0 110.288 179.98 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.975 HG22 HG23 ' A' ' 21' ' ' VAL . 46.1 p -128.92 144.36 51.16 Favored 'General case' 0 C--N 1.326 -0.452 0 O-C-N 124.463 1.102 . . . . 0.0 110.394 179.965 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 5' ' ' CYS . . . . . 0.526 ' O ' ' CD1' ' A' ' 19' ' ' TRP . 15.1 p -103.08 52.39 0.78 Allowed 'General case' 0 C--N 1.325 -0.472 0 O-C-N 124.505 1.128 . . . . 0.0 108.291 -179.984 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.8 t -59.26 -25.01 29.26 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 O-C-N 124.502 1.127 . . . . 0.0 109.328 -179.986 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -84.63 -32.91 20.68 Favored Glycine 0 CA--C 1.529 0.966 0 O-C-N 124.522 1.138 . . . . 0.0 110.982 179.988 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 124.4 14.63 3.55 Favored Glycine 0 CA--C 1.531 1.049 0 O-C-N 124.892 0.995 . . . . 0.0 110.97 177.996 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 49.1 m -150.29 165.15 33.88 Favored 'General case' 0 C--N 1.325 -0.468 0 O-C-N 124.483 0.755 . . . . 0.0 110.374 -180.0 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 98.4 m -118.37 141.4 48.57 Favored 'General case' 0 C--N 1.326 -0.449 0 O-C-N 124.458 1.099 . . . . 0.0 108.272 -179.989 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 47.2 t30 -89.89 -39.84 12.79 Favored 'General case' 0 C--N 1.325 -0.467 0 O-C-N 124.51 1.131 . . . . 0.0 109.33 179.973 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.652 HG23 ' HD2' ' A' ' 13' ' ' PRO . 16.9 m -64.68 143.02 98.64 Favored Pre-proline 0 C--N 1.325 -0.472 0 O-C-N 124.495 1.122 . . . . 0.0 110.377 -179.993 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.652 ' HD2' HG23 ' A' ' 12' ' ' THR . 20.1 Cg_endo -75.01 130.65 13.46 Favored 'Trans proline' 0 N--CA 1.453 -0.875 0 O-C-N 124.502 1.791 . . . . 0.0 110.955 -168.298 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 76.22 12.82 83.85 Favored Glycine 0 CA--C 1.53 0.979 0 O-C-N 124.514 1.134 . . . . 0.0 111.02 -179.987 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.498 ' SG ' ' CG2' ' A' ' 12' ' ' THR . 64.9 m -95.7 127.48 41.76 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 108.318 -0.993 . . . . 0.0 108.318 179.964 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 29.9 p -94.5 150.16 20.53 Favored 'General case' 0 C--N 1.325 -0.472 0 O-C-N 124.456 1.098 . . . . 0.0 110.466 179.958 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 37.5 t -76.96 96.18 4.31 Favored 'General case' 0 C--N 1.324 -0.523 0 O-C-N 124.557 1.161 . . . . 0.0 108.283 179.988 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 18' ' ' SER . . . . . 0.51 ' O ' ' C ' ' A' ' 19' ' ' TRP . 1.8 m -102.31 65.51 0.95 Allowed 'General case' 0 C--N 1.325 -0.482 0 O-C-N 124.506 1.128 . . . . 0.0 110.003 174.326 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 19' ' ' TRP . . . . . 0.602 ' CG ' ' HA ' ' A' ' 20' ' ' PRO . 0.0 OUTLIER -36.71 148.05 0.19 Allowed Pre-proline 0 C--N 1.325 -0.498 0 O-C-N 124.525 1.141 . . . . 0.0 108.008 -173.995 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 20' ' ' PRO . . . . . 0.602 ' HA ' ' CG ' ' A' ' 19' ' ' TRP . 18.5 Cg_endo -74.93 -12.53 23.78 Favored 'Cis proline' 0 C--N 1.36 1.149 0 C-N-CA 121.03 -2.487 . . . . 0.0 111.015 -8.509 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.975 HG23 HG22 ' A' ' 4' ' ' THR . 5.8 p -98.87 177.38 0.69 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 O-C-N 124.475 1.11 . . . . 0.0 109.324 -173.279 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.683 ' H ' HG22 ' A' ' 21' ' ' VAL . 1.8 m -102.07 169.74 8.56 Favored 'General case' 0 C--N 1.324 -0.507 0 O-C-N 124.521 1.138 . . . . 0.0 108.314 179.973 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 23' ' ' THR . . . . . 0.416 ' O ' ' HA ' ' A' ' 15' ' ' CYS . 0.9 OUTLIER -149.5 165.05 33.35 Favored 'General case' 0 C--N 1.324 -0.518 0 O-C-N 124.49 1.119 . . . . 0.0 110.429 -179.931 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.555 ' HB3' HG22 ' A' ' 29' ' ' VAL . 10.9 ttt85 -141.22 119.68 12.32 Favored 'General case' 0 C--N 1.325 -0.488 0 O-C-N 124.49 1.119 . . . . 0.0 110.289 179.952 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 25' ' ' ASN . . . . . 0.555 ' O ' ' ND2' ' A' ' 25' ' ' ASN . 1.9 t30 57.58 22.71 8.47 Favored 'General case' 0 C--N 1.325 -0.488 0 O-C-N 124.534 1.146 . . . . 0.0 109.329 -179.965 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 26' ' ' GLY . . . . . 0.463 ' O ' HD23 ' A' ' 27' ' ' LEU . . . 83.9 23.93 50.85 Favored Glycine 0 CA--C 1.53 0.997 0 O-C-N 124.533 1.146 . . . . 0.0 110.975 179.978 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 27' ' ' LEU . . . . . 0.463 HD23 ' O ' ' A' ' 26' ' ' GLY . 13.8 mt -145.93 128.37 7.94 Favored Pre-proline 0 C--N 1.325 -0.48 0 O-C-N 124.551 0.795 . . . . 0.0 109.281 179.976 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 20.3 Cg_endo -74.98 77.42 3.13 Favored 'Trans proline' 0 N--CA 1.453 -0.892 0 O-C-N 124.503 1.791 . . . . 0.0 111.014 -168.327 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.555 HG22 ' HB3' ' A' ' 24' ' ' ARG . 36.0 m . . . . . 0 C--N 1.325 -0.458 0 O-C-N 124.527 1.142 . . . . 0.0 109.259 -179.994 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 87.2 m . . . . . 0 N--CA 1.452 -0.33 0 N-CA-C 108.322 -0.992 . . . . 0.0 108.322 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 91.31 -15.27 61.6 Favored Glycine 0 CA--C 1.53 1.023 0 O-C-N 124.504 1.127 . . . . 0.0 110.98 179.996 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 15.2 tt0 -88.3 162.25 16.7 Favored 'General case' 0 C--N 1.324 -0.509 0 O-C-N 124.534 0.785 . . . . 0.0 110.291 179.98 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.666 HG22 HG23 ' A' ' 21' ' ' VAL . 47.7 p -120.73 131.83 54.73 Favored 'General case' 0 C--N 1.325 -0.484 0 O-C-N 124.456 1.098 . . . . 0.0 110.389 -179.993 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 5' ' ' CYS . . . . . 0.417 ' SG ' ' O ' ' A' ' 5' ' ' CYS . 14.6 p -100.11 52.08 0.9 Allowed 'General case' 0 C--N 1.325 -0.46 0 O-C-N 124.502 1.126 . . . . 0.0 108.316 179.963 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 11.9 t -59.27 -24.84 28.8 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 O-C-N 124.496 1.123 . . . . 0.0 109.318 179.951 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -84.54 -32.0 23.19 Favored Glycine 0 CA--C 1.53 0.983 0 O-C-N 124.503 1.127 . . . . 0.0 111.008 -179.945 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 123.84 15.91 3.44 Favored Glycine 0 CA--C 1.53 0.992 0 O-C-N 124.896 0.998 . . . . 0.0 110.996 178.112 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 62.2 m -150.11 165.57 32.41 Favored 'General case' 0 C--N 1.325 -0.476 0 O-C-N 124.508 0.769 . . . . 0.0 110.413 179.975 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 10' ' ' CYS . . . . . 0.405 ' SG ' ' O ' ' A' ' 16' ' ' THR . 96.9 m -122.15 143.45 49.55 Favored 'General case' 0 C--N 1.325 -0.464 0 O-C-N 124.512 1.133 . . . . 0.0 108.295 179.999 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 12.0 m-20 -90.11 -47.03 8.07 Favored 'General case' 0 C--N 1.324 -0.511 0 O-C-N 124.505 1.128 . . . . 0.0 109.26 -179.984 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.616 HG23 ' HD2' ' A' ' 13' ' ' PRO . 20.9 m -54.6 142.68 51.54 Favored Pre-proline 0 C--N 1.325 -0.461 0 O-C-N 124.462 1.101 . . . . 0.0 110.431 179.985 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.616 ' HD2' HG23 ' A' ' 12' ' ' THR . 20.1 Cg_endo -74.99 131.36 14.21 Favored 'Trans proline' 0 N--CA 1.453 -0.867 0 O-C-N 124.531 1.806 . . . . 0.0 110.977 -168.295 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 74.69 14.91 80.94 Favored Glycine 0 CA--C 1.53 1.028 0 O-C-N 124.495 1.122 . . . . 0.0 111.024 179.989 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.504 ' SG ' ' CG2' ' A' ' 12' ' ' THR . 63.9 m -96.08 134.58 38.95 Favored 'General case' 0 C--N 1.325 -0.483 0 N-CA-C 108.297 -1.001 . . . . 0.0 108.297 179.987 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 16' ' ' THR . . . . . 0.405 ' O ' ' SG ' ' A' ' 10' ' ' CYS . 82.7 p -101.11 152.97 19.98 Favored 'General case' 0 C--N 1.325 -0.466 0 O-C-N 124.445 1.091 . . . . 0.0 110.401 179.975 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 41.3 t -79.71 94.41 5.72 Favored 'General case' 0 C--N 1.325 -0.481 0 O-C-N 124.52 1.138 . . . . 0.0 108.363 179.942 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 18' ' ' SER . . . . . 0.517 ' O ' ' C ' ' A' ' 19' ' ' TRP . 17.5 t -101.45 65.48 1.05 Allowed 'General case' 0 C--N 1.325 -0.488 0 O-C-N 124.456 1.097 . . . . 0.0 110.002 174.236 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 19' ' ' TRP . . . . . 0.621 ' CG ' ' HA ' ' A' ' 20' ' ' PRO . 0.1 OUTLIER -36.14 147.01 0.19 Allowed Pre-proline 0 C--N 1.325 -0.477 0 O-C-N 124.515 1.134 . . . . 0.0 107.997 -174.129 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 20' ' ' PRO . . . . . 0.621 ' HA ' ' CG ' ' A' ' 19' ' ' TRP . 18.2 Cg_endo -74.97 -13.76 23.37 Favored 'Cis proline' 0 C--N 1.36 1.166 0 C-N-CA 121.009 -2.496 . . . . 0.0 111.003 -8.557 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.666 HG23 HG22 ' A' ' 4' ' ' THR . 0.9 OUTLIER -97.35 178.04 0.63 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 O-C-N 124.449 1.093 . . . . 0.0 109.29 -173.148 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.491 ' H ' HG22 ' A' ' 21' ' ' VAL . 36.8 m -101.72 170.48 8.14 Favored 'General case' 0 C--N 1.325 -0.461 0 O-C-N 124.549 1.156 . . . . 0.0 108.289 -179.991 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 23' ' ' THR . . . . . 0.501 HG23 ' HB3' ' A' ' 18' ' ' SER . 0.8 OUTLIER -146.88 166.81 25.61 Favored 'General case' 0 C--N 1.325 -0.487 0 O-C-N 124.483 1.115 . . . . 0.0 110.404 179.985 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.581 ' HB3' HG22 ' A' ' 29' ' ' VAL . 2.5 ttt180 -139.05 119.28 13.61 Favored 'General case' 0 C--N 1.325 -0.487 0 O-C-N 124.514 1.134 . . . . 0.0 110.327 179.995 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 81.1 m-20 57.16 22.99 8.08 Favored 'General case' 0 C--N 1.325 -0.478 0 O-C-N 124.515 1.134 . . . . 0.0 109.333 -179.973 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 83.7 25.58 45.64 Favored Glycine 0 CA--C 1.53 0.997 0 O-C-N 124.519 1.137 . . . . 0.0 110.968 179.949 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 12.9 mt -145.57 130.38 9.01 Favored Pre-proline 0 C--N 1.325 -0.488 0 O-C-N 124.457 0.739 . . . . 0.0 109.309 179.991 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 20.1 Cg_endo -75.01 82.48 2.0 Allowed 'Trans proline' 0 N--CA 1.453 -0.91 0 O-C-N 124.505 1.792 . . . . 0.0 110.955 -168.309 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.581 HG22 ' HB3' ' A' ' 24' ' ' ARG . 28.2 m . . . . . 0 C--N 1.325 -0.465 0 O-C-N 124.528 1.142 . . . . 0.0 109.346 179.951 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 93.5 m . . . . . 0 N--CA 1.453 -0.287 0 N-CA-C 108.32 -0.993 . . . . 0.0 108.32 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 95.54 -15.2 63.66 Favored Glycine 0 CA--C 1.53 1.03 0 O-C-N 124.486 1.116 . . . . 0.0 110.995 179.987 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 15.1 tt0 -86.4 161.82 18.47 Favored 'General case' 0 C--N 1.325 -0.459 0 O-C-N 124.504 0.767 . . . . 0.0 110.287 -179.992 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.404 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 48.0 p -119.03 132.23 56.03 Favored 'General case' 0 C--N 1.324 -0.508 0 O-C-N 124.505 1.128 . . . . 0.0 110.406 179.987 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 5' ' ' CYS . . . . . 0.427 ' O ' ' CD1' ' A' ' 19' ' ' TRP . 14.3 p -102.18 51.29 0.82 Allowed 'General case' 0 C--N 1.324 -0.509 0 O-C-N 124.531 1.144 . . . . 0.0 108.295 -179.965 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 6.6 t -59.27 -24.5 27.89 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 O-C-N 124.458 1.099 . . . . 0.0 109.289 -179.97 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -85.52 -34.31 14.25 Favored Glycine 0 CA--C 1.53 0.976 0 O-C-N 124.503 1.127 . . . . 0.0 111.041 -180.0 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 125.1 16.75 2.86 Favored Glycine 0 CA--C 1.53 1.0 0 O-C-N 124.945 1.026 . . . . 0.0 111.043 177.818 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 2.6 m -150.21 157.92 43.6 Favored 'General case' 0 C--N 1.325 -0.473 0 O-C-N 124.533 0.784 . . . . 0.0 110.414 -179.963 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 10' ' ' CYS . . . . . 0.411 ' SG ' ' O ' ' A' ' 16' ' ' THR . 84.0 m -118.59 144.56 46.03 Favored 'General case' 0 C--N 1.325 -0.471 0 O-C-N 124.487 1.117 . . . . 0.0 108.313 179.989 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 76.1 m-20 -89.86 -51.78 5.32 Favored 'General case' 0 C--N 1.325 -0.481 0 O-C-N 124.512 1.133 . . . . 0.0 109.314 179.977 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.605 HG23 ' HD2' ' A' ' 13' ' ' PRO . 22.0 m -49.72 142.58 12.19 Favored Pre-proline 0 C--N 1.325 -0.49 0 O-C-N 124.551 1.157 . . . . 0.0 110.405 179.982 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.605 ' HD2' HG23 ' A' ' 12' ' ' THR . 20.2 Cg_endo -74.99 131.7 14.59 Favored 'Trans proline' 0 N--CA 1.452 -0.947 0 O-C-N 124.45 1.763 . . . . 0.0 111.011 -168.267 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 74.36 13.78 81.31 Favored Glycine 0 CA--C 1.53 1.022 0 O-C-N 124.49 1.118 . . . . 0.0 111.009 -179.978 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.505 ' SG ' ' CG2' ' A' ' 12' ' ' THR . 67.4 m -96.31 126.18 41.34 Favored 'General case' 0 C--N 1.324 -0.504 0 N-CA-C 108.336 -0.987 . . . . 0.0 108.336 179.971 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 16' ' ' THR . . . . . 0.411 ' O ' ' SG ' ' A' ' 10' ' ' CYS . 30.8 p -94.24 158.32 15.65 Favored 'General case' 0 C--N 1.325 -0.481 0 O-C-N 124.482 1.114 . . . . 0.0 110.387 -180.0 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 42.4 t -82.37 94.99 7.5 Favored 'General case' 0 C--N 1.325 -0.484 0 O-C-N 124.524 1.14 . . . . 0.0 108.339 179.968 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 18' ' ' SER . . . . . 0.515 ' O ' ' C ' ' A' ' 19' ' ' TRP . 3.0 t -100.54 65.57 1.19 Allowed 'General case' 0 C--N 1.325 -0.463 0 O-C-N 124.526 1.141 . . . . 0.0 109.993 174.198 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 19' ' ' TRP . . . . . 0.592 ' CG ' ' HA ' ' A' ' 20' ' ' PRO . 0.0 OUTLIER -36.73 147.47 0.2 Allowed Pre-proline 0 C--N 1.325 -0.484 0 N-CA-C 107.958 -1.127 . . . . 0.0 107.958 -173.93 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 20' ' ' PRO . . . . . 0.592 ' HA ' ' CG ' ' A' ' 19' ' ' TRP . 18.2 Cg_endo -75.04 -12.83 23.99 Favored 'Cis proline' 0 C--N 1.36 1.184 0 C-N-CA 120.968 -2.513 . . . . 0.0 111.003 -8.478 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.492 ' O ' ' C ' ' A' ' 18' ' ' SER . 16.3 m -98.05 179.24 0.58 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.494 0 O-C-N 124.514 1.134 . . . . 0.0 109.293 -173.478 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 51.9 m -101.77 168.08 9.68 Favored 'General case' 0 C--N 1.325 -0.488 0 O-C-N 124.54 1.15 . . . . 0.0 108.311 179.979 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 23' ' ' THR . . . . . 0.498 HG23 ' HB3' ' A' ' 18' ' ' SER . 0.8 OUTLIER -146.97 168.06 22.44 Favored 'General case' 0 C--N 1.325 -0.458 0 O-C-N 124.515 1.135 . . . . 0.0 110.382 179.999 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.485 ' HB3' HG22 ' A' ' 29' ' ' VAL . 0.3 OUTLIER -141.54 119.69 12.12 Favored 'General case' 0 C--N 1.325 -0.468 0 O-C-N 124.506 1.128 . . . . 0.0 110.279 179.993 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 25' ' ' ASN . . . . . 0.545 ' O ' ' ND2' ' A' ' 25' ' ' ASN . 2.7 t30 57.84 23.07 9.27 Favored 'General case' 0 C--N 1.326 -0.455 0 O-C-N 124.479 1.112 . . . . 0.0 109.303 179.967 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 26' ' ' GLY . . . . . 0.441 ' O ' HD23 ' A' ' 27' ' ' LEU . . . 82.43 23.34 56.78 Favored Glycine 0 CA--C 1.53 1.019 0 O-C-N 124.467 1.104 . . . . 0.0 110.976 179.992 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 27' ' ' LEU . . . . . 0.441 HD23 ' O ' ' A' ' 26' ' ' GLY . 11.9 mt -143.53 129.62 10.19 Favored Pre-proline 0 C--N 1.325 -0.498 0 O-C-N 124.461 0.742 . . . . 0.0 109.331 -179.997 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 20.5 Cg_endo -74.92 82.53 1.97 Allowed 'Trans proline' 0 N--CA 1.453 -0.861 0 O-C-N 124.516 1.798 . . . . 0.0 111.031 -168.343 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.485 HG22 ' HB3' ' A' ' 24' ' ' ARG . 27.4 m . . . . . 0 C--N 1.325 -0.484 0 O-C-N 124.489 1.118 . . . . 0.0 109.343 179.982 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 69.1 m . . . . . 0 N--CA 1.452 -0.328 0 N-CA-C 108.276 -1.009 . . . . 0.0 108.276 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 93.89 -15.7 62.51 Favored Glycine 0 CA--C 1.53 1.004 0 O-C-N 124.524 1.14 . . . . 0.0 110.995 179.97 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 15.5 tt0 -86.75 162.53 17.8 Favored 'General case' 0 C--N 1.326 -0.446 0 O-C-N 124.474 0.749 . . . . 0.0 110.322 -179.971 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.504 HG22 HG23 ' A' ' 21' ' ' VAL . 65.9 p -120.16 132.97 55.59 Favored 'General case' 0 C--N 1.325 -0.486 0 O-C-N 124.452 1.095 . . . . 0.0 110.398 179.961 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 5' ' ' CYS . . . . . 0.425 ' SG ' ' O ' ' A' ' 5' ' ' CYS . 13.8 p -102.44 49.96 0.84 Allowed 'General case' 0 C--N 1.325 -0.457 0 O-C-N 124.449 1.093 . . . . 0.0 108.279 -179.981 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 15.1 t -59.09 -24.0 25.97 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 O-C-N 124.562 1.164 . . . . 0.0 109.351 179.947 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -83.61 -33.67 21.45 Favored Glycine 0 CA--C 1.53 1.0 0 O-C-N 124.488 1.118 . . . . 0.0 111.033 179.972 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 126.88 10.85 3.74 Favored Glycine 0 C--N 1.345 1.074 0 C-N-CA 119.774 -1.203 . . . . 0.0 110.989 177.917 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -149.92 166.96 28.0 Favored 'General case' 0 C--N 1.325 -0.496 0 O-C-N 124.522 0.778 . . . . 0.0 110.416 -179.994 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 10' ' ' CYS . . . . . 0.412 ' SG ' ' O ' ' A' ' 16' ' ' THR . 80.2 m -121.8 146.37 47.14 Favored 'General case' 0 C--N 1.325 -0.469 0 O-C-N 124.484 1.115 . . . . 0.0 108.293 179.996 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 22.2 t30 -92.41 -44.17 8.83 Favored 'General case' 0 C--N 1.325 -0.479 0 O-C-N 124.518 1.136 . . . . 0.0 109.306 -179.995 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.632 HG23 ' HD2' ' A' ' 13' ' ' PRO . 18.4 m -57.75 142.89 77.62 Favored Pre-proline 0 C--N 1.324 -0.506 0 O-C-N 124.495 1.122 . . . . 0.0 110.391 179.976 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.632 ' HD2' HG23 ' A' ' 12' ' ' THR . 20.3 Cg_endo -74.96 131.68 14.62 Favored 'Trans proline' 0 N--CA 1.453 -0.879 0 O-C-N 124.533 1.807 . . . . 0.0 111.003 -168.335 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 76.42 7.23 85.08 Favored Glycine 0 CA--C 1.53 0.985 0 O-C-N 124.428 1.08 . . . . 0.0 111.007 179.985 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.5 ' SG ' ' CG2' ' A' ' 12' ' ' THR . 69.2 m -92.14 126.28 37.16 Favored 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 108.283 -1.006 . . . . 0.0 108.283 -179.998 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 16' ' ' THR . . . . . 0.412 ' O ' ' SG ' ' A' ' 10' ' ' CYS . 34.3 p -95.28 156.52 16.29 Favored 'General case' 0 C--N 1.325 -0.484 0 O-C-N 124.543 1.152 . . . . 0.0 110.378 179.997 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 42.7 t -80.99 94.12 6.49 Favored 'General case' 0 C--N 1.325 -0.478 0 O-C-N 124.532 1.145 . . . . 0.0 108.276 -179.964 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 18' ' ' SER . . . . . 0.518 ' O ' ' C ' ' A' ' 19' ' ' TRP . 3.6 t -100.36 65.51 1.22 Allowed 'General case' 0 C--N 1.325 -0.484 0 O-C-N 124.506 1.128 . . . . 0.0 110.006 174.172 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 19' ' ' TRP . . . . . 0.603 ' CG ' ' HA ' ' A' ' 20' ' ' PRO . 0.0 OUTLIER -36.3 147.42 0.19 Allowed Pre-proline 0 C--N 1.325 -0.465 0 N-CA-C 107.992 -1.114 . . . . 0.0 107.992 -173.981 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 20' ' ' PRO . . . . . 0.603 ' HA ' ' CG ' ' A' ' 19' ' ' TRP . 18.3 Cg_endo -75.03 -12.92 23.97 Favored 'Cis proline' 0 C--N 1.36 1.166 0 C-N-CA 121.035 -2.485 . . . . 0.0 110.981 -8.374 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.69 HG22 ' H ' ' A' ' 22' ' ' CYS . 4.6 p -99.02 179.16 0.6 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.5 0 O-C-N 124.502 1.126 . . . . 0.0 109.292 -173.284 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.69 ' H ' HG22 ' A' ' 21' ' ' VAL . 53.3 m -101.63 168.9 9.18 Favored 'General case' 0 C--N 1.325 -0.473 0 O-C-N 124.476 1.11 . . . . 0.0 108.358 179.986 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 23' ' ' THR . . . . . 0.441 ' OG1' ' CB ' ' A' ' 18' ' ' SER . 0.8 OUTLIER -148.36 167.54 24.97 Favored 'General case' 0 C--N 1.325 -0.488 0 O-C-N 124.5 1.125 . . . . 0.0 110.389 -179.986 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.552 ' HB3' HG22 ' A' ' 29' ' ' VAL . 1.4 ttt85 -137.72 120.04 15.8 Favored 'General case' 0 C--N 1.325 -0.472 0 O-C-N 124.493 1.121 . . . . 0.0 110.263 -179.961 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 58.4 t30 56.3 23.33 7.11 Favored 'General case' 0 C--N 1.325 -0.48 0 O-C-N 124.521 1.138 . . . . 0.0 109.288 179.972 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 26' ' ' GLY . . . . . 0.615 ' O ' HD23 ' A' ' 27' ' ' LEU . . . 81.99 28.85 40.08 Favored Glycine 0 CA--C 1.53 0.992 0 O-C-N 124.513 1.133 . . . . 0.0 111.014 -179.988 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 27' ' ' LEU . . . . . 0.615 HD23 ' O ' ' A' ' 26' ' ' GLY . 22.9 mt -147.27 130.2 7.96 Favored Pre-proline 0 C--N 1.325 -0.461 0 O-C-N 124.513 0.772 . . . . 0.0 109.284 179.957 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 20.2 Cg_endo -75.0 84.28 1.69 Allowed 'Trans proline' 0 N--CA 1.453 -0.881 0 O-C-N 124.488 1.783 . . . . 0.0 110.995 -168.332 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.552 HG22 ' HB3' ' A' ' 24' ' ' ARG . 30.4 m . . . . . 0 C--N 1.326 -0.447 0 O-C-N 124.482 1.114 . . . . 0.0 109.308 179.962 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 16.7 m . . . . . 0 N--CA 1.453 -0.303 0 N-CA-C 108.314 -0.995 . . . . 0.0 108.314 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 92.96 -20.03 48.24 Favored Glycine 0 CA--C 1.53 1.021 0 O-C-N 124.49 1.119 . . . . 0.0 111.001 179.97 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 15.6 tt0 -83.86 162.07 20.67 Favored 'General case' 0 C--N 1.325 -0.475 0 O-C-N 124.487 0.757 . . . . 0.0 110.353 179.976 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.544 HG22 HG13 ' A' ' 21' ' ' VAL . 53.3 p -123.13 132.84 54.24 Favored 'General case' 0 C--N 1.325 -0.478 0 O-C-N 124.455 1.097 . . . . 0.0 110.371 -179.98 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 5' ' ' CYS . . . . . 0.404 ' SG ' ' O ' ' A' ' 5' ' ' CYS . 16.4 p -100.34 55.22 0.9 Allowed 'General case' 0 C--N 1.326 -0.447 0 O-C-N 124.508 1.13 . . . . 0.0 108.337 179.94 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 9.6 t -59.33 -25.35 30.52 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 O-C-N 124.45 1.094 . . . . 0.0 109.245 -179.944 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -83.79 -30.68 28.68 Favored Glycine 0 CA--C 1.529 0.964 0 O-C-N 124.52 1.138 . . . . 0.0 111.006 179.991 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 122.3 14.23 4.55 Favored Glycine 0 CA--C 1.53 1.013 0 O-C-N 125.006 1.062 . . . . 0.0 110.988 178.694 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 42.5 m -149.95 164.15 36.2 Favored 'General case' 0 C--N 1.325 -0.484 0 O-C-N 124.54 0.788 . . . . 0.0 110.362 -180.0 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 10' ' ' CYS . . . . . 0.401 ' SG ' ' O ' ' A' ' 16' ' ' THR . 97.2 m -120.45 140.98 50.59 Favored 'General case' 0 C--N 1.326 -0.447 0 O-C-N 124.467 1.104 . . . . 0.0 108.292 179.991 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 37.6 t30 -89.74 -45.02 9.59 Favored 'General case' 0 C--N 1.325 -0.463 0 O-C-N 124.493 1.121 . . . . 0.0 109.298 179.977 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.634 HG23 ' HD2' ' A' ' 13' ' ' PRO . 18.3 m -56.02 143.05 63.9 Favored Pre-proline 0 C--N 1.326 -0.453 0 O-C-N 124.462 1.101 . . . . 0.0 110.417 179.973 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.634 ' HD2' HG23 ' A' ' 12' ' ' THR . 20.2 Cg_endo -74.97 130.3 13.18 Favored 'Trans proline' 0 N--CA 1.452 -0.917 0 O-C-N 124.508 1.793 . . . . 0.0 110.987 -168.329 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 75.12 15.29 81.19 Favored Glycine 0 CA--C 1.53 0.995 0 O-C-N 124.442 1.089 . . . . 0.0 111.035 -179.999 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.5 ' SG ' ' CG2' ' A' ' 12' ' ' THR . 57.6 m -96.62 129.88 43.92 Favored 'General case' 0 C--N 1.325 -0.489 0 N-CA-C 108.323 -0.991 . . . . 0.0 108.323 179.999 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 16' ' ' THR . . . . . 0.401 ' O ' ' SG ' ' A' ' 10' ' ' CYS . 21.6 p -95.99 152.7 18.28 Favored 'General case' 0 C--N 1.325 -0.472 0 O-C-N 124.497 1.123 . . . . 0.0 110.366 -179.965 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 45.0 t -82.99 95.86 8.14 Favored 'General case' 0 C--N 1.325 -0.498 0 O-C-N 124.483 1.115 . . . . 0.0 108.285 179.973 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 18' ' ' SER . . . . . 0.778 ' OG ' HG23 ' A' ' 23' ' ' THR . 34.6 p -105.88 66.39 0.72 Allowed 'General case' 0 C--N 1.326 -0.453 0 O-C-N 124.464 1.102 . . . . 0.0 110.023 174.144 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 19' ' ' TRP . . . . . 0.642 ' CG ' ' HA ' ' A' ' 20' ' ' PRO . 0.8 OUTLIER -35.79 146.7 0.19 Allowed Pre-proline 0 C--N 1.324 -0.51 0 O-C-N 124.552 1.158 . . . . 0.0 107.975 -174.399 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 20' ' ' PRO . . . . . 0.642 ' HA ' ' CG ' ' A' ' 19' ' ' TRP . 18.2 Cg_endo -75.04 -14.83 22.94 Favored 'Cis proline' 0 C--N 1.36 1.159 0 C-N-CA 120.954 -2.519 . . . . 0.0 111.005 -8.67 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.614 HG12 ' H ' ' A' ' 22' ' ' CYS . 2.2 t -96.38 175.97 0.74 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.479 0 O-C-N 124.496 1.122 . . . . 0.0 109.31 -172.992 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.614 ' H ' HG12 ' A' ' 21' ' ' VAL . 33.4 m -102.47 170.13 8.24 Favored 'General case' 0 C--N 1.325 -0.481 0 O-C-N 124.465 1.103 . . . . 0.0 108.298 179.977 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 23' ' ' THR . . . . . 0.778 HG23 ' OG ' ' A' ' 18' ' ' SER . 1.0 OUTLIER -141.7 168.4 19.85 Favored 'General case' 0 C--N 1.325 -0.469 0 O-C-N 124.483 1.115 . . . . 0.0 110.427 179.949 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.643 ' HB3' HG22 ' A' ' 29' ' ' VAL . 0.1 OUTLIER -137.0 115.33 11.77 Favored 'General case' 0 C--N 1.325 -0.478 0 O-C-N 124.514 1.133 . . . . 0.0 110.297 -179.984 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 86.9 m-20 57.2 21.84 6.98 Favored 'General case' 0 C--N 1.325 -0.47 0 O-C-N 124.48 1.113 . . . . 0.0 109.295 -179.986 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 87.15 25.52 33.73 Favored Glycine 0 CA--C 1.531 1.049 0 O-C-N 124.464 1.102 . . . . 0.0 110.966 179.975 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 12.8 mt -145.03 130.29 9.3 Favored Pre-proline 0 C--N 1.325 -0.485 0 O-C-N 124.535 0.785 . . . . 0.0 109.289 -179.961 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 20.1 Cg_endo -74.97 79.99 2.53 Favored 'Trans proline' 0 N--CA 1.452 -0.927 0 O-C-N 124.515 1.797 . . . . 0.0 111.008 -168.285 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.643 HG22 ' HB3' ' A' ' 24' ' ' ARG . 18.0 m . . . . . 0 C--N 1.325 -0.482 0 O-C-N 124.51 1.131 . . . . 0.0 109.307 -179.99 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 83.6 m . . . . . 0 N--CA 1.454 -0.266 0 N-CA-C 108.297 -1.001 . . . . 0.0 108.297 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 103.53 -21.09 40.1 Favored Glycine 0 CA--C 1.53 1.01 0 O-C-N 124.515 1.135 . . . . 0.0 110.989 179.981 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 28.5 tt0 -84.4 150.45 25.33 Favored 'General case' 0 C--N 1.324 -0.5 0 O-C-N 124.456 0.739 . . . . 0.0 110.333 179.977 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.427 HG22 HG13 ' A' ' 21' ' ' VAL . 66.0 p -109.74 129.91 55.57 Favored 'General case' 0 C--N 1.325 -0.499 0 O-C-N 124.508 1.13 . . . . 0.0 110.429 -179.983 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 5' ' ' CYS . . . . . 0.42 ' SG ' ' O ' ' A' ' 5' ' ' CYS . 14.2 p -97.16 51.06 1.09 Allowed 'General case' 0 C--N 1.325 -0.474 0 O-C-N 124.523 1.14 . . . . 0.0 108.292 -179.988 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 9.4 t -59.03 -24.74 27.78 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 O-C-N 124.481 1.113 . . . . 0.0 109.317 179.966 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -83.96 -32.6 23.3 Favored Glycine 0 CA--C 1.53 1.028 0 O-C-N 124.512 1.132 . . . . 0.0 110.989 179.999 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 124.73 14.21 3.54 Favored Glycine 0 C--N 1.344 1.004 0 O-C-N 125.103 1.12 . . . . 0.0 111.013 177.972 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -149.6 166.73 28.39 Favored 'General case' 0 C--N 1.325 -0.476 0 O-C-N 124.501 0.765 . . . . 0.0 110.384 179.95 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 10' ' ' CYS . . . . . 0.406 ' SG ' ' O ' ' A' ' 16' ' ' THR . 75.9 m -123.78 141.96 51.54 Favored 'General case' 0 C--N 1.326 -0.449 0 O-C-N 124.466 1.104 . . . . 0.0 108.279 -179.981 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 34.0 t-20 -89.87 -43.07 10.86 Favored 'General case' 0 C--N 1.325 -0.457 0 O-C-N 124.492 1.12 . . . . 0.0 109.29 -179.998 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.617 HG23 ' HD2' ' A' ' 13' ' ' PRO . 20.2 m -58.35 142.8 81.17 Favored Pre-proline 0 C--N 1.325 -0.485 0 O-C-N 124.427 1.079 . . . . 0.0 110.355 -179.981 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.617 ' HD2' HG23 ' A' ' 12' ' ' THR . 20.2 Cg_endo -74.99 131.59 14.48 Favored 'Trans proline' 0 N--CA 1.453 -0.868 0 O-C-N 124.501 1.79 . . . . 0.0 110.997 -168.322 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 74.1 13.73 80.91 Favored Glycine 0 CA--C 1.53 1.025 0 O-C-N 124.482 1.114 . . . . 0.0 110.985 179.975 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.496 ' SG ' ' CG2' ' A' ' 12' ' ' THR . 66.8 m -97.29 125.93 42.19 Favored 'General case' 0 C--N 1.325 -0.469 0 N-CA-C 108.313 -0.995 . . . . 0.0 108.313 179.97 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 16' ' ' THR . . . . . 0.406 ' O ' ' SG ' ' A' ' 10' ' ' CYS . 68.9 p -93.48 156.07 16.97 Favored 'General case' 0 C--N 1.325 -0.483 0 O-C-N 124.481 1.113 . . . . 0.0 110.383 -179.969 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 43.1 t -82.26 91.53 6.78 Favored 'General case' 0 C--N 1.325 -0.486 0 O-C-N 124.535 1.147 . . . . 0.0 108.301 -179.985 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 18' ' ' SER . . . . . 0.598 ' HB2' HG23 ' A' ' 23' ' ' THR . 3.8 m -98.87 65.81 1.54 Allowed 'General case' 0 C--N 1.325 -0.488 0 O-C-N 124.477 1.111 . . . . 0.0 110.008 174.052 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 19' ' ' TRP . . . . . 0.608 ' CG ' ' HA ' ' A' ' 20' ' ' PRO . 0.1 OUTLIER -35.63 147.12 0.17 Allowed Pre-proline 0 C--N 1.325 -0.5 0 O-C-N 124.556 1.16 . . . . 0.0 107.971 -173.996 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 20' ' ' PRO . . . . . 0.608 ' HA ' ' CG ' ' A' ' 19' ' ' TRP . 18.4 Cg_endo -74.91 -13.48 23.37 Favored 'Cis proline' 0 C--N 1.36 1.16 0 C-N-CA 121.01 -2.496 . . . . 0.0 111.037 -8.647 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.635 HG12 ' H ' ' A' ' 22' ' ' CYS . 2.2 t -99.11 177.91 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 O-C-N 124.472 1.108 . . . . 0.0 109.288 -173.032 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.635 ' H ' HG12 ' A' ' 21' ' ' VAL . 69.3 m -101.98 169.1 8.98 Favored 'General case' 0 C--N 1.325 -0.485 0 O-C-N 124.501 1.126 . . . . 0.0 108.288 -179.957 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 23' ' ' THR . . . . . 0.598 HG23 ' HB2' ' A' ' 18' ' ' SER . 1.1 p -144.26 160.54 40.82 Favored 'General case' 0 C--N 1.325 -0.484 0 O-C-N 124.458 1.099 . . . . 0.0 110.398 179.982 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.607 ' HB3' HG22 ' A' ' 29' ' ' VAL . 1.1 ttt85 -132.23 118.33 19.37 Favored 'General case' 0 C--N 1.325 -0.471 0 O-C-N 124.537 1.148 . . . . 0.0 110.292 -179.985 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 76.2 m-20 57.47 24.55 10.37 Favored 'General case' 0 C--N 1.324 -0.514 0 O-C-N 124.535 1.147 . . . . 0.0 109.289 -179.973 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 82.59 23.36 56.43 Favored Glycine 0 CA--C 1.53 1.024 0 O-C-N 124.586 1.179 . . . . 0.0 111.002 179.982 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 8.0 mt -143.26 129.91 10.52 Favored Pre-proline 0 C--N 1.325 -0.499 0 O-C-N 124.548 0.793 . . . . 0.0 109.337 179.978 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 20.1 Cg_endo -74.99 81.95 2.1 Favored 'Trans proline' 0 N--CA 1.453 -0.87 0 O-C-N 124.511 1.795 . . . . 0.0 110.997 -168.279 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.607 HG22 ' HB3' ' A' ' 24' ' ' ARG . 21.9 m . . . . . 0 C--N 1.325 -0.477 0 O-C-N 124.517 1.136 . . . . 0.0 109.312 179.991 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 83.5 m . . . . . 0 N--CA 1.453 -0.301 0 N-CA-C 108.28 -1.007 . . . . 0.0 108.28 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 91.62 -17.58 55.75 Favored Glycine 0 CA--C 1.53 1.006 0 O-C-N 124.431 1.082 . . . . 0.0 110.994 -179.961 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 15.5 tt0 -85.59 161.72 19.17 Favored 'General case' 0 C--N 1.325 -0.471 0 O-C-N 124.47 0.747 . . . . 0.0 110.314 179.976 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.692 HG22 HG23 ' A' ' 21' ' ' VAL . 47.5 p -120.54 132.0 54.96 Favored 'General case' 0 C--N 1.325 -0.498 0 O-C-N 124.52 1.138 . . . . 0.0 110.456 179.978 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 5' ' ' CYS . . . . . 0.417 ' SG ' ' O ' ' A' ' 5' ' ' CYS . 14.5 p -98.97 51.64 0.96 Allowed 'General case' 0 C--N 1.325 -0.475 0 O-C-N 124.475 1.109 . . . . 0.0 108.286 -179.977 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 9.0 t -59.22 -24.99 29.07 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 O-C-N 124.497 1.123 . . . . 0.0 109.288 -179.988 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -84.32 -32.25 23.18 Favored Glycine 0 CA--C 1.53 0.979 0 O-C-N 124.507 1.129 . . . . 0.0 111.062 179.961 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 124.37 13.98 3.75 Favored Glycine 0 CA--C 1.529 0.969 0 O-C-N 125.024 1.073 . . . . 0.0 111.036 178.176 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 45.8 m -149.93 164.76 34.58 Favored 'General case' 0 C--N 1.325 -0.47 0 O-C-N 124.514 0.773 . . . . 0.0 110.427 179.995 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 10' ' ' CYS . . . . . 0.405 ' SG ' ' O ' ' A' ' 16' ' ' THR . 94.2 m -121.67 143.16 49.5 Favored 'General case' 0 C--N 1.325 -0.491 0 O-C-N 124.469 1.106 . . . . 0.0 108.254 -179.955 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 76.1 m-20 -90.26 -47.84 7.53 Favored 'General case' 0 C--N 1.325 -0.458 0 O-C-N 124.439 1.087 . . . . 0.0 109.273 -179.982 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.62 HG23 ' HD2' ' A' ' 13' ' ' PRO . 19.5 m -53.16 142.7 36.3 Favored Pre-proline 0 C--N 1.325 -0.474 0 O-C-N 124.495 1.122 . . . . 0.0 110.397 180.0 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.62 ' HD2' HG23 ' A' ' 12' ' ' THR . 20.4 Cg_endo -74.94 131.63 14.59 Favored 'Trans proline' 0 N--CA 1.453 -0.856 0 O-C-N 124.495 1.787 . . . . 0.0 110.975 -168.328 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 73.97 15.81 79.64 Favored Glycine 0 CA--C 1.53 0.977 0 O-C-N 124.524 1.14 . . . . 0.0 110.984 179.953 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.503 ' SG ' ' CG2' ' A' ' 12' ' ' THR . 63.8 m -97.64 131.5 44.15 Favored 'General case' 0 C--N 1.325 -0.47 0 N-CA-C 108.265 -1.013 . . . . 0.0 108.265 -179.991 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 16' ' ' THR . . . . . 0.405 ' O ' ' SG ' ' A' ' 10' ' ' CYS . 73.1 p -98.37 154.68 17.67 Favored 'General case' 0 C--N 1.325 -0.494 0 O-C-N 124.533 1.145 . . . . 0.0 110.405 -180.0 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 44.4 t -82.19 94.69 7.33 Favored 'General case' 0 C--N 1.325 -0.478 0 O-C-N 124.461 1.101 . . . . 0.0 108.261 -179.976 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 18' ' ' SER . . . . . 0.517 ' O ' ' C ' ' A' ' 19' ' ' TRP . 40.8 t -102.23 66.02 0.98 Allowed 'General case' 0 C--N 1.325 -0.494 0 O-C-N 124.506 1.129 . . . . 0.0 109.964 174.045 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 19' ' ' TRP . . . . . 0.619 ' CG ' ' HA ' ' A' ' 20' ' ' PRO . 0.1 OUTLIER -35.92 147.13 0.18 Allowed Pre-proline 0 C--N 1.325 -0.464 0 O-C-N 124.48 1.112 . . . . 0.0 108.02 -174.211 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 20' ' ' PRO . . . . . 0.619 ' HA ' ' CG ' ' A' ' 19' ' ' TRP . 18.3 Cg_endo -75.03 -13.9 23.44 Favored 'Cis proline' 0 C--N 1.36 1.148 0 C-N-CA 120.991 -2.504 . . . . 0.0 110.972 -8.69 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.692 HG23 HG22 ' A' ' 4' ' ' THR . 0.8 OUTLIER -97.63 177.0 0.69 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 O-C-N 124.512 1.132 . . . . 0.0 109.301 -172.977 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.467 ' H ' HG22 ' A' ' 21' ' ' VAL . 52.7 m -102.0 171.19 7.65 Favored 'General case' 0 C--N 1.325 -0.493 0 O-C-N 124.508 1.13 . . . . 0.0 108.292 -179.995 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 23' ' ' THR . . . . . 0.425 ' O ' ' HA ' ' A' ' 15' ' ' CYS . 0.9 OUTLIER -148.83 168.09 23.92 Favored 'General case' 0 C--N 1.325 -0.486 0 O-C-N 124.543 1.152 . . . . 0.0 110.342 179.993 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.495 ' HB3' HG22 ' A' ' 29' ' ' VAL . 8.6 ttt180 -140.57 118.67 11.94 Favored 'General case' 0 C--N 1.326 -0.451 0 O-C-N 124.459 1.099 . . . . 0.0 110.335 179.982 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 14.6 t-20 58.2 22.75 9.51 Favored 'General case' 0 C--N 1.325 -0.465 0 O-C-N 124.494 1.121 . . . . 0.0 109.319 -179.967 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 82.72 22.67 57.69 Favored Glycine 0 CA--C 1.53 0.982 0 O-C-N 124.435 1.085 . . . . 0.0 111.012 -179.997 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 6.2 mt -141.68 130.56 12.28 Favored Pre-proline 0 C--N 1.325 -0.467 0 O-C-N 124.478 0.752 . . . . 0.0 109.286 -179.985 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 20.1 Cg_endo -74.98 83.82 1.75 Allowed 'Trans proline' 0 N--CA 1.453 -0.904 0 O-C-N 124.468 1.773 . . . . 0.0 110.975 -168.258 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.495 HG22 ' HB3' ' A' ' 24' ' ' ARG . 35.5 m . . . . . 0 C--N 1.325 -0.477 0 O-C-N 124.507 1.13 . . . . 0.0 109.29 179.982 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 99.6 m . . . . . 0 N--CA 1.453 -0.286 0 N-CA-C 108.316 -0.994 . . . . 0.0 108.316 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 91.78 -26.92 10.83 Favored Glycine 0 CA--C 1.53 1.015 0 O-C-N 124.477 1.11 . . . . 0.0 111.005 179.98 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 25.3 tt0 -81.46 152.73 27.22 Favored 'General case' 0 C--N 1.326 -0.453 0 O-C-N 124.49 0.759 . . . . 0.0 110.258 -179.959 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.659 HG22 HG23 ' A' ' 21' ' ' VAL . 76.2 p -113.26 134.88 54.38 Favored 'General case' 0 C--N 1.325 -0.495 0 O-C-N 124.519 1.137 . . . . 0.0 110.394 179.962 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 5' ' ' CYS . . . . . 0.41 ' SG ' ' O ' ' A' ' 5' ' ' CYS . 15.0 p -98.79 52.65 0.99 Allowed 'General case' 0 C--N 1.326 -0.454 0 O-C-N 124.495 1.122 . . . . 0.0 108.332 179.965 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 8.6 t -59.32 -24.73 28.68 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 O-C-N 124.492 1.12 . . . . 0.0 109.301 -179.97 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -84.13 -34.06 18.79 Favored Glycine 0 CA--C 1.529 0.968 0 O-C-N 124.505 1.128 . . . . 0.0 110.975 -179.984 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 126.54 14.63 2.85 Favored Glycine 0 C--N 1.345 1.047 0 O-C-N 125.13 1.135 . . . . 0.0 110.998 177.776 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -150.0 166.94 28.15 Favored 'General case' 0 C--N 1.325 -0.488 0 O-C-N 124.53 0.782 . . . . 0.0 110.413 179.981 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 10' ' ' CYS . . . . . 0.408 ' SG ' ' O ' ' A' ' 16' ' ' THR . 72.8 m -124.22 141.78 51.78 Favored 'General case' 0 C--N 1.324 -0.52 0 O-C-N 124.54 1.15 . . . . 0.0 108.343 179.946 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 32.4 t-20 -89.65 -43.29 10.84 Favored 'General case' 0 C--N 1.325 -0.474 0 O-C-N 124.527 1.142 . . . . 0.0 109.335 -180.0 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.614 HG23 ' HD2' ' A' ' 13' ' ' PRO . 20.0 m -57.67 142.71 77.41 Favored Pre-proline 0 C--N 1.326 -0.448 0 O-C-N 124.505 1.128 . . . . 0.0 110.399 179.989 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.614 ' HD2' HG23 ' A' ' 12' ' ' THR . 20.1 Cg_endo -75.01 132.33 15.28 Favored 'Trans proline' 0 N--CA 1.453 -0.895 0 O-C-N 124.506 1.793 . . . . 0.0 110.99 -168.306 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 73.62 13.28 80.37 Favored Glycine 0 CA--C 1.529 0.969 0 O-C-N 124.476 1.11 . . . . 0.0 111.016 -179.98 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.511 ' SG ' HG22 ' A' ' 12' ' ' THR . 68.7 m -97.49 125.65 42.3 Favored 'General case' 0 C--N 1.325 -0.479 0 N-CA-C 108.29 -1.004 . . . . 0.0 108.29 -179.983 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 16' ' ' THR . . . . . 0.468 ' HG1' ' HG1' ' A' ' 23' ' ' THR . 70.7 p -93.61 156.82 16.5 Favored 'General case' 0 C--N 1.325 -0.491 0 O-C-N 124.558 1.161 . . . . 0.0 110.437 179.977 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 42.7 t -82.86 94.98 7.8 Favored 'General case' 0 C--N 1.325 -0.482 0 O-C-N 124.447 1.092 . . . . 0.0 108.315 -179.993 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 18' ' ' SER . . . . . 0.528 ' CB ' HG23 ' A' ' 23' ' ' THR . 1.0 OUTLIER -102.48 66.39 0.97 Allowed 'General case' 0 C--N 1.325 -0.486 0 O-C-N 124.494 1.121 . . . . 0.0 109.968 173.987 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 19' ' ' TRP . . . . . 0.614 ' CG ' ' HA ' ' A' ' 20' ' ' PRO . 0.1 OUTLIER -35.51 147.15 0.17 Allowed Pre-proline 0 C--N 1.326 -0.453 0 O-C-N 124.497 1.123 . . . . 0.0 108.0 -174.085 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 20' ' ' PRO . . . . . 0.614 ' HA ' ' CG ' ' A' ' 19' ' ' TRP . 18.3 Cg_endo -75.0 -13.85 23.39 Favored 'Cis proline' 0 C--N 1.36 1.135 0 C-N-CA 120.967 -2.514 . . . . 0.0 111.013 -8.645 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.659 HG23 HG22 ' A' ' 4' ' ' THR . 2.8 p -99.13 178.08 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 O-C-N 124.512 1.132 . . . . 0.0 109.34 -172.964 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.603 ' H ' HG22 ' A' ' 21' ' ' VAL . 66.7 m -102.29 172.75 6.71 Favored 'General case' 0 C--N 1.325 -0.471 0 O-C-N 124.486 1.116 . . . . 0.0 108.301 179.993 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 23' ' ' THR . . . . . 0.528 HG23 ' CB ' ' A' ' 18' ' ' SER . 8.4 p -146.59 159.31 43.61 Favored 'General case' 0 C--N 1.325 -0.467 0 O-C-N 124.486 1.117 . . . . 0.0 110.391 -179.985 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.56 ' HB3' HG22 ' A' ' 29' ' ' VAL . 0.5 OUTLIER -131.81 117.68 18.87 Favored 'General case' 0 C--N 1.325 -0.483 0 O-C-N 124.498 1.124 . . . . 0.0 110.291 179.965 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 78.8 m-20 57.52 23.4 9.14 Favored 'General case' 0 C--N 1.325 -0.469 0 O-C-N 124.491 1.119 . . . . 0.0 109.298 -179.987 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 84.04 23.01 53.71 Favored Glycine 0 CA--C 1.53 0.99 0 O-C-N 124.428 1.08 . . . . 0.0 110.983 179.988 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 8.1 mt -143.06 129.99 10.71 Favored Pre-proline 0 C--N 1.325 -0.481 0 O-C-N 124.476 0.751 . . . . 0.0 109.29 179.972 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 20.2 Cg_endo -74.99 85.66 1.5 Allowed 'Trans proline' 0 N--CA 1.453 -0.88 0 O-C-N 124.508 1.794 . . . . 0.0 110.965 -168.287 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.56 HG22 ' HB3' ' A' ' 24' ' ' ARG . 33.5 m . . . . . 0 C--N 1.325 -0.472 0 O-C-N 124.542 1.151 . . . . 0.0 109.324 179.968 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 1' ' ' CYS . . . . . 0.406 ' SG ' ' O ' ' A' ' 23' ' ' THR . 20.0 m . . . . . 0 N--CA 1.452 -0.333 0 N-CA-C 108.302 -0.999 . . . . 0.0 108.302 . . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 108.48 -11.0 36.03 Favored Glycine 0 CA--C 1.53 0.985 0 O-C-N 124.524 1.14 . . . . 0.0 111.011 179.982 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 15.4 mt-10 -99.99 164.4 12.01 Favored 'General case' 0 C--N 1.326 -0.449 0 O-C-N 124.465 0.744 . . . . 0.0 110.282 -179.975 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 76.5 p -122.22 134.81 54.7 Favored 'General case' 0 C--N 1.325 -0.499 0 O-C-N 124.455 1.097 . . . . 0.0 110.44 179.99 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 5' ' ' CYS . . . . . 0.441 ' SG ' ' O ' ' A' ' 5' ' ' CYS . 11.8 p -101.7 48.23 0.89 Allowed 'General case' 0 C--N 1.325 -0.475 0 O-C-N 124.493 1.121 . . . . 0.0 108.295 -179.965 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 27.0 t -59.06 -23.61 24.82 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 O-C-N 124.511 1.132 . . . . 0.0 109.266 -179.992 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -87.82 -29.14 21.78 Favored Glycine 0 CA--C 1.53 1.027 0 O-C-N 124.51 1.132 . . . . 0.0 111.002 179.986 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 121.7 16.1 4.24 Favored Glycine 0 CA--C 1.531 1.036 0 O-C-N 124.964 1.038 . . . . 0.0 111.015 178.398 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 89.8 m -150.18 166.29 30.3 Favored 'General case' 0 C--N 1.325 -0.493 0 O-C-N 124.513 0.772 . . . . 0.0 110.415 179.942 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 10' ' ' CYS . . . . . 0.407 ' SG ' ' O ' ' A' ' 16' ' ' THR . 87.9 m -124.38 143.95 50.31 Favored 'General case' 0 C--N 1.325 -0.476 0 O-C-N 124.526 1.141 . . . . 0.0 108.306 179.979 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 18.9 t30 -89.78 -50.44 6.05 Favored 'General case' 0 C--N 1.325 -0.486 0 O-C-N 124.489 1.118 . . . . 0.0 109.353 179.978 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.632 HG23 ' HD2' ' A' ' 13' ' ' PRO . 18.5 m -52.32 142.77 28.4 Favored Pre-proline 0 C--N 1.325 -0.479 0 O-C-N 124.464 1.102 . . . . 0.0 110.406 -179.999 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.632 ' HD2' HG23 ' A' ' 12' ' ' THR . 20.1 Cg_endo -74.95 129.52 12.47 Favored 'Trans proline' 0 N--CA 1.453 -0.892 0 O-C-N 124.504 1.792 . . . . 0.0 110.991 -168.284 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 14' ' ' GLY . . . . . 0.416 ' HA3' ' NH1' ' A' ' 24' ' ' ARG . . . 76.01 15.15 81.58 Favored Glycine 0 CA--C 1.53 0.997 0 O-C-N 124.497 1.123 . . . . 0.0 110.999 179.988 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.505 ' SG ' ' CG2' ' A' ' 12' ' ' THR . 55.9 m -95.78 126.33 40.97 Favored 'General case' 0 C--N 1.325 -0.481 0 N-CA-C 108.282 -1.007 . . . . 0.0 108.282 -179.952 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 16' ' ' THR . . . . . 0.414 ' HG1' ' HG1' ' A' ' 23' ' ' THR . 12.3 p -92.45 154.36 18.54 Favored 'General case' 0 C--N 1.325 -0.497 0 O-C-N 124.51 1.131 . . . . 0.0 110.408 -179.998 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 21.9 t -83.59 94.81 8.16 Favored 'General case' 0 C--N 1.324 -0.508 0 O-C-N 124.497 1.123 . . . . 0.0 108.3 -179.996 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 18' ' ' SER . . . . . 0.566 ' CB ' HG23 ' A' ' 23' ' ' THR . 1.1 t -102.68 68.06 1.02 Allowed 'General case' 0 C--N 1.325 -0.474 0 O-C-N 124.501 1.126 . . . . 0.0 110.011 174.02 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 19' ' ' TRP . . . . . 0.602 ' CG ' ' HA ' ' A' ' 20' ' ' PRO . 0.0 OUTLIER -36.03 147.02 0.19 Allowed Pre-proline 0 C--N 1.325 -0.5 0 O-C-N 124.501 1.125 . . . . 0.0 107.972 -174.213 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 20' ' ' PRO . . . . . 0.602 ' HA ' ' CG ' ' A' ' 19' ' ' TRP . 18.2 Cg_endo -75.04 -14.34 23.23 Favored 'Cis proline' 0 C--N 1.361 1.194 0 C-N-CA 120.988 -2.505 . . . . 0.0 110.998 -8.67 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.644 HG22 ' H ' ' A' ' 22' ' ' CYS . 3.8 p -97.61 178.46 0.61 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 O-C-N 124.508 1.13 . . . . 0.0 109.277 -172.984 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.644 ' H ' HG22 ' A' ' 21' ' ' VAL . 35.3 m -102.14 172.76 6.71 Favored 'General case' 0 C--N 1.326 -0.439 0 O-C-N 124.497 1.123 . . . . 0.0 108.279 -179.97 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 23' ' ' THR . . . . . 0.566 HG23 ' CB ' ' A' ' 18' ' ' SER . 5.9 p -145.53 160.57 41.42 Favored 'General case' 0 C--N 1.325 -0.497 0 O-C-N 124.51 1.131 . . . . 0.0 110.446 179.965 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.536 ' HB3' HG22 ' A' ' 29' ' ' VAL . 15.1 tpt180 -127.92 114.69 17.5 Favored 'General case' 0 C--N 1.325 -0.485 0 O-C-N 124.515 1.134 . . . . 0.0 110.304 -179.984 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 66.1 t30 57.07 25.55 10.94 Favored 'General case' 0 C--N 1.325 -0.49 0 O-C-N 124.496 1.123 . . . . 0.0 109.281 -179.997 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 82.74 22.18 58.46 Favored Glycine 0 CA--C 1.53 1.019 0 O-C-N 124.487 1.117 . . . . 0.0 110.999 -179.999 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 52.3 mt -140.35 132.23 14.37 Favored Pre-proline 0 C--N 1.325 -0.475 0 O-C-N 124.512 0.772 . . . . 0.0 109.261 179.996 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 20.2 Cg_endo -75.0 86.29 1.44 Allowed 'Trans proline' 0 N--CA 1.453 -0.89 0 O-C-N 124.465 1.771 . . . . 0.0 110.967 -168.321 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.536 HG22 ' HB3' ' A' ' 24' ' ' ARG . 19.0 m . . . . . 0 C--N 1.325 -0.477 0 O-C-N 124.467 1.104 . . . . 0.0 109.311 179.983 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 79.0 m . . . . . 0 N--CA 1.453 -0.306 0 N-CA-C 108.295 -1.002 . . . . 0.0 108.295 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 82.82 -9.74 58.93 Favored Glycine 0 CA--C 1.53 0.994 0 O-C-N 124.501 1.126 . . . . 0.0 111.057 -179.966 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 11.4 pt-20 -100.24 167.85 10.17 Favored 'General case' 0 C--N 1.326 -0.446 0 O-C-N 124.495 0.762 . . . . 0.0 110.272 -179.99 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.678 HG22 HG13 ' A' ' 21' ' ' VAL . 50.9 p -127.07 143.94 51.15 Favored 'General case' 0 C--N 1.325 -0.481 0 O-C-N 124.52 1.138 . . . . 0.0 110.392 179.998 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 5' ' ' CYS . . . . . 0.419 ' HB2' ' N ' ' A' ' 9' ' ' THR . 20.5 p -104.26 56.98 0.71 Allowed 'General case' 0 C--N 1.324 -0.5 0 O-C-N 124.494 1.121 . . . . 0.0 108.324 179.976 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 4.9 t -59.48 -24.74 29.18 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 O-C-N 124.493 1.121 . . . . 0.0 109.319 179.981 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -85.23 -33.94 15.95 Favored Glycine 0 CA--C 1.53 1.016 0 O-C-N 124.527 1.142 . . . . 0.0 110.952 -179.932 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 125.14 17.3 2.75 Favored Glycine 0 CA--C 1.53 1.023 0 O-C-N 124.889 0.994 . . . . 0.0 111.005 177.766 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 9' ' ' THR . . . . . 0.419 ' N ' ' HB2' ' A' ' 5' ' ' CYS . 32.1 m -150.38 164.01 36.92 Favored 'General case' 0 C--N 1.325 -0.485 0 O-C-N 124.495 0.762 . . . . 0.0 110.397 179.978 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 10' ' ' CYS . . . . . 0.405 ' SG ' ' O ' ' A' ' 16' ' ' THR . 74.9 m -118.55 142.41 47.63 Favored 'General case' 0 C--N 1.325 -0.485 0 O-C-N 124.505 1.128 . . . . 0.0 108.312 -179.998 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 3.9 m120 -90.87 -40.9 11.49 Favored 'General case' 0 C--N 1.325 -0.469 0 O-C-N 124.485 1.115 . . . . 0.0 109.275 -179.998 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.64 HG23 ' HD2' ' A' ' 13' ' ' PRO . 17.5 m -63.76 142.82 98.09 Favored Pre-proline 0 C--N 1.325 -0.484 0 O-C-N 124.483 1.115 . . . . 0.0 110.426 -179.993 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.64 ' HD2' HG23 ' A' ' 12' ' ' THR . 20.1 Cg_endo -74.97 130.73 13.58 Favored 'Trans proline' 0 N--CA 1.453 -0.876 0 O-C-N 124.481 1.779 . . . . 0.0 110.969 -168.246 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 77.16 10.37 86.29 Favored Glycine 0 CA--C 1.53 1.022 0 O-C-N 124.511 1.132 . . . . 0.0 111.001 179.985 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.5 ' SG ' ' CG2' ' A' ' 12' ' ' THR . 68.1 m -93.78 126.75 39.15 Favored 'General case' 0 C--N 1.325 -0.464 0 N-CA-C 108.268 -1.012 . . . . 0.0 108.268 -179.973 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 16' ' ' THR . . . . . 0.405 ' O ' ' SG ' ' A' ' 10' ' ' CYS . 11.2 p -93.8 152.41 18.93 Favored 'General case' 0 C--N 1.324 -0.511 0 O-C-N 124.456 1.098 . . . . 0.0 110.393 -179.981 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 43.4 t -80.0 98.14 7.07 Favored 'General case' 0 C--N 1.325 -0.473 0 O-C-N 124.475 1.109 . . . . 0.0 108.331 179.983 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 18' ' ' SER . . . . . 0.519 ' O ' ' C ' ' A' ' 19' ' ' TRP . 30.0 t -105.72 64.92 0.7 Allowed 'General case' 0 C--N 1.325 -0.472 0 O-C-N 124.502 1.126 . . . . 0.0 109.986 174.242 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 19' ' ' TRP . . . . . 0.643 ' CG ' ' HA ' ' A' ' 20' ' ' PRO . 0.4 OUTLIER -35.42 147.0 0.17 Allowed Pre-proline 0 C--N 1.325 -0.472 0 O-C-N 124.537 1.148 . . . . 0.0 108.024 -174.284 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 20' ' ' PRO . . . . . 0.643 ' HA ' ' CG ' ' A' ' 19' ' ' TRP . 18.3 Cg_endo -74.98 -13.97 23.3 Favored 'Cis proline' 0 C--N 1.36 1.148 0 C-N-CA 121.013 -2.495 . . . . 0.0 111.006 -8.605 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.678 HG13 HG22 ' A' ' 4' ' ' THR . 3.8 t -97.94 175.31 0.82 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 O-C-N 124.478 1.111 . . . . 0.0 109.239 -173.022 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.638 ' H ' HG12 ' A' ' 21' ' ' VAL . 3.5 m -102.36 170.0 8.34 Favored 'General case' 0 C--N 1.325 -0.483 0 O-C-N 124.463 1.102 . . . . 0.0 108.338 179.995 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 23' ' ' THR . . . . . 0.462 HG23 ' HB3' ' A' ' 18' ' ' SER . 1.9 p -147.27 163.41 36.49 Favored 'General case' 0 C--N 1.325 -0.495 0 O-C-N 124.49 1.119 . . . . 0.0 110.385 179.996 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.566 ' HB3' HG22 ' A' ' 29' ' ' VAL . 0.3 OUTLIER -139.77 118.91 12.7 Favored 'General case' 0 C--N 1.324 -0.509 0 O-C-N 124.573 1.17 . . . . 0.0 110.33 179.937 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 18.0 t-20 57.91 22.36 8.64 Favored 'General case' 0 C--N 1.325 -0.48 0 O-C-N 124.528 1.142 . . . . 0.0 109.277 -179.988 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 26' ' ' GLY . . . . . 0.473 ' O ' HD23 ' A' ' 27' ' ' LEU . . . 84.55 23.21 51.49 Favored Glycine 0 CA--C 1.531 1.042 0 O-C-N 124.504 1.128 . . . . 0.0 110.959 179.952 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 27' ' ' LEU . . . . . 0.473 HD23 ' O ' ' A' ' 26' ' ' GLY . 12.1 mt -145.96 128.04 7.79 Favored Pre-proline 0 C--N 1.325 -0.491 0 O-C-N 124.515 0.773 . . . . 0.0 109.311 -179.976 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 20.3 Cg_endo -74.92 78.25 2.91 Favored 'Trans proline' 0 N--CA 1.453 -0.889 0 O-C-N 124.515 1.797 . . . . 0.0 110.966 -168.294 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.566 HG22 ' HB3' ' A' ' 24' ' ' ARG . 30.8 m . . . . . 0 C--N 1.324 -0.517 0 O-C-N 124.509 1.131 . . . . 0.0 109.289 179.985 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 99.7 m . . . . . 0 N--CA 1.453 -0.311 0 N-CA-C 108.319 -0.993 . . . . 0.0 108.319 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 84.61 -13.21 53.47 Favored Glycine 0 CA--C 1.53 1.004 0 O-C-N 124.475 1.109 . . . . 0.0 110.958 179.936 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 3' ' ' GLU . . . . . 0.402 ' HG3' ' SG ' ' A' ' 22' ' ' CYS . 23.1 pt-20 -100.42 171.72 7.57 Favored 'General case' 0 C--N 1.325 -0.495 0 O-C-N 124.504 0.767 . . . . 0.0 110.262 -179.983 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 4' ' ' THR . . . . . 1.053 HG22 HG23 ' A' ' 21' ' ' VAL . 38.4 p -129.72 143.16 50.68 Favored 'General case' 0 C--N 1.325 -0.482 0 O-C-N 124.506 1.128 . . . . 0.0 110.377 179.991 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 5' ' ' CYS . . . . . 0.584 ' O ' ' CD1' ' A' ' 19' ' ' TRP . 14.8 p -96.67 52.46 1.2 Allowed 'General case' 0 C--N 1.325 -0.469 0 O-C-N 124.474 1.109 . . . . 0.0 108.301 179.953 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 4.5 t -59.01 -24.9 28.13 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 O-C-N 124.428 1.08 . . . . 0.0 109.309 179.992 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -84.02 -35.09 16.28 Favored Glycine 0 CA--C 1.53 1.028 0 O-C-N 124.467 1.104 . . . . 0.0 111.021 179.996 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 8' ' ' GLY . . . . . 0.4 ' O ' ' SG ' ' A' ' 17' ' ' CYS . . . 133.34 -13.24 4.91 Favored Glycine 0 C--N 1.346 1.106 0 O-C-N 125.139 1.14 . . . . 0.0 110.979 178.327 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -131.1 162.93 28.78 Favored 'General case' 0 C--N 1.324 -0.502 0 O-C-N 124.517 0.775 . . . . 0.0 110.411 -179.96 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 10' ' ' CYS . . . . . 0.406 ' SG ' ' O ' ' A' ' 16' ' ' THR . 86.9 m -107.16 141.64 38.11 Favored 'General case' 0 C--N 1.325 -0.49 0 O-C-N 124.499 1.124 . . . . 0.0 108.268 -179.951 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 64.1 t-20 -89.59 -38.13 14.17 Favored 'General case' 0 C--N 1.325 -0.481 0 O-C-N 124.522 1.139 . . . . 0.0 109.329 179.961 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.657 HG23 ' HD2' ' A' ' 13' ' ' PRO . 16.5 m -67.44 143.11 96.97 Favored Pre-proline 0 C--N 1.326 -0.454 0 O-C-N 124.509 1.131 . . . . 0.0 110.429 -179.996 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.657 ' HD2' HG23 ' A' ' 12' ' ' THR . 20.2 Cg_endo -74.98 129.15 12.09 Favored 'Trans proline' 0 N--CA 1.453 -0.88 0 O-C-N 124.569 1.826 . . . . 0.0 110.99 -168.27 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 76.86 14.27 82.76 Favored Glycine 0 CA--C 1.529 0.951 0 O-C-N 124.517 1.135 . . . . 0.0 111.035 -179.964 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.494 ' SG ' ' CG2' ' A' ' 12' ' ' THR . 57.7 m -96.45 129.38 43.82 Favored 'General case' 0 C--N 1.325 -0.459 0 N-CA-C 108.315 -0.994 . . . . 0.0 108.315 179.976 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 16' ' ' THR . . . . . 0.406 ' O ' ' SG ' ' A' ' 10' ' ' CYS . 23.4 p -93.57 148.71 21.84 Favored 'General case' 0 C--N 1.325 -0.474 0 O-C-N 124.492 1.12 . . . . 0.0 110.358 -179.977 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 17' ' ' CYS . . . . . 0.4 ' SG ' ' O ' ' A' ' 8' ' ' GLY . 11.9 t -81.23 95.06 6.82 Favored 'General case' 0 C--N 1.325 -0.462 0 O-C-N 124.5 1.125 . . . . 0.0 108.293 179.988 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 18' ' ' SER . . . . . 0.718 ' OG ' HG23 ' A' ' 23' ' ' THR . 20.4 p -102.31 65.79 0.97 Allowed 'General case' 0 C--N 1.325 -0.497 0 O-C-N 124.493 1.121 . . . . 0.0 110.036 173.993 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 19' ' ' TRP . . . . . 0.59 ' CG ' ' HA ' ' A' ' 20' ' ' PRO . 0.0 OUTLIER -36.02 147.23 0.18 Allowed Pre-proline 0 C--N 1.325 -0.459 0 N-CA-C 107.998 -1.112 . . . . 0.0 107.998 -174.047 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 20' ' ' PRO . . . . . 0.59 ' HA ' ' CG ' ' A' ' 19' ' ' TRP . 18.4 Cg_endo -74.95 -13.53 23.44 Favored 'Cis proline' 0 C--N 1.36 1.161 0 C-N-CA 120.995 -2.502 . . . . 0.0 111.01 -8.641 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 1.053 HG23 HG22 ' A' ' 4' ' ' THR . 2.3 p -96.35 173.99 0.9 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.478 0 O-C-N 124.53 1.144 . . . . 0.0 109.331 -173.224 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.524 ' H ' HG22 ' A' ' 21' ' ' VAL . 1.7 m -102.09 169.2 8.9 Favored 'General case' 0 C--N 1.325 -0.488 0 O-C-N 124.485 1.115 . . . . 0.0 108.324 -179.973 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 23' ' ' THR . . . . . 0.718 HG23 ' OG ' ' A' ' 18' ' ' SER . 1.1 p -141.99 169.1 18.22 Favored 'General case' 0 C--N 1.325 -0.488 0 O-C-N 124.494 1.121 . . . . 0.0 110.413 -179.981 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.554 ' HB3' HG22 ' A' ' 29' ' ' VAL . 6.0 ttt180 -143.74 117.02 9.0 Favored 'General case' 0 C--N 1.325 -0.475 0 O-C-N 124.527 1.142 . . . . 0.0 110.279 -179.986 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 71.1 m-20 58.47 22.23 9.36 Favored 'General case' 0 C--N 1.325 -0.482 0 O-C-N 124.516 1.135 . . . . 0.0 109.31 179.992 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 26' ' ' GLY . . . . . 0.41 ' O ' HD23 ' A' ' 27' ' ' LEU . . . 86.48 20.64 53.99 Favored Glycine 0 CA--C 1.53 0.974 0 O-C-N 124.498 1.124 . . . . 0.0 111.009 -179.997 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 27' ' ' LEU . . . . . 0.41 HD23 ' O ' ' A' ' 26' ' ' GLY . 9.7 mt -144.7 128.81 8.92 Favored Pre-proline 0 C--N 1.325 -0.493 0 O-C-N 124.514 0.773 . . . . 0.0 109.29 -179.98 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 20.2 Cg_endo -74.97 84.68 1.62 Allowed 'Trans proline' 0 N--CA 1.453 -0.895 0 O-C-N 124.499 1.789 . . . . 0.0 111.014 -168.321 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.554 HG22 ' HB3' ' A' ' 24' ' ' ARG . 28.4 m . . . . . 0 C--N 1.324 -0.508 0 O-C-N 124.547 1.154 . . . . 0.0 109.295 -179.968 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 83.0 m . . . . . 0 N--CA 1.453 -0.296 0 N-CA-C 108.286 -1.005 . . . . 0.0 108.286 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 100.56 -25.33 28.71 Favored Glycine 0 CA--C 1.53 1.017 0 O-C-N 124.475 1.109 . . . . 0.0 110.99 -179.996 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 28.6 tt0 -78.51 150.47 32.9 Favored 'General case' 0 C--N 1.324 -0.511 0 O-C-N 124.519 0.776 . . . . 0.0 110.293 -179.969 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.608 HG22 HG12 ' A' ' 21' ' ' VAL . 75.2 p -110.21 130.94 55.45 Favored 'General case' 0 C--N 1.325 -0.476 0 O-C-N 124.453 1.095 . . . . 0.0 110.42 179.977 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 5' ' ' CYS . . . . . 0.416 ' SG ' ' O ' ' A' ' 5' ' ' CYS . 14.5 p -99.0 51.58 0.96 Allowed 'General case' 0 C--N 1.325 -0.46 0 O-C-N 124.452 1.095 . . . . 0.0 108.301 -179.975 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 9.6 t -59.22 -24.59 27.94 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 O-C-N 124.553 1.158 . . . . 0.0 109.334 -179.991 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -83.89 -33.42 21.31 Favored Glycine 0 CA--C 1.53 0.984 0 O-C-N 124.52 1.138 . . . . 0.0 110.972 -179.978 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 125.95 14.24 3.12 Favored Glycine 0 C--N 1.346 1.086 0 C-N-CA 119.776 -1.202 . . . . 0.0 110.982 177.846 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -150.07 166.25 30.31 Favored 'General case' 0 C--N 1.325 -0.494 0 O-C-N 124.456 0.739 . . . . 0.0 110.355 -179.997 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 10' ' ' CYS . . . . . 0.405 ' SG ' ' O ' ' A' ' 16' ' ' THR . 74.8 m -123.14 144.28 49.45 Favored 'General case' 0 C--N 1.326 -0.439 0 O-C-N 124.477 1.11 . . . . 0.0 108.288 -179.989 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 9.8 t-20 -91.18 -44.39 9.27 Favored 'General case' 0 C--N 1.325 -0.464 0 O-C-N 124.463 1.102 . . . . 0.0 109.313 -179.971 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.609 HG23 ' HD2' ' A' ' 13' ' ' PRO . 20.6 m -58.03 142.73 79.47 Favored Pre-proline 0 C--N 1.325 -0.48 0 O-C-N 124.487 1.117 . . . . 0.0 110.392 -179.984 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.609 ' HD2' HG23 ' A' ' 12' ' ' THR . 20.2 Cg_endo -74.98 132.34 15.34 Favored 'Trans proline' 0 N--CA 1.453 -0.871 0 O-C-N 124.443 1.76 . . . . 0.0 110.937 -168.251 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 75.47 8.71 84.2 Favored Glycine 0 CA--C 1.53 1.014 0 O-C-N 124.472 1.107 . . . . 0.0 111.028 179.993 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.496 ' SG ' ' CG2' ' A' ' 12' ' ' THR . 81.5 m -93.29 125.43 37.89 Favored 'General case' 0 C--N 1.324 -0.509 0 N-CA-C 108.279 -1.008 . . . . 0.0 108.279 179.995 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 16' ' ' THR . . . . . 0.405 ' O ' ' SG ' ' A' ' 10' ' ' CYS . 2.2 p -94.0 156.07 16.8 Favored 'General case' 0 C--N 1.325 -0.483 0 O-C-N 124.524 1.14 . . . . 0.0 110.393 -179.994 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 48.5 t -81.25 91.14 6.16 Favored 'General case' 0 C--N 1.325 -0.495 0 O-C-N 124.512 1.133 . . . . 0.0 108.336 179.968 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 18' ' ' SER . . . . . 0.525 ' O ' ' C ' ' A' ' 19' ' ' TRP . 1.9 m -98.09 65.23 1.73 Allowed 'General case' 0 C--N 1.324 -0.502 0 O-C-N 124.503 1.127 . . . . 0.0 110.001 174.231 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 19' ' ' TRP . . . . . 0.607 ' CG ' ' HA ' ' A' ' 20' ' ' PRO . 0.0 OUTLIER -35.52 147.1 0.17 Allowed Pre-proline 0 C--N 1.324 -0.506 0 O-C-N 124.503 1.127 . . . . 0.0 107.993 -173.882 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 20' ' ' PRO . . . . . 0.607 ' HA ' ' CG ' ' A' ' 19' ' ' TRP . 18.4 Cg_endo -74.98 -13.27 23.65 Favored 'Cis proline' 0 C--N 1.36 1.143 0 C-N-CA 121.012 -2.495 . . . . 0.0 110.98 -8.386 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.608 HG12 HG22 ' A' ' 4' ' ' THR . 2.4 m -99.92 178.65 0.64 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.494 0 O-C-N 124.468 1.105 . . . . 0.0 109.295 -173.117 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 82.7 m -102.21 171.75 7.3 Favored 'General case' 0 C--N 1.325 -0.486 0 O-C-N 124.524 1.14 . . . . 0.0 108.281 -179.997 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 23' ' ' THR . . . . . 0.408 ' O ' ' HA ' ' A' ' 15' ' ' CYS . 0.8 OUTLIER -150.3 161.0 43.3 Favored 'General case' 0 C--N 1.325 -0.477 0 O-C-N 124.526 1.141 . . . . 0.0 110.396 179.991 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.475 ' HB3' ' CG2' ' A' ' 29' ' ' VAL . 8.6 ttt180 -132.4 119.08 20.18 Favored 'General case' 0 C--N 1.325 -0.493 0 O-C-N 124.552 1.157 . . . . 0.0 110.289 -179.99 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 25' ' ' ASN . . . . . 0.517 ' O ' ' ND2' ' A' ' 25' ' ' ASN . 0.1 OUTLIER 57.24 28.87 15.8 Favored 'General case' 0 C--N 1.325 -0.484 0 O-C-N 124.507 1.129 . . . . 0.0 109.291 179.992 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 76.05 23.3 72.04 Favored Glycine 0 CA--C 1.531 1.038 0 O-C-N 124.504 1.127 . . . . 0.0 110.989 179.988 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 7.3 mt -141.4 129.22 11.99 Favored Pre-proline 0 C--N 1.324 -0.509 0 O-C-N 124.554 0.796 . . . . 0.0 109.311 -179.971 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 20.2 Cg_endo -75.0 88.3 1.25 Allowed 'Trans proline' 0 N--CA 1.453 -0.875 0 O-C-N 124.487 1.783 . . . . 0.0 110.944 -168.261 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.475 ' CG2' ' HB3' ' A' ' 24' ' ' ARG . 27.1 m . . . . . 0 C--N 1.325 -0.468 0 O-C-N 124.476 1.11 . . . . 0.0 109.345 179.958 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 91.6 m . . . . . 0 N--CA 1.453 -0.284 0 N-CA-C 108.271 -1.011 . . . . 0.0 108.271 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 92.57 7.93 62.83 Favored Glycine 0 CA--C 1.53 1.023 0 O-C-N 124.486 1.116 . . . . 0.0 110.972 -179.985 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 89.8 mt-10 -100.23 165.01 11.7 Favored 'General case' 0 C--N 1.325 -0.495 0 O-C-N 124.493 0.761 . . . . 0.0 110.308 179.999 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 23.9 p -121.51 114.99 22.01 Favored 'General case' 0 C--N 1.325 -0.485 0 O-C-N 124.456 1.098 . . . . 0.0 110.4 -179.984 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 5' ' ' CYS . . . . . 0.432 ' O ' ' SG ' ' A' ' 5' ' ' CYS . 13.3 p -91.08 49.62 1.66 Allowed 'General case' 0 C--N 1.325 -0.474 0 O-C-N 124.5 1.125 . . . . 0.0 108.315 -179.976 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 17.5 t -59.19 -24.54 27.75 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 O-C-N 124.5 1.125 . . . . 0.0 109.355 -179.985 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -84.62 -34.25 16.73 Favored Glycine 0 CA--C 1.531 1.036 0 O-C-N 124.498 1.124 . . . . 0.0 110.981 -179.994 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 125.84 13.1 3.43 Favored Glycine 0 CA--C 1.53 1.006 0 O-C-N 125.1 1.118 . . . . 0.0 111.041 178.05 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 2.5 m -150.02 161.4 42.4 Favored 'General case' 0 C--N 1.326 -0.452 0 O-C-N 124.529 0.782 . . . . 0.0 110.383 -179.975 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 10' ' ' CYS . . . . . 0.402 ' SG ' ' O ' ' A' ' 16' ' ' THR . 72.3 m -119.11 156.37 29.88 Favored 'General case' 0 C--N 1.325 -0.489 0 O-C-N 124.468 1.105 . . . . 0.0 108.327 179.974 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 17.6 t30 -97.98 -58.17 2.05 Favored 'General case' 0 C--N 1.325 -0.475 0 O-C-N 124.518 1.136 . . . . 0.0 109.341 179.97 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.66 HG23 ' HD2' ' A' ' 13' ' ' PRO . 5.3 m -44.69 142.64 2.45 Favored Pre-proline 0 C--N 1.324 -0.501 0 O-C-N 124.558 1.161 . . . . 0.0 110.405 179.954 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.66 ' HD2' HG23 ' A' ' 12' ' ' THR . 20.4 Cg_endo -74.94 129.53 12.49 Favored 'Trans proline' 0 N--CA 1.453 -0.871 0 O-C-N 124.493 1.786 . . . . 0.0 111.023 -168.34 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 78.88 11.57 85.08 Favored Glycine 0 CA--C 1.53 0.986 0 O-C-N 124.513 1.133 . . . . 0.0 111.034 -179.988 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.503 ' SG ' HG22 ' A' ' 12' ' ' THR . 57.7 m -95.29 125.71 40.11 Favored 'General case' 0 C--N 1.325 -0.461 0 N-CA-C 108.306 -0.998 . . . . 0.0 108.306 -179.943 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 16' ' ' THR . . . . . 0.402 ' O ' ' SG ' ' A' ' 10' ' ' CYS . 18.7 p -95.16 157.35 15.93 Favored 'General case' 0 C--N 1.326 -0.449 0 O-C-N 124.469 1.106 . . . . 0.0 110.423 -179.989 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 24.5 t -82.74 95.84 7.99 Favored 'General case' 0 C--N 1.325 -0.486 0 O-C-N 124.543 1.152 . . . . 0.0 108.291 179.989 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 18' ' ' SER . . . . . 0.598 ' HB3' HG23 ' A' ' 23' ' ' THR . 11.2 t -100.45 64.56 1.15 Allowed 'General case' 0 C--N 1.325 -0.469 0 O-C-N 124.504 1.128 . . . . 0.0 110.057 173.855 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 19' ' ' TRP . . . . . 0.611 ' CG ' ' HA ' ' A' ' 20' ' ' PRO . 0.3 OUTLIER -35.39 145.96 0.19 Allowed Pre-proline 0 C--N 1.325 -0.496 0 O-C-N 124.549 1.155 . . . . 0.0 108.033 -174.124 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 20' ' ' PRO . . . . . 0.611 ' HA ' ' CG ' ' A' ' 19' ' ' TRP . 18.3 Cg_endo -75.04 -14.88 22.92 Favored 'Cis proline' 0 C--N 1.359 1.13 0 C-N-CA 121.021 -2.491 . . . . 0.0 110.973 -8.459 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.492 ' O ' ' C ' ' A' ' 18' ' ' SER . 3.1 m -95.76 177.09 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 O-C-N 124.515 1.134 . . . . 0.0 109.241 -173.101 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 43.9 m -101.85 166.71 10.51 Favored 'General case' 0 C--N 1.325 -0.487 0 O-C-N 124.537 1.148 . . . . 0.0 108.333 179.987 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 23' ' ' THR . . . . . 0.598 HG23 ' HB3' ' A' ' 18' ' ' SER . 1.0 OUTLIER -145.04 169.51 17.98 Favored 'General case' 0 C--N 1.325 -0.485 0 O-C-N 124.516 1.135 . . . . 0.0 110.384 179.991 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.569 ' HB3' HG22 ' A' ' 29' ' ' VAL . 0.1 OUTLIER -142.18 118.22 10.65 Favored 'General case' 0 C--N 1.325 -0.474 0 O-C-N 124.524 1.14 . . . . 0.0 110.304 -179.972 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 72.0 m-20 57.77 23.37 9.51 Favored 'General case' 0 C--N 1.325 -0.466 0 O-C-N 124.557 1.16 . . . . 0.0 109.357 -179.957 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 82.17 24.14 55.41 Favored Glycine 0 CA--C 1.531 1.036 0 O-C-N 124.524 1.14 . . . . 0.0 111.039 -179.994 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 7.5 mt -143.31 129.57 10.34 Favored Pre-proline 0 C--N 1.325 -0.467 0 O-C-N 124.487 0.757 . . . . 0.0 109.317 -179.973 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 20.4 Cg_endo -74.89 82.18 2.03 Favored 'Trans proline' 0 N--CA 1.453 -0.904 0 O-C-N 124.535 1.808 . . . . 0.0 111.02 -168.348 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.569 HG22 ' HB3' ' A' ' 24' ' ' ARG . 32.7 m . . . . . 0 C--N 1.324 -0.51 0 O-C-N 124.526 1.141 . . . . 0.0 109.308 179.997 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 95.2 m . . . . . 0 N--CA 1.452 -0.327 0 N-CA-C 108.266 -1.013 . . . . 0.0 108.266 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 91.03 -27.22 9.35 Favored Glycine 0 CA--C 1.53 0.975 0 O-C-N 124.569 1.168 . . . . 0.0 111.041 -179.976 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 23.5 tt0 -83.53 151.88 25.18 Favored 'General case' 0 C--N 1.325 -0.495 0 O-C-N 124.503 0.767 . . . . 0.0 110.292 -179.988 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.63 HG22 HG23 ' A' ' 21' ' ' VAL . 60.2 p -112.83 137.93 50.43 Favored 'General case' 0 C--N 1.324 -0.505 0 O-C-N 124.532 1.145 . . . . 0.0 110.372 179.995 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 5' ' ' CYS . . . . . 0.407 ' SG ' ' O ' ' A' ' 5' ' ' CYS . 15.0 p -100.88 52.79 0.85 Allowed 'General case' 0 C--N 1.325 -0.477 0 O-C-N 124.551 1.157 . . . . 0.0 108.29 179.99 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 10.3 t -59.22 -24.14 26.74 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 O-C-N 124.508 1.13 . . . . 0.0 109.288 -179.996 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -84.75 -34.6 15.26 Favored Glycine 0 CA--C 1.53 1.006 0 O-C-N 124.524 1.14 . . . . 0.0 110.968 -179.976 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 127.19 14.78 2.64 Favored Glycine 0 CA--C 1.531 1.043 0 O-C-N 125.138 1.14 . . . . 0.0 111.029 177.62 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -150.08 166.73 28.88 Favored 'General case' 0 C--N 1.325 -0.476 0 O-C-N 124.489 0.758 . . . . 0.0 110.386 -179.971 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 10' ' ' CYS . . . . . 0.414 ' SG ' ' O ' ' A' ' 16' ' ' THR . 72.3 m -124.56 140.71 52.69 Favored 'General case' 0 C--N 1.325 -0.486 0 O-C-N 124.525 1.14 . . . . 0.0 108.298 180.0 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 3.0 m120 -89.58 -40.13 12.81 Favored 'General case' 0 C--N 1.325 -0.465 0 O-C-N 124.428 1.08 . . . . 0.0 109.291 -179.989 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.608 HG23 ' HD2' ' A' ' 13' ' ' PRO . 20.9 m -60.05 142.69 89.08 Favored Pre-proline 0 C--N 1.325 -0.467 0 O-C-N 124.465 1.103 . . . . 0.0 110.393 179.995 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.608 ' HD2' HG23 ' A' ' 12' ' ' THR . 20.2 Cg_endo -74.97 132.08 15.05 Favored 'Trans proline' 0 N--CA 1.453 -0.877 0 O-C-N 124.485 1.781 . . . . 0.0 110.947 -168.269 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 73.34 13.35 79.85 Favored Glycine 0 CA--C 1.53 0.999 0 O-C-N 124.563 1.165 . . . . 0.0 110.999 179.974 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.513 ' SG ' HG22 ' A' ' 12' ' ' THR . 68.7 m -97.97 125.64 42.99 Favored 'General case' 0 C--N 1.325 -0.486 0 N-CA-C 108.306 -0.998 . . . . 0.0 108.306 -179.989 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 16' ' ' THR . . . . . 0.414 ' O ' ' SG ' ' A' ' 10' ' ' CYS . 44.4 p -93.73 157.56 16.1 Favored 'General case' 0 C--N 1.325 -0.498 0 O-C-N 124.479 1.112 . . . . 0.0 110.387 179.985 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 46.8 t -83.09 95.04 7.94 Favored 'General case' 0 C--N 1.326 -0.454 0 O-C-N 124.491 1.12 . . . . 0.0 108.273 -179.948 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 18' ' ' SER . . . . . 0.52 ' O ' ' C ' ' A' ' 19' ' ' TRP . 1.0 OUTLIER -102.79 66.92 0.96 Allowed 'General case' 0 C--N 1.325 -0.469 0 O-C-N 124.459 1.099 . . . . 0.0 110.029 173.96 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 19' ' ' TRP . . . . . 0.612 ' CG ' ' HA ' ' A' ' 20' ' ' PRO . 0.0 OUTLIER -35.7 147.46 0.17 Allowed Pre-proline 0 C--N 1.326 -0.455 0 O-C-N 124.496 1.123 . . . . 0.0 107.982 -174.009 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 20' ' ' PRO . . . . . 0.612 ' HA ' ' CG ' ' A' ' 19' ' ' TRP . 18.3 Cg_endo -75.01 -13.5 23.62 Favored 'Cis proline' 0 C--N 1.361 1.206 0 C-N-CA 121.001 -2.5 . . . . 0.0 111.025 -8.572 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.689 HG22 ' H ' ' A' ' 22' ' ' CYS . 4.8 p -100.05 178.84 0.63 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 O-C-N 124.547 1.154 . . . . 0.0 109.323 -173.006 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.689 ' H ' HG22 ' A' ' 21' ' ' VAL . 81.4 m -102.22 174.0 6.12 Favored 'General case' 0 C--N 1.325 -0.492 0 O-C-N 124.503 1.127 . . . . 0.0 108.285 179.991 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 23' ' ' THR . . . . . 0.515 HG23 ' CB ' ' A' ' 18' ' ' SER . 7.2 p -147.02 159.19 43.88 Favored 'General case' 0 C--N 1.325 -0.496 0 O-C-N 124.519 1.137 . . . . 0.0 110.402 179.985 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.581 ' HB3' HG22 ' A' ' 29' ' ' VAL . 3.4 ttt180 -130.5 116.49 18.26 Favored 'General case' 0 C--N 1.325 -0.465 0 O-C-N 124.513 1.133 . . . . 0.0 110.326 179.948 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 74.9 m-20 57.61 23.46 9.34 Favored 'General case' 0 C--N 1.325 -0.476 0 O-C-N 124.51 1.131 . . . . 0.0 109.329 -179.939 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 84.27 24.72 46.57 Favored Glycine 0 CA--C 1.53 1.002 0 O-C-N 124.522 1.139 . . . . 0.0 111.013 180.0 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 10.7 mt -144.84 130.31 9.44 Favored Pre-proline 0 C--N 1.325 -0.481 0 O-C-N 124.495 0.762 . . . . 0.0 109.262 -179.984 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 20.2 Cg_endo -74.99 88.24 1.26 Allowed 'Trans proline' 0 N--CA 1.453 -0.891 0 O-C-N 124.5 1.789 . . . . 0.0 110.986 -168.312 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.581 HG22 ' HB3' ' A' ' 24' ' ' ARG . 32.4 m . . . . . 0 C--N 1.325 -0.482 0 O-C-N 124.51 1.131 . . . . 0.0 109.294 -179.998 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 58.5 m . . . . . 0 N--CA 1.453 -0.307 0 N-CA-C 108.301 -1.0 . . . . 0.0 108.301 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 90.93 -15.76 60.06 Favored Glycine 0 CA--C 1.531 1.042 0 O-C-N 124.483 1.115 . . . . 0.0 110.96 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 15.6 tt0 -88.76 162.72 16.07 Favored 'General case' 0 C--N 1.325 -0.471 0 O-C-N 124.541 0.789 . . . . 0.0 110.316 179.999 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.604 HG22 HG23 ' A' ' 21' ' ' VAL . 53.0 p -120.39 134.97 55.18 Favored 'General case' 0 C--N 1.324 -0.502 0 O-C-N 124.496 1.123 . . . . 0.0 110.425 179.998 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.417 ' O ' ' CD1' ' A' ' 19' ' ' TRP . 13.8 p -105.05 49.06 0.82 Allowed 'General case' 0 C--N 1.325 -0.487 0 O-C-N 124.487 1.117 . . . . 0.0 108.334 179.982 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 37.9 t -59.12 -23.37 24.35 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 O-C-N 124.491 1.12 . . . . 0.0 109.327 179.986 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -82.89 -32.69 26.04 Favored Glycine 0 CA--C 1.531 1.033 0 O-C-N 124.477 1.111 . . . . 0.0 110.985 -179.967 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 125.64 10.8 4.3 Favored Glycine 0 CA--C 1.53 0.997 0 O-C-N 125.068 1.099 . . . . 0.0 110.959 178.183 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 83.6 m -150.19 165.38 33.08 Favored 'General case' 0 C--N 1.325 -0.495 0 O-C-N 124.493 0.761 . . . . 0.0 110.398 179.947 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 91.4 m -118.45 141.85 48.14 Favored 'General case' 0 C--N 1.325 -0.473 0 O-C-N 124.498 1.124 . . . . 0.0 108.29 -179.976 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 13.0 t-20 -89.79 -39.9 12.81 Favored 'General case' 0 C--N 1.325 -0.488 0 O-C-N 124.526 1.141 . . . . 0.0 109.342 179.959 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.642 HG23 ' HD2' ' A' ' 13' ' ' PRO . 17.6 m -62.32 142.99 95.9 Favored Pre-proline 0 C--N 1.325 -0.49 0 O-C-N 124.458 1.099 . . . . 0.0 110.383 -179.989 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.642 ' HD2' HG23 ' A' ' 12' ' ' THR . 20.3 Cg_endo -74.9 132.06 15.12 Favored 'Trans proline' 0 N--CA 1.453 -0.875 0 O-C-N 124.524 1.802 . . . . 0.0 110.983 -168.314 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 74.37 12.46 82.04 Favored Glycine 0 CA--C 1.53 1.023 0 O-C-N 124.465 1.103 . . . . 0.0 110.962 179.935 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.503 ' SG ' HG22 ' A' ' 12' ' ' THR . 67.3 m -96.71 127.64 42.89 Favored 'General case' 0 C--N 1.325 -0.465 0 N-CA-C 108.307 -0.997 . . . . 0.0 108.307 179.97 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 77.5 p -95.15 152.85 17.99 Favored 'General case' 0 C--N 1.325 -0.457 0 O-C-N 124.511 1.132 . . . . 0.0 110.383 -179.986 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 54.1 t -77.72 93.86 4.35 Favored 'General case' 0 C--N 1.325 -0.493 0 O-C-N 124.487 1.117 . . . . 0.0 108.33 179.983 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' SER . . . . . 0.609 ' HB3' HG23 ' A' ' 23' ' ' THR . 3.1 t -100.41 65.9 1.23 Allowed 'General case' 0 C--N 1.324 -0.526 0 O-C-N 124.494 1.121 . . . . 0.0 109.992 174.321 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 19' ' ' TRP . . . . . 0.583 ' CG ' ' HA ' ' A' ' 20' ' ' PRO . 0.0 OUTLIER -36.93 147.89 0.2 Allowed Pre-proline 0 C--N 1.325 -0.472 0 O-C-N 124.52 1.138 . . . . 0.0 108.009 -173.973 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.583 ' HA ' ' CG ' ' A' ' 19' ' ' TRP . 18.5 Cg_endo -74.98 -12.11 23.98 Favored 'Cis proline' 0 C--N 1.36 1.176 0 C-N-CA 121.023 -2.49 . . . . 0.0 111.047 -8.5 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.675 HG22 ' H ' ' A' ' 22' ' ' CYS . 3.7 p -99.33 -179.55 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 O-C-N 124.5 1.125 . . . . 0.0 109.232 -173.465 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.675 ' H ' HG22 ' A' ' 21' ' ' VAL . 43.2 m -101.32 168.4 9.57 Favored 'General case' 0 C--N 1.325 -0.478 0 O-C-N 124.509 1.131 . . . . 0.0 108.3 179.99 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.609 HG23 ' HB3' ' A' ' 18' ' ' SER . 0.7 OUTLIER -144.95 164.95 29.56 Favored 'General case' 0 C--N 1.325 -0.478 0 O-C-N 124.553 1.158 . . . . 0.0 110.383 -179.983 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.574 ' HB3' HG22 ' A' ' 29' ' ' VAL . 0.0 OUTLIER -133.87 117.55 16.94 Favored 'General case' 0 C--N 1.325 -0.463 0 O-C-N 124.539 1.149 . . . . 0.0 110.298 179.969 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 74.0 m-20 57.68 23.42 9.43 Favored 'General case' 0 C--N 1.326 -0.456 0 O-C-N 124.447 1.092 . . . . 0.0 109.332 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 84.01 24.59 48.11 Favored Glycine 0 CA--C 1.53 0.993 0 O-C-N 124.52 1.137 . . . . 0.0 110.994 179.986 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 9.6 mt -143.67 130.32 10.37 Favored Pre-proline 0 C--N 1.325 -0.471 0 O-C-N 124.485 0.756 . . . . 0.0 109.339 -179.992 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 20.1 Cg_endo -74.95 89.32 1.16 Allowed 'Trans proline' 0 N--CA 1.453 -0.899 0 O-C-N 124.5 1.79 . . . . 0.0 110.981 -168.294 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.574 HG22 ' HB3' ' A' ' 24' ' ' ARG . 22.4 m . . . . . 0 C--N 1.325 -0.496 0 O-C-N 124.501 1.125 . . . . 0.0 109.312 179.991 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 64.8 m . . . . . 0 N--CA 1.453 -0.294 0 N-CA-C 108.305 -0.998 . . . . 0.0 108.305 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 89.63 -17.35 53.02 Favored Glycine 0 CA--C 1.53 0.979 0 O-C-N 124.507 1.129 . . . . 0.0 111.03 179.999 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 14.8 tt0 -87.94 162.62 16.78 Favored 'General case' 0 C--N 1.325 -0.499 0 O-C-N 124.491 0.759 . . . . 0.0 110.291 179.99 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.791 HG22 HG13 ' A' ' 21' ' ' VAL . 40.0 p -121.52 137.71 54.61 Favored 'General case' 0 C--N 1.326 -0.445 0 O-C-N 124.497 1.123 . . . . 0.0 110.424 179.98 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.448 ' O ' ' CD1' ' A' ' 19' ' ' TRP . 14.3 p -105.87 51.13 0.76 Allowed 'General case' 0 C--N 1.325 -0.487 0 O-C-N 124.511 1.132 . . . . 0.0 108.289 -179.967 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 6.0 t -59.1 -24.74 27.99 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 O-C-N 124.482 1.114 . . . . 0.0 109.312 179.994 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -83.91 -33.8 20.18 Favored Glycine 0 CA--C 1.53 0.969 0 O-C-N 124.45 1.093 . . . . 0.0 110.982 -179.992 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 126.27 13.96 3.09 Favored Glycine 0 CA--C 1.53 1.012 0 O-C-N 125.044 1.085 . . . . 0.0 111.031 177.78 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 28.8 m -149.91 163.64 37.54 Favored 'General case' 0 C--N 1.325 -0.483 0 O-C-N 124.509 0.77 . . . . 0.0 110.364 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 10' ' ' CYS . . . . . 0.409 ' SG ' ' O ' ' A' ' 16' ' ' THR . 90.2 m -120.55 143.13 48.75 Favored 'General case' 0 C--N 1.325 -0.475 0 O-C-N 124.481 1.113 . . . . 0.0 108.331 179.987 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 76.2 m-20 -89.96 -46.99 8.14 Favored 'General case' 0 C--N 1.325 -0.462 0 O-C-N 124.462 1.101 . . . . 0.0 109.287 -179.968 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.613 HG23 ' HD2' ' A' ' 13' ' ' PRO . 20.7 m -55.23 142.71 57.66 Favored Pre-proline 0 C--N 1.325 -0.489 0 O-C-N 124.524 1.14 . . . . 0.0 110.343 -179.958 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.613 ' HD2' HG23 ' A' ' 12' ' ' THR . 20.3 Cg_endo -74.92 132.0 15.03 Favored 'Trans proline' 0 N--CA 1.453 -0.872 0 O-C-N 124.572 1.827 . . . . 0.0 111.028 -168.334 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 74.76 12.29 82.92 Favored Glycine 0 CA--C 1.53 1.011 0 O-C-N 124.478 1.111 . . . . 0.0 110.956 179.976 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.498 ' SG ' ' CG2' ' A' ' 12' ' ' THR . 69.6 m -95.52 126.02 40.52 Favored 'General case' 0 C--N 1.324 -0.507 0 N-CA-C 108.262 -1.014 . . . . 0.0 108.262 -179.986 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 16' ' ' THR . . . . . 0.409 ' O ' ' SG ' ' A' ' 10' ' ' CYS . 29.1 p -93.75 156.2 16.81 Favored 'General case' 0 C--N 1.325 -0.492 0 O-C-N 124.526 1.141 . . . . 0.0 110.387 179.999 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 51.6 t -81.34 94.06 6.69 Favored 'General case' 0 C--N 1.325 -0.498 0 O-C-N 124.531 1.144 . . . . 0.0 108.291 179.997 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 18' ' ' SER . . . . . 0.567 ' HB2' HG23 ' A' ' 23' ' ' THR . 1.9 m -101.07 66.39 1.14 Allowed 'General case' 0 C--N 1.325 -0.488 0 O-C-N 124.552 1.157 . . . . 0.0 109.989 174.26 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 19' ' ' TRP . . . . . 0.592 ' CG ' ' HA ' ' A' ' 20' ' ' PRO . 0.0 OUTLIER -36.74 148.19 0.19 Allowed Pre-proline 0 C--N 1.325 -0.481 0 N-CA-C 107.964 -1.124 . . . . 0.0 107.964 -174.019 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.592 ' HA ' ' CG ' ' A' ' 19' ' ' TRP . 18.2 Cg_endo -75.03 -11.87 24.19 Favored 'Cis proline' 0 C--N 1.361 1.192 0 C-N-CA 120.967 -2.514 . . . . 0.0 110.997 -8.474 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.791 HG13 HG22 ' A' ' 4' ' ' THR . 2.2 t -100.2 179.92 0.58 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 O-C-N 124.521 1.138 . . . . 0.0 109.285 -173.386 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.663 ' H ' HG12 ' A' ' 21' ' ' VAL . 57.0 m -101.63 168.43 9.48 Favored 'General case' 0 C--N 1.325 -0.491 0 O-C-N 124.494 1.121 . . . . 0.0 108.312 179.987 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.567 HG23 ' HB2' ' A' ' 18' ' ' SER . 0.8 OUTLIER -145.25 165.06 29.47 Favored 'General case' 0 C--N 1.325 -0.476 0 O-C-N 124.558 1.161 . . . . 0.0 110.427 179.975 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.58 ' HB3' HG22 ' A' ' 29' ' ' VAL . 1.3 ttt-85 -132.81 116.26 16.32 Favored 'General case' 0 C--N 1.324 -0.5 0 O-C-N 124.523 1.139 . . . . 0.0 110.327 -179.991 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 78.4 m-20 57.79 23.08 9.21 Favored 'General case' 0 C--N 1.324 -0.502 0 O-C-N 124.501 1.126 . . . . 0.0 109.291 179.996 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 84.78 23.51 49.54 Favored Glycine 0 CA--C 1.529 0.968 0 O-C-N 124.487 1.117 . . . . 0.0 111.012 -179.966 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 7.2 mt -142.46 129.93 11.26 Favored Pre-proline 0 C--N 1.325 -0.497 0 O-C-N 124.496 0.762 . . . . 0.0 109.288 -179.935 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 20.2 Cg_endo -74.98 89.59 1.15 Allowed 'Trans proline' 0 N--CA 1.453 -0.876 0 O-C-N 124.534 1.807 . . . . 0.0 110.987 -168.323 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.58 HG22 ' HB3' ' A' ' 24' ' ' ARG . 32.6 m . . . . . 0 C--N 1.325 -0.479 0 O-C-N 124.487 1.117 . . . . 0.0 109.276 179.997 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 32.9 m . . . . . 0 N--CA 1.453 -0.282 0 N-CA-C 108.28 -1.008 . . . . 0.0 108.28 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 88.54 -16.01 55.02 Favored Glycine 0 CA--C 1.531 1.044 0 O-C-N 124.503 1.127 . . . . 0.0 110.985 -179.992 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 16.4 tt0 -90.21 161.92 15.49 Favored 'General case' 0 C--N 1.325 -0.483 0 O-C-N 124.515 0.774 . . . . 0.0 110.329 179.982 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.787 HG22 HG12 ' A' ' 21' ' ' VAL . 37.3 p -122.67 135.99 54.75 Favored 'General case' 0 C--N 1.324 -0.518 0 O-C-N 124.481 1.113 . . . . 0.0 110.417 179.992 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.406 ' SG ' ' O ' ' A' ' 5' ' ' CYS . 15.3 p -102.65 53.04 0.79 Allowed 'General case' 0 C--N 1.325 -0.484 0 O-C-N 124.528 1.142 . . . . 0.0 108.281 -179.971 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 15.6 t -59.43 -24.51 28.41 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 O-C-N 124.471 1.107 . . . . 0.0 109.331 179.97 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -84.54 -30.96 25.79 Favored Glycine 0 CA--C 1.53 0.982 0 O-C-N 124.485 1.116 . . . . 0.0 110.992 179.97 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 122.6 13.26 4.74 Favored Glycine 0 CA--C 1.53 1.012 0 O-C-N 124.953 1.031 . . . . 0.0 110.979 178.611 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 5.9 m -150.14 158.76 44.5 Favored 'General case' 0 C--N 1.325 -0.497 0 O-C-N 124.512 0.772 . . . . 0.0 110.41 179.973 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 10' ' ' CYS . . . . . 0.403 ' SG ' ' O ' ' A' ' 16' ' ' THR . 97.2 m -114.3 141.58 47.41 Favored 'General case' 0 C--N 1.325 -0.461 0 O-C-N 124.491 1.12 . . . . 0.0 108.307 -179.971 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 64.3 t30 -89.83 -44.5 9.91 Favored 'General case' 0 C--N 1.325 -0.48 0 O-C-N 124.518 1.136 . . . . 0.0 109.284 -179.965 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.625 HG23 ' HD2' ' A' ' 13' ' ' PRO . 18.9 m -57.65 142.85 77.07 Favored Pre-proline 0 C--N 1.325 -0.472 0 O-C-N 124.487 1.117 . . . . 0.0 110.348 -179.987 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.625 ' HD2' HG23 ' A' ' 12' ' ' THR . 20.3 Cg_endo -75.01 130.57 13.38 Favored 'Trans proline' 0 N--CA 1.452 -0.925 0 O-C-N 124.488 1.783 . . . . 0.0 111.026 -168.328 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 75.59 14.09 82.36 Favored Glycine 0 CA--C 1.531 1.034 0 O-C-N 124.518 1.136 . . . . 0.0 110.975 -179.989 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.5 ' SG ' ' CG2' ' A' ' 12' ' ' THR . 62.3 m -95.69 129.54 42.86 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 108.274 -1.01 . . . . 0.0 108.274 -179.971 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 16' ' ' THR . . . . . 0.403 ' O ' ' SG ' ' A' ' 10' ' ' CYS . 7.7 p -95.54 152.35 18.5 Favored 'General case' 0 C--N 1.325 -0.481 0 O-C-N 124.491 1.12 . . . . 0.0 110.388 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 45.6 t -81.67 94.92 7.06 Favored 'General case' 0 C--N 1.325 -0.497 0 O-C-N 124.515 1.134 . . . . 0.0 108.328 179.999 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 18' ' ' SER . . . . . 0.566 ' CB ' HG23 ' A' ' 23' ' ' THR . 1.2 t -104.13 67.05 0.84 Allowed 'General case' 0 C--N 1.324 -0.504 0 O-C-N 124.551 1.157 . . . . 0.0 109.98 174.221 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 19' ' ' TRP . . . . . 0.623 ' CG ' ' HA ' ' A' ' 20' ' ' PRO . 0.1 OUTLIER -36.1 147.23 0.19 Allowed Pre-proline 0 C--N 1.325 -0.485 0 O-C-N 124.502 1.127 . . . . 0.0 108.011 -174.257 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.623 ' HA ' ' CG ' ' A' ' 19' ' ' TRP . 18.1 Cg_endo -74.98 -14.0 23.26 Favored 'Cis proline' 0 C--N 1.36 1.136 0 C-N-CA 121.014 -2.494 . . . . 0.0 110.996 -8.659 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.787 HG12 HG22 ' A' ' 4' ' ' THR . 3.0 m -97.67 177.83 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.478 0 O-C-N 124.496 1.123 . . . . 0.0 109.294 -173.075 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 52.9 m -102.18 172.5 6.86 Favored 'General case' 0 C--N 1.325 -0.485 0 O-C-N 124.477 1.111 . . . . 0.0 108.317 179.98 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.566 HG23 ' CB ' ' A' ' 18' ' ' SER . 6.5 p -145.56 165.1 29.64 Favored 'General case' 0 C--N 1.324 -0.504 0 O-C-N 124.539 1.149 . . . . 0.0 110.416 -179.982 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.666 ' HB3' HG22 ' A' ' 29' ' ' VAL . 0.1 OUTLIER -131.89 112.97 12.9 Favored 'General case' 0 C--N 1.325 -0.464 0 O-C-N 124.459 1.099 . . . . 0.0 110.293 179.986 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 3.6 m120 57.12 22.96 7.99 Favored 'General case' 0 C--N 1.326 -0.451 0 O-C-N 124.498 1.124 . . . . 0.0 109.319 -179.986 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 86.15 25.3 37.56 Favored Glycine 0 CA--C 1.53 0.985 0 O-C-N 124.522 1.139 . . . . 0.0 111.016 -179.986 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 7.9 mt -143.37 130.01 10.48 Favored Pre-proline 0 C--N 1.325 -0.477 0 O-C-N 124.511 0.771 . . . . 0.0 109.3 179.983 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 20.2 Cg_endo -74.97 85.99 1.46 Allowed 'Trans proline' 0 N--CA 1.453 -0.891 0 O-C-N 124.55 1.816 . . . . 0.0 111.043 -168.34 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.666 HG22 ' HB3' ' A' ' 24' ' ' ARG . 21.6 m . . . . . 0 C--N 1.325 -0.469 0 O-C-N 124.512 1.133 . . . . 0.0 109.3 179.995 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 37.6 m . . . . . 0 N--CA 1.453 -0.304 0 N-CA-C 108.294 -1.002 . . . . 0.0 108.294 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 91.42 -21.64 34.21 Favored Glycine 0 CA--C 1.531 1.06 0 O-C-N 124.505 1.128 . . . . 0.0 110.999 179.989 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 16.0 tt0 -85.23 161.1 19.71 Favored 'General case' 0 C--N 1.325 -0.466 0 O-C-N 124.541 0.789 . . . . 0.0 110.274 -179.987 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.866 HG22 HG23 ' A' ' 21' ' ' VAL . 72.5 p -121.94 136.2 54.91 Favored 'General case' 0 C--N 1.325 -0.457 0 O-C-N 124.445 1.09 . . . . 0.0 110.455 179.996 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.426 ' O ' ' CD1' ' A' ' 19' ' ' TRP . 15.2 p -102.1 53.78 0.8 Allowed 'General case' 0 C--N 1.325 -0.493 0 O-C-N 124.573 1.17 . . . . 0.0 108.283 -179.978 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 4.7 t -59.5 -24.85 29.54 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 O-C-N 124.515 1.135 . . . . 0.0 109.302 -179.993 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -85.42 -32.97 18.11 Favored Glycine 0 CA--C 1.53 0.991 0 O-C-N 124.524 1.14 . . . . 0.0 110.978 -179.979 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 124.31 15.34 3.4 Favored Glycine 0 CA--C 1.53 0.983 0 O-C-N 125.021 1.071 . . . . 0.0 110.977 178.057 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 6.0 m -150.17 158.95 44.7 Favored 'General case' 0 C--N 1.325 -0.48 0 O-C-N 124.494 0.761 . . . . 0.0 110.397 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 74.9 m -117.8 141.75 48.07 Favored 'General case' 0 C--N 1.325 -0.476 0 O-C-N 124.496 1.123 . . . . 0.0 108.302 179.975 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 4.6 m120 -89.7 -47.62 7.81 Favored 'General case' 0 C--N 1.325 -0.475 0 O-C-N 124.498 1.124 . . . . 0.0 109.294 179.997 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.607 HG23 ' HD2' ' A' ' 13' ' ' PRO . 20.8 m -53.87 142.75 43.57 Favored Pre-proline 0 C--N 1.325 -0.479 0 O-C-N 124.442 1.089 . . . . 0.0 110.392 -179.975 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.607 ' HD2' HG23 ' A' ' 12' ' ' THR . 20.2 Cg_endo -75.04 130.78 13.54 Favored 'Trans proline' 0 N--CA 1.453 -0.866 0 O-C-N 124.443 1.759 . . . . 0.0 110.928 -168.237 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 75.36 13.55 82.75 Favored Glycine 0 CA--C 1.53 0.986 0 O-C-N 124.497 1.123 . . . . 0.0 111.022 -179.978 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.498 ' SG ' ' CG2' ' A' ' 12' ' ' THR . 64.2 m -95.54 126.65 40.97 Favored 'General case' 0 C--N 1.325 -0.476 0 N-CA-C 108.316 -0.994 . . . . 0.0 108.316 -179.967 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 17.6 p -94.0 155.23 17.24 Favored 'General case' 0 C--N 1.325 -0.485 0 O-C-N 124.48 1.112 . . . . 0.0 110.437 179.991 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 43.4 t -83.4 94.27 7.94 Favored 'General case' 0 C--N 1.325 -0.48 0 O-C-N 124.482 1.114 . . . . 0.0 108.325 -179.965 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 18' ' ' SER . . . . . 0.564 ' HB3' HG23 ' A' ' 23' ' ' THR . 47.9 t -102.53 66.67 0.98 Allowed 'General case' 0 C--N 1.325 -0.497 0 O-C-N 124.486 1.116 . . . . 0.0 109.971 174.166 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 19' ' ' TRP . . . . . 0.603 ' CG ' ' HA ' ' A' ' 20' ' ' PRO . 0.0 OUTLIER -36.0 147.3 0.18 Allowed Pre-proline 0 C--N 1.325 -0.485 0 O-C-N 124.483 1.114 . . . . 0.0 108.022 -174.167 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.603 ' HA ' ' CG ' ' A' ' 19' ' ' TRP . 18.3 Cg_endo -74.94 -13.69 23.34 Favored 'Cis proline' 0 C--N 1.36 1.159 0 C-N-CA 121.006 -2.498 . . . . 0.0 111.038 -8.513 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.866 HG23 HG22 ' A' ' 4' ' ' THR . 1.1 p -98.42 177.75 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 O-C-N 124.512 1.132 . . . . 0.0 109.305 -173.083 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.505 ' H ' HG22 ' A' ' 21' ' ' VAL . 56.6 m -102.1 170.52 8.05 Favored 'General case' 0 C--N 1.325 -0.472 0 O-C-N 124.502 1.126 . . . . 0.0 108.271 -179.983 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.564 HG23 ' HB3' ' A' ' 18' ' ' SER . 1.1 p -144.98 164.86 29.86 Favored 'General case' 0 C--N 1.325 -0.466 0 O-C-N 124.561 1.163 . . . . 0.0 110.423 179.974 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.53 ' HB3' HG22 ' A' ' 29' ' ' VAL . 7.5 ttt180 -132.87 116.91 17.08 Favored 'General case' 0 C--N 1.325 -0.488 0 O-C-N 124.476 1.11 . . . . 0.0 110.341 179.966 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 75.7 m-20 57.39 23.37 8.89 Favored 'General case' 0 C--N 1.325 -0.48 0 O-C-N 124.452 1.095 . . . . 0.0 109.278 -179.991 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 83.89 25.22 46.26 Favored Glycine 0 CA--C 1.53 1.004 0 O-C-N 124.453 1.096 . . . . 0.0 110.995 -179.982 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 10.0 mt -144.22 131.19 10.31 Favored Pre-proline 0 C--N 1.325 -0.492 0 O-C-N 124.516 0.774 . . . . 0.0 109.268 179.995 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 20.1 Cg_endo -74.97 89.08 1.18 Allowed 'Trans proline' 0 N--CA 1.453 -0.872 0 O-C-N 124.462 1.77 . . . . 0.0 110.986 -168.308 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.53 HG22 ' HB3' ' A' ' 24' ' ' ARG . 33.5 m . . . . . 0 C--N 1.325 -0.485 0 O-C-N 124.443 1.09 . . . . 0.0 109.327 179.99 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 52.7 m . . . . . 0 N--CA 1.453 -0.279 0 N-CA-C 108.32 -0.993 . . . . 0.0 108.32 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 100.81 -10.16 58.75 Favored Glycine 0 CA--C 1.53 0.995 0 O-C-N 124.527 1.142 . . . . 0.0 110.997 -179.976 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 14.6 tt0 -99.17 162.77 12.87 Favored 'General case' 0 C--N 1.325 -0.484 0 O-C-N 124.51 0.77 . . . . 0.0 110.262 -179.96 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.674 HG22 HG23 ' A' ' 21' ' ' VAL . 80.9 p -120.12 138.09 53.77 Favored 'General case' 0 C--N 1.326 -0.446 0 O-C-N 124.541 1.151 . . . . 0.0 110.395 179.945 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.431 ' O ' ' CD1' ' A' ' 19' ' ' TRP . 14.5 p -107.72 51.26 0.75 Allowed 'General case' 0 C--N 1.325 -0.482 0 O-C-N 124.515 1.134 . . . . 0.0 108.301 179.999 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 15.0 t -59.15 -23.89 25.86 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.468 0 O-C-N 124.461 1.101 . . . . 0.0 109.28 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -85.68 -34.07 14.5 Favored Glycine 0 CA--C 1.53 1.025 0 O-C-N 124.523 1.139 . . . . 0.0 111.019 179.981 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 126.19 17.57 2.44 Favored Glycine 0 C--N 1.344 0.993 0 O-C-N 125.223 1.19 . . . . 0.0 111.003 177.32 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -150.34 166.02 31.29 Favored 'General case' 0 C--N 1.325 -0.488 0 O-C-N 124.534 0.785 . . . . 0.0 110.377 -179.987 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 10' ' ' CYS . . . . . 0.41 ' SG ' ' O ' ' A' ' 16' ' ' THR . 80.1 m -125.97 142.76 51.38 Favored 'General case' 0 C--N 1.325 -0.468 0 O-C-N 124.485 1.116 . . . . 0.0 108.285 179.996 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 4.3 m-20 -89.99 -48.3 7.3 Favored 'General case' 0 C--N 1.324 -0.514 0 O-C-N 124.489 1.118 . . . . 0.0 109.286 -179.992 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.623 HG23 ' HD2' ' A' ' 13' ' ' PRO . 18.9 m -53.04 142.78 34.79 Favored Pre-proline 0 C--N 1.326 -0.453 0 O-C-N 124.497 1.123 . . . . 0.0 110.417 179.971 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.623 ' HD2' HG23 ' A' ' 12' ' ' THR . 20.1 Cg_endo -75.01 131.39 14.22 Favored 'Trans proline' 0 N--CA 1.453 -0.906 0 O-C-N 124.495 1.787 . . . . 0.0 110.969 -168.3 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 74.2 15.11 80.15 Favored Glycine 0 CA--C 1.53 0.999 0 O-C-N 124.46 1.1 . . . . 0.0 110.984 179.965 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.504 ' SG ' ' CG2' ' A' ' 12' ' ' THR . 63.7 m -97.47 125.93 42.44 Favored 'General case' 0 C--N 1.325 -0.483 0 N-CA-C 108.285 -1.006 . . . . 0.0 108.285 179.996 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 16' ' ' THR . . . . . 0.41 ' O ' ' SG ' ' A' ' 10' ' ' CYS . 18.6 p -94.11 158.61 15.53 Favored 'General case' 0 C--N 1.324 -0.504 0 O-C-N 124.489 1.118 . . . . 0.0 110.393 -179.993 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 42.4 t -81.72 94.11 6.93 Favored 'General case' 0 C--N 1.325 -0.473 0 O-C-N 124.467 1.104 . . . . 0.0 108.334 179.951 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 18' ' ' SER . . . . . 0.606 ' HB3' HG23 ' A' ' 23' ' ' THR . 2.5 t -100.98 65.57 1.11 Allowed 'General case' 0 C--N 1.325 -0.457 0 O-C-N 124.475 1.109 . . . . 0.0 109.989 174.214 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 19' ' ' TRP . . . . . 0.585 ' CG ' ' HA ' ' A' ' 20' ' ' PRO . 0.0 OUTLIER -36.64 148.04 0.19 Allowed Pre-proline 0 C--N 1.324 -0.507 0 O-C-N 124.489 1.118 . . . . 0.0 108.0 -174.067 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.585 ' HA ' ' CG ' ' A' ' 19' ' ' TRP . 18.1 Cg_endo -75.02 -11.49 24.25 Favored 'Cis proline' 0 C--N 1.361 1.186 0 C-N-CA 121.017 -2.493 . . . . 0.0 110.97 -8.309 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.674 HG23 HG22 ' A' ' 4' ' ' THR . 3.2 p -100.5 -179.6 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 O-C-N 124.499 1.124 . . . . 0.0 109.291 -173.528 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.661 ' H ' HG22 ' A' ' 21' ' ' VAL . 60.4 m -101.67 167.01 10.39 Favored 'General case' 0 C--N 1.326 -0.456 0 O-C-N 124.526 1.141 . . . . 0.0 108.316 179.999 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.606 HG23 ' HB3' ' A' ' 18' ' ' SER . 0.8 OUTLIER -144.45 165.7 27.22 Favored 'General case' 0 C--N 1.324 -0.517 0 O-C-N 124.487 1.117 . . . . 0.0 110.412 179.958 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.425 ' HB3' ' CG2' ' A' ' 29' ' ' VAL . 15.0 ttt180 -135.18 120.2 18.67 Favored 'General case' 0 C--N 1.325 -0.495 0 O-C-N 124.542 1.151 . . . . 0.0 110.293 -179.958 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 25' ' ' ASN . . . . . 0.527 ' O ' ' ND2' ' A' ' 25' ' ' ASN . 0.2 OUTLIER 56.46 25.42 9.64 Favored 'General case' 0 C--N 1.324 -0.5 0 O-C-N 124.493 1.121 . . . . 0.0 109.296 179.977 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 79.41 27.93 53.78 Favored Glycine 0 CA--C 1.529 0.966 0 O-C-N 124.457 1.098 . . . . 0.0 111.021 179.999 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 40.1 mt -146.8 132.49 9.32 Favored Pre-proline 0 C--N 1.325 -0.469 0 O-C-N 124.47 0.747 . . . . 0.0 109.26 -179.986 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 20.1 Cg_endo -74.99 87.52 1.32 Allowed 'Trans proline' 0 N--CA 1.453 -0.895 0 O-C-N 124.543 1.812 . . . . 0.0 110.968 -168.319 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.425 ' CG2' ' HB3' ' A' ' 24' ' ' ARG . 18.2 m . . . . . 0 C--N 1.325 -0.465 0 O-C-N 124.532 1.145 . . . . 0.0 109.287 179.993 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 72.9 m . . . . . 0 N--CA 1.452 -0.336 0 N-CA-C 108.332 -0.988 . . . . 0.0 108.332 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 83.42 -10.96 57.67 Favored Glycine 0 CA--C 1.53 0.981 0 O-C-N 124.551 1.157 . . . . 0.0 110.988 179.981 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 7.7 pt-20 -100.28 171.59 7.68 Favored 'General case' 0 C--N 1.325 -0.46 0 O-C-N 124.493 0.76 . . . . 0.0 110.346 179.994 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' THR . . . . . 1.039 HG22 HG23 ' A' ' 21' ' ' VAL . 67.8 p -129.62 145.1 51.52 Favored 'General case' 0 C--N 1.325 -0.486 0 O-C-N 124.469 1.106 . . . . 0.0 110.455 179.997 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.429 ' O ' ' CD1' ' A' ' 19' ' ' TRP . 22.6 p -107.35 56.41 0.64 Allowed 'General case' 0 C--N 1.324 -0.524 0 O-C-N 124.52 1.138 . . . . 0.0 108.292 -179.95 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.4 t -59.45 -24.87 29.46 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 O-C-N 124.508 1.13 . . . . 0.0 109.284 -179.956 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -84.85 -35.1 13.55 Favored Glycine 0 CA--C 1.53 1.009 0 O-C-N 124.509 1.13 . . . . 0.0 110.981 -179.986 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 125.48 17.22 2.67 Favored Glycine 0 C--N 1.344 1.025 0 O-C-N 125.055 1.091 . . . . 0.0 111.047 177.698 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 2.4 m -150.33 155.62 39.99 Favored 'General case' 0 C--N 1.326 -0.45 0 O-C-N 124.484 0.755 . . . . 0.0 110.436 179.969 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 94.5 m -110.89 140.56 45.26 Favored 'General case' 0 C--N 1.325 -0.477 0 O-C-N 124.501 1.126 . . . . 0.0 108.268 -179.969 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 30.5 m-20 -90.01 -38.74 13.41 Favored 'General case' 0 C--N 1.325 -0.477 0 O-C-N 124.47 1.106 . . . . 0.0 109.306 -179.999 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.667 HG23 ' HD2' ' A' ' 13' ' ' PRO . 15.6 m -65.58 143.25 98.58 Favored Pre-proline 0 C--N 1.325 -0.474 0 O-C-N 124.521 1.138 . . . . 0.0 110.43 179.988 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.667 ' HD2' HG23 ' A' ' 12' ' ' THR . 20.3 Cg_endo -74.92 131.05 13.96 Favored 'Trans proline' 0 N--CA 1.453 -0.894 0 O-C-N 124.496 1.787 . . . . 0.0 110.976 -168.302 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 75.04 15.13 81.25 Favored Glycine 0 CA--C 1.53 1.02 0 O-C-N 124.504 1.128 . . . . 0.0 110.97 179.963 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.494 ' SG ' HG22 ' A' ' 12' ' ' THR . 64.3 m -98.1 127.61 44.14 Favored 'General case' 0 C--N 1.325 -0.464 0 N-CA-C 108.308 -0.997 . . . . 0.0 108.308 179.971 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 71.0 p -94.28 152.25 18.81 Favored 'General case' 0 C--N 1.325 -0.484 0 O-C-N 124.48 1.112 . . . . 0.0 110.44 179.97 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 47.4 t -78.18 98.09 5.72 Favored 'General case' 0 C--N 1.325 -0.492 0 O-C-N 124.479 1.112 . . . . 0.0 108.243 -179.951 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 18' ' ' SER . . . . . 0.567 ' HB3' HG23 ' A' ' 23' ' ' THR . 10.8 t -104.78 65.89 0.76 Allowed 'General case' 0 C--N 1.324 -0.51 0 O-C-N 124.553 1.158 . . . . 0.0 109.958 174.442 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 19' ' ' TRP . . . . . 0.604 ' CG ' ' HA ' ' A' ' 20' ' ' PRO . 0.0 OUTLIER -36.88 147.87 0.2 Allowed Pre-proline 0 C--N 1.325 -0.489 0 O-C-N 124.505 1.128 . . . . 0.0 107.99 -174.18 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.604 ' HA ' ' CG ' ' A' ' 19' ' ' TRP . 18.1 Cg_endo -75.04 -12.57 24.07 Favored 'Cis proline' 0 C--N 1.36 1.144 0 C-N-CA 120.974 -2.511 . . . . 0.0 110.957 -8.505 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 1.039 HG23 HG22 ' A' ' 4' ' ' THR . 4.4 p -98.09 178.85 0.6 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 O-C-N 124.521 1.138 . . . . 0.0 109.289 -173.628 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.683 ' H ' HG22 ' A' ' 21' ' ' VAL . 1.7 m -101.95 168.51 9.36 Favored 'General case' 0 C--N 1.325 -0.477 0 O-C-N 124.49 1.119 . . . . 0.0 108.348 -179.993 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.567 HG23 ' HB3' ' A' ' 18' ' ' SER . 0.8 OUTLIER -145.34 168.31 20.8 Favored 'General case' 0 C--N 1.325 -0.488 0 O-C-N 124.486 1.116 . . . . 0.0 110.399 -179.976 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.468 ' HB3' ' CG2' ' A' ' 29' ' ' VAL . 29.3 ttt-85 -144.64 119.39 9.85 Favored 'General case' 0 C--N 1.324 -0.506 0 O-C-N 124.514 1.133 . . . . 0.0 110.332 -179.979 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 25' ' ' ASN . . . . . 0.558 ' O ' ' ND2' ' A' ' 25' ' ' ASN . 2.5 t30 57.42 23.28 8.84 Favored 'General case' 0 C--N 1.325 -0.491 0 O-C-N 124.506 1.129 . . . . 0.0 109.293 -179.997 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 83.44 24.27 51.37 Favored Glycine 0 CA--C 1.53 0.974 0 O-C-N 124.514 1.134 . . . . 0.0 111.027 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 19.1 mt -147.3 128.27 7.09 Favored Pre-proline 0 C--N 1.325 -0.463 0 O-C-N 124.464 0.744 . . . . 0.0 109.325 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 20.2 Cg_endo -74.97 80.96 2.31 Favored 'Trans proline' 0 N--CA 1.453 -0.891 0 O-C-N 124.474 1.776 . . . . 0.0 110.972 -168.271 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.468 ' CG2' ' HB3' ' A' ' 24' ' ' ARG . 17.6 m . . . . . 0 C--N 1.325 -0.46 0 O-C-N 124.482 1.114 . . . . 0.0 109.289 -179.982 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 80.8 m . . . . . 0 N--CA 1.453 -0.319 0 N-CA-C 108.317 -0.994 . . . . 0.0 108.317 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 82.75 -10.69 55.96 Favored Glycine 0 CA--C 1.53 0.992 0 O-C-N 124.525 1.141 . . . . 0.0 111.042 -179.993 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 7.6 pt-20 -100.28 171.87 7.51 Favored 'General case' 0 C--N 1.325 -0.478 0 O-C-N 124.497 0.763 . . . . 0.0 110.288 179.98 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.975 HG22 HG23 ' A' ' 21' ' ' VAL . 46.1 p -128.92 144.36 51.16 Favored 'General case' 0 C--N 1.326 -0.452 0 O-C-N 124.463 1.102 . . . . 0.0 110.394 179.965 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.526 ' O ' ' CD1' ' A' ' 19' ' ' TRP . 15.1 p -103.08 52.39 0.78 Allowed 'General case' 0 C--N 1.325 -0.472 0 O-C-N 124.505 1.128 . . . . 0.0 108.291 -179.984 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.8 t -59.26 -25.01 29.26 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 O-C-N 124.502 1.127 . . . . 0.0 109.328 -179.986 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -84.63 -32.91 20.68 Favored Glycine 0 CA--C 1.529 0.966 0 O-C-N 124.522 1.138 . . . . 0.0 110.982 179.988 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 124.4 14.63 3.55 Favored Glycine 0 CA--C 1.531 1.049 0 O-C-N 124.892 0.995 . . . . 0.0 110.97 177.996 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 49.1 m -150.29 165.15 33.88 Favored 'General case' 0 C--N 1.325 -0.468 0 O-C-N 124.483 0.755 . . . . 0.0 110.374 -180.0 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 98.4 m -118.37 141.4 48.57 Favored 'General case' 0 C--N 1.326 -0.449 0 O-C-N 124.458 1.099 . . . . 0.0 108.272 -179.989 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 47.2 t30 -89.89 -39.84 12.79 Favored 'General case' 0 C--N 1.325 -0.467 0 O-C-N 124.51 1.131 . . . . 0.0 109.33 179.973 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.652 HG23 ' HD2' ' A' ' 13' ' ' PRO . 16.9 m -64.68 143.02 98.64 Favored Pre-proline 0 C--N 1.325 -0.472 0 O-C-N 124.495 1.122 . . . . 0.0 110.377 -179.993 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.652 ' HD2' HG23 ' A' ' 12' ' ' THR . 20.1 Cg_endo -75.01 130.65 13.46 Favored 'Trans proline' 0 N--CA 1.453 -0.875 0 O-C-N 124.502 1.791 . . . . 0.0 110.955 -168.298 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 76.22 12.82 83.85 Favored Glycine 0 CA--C 1.53 0.979 0 O-C-N 124.514 1.134 . . . . 0.0 111.02 -179.987 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.498 ' SG ' ' CG2' ' A' ' 12' ' ' THR . 64.9 m -95.7 127.48 41.76 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 108.318 -0.993 . . . . 0.0 108.318 179.964 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 29.9 p -94.5 150.16 20.53 Favored 'General case' 0 C--N 1.325 -0.472 0 O-C-N 124.456 1.098 . . . . 0.0 110.466 179.958 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 37.5 t -76.96 96.18 4.31 Favored 'General case' 0 C--N 1.324 -0.523 0 O-C-N 124.557 1.161 . . . . 0.0 108.283 179.988 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 18' ' ' SER . . . . . 0.51 ' O ' ' C ' ' A' ' 19' ' ' TRP . 1.8 m -102.31 65.51 0.95 Allowed 'General case' 0 C--N 1.325 -0.482 0 O-C-N 124.506 1.128 . . . . 0.0 110.003 174.326 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 19' ' ' TRP . . . . . 0.602 ' CG ' ' HA ' ' A' ' 20' ' ' PRO . 0.0 OUTLIER -36.71 148.05 0.19 Allowed Pre-proline 0 C--N 1.325 -0.498 0 O-C-N 124.525 1.141 . . . . 0.0 108.008 -173.995 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.602 ' HA ' ' CG ' ' A' ' 19' ' ' TRP . 18.5 Cg_endo -74.93 -12.53 23.78 Favored 'Cis proline' 0 C--N 1.36 1.149 0 C-N-CA 121.03 -2.487 . . . . 0.0 111.015 -8.509 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.975 HG23 HG22 ' A' ' 4' ' ' THR . 5.8 p -98.87 177.38 0.69 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 O-C-N 124.475 1.11 . . . . 0.0 109.324 -173.279 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.683 ' H ' HG22 ' A' ' 21' ' ' VAL . 1.8 m -102.07 169.74 8.56 Favored 'General case' 0 C--N 1.324 -0.507 0 O-C-N 124.521 1.138 . . . . 0.0 108.314 179.973 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.416 ' O ' ' HA ' ' A' ' 15' ' ' CYS . 0.9 OUTLIER -149.5 165.05 33.35 Favored 'General case' 0 C--N 1.324 -0.518 0 O-C-N 124.49 1.119 . . . . 0.0 110.429 -179.931 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.555 ' HB3' HG22 ' A' ' 29' ' ' VAL . 10.9 ttt85 -141.22 119.68 12.32 Favored 'General case' 0 C--N 1.325 -0.488 0 O-C-N 124.49 1.119 . . . . 0.0 110.289 179.952 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 25' ' ' ASN . . . . . 0.555 ' O ' ' ND2' ' A' ' 25' ' ' ASN . 1.9 t30 57.58 22.71 8.47 Favored 'General case' 0 C--N 1.325 -0.488 0 O-C-N 124.534 1.146 . . . . 0.0 109.329 -179.965 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 26' ' ' GLY . . . . . 0.463 ' O ' HD23 ' A' ' 27' ' ' LEU . . . 83.9 23.93 50.85 Favored Glycine 0 CA--C 1.53 0.997 0 O-C-N 124.533 1.146 . . . . 0.0 110.975 179.978 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.463 HD23 ' O ' ' A' ' 26' ' ' GLY . 13.8 mt -145.93 128.37 7.94 Favored Pre-proline 0 C--N 1.325 -0.48 0 O-C-N 124.551 0.795 . . . . 0.0 109.281 179.976 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 20.3 Cg_endo -74.98 77.42 3.13 Favored 'Trans proline' 0 N--CA 1.453 -0.892 0 O-C-N 124.503 1.791 . . . . 0.0 111.014 -168.327 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.555 HG22 ' HB3' ' A' ' 24' ' ' ARG . 36.0 m . . . . . 0 C--N 1.325 -0.458 0 O-C-N 124.527 1.142 . . . . 0.0 109.259 -179.994 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 87.2 m . . . . . 0 N--CA 1.452 -0.33 0 N-CA-C 108.322 -0.992 . . . . 0.0 108.322 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 91.31 -15.27 61.6 Favored Glycine 0 CA--C 1.53 1.023 0 O-C-N 124.504 1.127 . . . . 0.0 110.98 179.996 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 15.2 tt0 -88.3 162.25 16.7 Favored 'General case' 0 C--N 1.324 -0.509 0 O-C-N 124.534 0.785 . . . . 0.0 110.291 179.98 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.666 HG22 HG23 ' A' ' 21' ' ' VAL . 47.7 p -120.73 131.83 54.73 Favored 'General case' 0 C--N 1.325 -0.484 0 O-C-N 124.456 1.098 . . . . 0.0 110.389 -179.993 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.417 ' SG ' ' O ' ' A' ' 5' ' ' CYS . 14.6 p -100.11 52.08 0.9 Allowed 'General case' 0 C--N 1.325 -0.46 0 O-C-N 124.502 1.126 . . . . 0.0 108.316 179.963 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 11.9 t -59.27 -24.84 28.8 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 O-C-N 124.496 1.123 . . . . 0.0 109.318 179.951 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -84.54 -32.0 23.19 Favored Glycine 0 CA--C 1.53 0.983 0 O-C-N 124.503 1.127 . . . . 0.0 111.008 -179.945 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 123.84 15.91 3.44 Favored Glycine 0 CA--C 1.53 0.992 0 O-C-N 124.896 0.998 . . . . 0.0 110.996 178.112 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 62.2 m -150.11 165.57 32.41 Favored 'General case' 0 C--N 1.325 -0.476 0 O-C-N 124.508 0.769 . . . . 0.0 110.413 179.975 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 10' ' ' CYS . . . . . 0.405 ' SG ' ' O ' ' A' ' 16' ' ' THR . 96.9 m -122.15 143.45 49.55 Favored 'General case' 0 C--N 1.325 -0.464 0 O-C-N 124.512 1.133 . . . . 0.0 108.295 179.999 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 12.0 m-20 -90.11 -47.03 8.07 Favored 'General case' 0 C--N 1.324 -0.511 0 O-C-N 124.505 1.128 . . . . 0.0 109.26 -179.984 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.616 HG23 ' HD2' ' A' ' 13' ' ' PRO . 20.9 m -54.6 142.68 51.54 Favored Pre-proline 0 C--N 1.325 -0.461 0 O-C-N 124.462 1.101 . . . . 0.0 110.431 179.985 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.616 ' HD2' HG23 ' A' ' 12' ' ' THR . 20.1 Cg_endo -74.99 131.36 14.21 Favored 'Trans proline' 0 N--CA 1.453 -0.867 0 O-C-N 124.531 1.806 . . . . 0.0 110.977 -168.295 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 74.69 14.91 80.94 Favored Glycine 0 CA--C 1.53 1.028 0 O-C-N 124.495 1.122 . . . . 0.0 111.024 179.989 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.504 ' SG ' ' CG2' ' A' ' 12' ' ' THR . 63.9 m -96.08 134.58 38.95 Favored 'General case' 0 C--N 1.325 -0.483 0 N-CA-C 108.297 -1.001 . . . . 0.0 108.297 179.987 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 16' ' ' THR . . . . . 0.405 ' O ' ' SG ' ' A' ' 10' ' ' CYS . 82.7 p -101.11 152.97 19.98 Favored 'General case' 0 C--N 1.325 -0.466 0 O-C-N 124.445 1.091 . . . . 0.0 110.401 179.975 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 41.3 t -79.71 94.41 5.72 Favored 'General case' 0 C--N 1.325 -0.481 0 O-C-N 124.52 1.138 . . . . 0.0 108.363 179.942 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 18' ' ' SER . . . . . 0.517 ' O ' ' C ' ' A' ' 19' ' ' TRP . 17.5 t -101.45 65.48 1.05 Allowed 'General case' 0 C--N 1.325 -0.488 0 O-C-N 124.456 1.097 . . . . 0.0 110.002 174.236 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 19' ' ' TRP . . . . . 0.621 ' CG ' ' HA ' ' A' ' 20' ' ' PRO . 0.1 OUTLIER -36.14 147.01 0.19 Allowed Pre-proline 0 C--N 1.325 -0.477 0 O-C-N 124.515 1.134 . . . . 0.0 107.997 -174.129 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.621 ' HA ' ' CG ' ' A' ' 19' ' ' TRP . 18.2 Cg_endo -74.97 -13.76 23.37 Favored 'Cis proline' 0 C--N 1.36 1.166 0 C-N-CA 121.009 -2.496 . . . . 0.0 111.003 -8.557 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.666 HG23 HG22 ' A' ' 4' ' ' THR . 0.9 OUTLIER -97.35 178.04 0.63 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 O-C-N 124.449 1.093 . . . . 0.0 109.29 -173.148 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.491 ' H ' HG22 ' A' ' 21' ' ' VAL . 36.8 m -101.72 170.48 8.14 Favored 'General case' 0 C--N 1.325 -0.461 0 O-C-N 124.549 1.156 . . . . 0.0 108.289 -179.991 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.501 HG23 ' HB3' ' A' ' 18' ' ' SER . 0.8 OUTLIER -146.88 166.81 25.61 Favored 'General case' 0 C--N 1.325 -0.487 0 O-C-N 124.483 1.115 . . . . 0.0 110.404 179.985 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.581 ' HB3' HG22 ' A' ' 29' ' ' VAL . 2.5 ttt180 -139.05 119.28 13.61 Favored 'General case' 0 C--N 1.325 -0.487 0 O-C-N 124.514 1.134 . . . . 0.0 110.327 179.995 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 81.1 m-20 57.16 22.99 8.08 Favored 'General case' 0 C--N 1.325 -0.478 0 O-C-N 124.515 1.134 . . . . 0.0 109.333 -179.973 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 83.7 25.58 45.64 Favored Glycine 0 CA--C 1.53 0.997 0 O-C-N 124.519 1.137 . . . . 0.0 110.968 179.949 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 12.9 mt -145.57 130.38 9.01 Favored Pre-proline 0 C--N 1.325 -0.488 0 O-C-N 124.457 0.739 . . . . 0.0 109.309 179.991 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 20.1 Cg_endo -75.01 82.48 2.0 Allowed 'Trans proline' 0 N--CA 1.453 -0.91 0 O-C-N 124.505 1.792 . . . . 0.0 110.955 -168.309 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.581 HG22 ' HB3' ' A' ' 24' ' ' ARG . 28.2 m . . . . . 0 C--N 1.325 -0.465 0 O-C-N 124.528 1.142 . . . . 0.0 109.346 179.951 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 93.5 m . . . . . 0 N--CA 1.453 -0.287 0 N-CA-C 108.32 -0.993 . . . . 0.0 108.32 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 95.54 -15.2 63.66 Favored Glycine 0 CA--C 1.53 1.03 0 O-C-N 124.486 1.116 . . . . 0.0 110.995 179.987 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 15.1 tt0 -86.4 161.82 18.47 Favored 'General case' 0 C--N 1.325 -0.459 0 O-C-N 124.504 0.767 . . . . 0.0 110.287 -179.992 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.404 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 48.0 p -119.03 132.23 56.03 Favored 'General case' 0 C--N 1.324 -0.508 0 O-C-N 124.505 1.128 . . . . 0.0 110.406 179.987 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.427 ' O ' ' CD1' ' A' ' 19' ' ' TRP . 14.3 p -102.18 51.29 0.82 Allowed 'General case' 0 C--N 1.324 -0.509 0 O-C-N 124.531 1.144 . . . . 0.0 108.295 -179.965 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 6.6 t -59.27 -24.5 27.89 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 O-C-N 124.458 1.099 . . . . 0.0 109.289 -179.97 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -85.52 -34.31 14.25 Favored Glycine 0 CA--C 1.53 0.976 0 O-C-N 124.503 1.127 . . . . 0.0 111.041 -180.0 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 125.1 16.75 2.86 Favored Glycine 0 CA--C 1.53 1.0 0 O-C-N 124.945 1.026 . . . . 0.0 111.043 177.818 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 2.6 m -150.21 157.92 43.6 Favored 'General case' 0 C--N 1.325 -0.473 0 O-C-N 124.533 0.784 . . . . 0.0 110.414 -179.963 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 10' ' ' CYS . . . . . 0.411 ' SG ' ' O ' ' A' ' 16' ' ' THR . 84.0 m -118.59 144.56 46.03 Favored 'General case' 0 C--N 1.325 -0.471 0 O-C-N 124.487 1.117 . . . . 0.0 108.313 179.989 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 76.1 m-20 -89.86 -51.78 5.32 Favored 'General case' 0 C--N 1.325 -0.481 0 O-C-N 124.512 1.133 . . . . 0.0 109.314 179.977 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.605 HG23 ' HD2' ' A' ' 13' ' ' PRO . 22.0 m -49.72 142.58 12.19 Favored Pre-proline 0 C--N 1.325 -0.49 0 O-C-N 124.551 1.157 . . . . 0.0 110.405 179.982 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.605 ' HD2' HG23 ' A' ' 12' ' ' THR . 20.2 Cg_endo -74.99 131.7 14.59 Favored 'Trans proline' 0 N--CA 1.452 -0.947 0 O-C-N 124.45 1.763 . . . . 0.0 111.011 -168.267 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 74.36 13.78 81.31 Favored Glycine 0 CA--C 1.53 1.022 0 O-C-N 124.49 1.118 . . . . 0.0 111.009 -179.978 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.505 ' SG ' ' CG2' ' A' ' 12' ' ' THR . 67.4 m -96.31 126.18 41.34 Favored 'General case' 0 C--N 1.324 -0.504 0 N-CA-C 108.336 -0.987 . . . . 0.0 108.336 179.971 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 16' ' ' THR . . . . . 0.411 ' O ' ' SG ' ' A' ' 10' ' ' CYS . 30.8 p -94.24 158.32 15.65 Favored 'General case' 0 C--N 1.325 -0.481 0 O-C-N 124.482 1.114 . . . . 0.0 110.387 -180.0 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 42.4 t -82.37 94.99 7.5 Favored 'General case' 0 C--N 1.325 -0.484 0 O-C-N 124.524 1.14 . . . . 0.0 108.339 179.968 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 18' ' ' SER . . . . . 0.515 ' O ' ' C ' ' A' ' 19' ' ' TRP . 3.0 t -100.54 65.57 1.19 Allowed 'General case' 0 C--N 1.325 -0.463 0 O-C-N 124.526 1.141 . . . . 0.0 109.993 174.198 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 19' ' ' TRP . . . . . 0.592 ' CG ' ' HA ' ' A' ' 20' ' ' PRO . 0.0 OUTLIER -36.73 147.47 0.2 Allowed Pre-proline 0 C--N 1.325 -0.484 0 N-CA-C 107.958 -1.127 . . . . 0.0 107.958 -173.93 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.592 ' HA ' ' CG ' ' A' ' 19' ' ' TRP . 18.2 Cg_endo -75.04 -12.83 23.99 Favored 'Cis proline' 0 C--N 1.36 1.184 0 C-N-CA 120.968 -2.513 . . . . 0.0 111.003 -8.478 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.492 ' O ' ' C ' ' A' ' 18' ' ' SER . 16.3 m -98.05 179.24 0.58 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.494 0 O-C-N 124.514 1.134 . . . . 0.0 109.293 -173.478 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 51.9 m -101.77 168.08 9.68 Favored 'General case' 0 C--N 1.325 -0.488 0 O-C-N 124.54 1.15 . . . . 0.0 108.311 179.979 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.498 HG23 ' HB3' ' A' ' 18' ' ' SER . 0.8 OUTLIER -146.97 168.06 22.44 Favored 'General case' 0 C--N 1.325 -0.458 0 O-C-N 124.515 1.135 . . . . 0.0 110.382 179.999 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.485 ' HB3' HG22 ' A' ' 29' ' ' VAL . 0.3 OUTLIER -141.54 119.69 12.12 Favored 'General case' 0 C--N 1.325 -0.468 0 O-C-N 124.506 1.128 . . . . 0.0 110.279 179.993 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 25' ' ' ASN . . . . . 0.545 ' O ' ' ND2' ' A' ' 25' ' ' ASN . 2.7 t30 57.84 23.07 9.27 Favored 'General case' 0 C--N 1.326 -0.455 0 O-C-N 124.479 1.112 . . . . 0.0 109.303 179.967 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 26' ' ' GLY . . . . . 0.441 ' O ' HD23 ' A' ' 27' ' ' LEU . . . 82.43 23.34 56.78 Favored Glycine 0 CA--C 1.53 1.019 0 O-C-N 124.467 1.104 . . . . 0.0 110.976 179.992 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.441 HD23 ' O ' ' A' ' 26' ' ' GLY . 11.9 mt -143.53 129.62 10.19 Favored Pre-proline 0 C--N 1.325 -0.498 0 O-C-N 124.461 0.742 . . . . 0.0 109.331 -179.997 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 20.5 Cg_endo -74.92 82.53 1.97 Allowed 'Trans proline' 0 N--CA 1.453 -0.861 0 O-C-N 124.516 1.798 . . . . 0.0 111.031 -168.343 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.485 HG22 ' HB3' ' A' ' 24' ' ' ARG . 27.4 m . . . . . 0 C--N 1.325 -0.484 0 O-C-N 124.489 1.118 . . . . 0.0 109.343 179.982 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 69.1 m . . . . . 0 N--CA 1.452 -0.328 0 N-CA-C 108.276 -1.009 . . . . 0.0 108.276 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 93.89 -15.7 62.51 Favored Glycine 0 CA--C 1.53 1.004 0 O-C-N 124.524 1.14 . . . . 0.0 110.995 179.97 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 15.5 tt0 -86.75 162.53 17.8 Favored 'General case' 0 C--N 1.326 -0.446 0 O-C-N 124.474 0.749 . . . . 0.0 110.322 -179.971 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.504 HG22 HG23 ' A' ' 21' ' ' VAL . 65.9 p -120.16 132.97 55.59 Favored 'General case' 0 C--N 1.325 -0.486 0 O-C-N 124.452 1.095 . . . . 0.0 110.398 179.961 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.425 ' SG ' ' O ' ' A' ' 5' ' ' CYS . 13.8 p -102.44 49.96 0.84 Allowed 'General case' 0 C--N 1.325 -0.457 0 O-C-N 124.449 1.093 . . . . 0.0 108.279 -179.981 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 15.1 t -59.09 -24.0 25.97 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 O-C-N 124.562 1.164 . . . . 0.0 109.351 179.947 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -83.61 -33.67 21.45 Favored Glycine 0 CA--C 1.53 1.0 0 O-C-N 124.488 1.118 . . . . 0.0 111.033 179.972 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 126.88 10.85 3.74 Favored Glycine 0 C--N 1.345 1.074 0 C-N-CA 119.774 -1.203 . . . . 0.0 110.989 177.917 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -149.92 166.96 28.0 Favored 'General case' 0 C--N 1.325 -0.496 0 O-C-N 124.522 0.778 . . . . 0.0 110.416 -179.994 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 10' ' ' CYS . . . . . 0.412 ' SG ' ' O ' ' A' ' 16' ' ' THR . 80.2 m -121.8 146.37 47.14 Favored 'General case' 0 C--N 1.325 -0.469 0 O-C-N 124.484 1.115 . . . . 0.0 108.293 179.996 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 22.2 t30 -92.41 -44.17 8.83 Favored 'General case' 0 C--N 1.325 -0.479 0 O-C-N 124.518 1.136 . . . . 0.0 109.306 -179.995 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.632 HG23 ' HD2' ' A' ' 13' ' ' PRO . 18.4 m -57.75 142.89 77.62 Favored Pre-proline 0 C--N 1.324 -0.506 0 O-C-N 124.495 1.122 . . . . 0.0 110.391 179.976 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.632 ' HD2' HG23 ' A' ' 12' ' ' THR . 20.3 Cg_endo -74.96 131.68 14.62 Favored 'Trans proline' 0 N--CA 1.453 -0.879 0 O-C-N 124.533 1.807 . . . . 0.0 111.003 -168.335 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 76.42 7.23 85.08 Favored Glycine 0 CA--C 1.53 0.985 0 O-C-N 124.428 1.08 . . . . 0.0 111.007 179.985 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.5 ' SG ' ' CG2' ' A' ' 12' ' ' THR . 69.2 m -92.14 126.28 37.16 Favored 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 108.283 -1.006 . . . . 0.0 108.283 -179.998 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 16' ' ' THR . . . . . 0.412 ' O ' ' SG ' ' A' ' 10' ' ' CYS . 34.3 p -95.28 156.52 16.29 Favored 'General case' 0 C--N 1.325 -0.484 0 O-C-N 124.543 1.152 . . . . 0.0 110.378 179.997 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 42.7 t -80.99 94.12 6.49 Favored 'General case' 0 C--N 1.325 -0.478 0 O-C-N 124.532 1.145 . . . . 0.0 108.276 -179.964 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 18' ' ' SER . . . . . 0.518 ' O ' ' C ' ' A' ' 19' ' ' TRP . 3.6 t -100.36 65.51 1.22 Allowed 'General case' 0 C--N 1.325 -0.484 0 O-C-N 124.506 1.128 . . . . 0.0 110.006 174.172 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 19' ' ' TRP . . . . . 0.603 ' CG ' ' HA ' ' A' ' 20' ' ' PRO . 0.0 OUTLIER -36.3 147.42 0.19 Allowed Pre-proline 0 C--N 1.325 -0.465 0 N-CA-C 107.992 -1.114 . . . . 0.0 107.992 -173.981 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.603 ' HA ' ' CG ' ' A' ' 19' ' ' TRP . 18.3 Cg_endo -75.03 -12.92 23.97 Favored 'Cis proline' 0 C--N 1.36 1.166 0 C-N-CA 121.035 -2.485 . . . . 0.0 110.981 -8.374 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.69 HG22 ' H ' ' A' ' 22' ' ' CYS . 4.6 p -99.02 179.16 0.6 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.5 0 O-C-N 124.502 1.126 . . . . 0.0 109.292 -173.284 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.69 ' H ' HG22 ' A' ' 21' ' ' VAL . 53.3 m -101.63 168.9 9.18 Favored 'General case' 0 C--N 1.325 -0.473 0 O-C-N 124.476 1.11 . . . . 0.0 108.358 179.986 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.441 ' OG1' ' CB ' ' A' ' 18' ' ' SER . 0.8 OUTLIER -148.36 167.54 24.97 Favored 'General case' 0 C--N 1.325 -0.488 0 O-C-N 124.5 1.125 . . . . 0.0 110.389 -179.986 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.552 ' HB3' HG22 ' A' ' 29' ' ' VAL . 1.4 ttt85 -137.72 120.04 15.8 Favored 'General case' 0 C--N 1.325 -0.472 0 O-C-N 124.493 1.121 . . . . 0.0 110.263 -179.961 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 58.4 t30 56.3 23.33 7.11 Favored 'General case' 0 C--N 1.325 -0.48 0 O-C-N 124.521 1.138 . . . . 0.0 109.288 179.972 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 26' ' ' GLY . . . . . 0.615 ' O ' HD23 ' A' ' 27' ' ' LEU . . . 81.99 28.85 40.08 Favored Glycine 0 CA--C 1.53 0.992 0 O-C-N 124.513 1.133 . . . . 0.0 111.014 -179.988 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.615 HD23 ' O ' ' A' ' 26' ' ' GLY . 22.9 mt -147.27 130.2 7.96 Favored Pre-proline 0 C--N 1.325 -0.461 0 O-C-N 124.513 0.772 . . . . 0.0 109.284 179.957 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 20.2 Cg_endo -75.0 84.28 1.69 Allowed 'Trans proline' 0 N--CA 1.453 -0.881 0 O-C-N 124.488 1.783 . . . . 0.0 110.995 -168.332 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.552 HG22 ' HB3' ' A' ' 24' ' ' ARG . 30.4 m . . . . . 0 C--N 1.326 -0.447 0 O-C-N 124.482 1.114 . . . . 0.0 109.308 179.962 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 16.7 m . . . . . 0 N--CA 1.453 -0.303 0 N-CA-C 108.314 -0.995 . . . . 0.0 108.314 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 92.96 -20.03 48.24 Favored Glycine 0 CA--C 1.53 1.021 0 O-C-N 124.49 1.119 . . . . 0.0 111.001 179.97 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 15.6 tt0 -83.86 162.07 20.67 Favored 'General case' 0 C--N 1.325 -0.475 0 O-C-N 124.487 0.757 . . . . 0.0 110.353 179.976 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.544 HG22 HG13 ' A' ' 21' ' ' VAL . 53.3 p -123.13 132.84 54.24 Favored 'General case' 0 C--N 1.325 -0.478 0 O-C-N 124.455 1.097 . . . . 0.0 110.371 -179.98 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.404 ' SG ' ' O ' ' A' ' 5' ' ' CYS . 16.4 p -100.34 55.22 0.9 Allowed 'General case' 0 C--N 1.326 -0.447 0 O-C-N 124.508 1.13 . . . . 0.0 108.337 179.94 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 9.6 t -59.33 -25.35 30.52 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 O-C-N 124.45 1.094 . . . . 0.0 109.245 -179.944 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -83.79 -30.68 28.68 Favored Glycine 0 CA--C 1.529 0.964 0 O-C-N 124.52 1.138 . . . . 0.0 111.006 179.991 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 122.3 14.23 4.55 Favored Glycine 0 CA--C 1.53 1.013 0 O-C-N 125.006 1.062 . . . . 0.0 110.988 178.694 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 42.5 m -149.95 164.15 36.2 Favored 'General case' 0 C--N 1.325 -0.484 0 O-C-N 124.54 0.788 . . . . 0.0 110.362 -180.0 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 10' ' ' CYS . . . . . 0.401 ' SG ' ' O ' ' A' ' 16' ' ' THR . 97.2 m -120.45 140.98 50.59 Favored 'General case' 0 C--N 1.326 -0.447 0 O-C-N 124.467 1.104 . . . . 0.0 108.292 179.991 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 37.6 t30 -89.74 -45.02 9.59 Favored 'General case' 0 C--N 1.325 -0.463 0 O-C-N 124.493 1.121 . . . . 0.0 109.298 179.977 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.634 HG23 ' HD2' ' A' ' 13' ' ' PRO . 18.3 m -56.02 143.05 63.9 Favored Pre-proline 0 C--N 1.326 -0.453 0 O-C-N 124.462 1.101 . . . . 0.0 110.417 179.973 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.634 ' HD2' HG23 ' A' ' 12' ' ' THR . 20.2 Cg_endo -74.97 130.3 13.18 Favored 'Trans proline' 0 N--CA 1.452 -0.917 0 O-C-N 124.508 1.793 . . . . 0.0 110.987 -168.329 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 75.12 15.29 81.19 Favored Glycine 0 CA--C 1.53 0.995 0 O-C-N 124.442 1.089 . . . . 0.0 111.035 -179.999 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.5 ' SG ' ' CG2' ' A' ' 12' ' ' THR . 57.6 m -96.62 129.88 43.92 Favored 'General case' 0 C--N 1.325 -0.489 0 N-CA-C 108.323 -0.991 . . . . 0.0 108.323 179.999 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 16' ' ' THR . . . . . 0.401 ' O ' ' SG ' ' A' ' 10' ' ' CYS . 21.6 p -95.99 152.7 18.28 Favored 'General case' 0 C--N 1.325 -0.472 0 O-C-N 124.497 1.123 . . . . 0.0 110.366 -179.965 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 45.0 t -82.99 95.86 8.14 Favored 'General case' 0 C--N 1.325 -0.498 0 O-C-N 124.483 1.115 . . . . 0.0 108.285 179.973 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 18' ' ' SER . . . . . 0.778 ' OG ' HG23 ' A' ' 23' ' ' THR . 34.6 p -105.88 66.39 0.72 Allowed 'General case' 0 C--N 1.326 -0.453 0 O-C-N 124.464 1.102 . . . . 0.0 110.023 174.144 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 19' ' ' TRP . . . . . 0.642 ' CG ' ' HA ' ' A' ' 20' ' ' PRO . 0.8 OUTLIER -35.79 146.7 0.19 Allowed Pre-proline 0 C--N 1.324 -0.51 0 O-C-N 124.552 1.158 . . . . 0.0 107.975 -174.399 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.642 ' HA ' ' CG ' ' A' ' 19' ' ' TRP . 18.2 Cg_endo -75.04 -14.83 22.94 Favored 'Cis proline' 0 C--N 1.36 1.159 0 C-N-CA 120.954 -2.519 . . . . 0.0 111.005 -8.67 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.614 HG12 ' H ' ' A' ' 22' ' ' CYS . 2.2 t -96.38 175.97 0.74 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.479 0 O-C-N 124.496 1.122 . . . . 0.0 109.31 -172.992 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.614 ' H ' HG12 ' A' ' 21' ' ' VAL . 33.4 m -102.47 170.13 8.24 Favored 'General case' 0 C--N 1.325 -0.481 0 O-C-N 124.465 1.103 . . . . 0.0 108.298 179.977 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.778 HG23 ' OG ' ' A' ' 18' ' ' SER . 1.0 OUTLIER -141.7 168.4 19.85 Favored 'General case' 0 C--N 1.325 -0.469 0 O-C-N 124.483 1.115 . . . . 0.0 110.427 179.949 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.643 ' HB3' HG22 ' A' ' 29' ' ' VAL . 0.1 OUTLIER -137.0 115.33 11.77 Favored 'General case' 0 C--N 1.325 -0.478 0 O-C-N 124.514 1.133 . . . . 0.0 110.297 -179.984 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 86.9 m-20 57.2 21.84 6.98 Favored 'General case' 0 C--N 1.325 -0.47 0 O-C-N 124.48 1.113 . . . . 0.0 109.295 -179.986 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 87.15 25.52 33.73 Favored Glycine 0 CA--C 1.531 1.049 0 O-C-N 124.464 1.102 . . . . 0.0 110.966 179.975 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 12.8 mt -145.03 130.29 9.3 Favored Pre-proline 0 C--N 1.325 -0.485 0 O-C-N 124.535 0.785 . . . . 0.0 109.289 -179.961 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 20.1 Cg_endo -74.97 79.99 2.53 Favored 'Trans proline' 0 N--CA 1.452 -0.927 0 O-C-N 124.515 1.797 . . . . 0.0 111.008 -168.285 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.643 HG22 ' HB3' ' A' ' 24' ' ' ARG . 18.0 m . . . . . 0 C--N 1.325 -0.482 0 O-C-N 124.51 1.131 . . . . 0.0 109.307 -179.99 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 83.6 m . . . . . 0 N--CA 1.454 -0.266 0 N-CA-C 108.297 -1.001 . . . . 0.0 108.297 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 103.53 -21.09 40.1 Favored Glycine 0 CA--C 1.53 1.01 0 O-C-N 124.515 1.135 . . . . 0.0 110.989 179.981 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 28.5 tt0 -84.4 150.45 25.33 Favored 'General case' 0 C--N 1.324 -0.5 0 O-C-N 124.456 0.739 . . . . 0.0 110.333 179.977 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.427 HG22 HG13 ' A' ' 21' ' ' VAL . 66.0 p -109.74 129.91 55.57 Favored 'General case' 0 C--N 1.325 -0.499 0 O-C-N 124.508 1.13 . . . . 0.0 110.429 -179.983 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.42 ' SG ' ' O ' ' A' ' 5' ' ' CYS . 14.2 p -97.16 51.06 1.09 Allowed 'General case' 0 C--N 1.325 -0.474 0 O-C-N 124.523 1.14 . . . . 0.0 108.292 -179.988 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 9.4 t -59.03 -24.74 27.78 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 O-C-N 124.481 1.113 . . . . 0.0 109.317 179.966 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -83.96 -32.6 23.3 Favored Glycine 0 CA--C 1.53 1.028 0 O-C-N 124.512 1.132 . . . . 0.0 110.989 179.999 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 124.73 14.21 3.54 Favored Glycine 0 C--N 1.344 1.004 0 O-C-N 125.103 1.12 . . . . 0.0 111.013 177.972 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -149.6 166.73 28.39 Favored 'General case' 0 C--N 1.325 -0.476 0 O-C-N 124.501 0.765 . . . . 0.0 110.384 179.95 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 10' ' ' CYS . . . . . 0.406 ' SG ' ' O ' ' A' ' 16' ' ' THR . 75.9 m -123.78 141.96 51.54 Favored 'General case' 0 C--N 1.326 -0.449 0 O-C-N 124.466 1.104 . . . . 0.0 108.279 -179.981 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 34.0 t-20 -89.87 -43.07 10.86 Favored 'General case' 0 C--N 1.325 -0.457 0 O-C-N 124.492 1.12 . . . . 0.0 109.29 -179.998 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.617 HG23 ' HD2' ' A' ' 13' ' ' PRO . 20.2 m -58.35 142.8 81.17 Favored Pre-proline 0 C--N 1.325 -0.485 0 O-C-N 124.427 1.079 . . . . 0.0 110.355 -179.981 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.617 ' HD2' HG23 ' A' ' 12' ' ' THR . 20.2 Cg_endo -74.99 131.59 14.48 Favored 'Trans proline' 0 N--CA 1.453 -0.868 0 O-C-N 124.501 1.79 . . . . 0.0 110.997 -168.322 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 74.1 13.73 80.91 Favored Glycine 0 CA--C 1.53 1.025 0 O-C-N 124.482 1.114 . . . . 0.0 110.985 179.975 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.496 ' SG ' ' CG2' ' A' ' 12' ' ' THR . 66.8 m -97.29 125.93 42.19 Favored 'General case' 0 C--N 1.325 -0.469 0 N-CA-C 108.313 -0.995 . . . . 0.0 108.313 179.97 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 16' ' ' THR . . . . . 0.406 ' O ' ' SG ' ' A' ' 10' ' ' CYS . 68.9 p -93.48 156.07 16.97 Favored 'General case' 0 C--N 1.325 -0.483 0 O-C-N 124.481 1.113 . . . . 0.0 110.383 -179.969 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 43.1 t -82.26 91.53 6.78 Favored 'General case' 0 C--N 1.325 -0.486 0 O-C-N 124.535 1.147 . . . . 0.0 108.301 -179.985 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 18' ' ' SER . . . . . 0.598 ' HB2' HG23 ' A' ' 23' ' ' THR . 3.8 m -98.87 65.81 1.54 Allowed 'General case' 0 C--N 1.325 -0.488 0 O-C-N 124.477 1.111 . . . . 0.0 110.008 174.052 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 19' ' ' TRP . . . . . 0.608 ' CG ' ' HA ' ' A' ' 20' ' ' PRO . 0.1 OUTLIER -35.63 147.12 0.17 Allowed Pre-proline 0 C--N 1.325 -0.5 0 O-C-N 124.556 1.16 . . . . 0.0 107.971 -173.996 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.608 ' HA ' ' CG ' ' A' ' 19' ' ' TRP . 18.4 Cg_endo -74.91 -13.48 23.37 Favored 'Cis proline' 0 C--N 1.36 1.16 0 C-N-CA 121.01 -2.496 . . . . 0.0 111.037 -8.647 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.635 HG12 ' H ' ' A' ' 22' ' ' CYS . 2.2 t -99.11 177.91 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 O-C-N 124.472 1.108 . . . . 0.0 109.288 -173.032 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.635 ' H ' HG12 ' A' ' 21' ' ' VAL . 69.3 m -101.98 169.1 8.98 Favored 'General case' 0 C--N 1.325 -0.485 0 O-C-N 124.501 1.126 . . . . 0.0 108.288 -179.957 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.598 HG23 ' HB2' ' A' ' 18' ' ' SER . 1.1 p -144.26 160.54 40.82 Favored 'General case' 0 C--N 1.325 -0.484 0 O-C-N 124.458 1.099 . . . . 0.0 110.398 179.982 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.607 ' HB3' HG22 ' A' ' 29' ' ' VAL . 1.1 ttt85 -132.23 118.33 19.37 Favored 'General case' 0 C--N 1.325 -0.471 0 O-C-N 124.537 1.148 . . . . 0.0 110.292 -179.985 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 76.2 m-20 57.47 24.55 10.37 Favored 'General case' 0 C--N 1.324 -0.514 0 O-C-N 124.535 1.147 . . . . 0.0 109.289 -179.973 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 82.59 23.36 56.43 Favored Glycine 0 CA--C 1.53 1.024 0 O-C-N 124.586 1.179 . . . . 0.0 111.002 179.982 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 8.0 mt -143.26 129.91 10.52 Favored Pre-proline 0 C--N 1.325 -0.499 0 O-C-N 124.548 0.793 . . . . 0.0 109.337 179.978 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 20.1 Cg_endo -74.99 81.95 2.1 Favored 'Trans proline' 0 N--CA 1.453 -0.87 0 O-C-N 124.511 1.795 . . . . 0.0 110.997 -168.279 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.607 HG22 ' HB3' ' A' ' 24' ' ' ARG . 21.9 m . . . . . 0 C--N 1.325 -0.477 0 O-C-N 124.517 1.136 . . . . 0.0 109.312 179.991 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 83.5 m . . . . . 0 N--CA 1.453 -0.301 0 N-CA-C 108.28 -1.007 . . . . 0.0 108.28 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 91.62 -17.58 55.75 Favored Glycine 0 CA--C 1.53 1.006 0 O-C-N 124.431 1.082 . . . . 0.0 110.994 -179.961 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 15.5 tt0 -85.59 161.72 19.17 Favored 'General case' 0 C--N 1.325 -0.471 0 O-C-N 124.47 0.747 . . . . 0.0 110.314 179.976 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.692 HG22 HG23 ' A' ' 21' ' ' VAL . 47.5 p -120.54 132.0 54.96 Favored 'General case' 0 C--N 1.325 -0.498 0 O-C-N 124.52 1.138 . . . . 0.0 110.456 179.978 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.417 ' SG ' ' O ' ' A' ' 5' ' ' CYS . 14.5 p -98.97 51.64 0.96 Allowed 'General case' 0 C--N 1.325 -0.475 0 O-C-N 124.475 1.109 . . . . 0.0 108.286 -179.977 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 9.0 t -59.22 -24.99 29.07 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 O-C-N 124.497 1.123 . . . . 0.0 109.288 -179.988 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -84.32 -32.25 23.18 Favored Glycine 0 CA--C 1.53 0.979 0 O-C-N 124.507 1.129 . . . . 0.0 111.062 179.961 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 124.37 13.98 3.75 Favored Glycine 0 CA--C 1.529 0.969 0 O-C-N 125.024 1.073 . . . . 0.0 111.036 178.176 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 45.8 m -149.93 164.76 34.58 Favored 'General case' 0 C--N 1.325 -0.47 0 O-C-N 124.514 0.773 . . . . 0.0 110.427 179.995 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 10' ' ' CYS . . . . . 0.405 ' SG ' ' O ' ' A' ' 16' ' ' THR . 94.2 m -121.67 143.16 49.5 Favored 'General case' 0 C--N 1.325 -0.491 0 O-C-N 124.469 1.106 . . . . 0.0 108.254 -179.955 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 76.1 m-20 -90.26 -47.84 7.53 Favored 'General case' 0 C--N 1.325 -0.458 0 O-C-N 124.439 1.087 . . . . 0.0 109.273 -179.982 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.62 HG23 ' HD2' ' A' ' 13' ' ' PRO . 19.5 m -53.16 142.7 36.3 Favored Pre-proline 0 C--N 1.325 -0.474 0 O-C-N 124.495 1.122 . . . . 0.0 110.397 180.0 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.62 ' HD2' HG23 ' A' ' 12' ' ' THR . 20.4 Cg_endo -74.94 131.63 14.59 Favored 'Trans proline' 0 N--CA 1.453 -0.856 0 O-C-N 124.495 1.787 . . . . 0.0 110.975 -168.328 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 73.97 15.81 79.64 Favored Glycine 0 CA--C 1.53 0.977 0 O-C-N 124.524 1.14 . . . . 0.0 110.984 179.953 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.503 ' SG ' ' CG2' ' A' ' 12' ' ' THR . 63.8 m -97.64 131.5 44.15 Favored 'General case' 0 C--N 1.325 -0.47 0 N-CA-C 108.265 -1.013 . . . . 0.0 108.265 -179.991 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 16' ' ' THR . . . . . 0.405 ' O ' ' SG ' ' A' ' 10' ' ' CYS . 73.1 p -98.37 154.68 17.67 Favored 'General case' 0 C--N 1.325 -0.494 0 O-C-N 124.533 1.145 . . . . 0.0 110.405 -180.0 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 44.4 t -82.19 94.69 7.33 Favored 'General case' 0 C--N 1.325 -0.478 0 O-C-N 124.461 1.101 . . . . 0.0 108.261 -179.976 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 18' ' ' SER . . . . . 0.517 ' O ' ' C ' ' A' ' 19' ' ' TRP . 40.8 t -102.23 66.02 0.98 Allowed 'General case' 0 C--N 1.325 -0.494 0 O-C-N 124.506 1.129 . . . . 0.0 109.964 174.045 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 19' ' ' TRP . . . . . 0.619 ' CG ' ' HA ' ' A' ' 20' ' ' PRO . 0.1 OUTLIER -35.92 147.13 0.18 Allowed Pre-proline 0 C--N 1.325 -0.464 0 O-C-N 124.48 1.112 . . . . 0.0 108.02 -174.211 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.619 ' HA ' ' CG ' ' A' ' 19' ' ' TRP . 18.3 Cg_endo -75.03 -13.9 23.44 Favored 'Cis proline' 0 C--N 1.36 1.148 0 C-N-CA 120.991 -2.504 . . . . 0.0 110.972 -8.69 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.692 HG23 HG22 ' A' ' 4' ' ' THR . 0.8 OUTLIER -97.63 177.0 0.69 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 O-C-N 124.512 1.132 . . . . 0.0 109.301 -172.977 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.467 ' H ' HG22 ' A' ' 21' ' ' VAL . 52.7 m -102.0 171.19 7.65 Favored 'General case' 0 C--N 1.325 -0.493 0 O-C-N 124.508 1.13 . . . . 0.0 108.292 -179.995 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.425 ' O ' ' HA ' ' A' ' 15' ' ' CYS . 0.9 OUTLIER -148.83 168.09 23.92 Favored 'General case' 0 C--N 1.325 -0.486 0 O-C-N 124.543 1.152 . . . . 0.0 110.342 179.993 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.495 ' HB3' HG22 ' A' ' 29' ' ' VAL . 8.6 ttt180 -140.57 118.67 11.94 Favored 'General case' 0 C--N 1.326 -0.451 0 O-C-N 124.459 1.099 . . . . 0.0 110.335 179.982 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 14.6 t-20 58.2 22.75 9.51 Favored 'General case' 0 C--N 1.325 -0.465 0 O-C-N 124.494 1.121 . . . . 0.0 109.319 -179.967 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 82.72 22.67 57.69 Favored Glycine 0 CA--C 1.53 0.982 0 O-C-N 124.435 1.085 . . . . 0.0 111.012 -179.997 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 6.2 mt -141.68 130.56 12.28 Favored Pre-proline 0 C--N 1.325 -0.467 0 O-C-N 124.478 0.752 . . . . 0.0 109.286 -179.985 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 20.1 Cg_endo -74.98 83.82 1.75 Allowed 'Trans proline' 0 N--CA 1.453 -0.904 0 O-C-N 124.468 1.773 . . . . 0.0 110.975 -168.258 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.495 HG22 ' HB3' ' A' ' 24' ' ' ARG . 35.5 m . . . . . 0 C--N 1.325 -0.477 0 O-C-N 124.507 1.13 . . . . 0.0 109.29 179.982 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 99.6 m . . . . . 0 N--CA 1.453 -0.286 0 N-CA-C 108.316 -0.994 . . . . 0.0 108.316 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 91.78 -26.92 10.83 Favored Glycine 0 CA--C 1.53 1.015 0 O-C-N 124.477 1.11 . . . . 0.0 111.005 179.98 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 25.3 tt0 -81.46 152.73 27.22 Favored 'General case' 0 C--N 1.326 -0.453 0 O-C-N 124.49 0.759 . . . . 0.0 110.258 -179.959 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.659 HG22 HG23 ' A' ' 21' ' ' VAL . 76.2 p -113.26 134.88 54.38 Favored 'General case' 0 C--N 1.325 -0.495 0 O-C-N 124.519 1.137 . . . . 0.0 110.394 179.962 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.41 ' SG ' ' O ' ' A' ' 5' ' ' CYS . 15.0 p -98.79 52.65 0.99 Allowed 'General case' 0 C--N 1.326 -0.454 0 O-C-N 124.495 1.122 . . . . 0.0 108.332 179.965 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 8.6 t -59.32 -24.73 28.68 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 O-C-N 124.492 1.12 . . . . 0.0 109.301 -179.97 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -84.13 -34.06 18.79 Favored Glycine 0 CA--C 1.529 0.968 0 O-C-N 124.505 1.128 . . . . 0.0 110.975 -179.984 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 126.54 14.63 2.85 Favored Glycine 0 C--N 1.345 1.047 0 O-C-N 125.13 1.135 . . . . 0.0 110.998 177.776 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -150.0 166.94 28.15 Favored 'General case' 0 C--N 1.325 -0.488 0 O-C-N 124.53 0.782 . . . . 0.0 110.413 179.981 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 10' ' ' CYS . . . . . 0.408 ' SG ' ' O ' ' A' ' 16' ' ' THR . 72.8 m -124.22 141.78 51.78 Favored 'General case' 0 C--N 1.324 -0.52 0 O-C-N 124.54 1.15 . . . . 0.0 108.343 179.946 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 32.4 t-20 -89.65 -43.29 10.84 Favored 'General case' 0 C--N 1.325 -0.474 0 O-C-N 124.527 1.142 . . . . 0.0 109.335 -180.0 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.614 HG23 ' HD2' ' A' ' 13' ' ' PRO . 20.0 m -57.67 142.71 77.41 Favored Pre-proline 0 C--N 1.326 -0.448 0 O-C-N 124.505 1.128 . . . . 0.0 110.399 179.989 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.614 ' HD2' HG23 ' A' ' 12' ' ' THR . 20.1 Cg_endo -75.01 132.33 15.28 Favored 'Trans proline' 0 N--CA 1.453 -0.895 0 O-C-N 124.506 1.793 . . . . 0.0 110.99 -168.306 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 73.62 13.28 80.37 Favored Glycine 0 CA--C 1.529 0.969 0 O-C-N 124.476 1.11 . . . . 0.0 111.016 -179.98 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.511 ' SG ' HG22 ' A' ' 12' ' ' THR . 68.7 m -97.49 125.65 42.3 Favored 'General case' 0 C--N 1.325 -0.479 0 N-CA-C 108.29 -1.004 . . . . 0.0 108.29 -179.983 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 16' ' ' THR . . . . . 0.468 ' HG1' ' HG1' ' A' ' 23' ' ' THR . 70.7 p -93.61 156.82 16.5 Favored 'General case' 0 C--N 1.325 -0.491 0 O-C-N 124.558 1.161 . . . . 0.0 110.437 179.977 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 42.7 t -82.86 94.98 7.8 Favored 'General case' 0 C--N 1.325 -0.482 0 O-C-N 124.447 1.092 . . . . 0.0 108.315 -179.993 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 18' ' ' SER . . . . . 0.528 ' CB ' HG23 ' A' ' 23' ' ' THR . 1.0 OUTLIER -102.48 66.39 0.97 Allowed 'General case' 0 C--N 1.325 -0.486 0 O-C-N 124.494 1.121 . . . . 0.0 109.968 173.987 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 19' ' ' TRP . . . . . 0.614 ' CG ' ' HA ' ' A' ' 20' ' ' PRO . 0.1 OUTLIER -35.51 147.15 0.17 Allowed Pre-proline 0 C--N 1.326 -0.453 0 O-C-N 124.497 1.123 . . . . 0.0 108.0 -174.085 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.614 ' HA ' ' CG ' ' A' ' 19' ' ' TRP . 18.3 Cg_endo -75.0 -13.85 23.39 Favored 'Cis proline' 0 C--N 1.36 1.135 0 C-N-CA 120.967 -2.514 . . . . 0.0 111.013 -8.645 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.659 HG23 HG22 ' A' ' 4' ' ' THR . 2.8 p -99.13 178.08 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 O-C-N 124.512 1.132 . . . . 0.0 109.34 -172.964 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.603 ' H ' HG22 ' A' ' 21' ' ' VAL . 66.7 m -102.29 172.75 6.71 Favored 'General case' 0 C--N 1.325 -0.471 0 O-C-N 124.486 1.116 . . . . 0.0 108.301 179.993 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.528 HG23 ' CB ' ' A' ' 18' ' ' SER . 8.4 p -146.59 159.31 43.61 Favored 'General case' 0 C--N 1.325 -0.467 0 O-C-N 124.486 1.117 . . . . 0.0 110.391 -179.985 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.56 ' HB3' HG22 ' A' ' 29' ' ' VAL . 0.5 OUTLIER -131.81 117.68 18.87 Favored 'General case' 0 C--N 1.325 -0.483 0 O-C-N 124.498 1.124 . . . . 0.0 110.291 179.965 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 78.8 m-20 57.52 23.4 9.14 Favored 'General case' 0 C--N 1.325 -0.469 0 O-C-N 124.491 1.119 . . . . 0.0 109.298 -179.987 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 84.04 23.01 53.71 Favored Glycine 0 CA--C 1.53 0.99 0 O-C-N 124.428 1.08 . . . . 0.0 110.983 179.988 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 8.1 mt -143.06 129.99 10.71 Favored Pre-proline 0 C--N 1.325 -0.481 0 O-C-N 124.476 0.751 . . . . 0.0 109.29 179.972 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 20.2 Cg_endo -74.99 85.66 1.5 Allowed 'Trans proline' 0 N--CA 1.453 -0.88 0 O-C-N 124.508 1.794 . . . . 0.0 110.965 -168.287 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.56 HG22 ' HB3' ' A' ' 24' ' ' ARG . 33.5 m . . . . . 0 C--N 1.325 -0.472 0 O-C-N 124.542 1.151 . . . . 0.0 109.324 179.968 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 1' ' ' CYS . . . . . 0.406 ' SG ' ' O ' ' A' ' 23' ' ' THR . 20.0 m . . . . . 0 N--CA 1.452 -0.333 0 N-CA-C 108.302 -0.999 . . . . 0.0 108.302 . . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 108.48 -11.0 36.03 Favored Glycine 0 CA--C 1.53 0.985 0 O-C-N 124.524 1.14 . . . . 0.0 111.011 179.982 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 15.4 mt-10 -99.99 164.4 12.01 Favored 'General case' 0 C--N 1.326 -0.449 0 O-C-N 124.465 0.744 . . . . 0.0 110.282 -179.975 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 76.5 p -122.22 134.81 54.7 Favored 'General case' 0 C--N 1.325 -0.499 0 O-C-N 124.455 1.097 . . . . 0.0 110.44 179.99 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.441 ' SG ' ' O ' ' A' ' 5' ' ' CYS . 11.8 p -101.7 48.23 0.89 Allowed 'General case' 0 C--N 1.325 -0.475 0 O-C-N 124.493 1.121 . . . . 0.0 108.295 -179.965 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 27.0 t -59.06 -23.61 24.82 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 O-C-N 124.511 1.132 . . . . 0.0 109.266 -179.992 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -87.82 -29.14 21.78 Favored Glycine 0 CA--C 1.53 1.027 0 O-C-N 124.51 1.132 . . . . 0.0 111.002 179.986 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 121.7 16.1 4.24 Favored Glycine 0 CA--C 1.531 1.036 0 O-C-N 124.964 1.038 . . . . 0.0 111.015 178.398 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 89.8 m -150.18 166.29 30.3 Favored 'General case' 0 C--N 1.325 -0.493 0 O-C-N 124.513 0.772 . . . . 0.0 110.415 179.942 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 10' ' ' CYS . . . . . 0.407 ' SG ' ' O ' ' A' ' 16' ' ' THR . 87.9 m -124.38 143.95 50.31 Favored 'General case' 0 C--N 1.325 -0.476 0 O-C-N 124.526 1.141 . . . . 0.0 108.306 179.979 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 18.9 t30 -89.78 -50.44 6.05 Favored 'General case' 0 C--N 1.325 -0.486 0 O-C-N 124.489 1.118 . . . . 0.0 109.353 179.978 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.632 HG23 ' HD2' ' A' ' 13' ' ' PRO . 18.5 m -52.32 142.77 28.4 Favored Pre-proline 0 C--N 1.325 -0.479 0 O-C-N 124.464 1.102 . . . . 0.0 110.406 -179.999 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.632 ' HD2' HG23 ' A' ' 12' ' ' THR . 20.1 Cg_endo -74.95 129.52 12.47 Favored 'Trans proline' 0 N--CA 1.453 -0.892 0 O-C-N 124.504 1.792 . . . . 0.0 110.991 -168.284 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.416 ' HA3' ' NH1' ' A' ' 24' ' ' ARG . . . 76.01 15.15 81.58 Favored Glycine 0 CA--C 1.53 0.997 0 O-C-N 124.497 1.123 . . . . 0.0 110.999 179.988 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.505 ' SG ' ' CG2' ' A' ' 12' ' ' THR . 55.9 m -95.78 126.33 40.97 Favored 'General case' 0 C--N 1.325 -0.481 0 N-CA-C 108.282 -1.007 . . . . 0.0 108.282 -179.952 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 16' ' ' THR . . . . . 0.414 ' HG1' ' HG1' ' A' ' 23' ' ' THR . 12.3 p -92.45 154.36 18.54 Favored 'General case' 0 C--N 1.325 -0.497 0 O-C-N 124.51 1.131 . . . . 0.0 110.408 -179.998 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 21.9 t -83.59 94.81 8.16 Favored 'General case' 0 C--N 1.324 -0.508 0 O-C-N 124.497 1.123 . . . . 0.0 108.3 -179.996 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 18' ' ' SER . . . . . 0.566 ' CB ' HG23 ' A' ' 23' ' ' THR . 1.1 t -102.68 68.06 1.02 Allowed 'General case' 0 C--N 1.325 -0.474 0 O-C-N 124.501 1.126 . . . . 0.0 110.011 174.02 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 19' ' ' TRP . . . . . 0.602 ' CG ' ' HA ' ' A' ' 20' ' ' PRO . 0.0 OUTLIER -36.03 147.02 0.19 Allowed Pre-proline 0 C--N 1.325 -0.5 0 O-C-N 124.501 1.125 . . . . 0.0 107.972 -174.213 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.602 ' HA ' ' CG ' ' A' ' 19' ' ' TRP . 18.2 Cg_endo -75.04 -14.34 23.23 Favored 'Cis proline' 0 C--N 1.361 1.194 0 C-N-CA 120.988 -2.505 . . . . 0.0 110.998 -8.67 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.644 HG22 ' H ' ' A' ' 22' ' ' CYS . 3.8 p -97.61 178.46 0.61 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 O-C-N 124.508 1.13 . . . . 0.0 109.277 -172.984 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.644 ' H ' HG22 ' A' ' 21' ' ' VAL . 35.3 m -102.14 172.76 6.71 Favored 'General case' 0 C--N 1.326 -0.439 0 O-C-N 124.497 1.123 . . . . 0.0 108.279 -179.97 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.566 HG23 ' CB ' ' A' ' 18' ' ' SER . 5.9 p -145.53 160.57 41.42 Favored 'General case' 0 C--N 1.325 -0.497 0 O-C-N 124.51 1.131 . . . . 0.0 110.446 179.965 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.536 ' HB3' HG22 ' A' ' 29' ' ' VAL . 15.1 tpt180 -127.92 114.69 17.5 Favored 'General case' 0 C--N 1.325 -0.485 0 O-C-N 124.515 1.134 . . . . 0.0 110.304 -179.984 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 66.1 t30 57.07 25.55 10.94 Favored 'General case' 0 C--N 1.325 -0.49 0 O-C-N 124.496 1.123 . . . . 0.0 109.281 -179.997 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 82.74 22.18 58.46 Favored Glycine 0 CA--C 1.53 1.019 0 O-C-N 124.487 1.117 . . . . 0.0 110.999 -179.999 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 52.3 mt -140.35 132.23 14.37 Favored Pre-proline 0 C--N 1.325 -0.475 0 O-C-N 124.512 0.772 . . . . 0.0 109.261 179.996 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 20.2 Cg_endo -75.0 86.29 1.44 Allowed 'Trans proline' 0 N--CA 1.453 -0.89 0 O-C-N 124.465 1.771 . . . . 0.0 110.967 -168.321 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.536 HG22 ' HB3' ' A' ' 24' ' ' ARG . 19.0 m . . . . . 0 C--N 1.325 -0.477 0 O-C-N 124.467 1.104 . . . . 0.0 109.311 179.983 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 79.0 m . . . . . 0 N--CA 1.453 -0.306 0 N-CA-C 108.295 -1.002 . . . . 0.0 108.295 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 82.82 -9.74 58.93 Favored Glycine 0 CA--C 1.53 0.994 0 O-C-N 124.501 1.126 . . . . 0.0 111.057 -179.966 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 11.4 pt-20 -100.24 167.85 10.17 Favored 'General case' 0 C--N 1.326 -0.446 0 O-C-N 124.495 0.762 . . . . 0.0 110.272 -179.99 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.678 HG22 HG13 ' A' ' 21' ' ' VAL . 50.9 p -127.07 143.94 51.15 Favored 'General case' 0 C--N 1.325 -0.481 0 O-C-N 124.52 1.138 . . . . 0.0 110.392 179.998 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.419 ' HB2' ' N ' ' A' ' 9' ' ' THR . 20.5 p -104.26 56.98 0.71 Allowed 'General case' 0 C--N 1.324 -0.5 0 O-C-N 124.494 1.121 . . . . 0.0 108.324 179.976 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 4.9 t -59.48 -24.74 29.18 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 O-C-N 124.493 1.121 . . . . 0.0 109.319 179.981 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -85.23 -33.94 15.95 Favored Glycine 0 CA--C 1.53 1.016 0 O-C-N 124.527 1.142 . . . . 0.0 110.952 -179.932 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 125.14 17.3 2.75 Favored Glycine 0 CA--C 1.53 1.023 0 O-C-N 124.889 0.994 . . . . 0.0 111.005 177.766 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 9' ' ' THR . . . . . 0.419 ' N ' ' HB2' ' A' ' 5' ' ' CYS . 32.1 m -150.38 164.01 36.92 Favored 'General case' 0 C--N 1.325 -0.485 0 O-C-N 124.495 0.762 . . . . 0.0 110.397 179.978 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 10' ' ' CYS . . . . . 0.405 ' SG ' ' O ' ' A' ' 16' ' ' THR . 74.9 m -118.55 142.41 47.63 Favored 'General case' 0 C--N 1.325 -0.485 0 O-C-N 124.505 1.128 . . . . 0.0 108.312 -179.998 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 3.9 m120 -90.87 -40.9 11.49 Favored 'General case' 0 C--N 1.325 -0.469 0 O-C-N 124.485 1.115 . . . . 0.0 109.275 -179.998 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.64 HG23 ' HD2' ' A' ' 13' ' ' PRO . 17.5 m -63.76 142.82 98.09 Favored Pre-proline 0 C--N 1.325 -0.484 0 O-C-N 124.483 1.115 . . . . 0.0 110.426 -179.993 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.64 ' HD2' HG23 ' A' ' 12' ' ' THR . 20.1 Cg_endo -74.97 130.73 13.58 Favored 'Trans proline' 0 N--CA 1.453 -0.876 0 O-C-N 124.481 1.779 . . . . 0.0 110.969 -168.246 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 77.16 10.37 86.29 Favored Glycine 0 CA--C 1.53 1.022 0 O-C-N 124.511 1.132 . . . . 0.0 111.001 179.985 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.5 ' SG ' ' CG2' ' A' ' 12' ' ' THR . 68.1 m -93.78 126.75 39.15 Favored 'General case' 0 C--N 1.325 -0.464 0 N-CA-C 108.268 -1.012 . . . . 0.0 108.268 -179.973 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 16' ' ' THR . . . . . 0.405 ' O ' ' SG ' ' A' ' 10' ' ' CYS . 11.2 p -93.8 152.41 18.93 Favored 'General case' 0 C--N 1.324 -0.511 0 O-C-N 124.456 1.098 . . . . 0.0 110.393 -179.981 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 43.4 t -80.0 98.14 7.07 Favored 'General case' 0 C--N 1.325 -0.473 0 O-C-N 124.475 1.109 . . . . 0.0 108.331 179.983 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 18' ' ' SER . . . . . 0.519 ' O ' ' C ' ' A' ' 19' ' ' TRP . 30.0 t -105.72 64.92 0.7 Allowed 'General case' 0 C--N 1.325 -0.472 0 O-C-N 124.502 1.126 . . . . 0.0 109.986 174.242 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 19' ' ' TRP . . . . . 0.643 ' CG ' ' HA ' ' A' ' 20' ' ' PRO . 0.4 OUTLIER -35.42 147.0 0.17 Allowed Pre-proline 0 C--N 1.325 -0.472 0 O-C-N 124.537 1.148 . . . . 0.0 108.024 -174.284 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.643 ' HA ' ' CG ' ' A' ' 19' ' ' TRP . 18.3 Cg_endo -74.98 -13.97 23.3 Favored 'Cis proline' 0 C--N 1.36 1.148 0 C-N-CA 121.013 -2.495 . . . . 0.0 111.006 -8.605 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.678 HG13 HG22 ' A' ' 4' ' ' THR . 3.8 t -97.94 175.31 0.82 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 O-C-N 124.478 1.111 . . . . 0.0 109.239 -173.022 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.638 ' H ' HG12 ' A' ' 21' ' ' VAL . 3.5 m -102.36 170.0 8.34 Favored 'General case' 0 C--N 1.325 -0.483 0 O-C-N 124.463 1.102 . . . . 0.0 108.338 179.995 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.462 HG23 ' HB3' ' A' ' 18' ' ' SER . 1.9 p -147.27 163.41 36.49 Favored 'General case' 0 C--N 1.325 -0.495 0 O-C-N 124.49 1.119 . . . . 0.0 110.385 179.996 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.566 ' HB3' HG22 ' A' ' 29' ' ' VAL . 0.3 OUTLIER -139.77 118.91 12.7 Favored 'General case' 0 C--N 1.324 -0.509 0 O-C-N 124.573 1.17 . . . . 0.0 110.33 179.937 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 18.0 t-20 57.91 22.36 8.64 Favored 'General case' 0 C--N 1.325 -0.48 0 O-C-N 124.528 1.142 . . . . 0.0 109.277 -179.988 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 26' ' ' GLY . . . . . 0.473 ' O ' HD23 ' A' ' 27' ' ' LEU . . . 84.55 23.21 51.49 Favored Glycine 0 CA--C 1.531 1.042 0 O-C-N 124.504 1.128 . . . . 0.0 110.959 179.952 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.473 HD23 ' O ' ' A' ' 26' ' ' GLY . 12.1 mt -145.96 128.04 7.79 Favored Pre-proline 0 C--N 1.325 -0.491 0 O-C-N 124.515 0.773 . . . . 0.0 109.311 -179.976 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 20.3 Cg_endo -74.92 78.25 2.91 Favored 'Trans proline' 0 N--CA 1.453 -0.889 0 O-C-N 124.515 1.797 . . . . 0.0 110.966 -168.294 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.566 HG22 ' HB3' ' A' ' 24' ' ' ARG . 30.8 m . . . . . 0 C--N 1.324 -0.517 0 O-C-N 124.509 1.131 . . . . 0.0 109.289 179.985 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 99.7 m . . . . . 0 N--CA 1.453 -0.311 0 N-CA-C 108.319 -0.993 . . . . 0.0 108.319 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 84.61 -13.21 53.47 Favored Glycine 0 CA--C 1.53 1.004 0 O-C-N 124.475 1.109 . . . . 0.0 110.958 179.936 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 3' ' ' GLU . . . . . 0.402 ' HG3' ' SG ' ' A' ' 22' ' ' CYS . 23.1 pt-20 -100.42 171.72 7.57 Favored 'General case' 0 C--N 1.325 -0.495 0 O-C-N 124.504 0.767 . . . . 0.0 110.262 -179.983 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 4' ' ' THR . . . . . 1.053 HG22 HG23 ' A' ' 21' ' ' VAL . 38.4 p -129.72 143.16 50.68 Favored 'General case' 0 C--N 1.325 -0.482 0 O-C-N 124.506 1.128 . . . . 0.0 110.377 179.991 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.584 ' O ' ' CD1' ' A' ' 19' ' ' TRP . 14.8 p -96.67 52.46 1.2 Allowed 'General case' 0 C--N 1.325 -0.469 0 O-C-N 124.474 1.109 . . . . 0.0 108.301 179.953 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 4.5 t -59.01 -24.9 28.13 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 O-C-N 124.428 1.08 . . . . 0.0 109.309 179.992 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -84.02 -35.09 16.28 Favored Glycine 0 CA--C 1.53 1.028 0 O-C-N 124.467 1.104 . . . . 0.0 111.021 179.996 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 8' ' ' GLY . . . . . 0.4 ' O ' ' SG ' ' A' ' 17' ' ' CYS . . . 133.34 -13.24 4.91 Favored Glycine 0 C--N 1.346 1.106 0 O-C-N 125.139 1.14 . . . . 0.0 110.979 178.327 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -131.1 162.93 28.78 Favored 'General case' 0 C--N 1.324 -0.502 0 O-C-N 124.517 0.775 . . . . 0.0 110.411 -179.96 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 10' ' ' CYS . . . . . 0.406 ' SG ' ' O ' ' A' ' 16' ' ' THR . 86.9 m -107.16 141.64 38.11 Favored 'General case' 0 C--N 1.325 -0.49 0 O-C-N 124.499 1.124 . . . . 0.0 108.268 -179.951 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 64.1 t-20 -89.59 -38.13 14.17 Favored 'General case' 0 C--N 1.325 -0.481 0 O-C-N 124.522 1.139 . . . . 0.0 109.329 179.961 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.657 HG23 ' HD2' ' A' ' 13' ' ' PRO . 16.5 m -67.44 143.11 96.97 Favored Pre-proline 0 C--N 1.326 -0.454 0 O-C-N 124.509 1.131 . . . . 0.0 110.429 -179.996 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.657 ' HD2' HG23 ' A' ' 12' ' ' THR . 20.2 Cg_endo -74.98 129.15 12.09 Favored 'Trans proline' 0 N--CA 1.453 -0.88 0 O-C-N 124.569 1.826 . . . . 0.0 110.99 -168.27 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 76.86 14.27 82.76 Favored Glycine 0 CA--C 1.529 0.951 0 O-C-N 124.517 1.135 . . . . 0.0 111.035 -179.964 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.494 ' SG ' ' CG2' ' A' ' 12' ' ' THR . 57.7 m -96.45 129.38 43.82 Favored 'General case' 0 C--N 1.325 -0.459 0 N-CA-C 108.315 -0.994 . . . . 0.0 108.315 179.976 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 16' ' ' THR . . . . . 0.406 ' O ' ' SG ' ' A' ' 10' ' ' CYS . 23.4 p -93.57 148.71 21.84 Favored 'General case' 0 C--N 1.325 -0.474 0 O-C-N 124.492 1.12 . . . . 0.0 110.358 -179.977 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 17' ' ' CYS . . . . . 0.4 ' SG ' ' O ' ' A' ' 8' ' ' GLY . 11.9 t -81.23 95.06 6.82 Favored 'General case' 0 C--N 1.325 -0.462 0 O-C-N 124.5 1.125 . . . . 0.0 108.293 179.988 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 18' ' ' SER . . . . . 0.718 ' OG ' HG23 ' A' ' 23' ' ' THR . 20.4 p -102.31 65.79 0.97 Allowed 'General case' 0 C--N 1.325 -0.497 0 O-C-N 124.493 1.121 . . . . 0.0 110.036 173.993 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 19' ' ' TRP . . . . . 0.59 ' CG ' ' HA ' ' A' ' 20' ' ' PRO . 0.0 OUTLIER -36.02 147.23 0.18 Allowed Pre-proline 0 C--N 1.325 -0.459 0 N-CA-C 107.998 -1.112 . . . . 0.0 107.998 -174.047 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.59 ' HA ' ' CG ' ' A' ' 19' ' ' TRP . 18.4 Cg_endo -74.95 -13.53 23.44 Favored 'Cis proline' 0 C--N 1.36 1.161 0 C-N-CA 120.995 -2.502 . . . . 0.0 111.01 -8.641 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 1.053 HG23 HG22 ' A' ' 4' ' ' THR . 2.3 p -96.35 173.99 0.9 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.478 0 O-C-N 124.53 1.144 . . . . 0.0 109.331 -173.224 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.524 ' H ' HG22 ' A' ' 21' ' ' VAL . 1.7 m -102.09 169.2 8.9 Favored 'General case' 0 C--N 1.325 -0.488 0 O-C-N 124.485 1.115 . . . . 0.0 108.324 -179.973 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.718 HG23 ' OG ' ' A' ' 18' ' ' SER . 1.1 p -141.99 169.1 18.22 Favored 'General case' 0 C--N 1.325 -0.488 0 O-C-N 124.494 1.121 . . . . 0.0 110.413 -179.981 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.554 ' HB3' HG22 ' A' ' 29' ' ' VAL . 6.0 ttt180 -143.74 117.02 9.0 Favored 'General case' 0 C--N 1.325 -0.475 0 O-C-N 124.527 1.142 . . . . 0.0 110.279 -179.986 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 71.1 m-20 58.47 22.23 9.36 Favored 'General case' 0 C--N 1.325 -0.482 0 O-C-N 124.516 1.135 . . . . 0.0 109.31 179.992 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 26' ' ' GLY . . . . . 0.41 ' O ' HD23 ' A' ' 27' ' ' LEU . . . 86.48 20.64 53.99 Favored Glycine 0 CA--C 1.53 0.974 0 O-C-N 124.498 1.124 . . . . 0.0 111.009 -179.997 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.41 HD23 ' O ' ' A' ' 26' ' ' GLY . 9.7 mt -144.7 128.81 8.92 Favored Pre-proline 0 C--N 1.325 -0.493 0 O-C-N 124.514 0.773 . . . . 0.0 109.29 -179.98 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 20.2 Cg_endo -74.97 84.68 1.62 Allowed 'Trans proline' 0 N--CA 1.453 -0.895 0 O-C-N 124.499 1.789 . . . . 0.0 111.014 -168.321 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.554 HG22 ' HB3' ' A' ' 24' ' ' ARG . 28.4 m . . . . . 0 C--N 1.324 -0.508 0 O-C-N 124.547 1.154 . . . . 0.0 109.295 -179.968 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 83.0 m . . . . . 0 N--CA 1.453 -0.296 0 N-CA-C 108.286 -1.005 . . . . 0.0 108.286 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 100.56 -25.33 28.71 Favored Glycine 0 CA--C 1.53 1.017 0 O-C-N 124.475 1.109 . . . . 0.0 110.99 -179.996 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 28.6 tt0 -78.51 150.47 32.9 Favored 'General case' 0 C--N 1.324 -0.511 0 O-C-N 124.519 0.776 . . . . 0.0 110.293 -179.969 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.608 HG22 HG12 ' A' ' 21' ' ' VAL . 75.2 p -110.21 130.94 55.45 Favored 'General case' 0 C--N 1.325 -0.476 0 O-C-N 124.453 1.095 . . . . 0.0 110.42 179.977 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.416 ' SG ' ' O ' ' A' ' 5' ' ' CYS . 14.5 p -99.0 51.58 0.96 Allowed 'General case' 0 C--N 1.325 -0.46 0 O-C-N 124.452 1.095 . . . . 0.0 108.301 -179.975 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 9.6 t -59.22 -24.59 27.94 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 O-C-N 124.553 1.158 . . . . 0.0 109.334 -179.991 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -83.89 -33.42 21.31 Favored Glycine 0 CA--C 1.53 0.984 0 O-C-N 124.52 1.138 . . . . 0.0 110.972 -179.978 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 125.95 14.24 3.12 Favored Glycine 0 C--N 1.346 1.086 0 C-N-CA 119.776 -1.202 . . . . 0.0 110.982 177.846 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -150.07 166.25 30.31 Favored 'General case' 0 C--N 1.325 -0.494 0 O-C-N 124.456 0.739 . . . . 0.0 110.355 -179.997 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 10' ' ' CYS . . . . . 0.405 ' SG ' ' O ' ' A' ' 16' ' ' THR . 74.8 m -123.14 144.28 49.45 Favored 'General case' 0 C--N 1.326 -0.439 0 O-C-N 124.477 1.11 . . . . 0.0 108.288 -179.989 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 9.8 t-20 -91.18 -44.39 9.27 Favored 'General case' 0 C--N 1.325 -0.464 0 O-C-N 124.463 1.102 . . . . 0.0 109.313 -179.971 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.609 HG23 ' HD2' ' A' ' 13' ' ' PRO . 20.6 m -58.03 142.73 79.47 Favored Pre-proline 0 C--N 1.325 -0.48 0 O-C-N 124.487 1.117 . . . . 0.0 110.392 -179.984 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.609 ' HD2' HG23 ' A' ' 12' ' ' THR . 20.2 Cg_endo -74.98 132.34 15.34 Favored 'Trans proline' 0 N--CA 1.453 -0.871 0 O-C-N 124.443 1.76 . . . . 0.0 110.937 -168.251 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 75.47 8.71 84.2 Favored Glycine 0 CA--C 1.53 1.014 0 O-C-N 124.472 1.107 . . . . 0.0 111.028 179.993 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.496 ' SG ' ' CG2' ' A' ' 12' ' ' THR . 81.5 m -93.29 125.43 37.89 Favored 'General case' 0 C--N 1.324 -0.509 0 N-CA-C 108.279 -1.008 . . . . 0.0 108.279 179.995 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 16' ' ' THR . . . . . 0.405 ' O ' ' SG ' ' A' ' 10' ' ' CYS . 2.2 p -94.0 156.07 16.8 Favored 'General case' 0 C--N 1.325 -0.483 0 O-C-N 124.524 1.14 . . . . 0.0 110.393 -179.994 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 48.5 t -81.25 91.14 6.16 Favored 'General case' 0 C--N 1.325 -0.495 0 O-C-N 124.512 1.133 . . . . 0.0 108.336 179.968 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 18' ' ' SER . . . . . 0.525 ' O ' ' C ' ' A' ' 19' ' ' TRP . 1.9 m -98.09 65.23 1.73 Allowed 'General case' 0 C--N 1.324 -0.502 0 O-C-N 124.503 1.127 . . . . 0.0 110.001 174.231 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 19' ' ' TRP . . . . . 0.607 ' CG ' ' HA ' ' A' ' 20' ' ' PRO . 0.0 OUTLIER -35.52 147.1 0.17 Allowed Pre-proline 0 C--N 1.324 -0.506 0 O-C-N 124.503 1.127 . . . . 0.0 107.993 -173.882 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.607 ' HA ' ' CG ' ' A' ' 19' ' ' TRP . 18.4 Cg_endo -74.98 -13.27 23.65 Favored 'Cis proline' 0 C--N 1.36 1.143 0 C-N-CA 121.012 -2.495 . . . . 0.0 110.98 -8.386 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.608 HG12 HG22 ' A' ' 4' ' ' THR . 2.4 m -99.92 178.65 0.64 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.494 0 O-C-N 124.468 1.105 . . . . 0.0 109.295 -173.117 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 82.7 m -102.21 171.75 7.3 Favored 'General case' 0 C--N 1.325 -0.486 0 O-C-N 124.524 1.14 . . . . 0.0 108.281 -179.997 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.408 ' O ' ' HA ' ' A' ' 15' ' ' CYS . 0.8 OUTLIER -150.3 161.0 43.3 Favored 'General case' 0 C--N 1.325 -0.477 0 O-C-N 124.526 1.141 . . . . 0.0 110.396 179.991 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.475 ' HB3' ' CG2' ' A' ' 29' ' ' VAL . 8.6 ttt180 -132.4 119.08 20.18 Favored 'General case' 0 C--N 1.325 -0.493 0 O-C-N 124.552 1.157 . . . . 0.0 110.289 -179.99 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 25' ' ' ASN . . . . . 0.517 ' O ' ' ND2' ' A' ' 25' ' ' ASN . 0.1 OUTLIER 57.24 28.87 15.8 Favored 'General case' 0 C--N 1.325 -0.484 0 O-C-N 124.507 1.129 . . . . 0.0 109.291 179.992 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 76.05 23.3 72.04 Favored Glycine 0 CA--C 1.531 1.038 0 O-C-N 124.504 1.127 . . . . 0.0 110.989 179.988 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 7.3 mt -141.4 129.22 11.99 Favored Pre-proline 0 C--N 1.324 -0.509 0 O-C-N 124.554 0.796 . . . . 0.0 109.311 -179.971 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 20.2 Cg_endo -75.0 88.3 1.25 Allowed 'Trans proline' 0 N--CA 1.453 -0.875 0 O-C-N 124.487 1.783 . . . . 0.0 110.944 -168.261 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.475 ' CG2' ' HB3' ' A' ' 24' ' ' ARG . 27.1 m . . . . . 0 C--N 1.325 -0.468 0 O-C-N 124.476 1.11 . . . . 0.0 109.345 179.958 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 91.6 m . . . . . 0 N--CA 1.453 -0.284 0 N-CA-C 108.271 -1.011 . . . . 0.0 108.271 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 92.57 7.93 62.83 Favored Glycine 0 CA--C 1.53 1.023 0 O-C-N 124.486 1.116 . . . . 0.0 110.972 -179.985 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 89.8 mt-10 -100.23 165.01 11.7 Favored 'General case' 0 C--N 1.325 -0.495 0 O-C-N 124.493 0.761 . . . . 0.0 110.308 179.999 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 23.9 p -121.51 114.99 22.01 Favored 'General case' 0 C--N 1.325 -0.485 0 O-C-N 124.456 1.098 . . . . 0.0 110.4 -179.984 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.432 ' O ' ' SG ' ' A' ' 5' ' ' CYS . 13.3 p -91.08 49.62 1.66 Allowed 'General case' 0 C--N 1.325 -0.474 0 O-C-N 124.5 1.125 . . . . 0.0 108.315 -179.976 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 17.5 t -59.19 -24.54 27.75 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 O-C-N 124.5 1.125 . . . . 0.0 109.355 -179.985 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -84.62 -34.25 16.73 Favored Glycine 0 CA--C 1.531 1.036 0 O-C-N 124.498 1.124 . . . . 0.0 110.981 -179.994 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 125.84 13.1 3.43 Favored Glycine 0 CA--C 1.53 1.006 0 O-C-N 125.1 1.118 . . . . 0.0 111.041 178.05 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 2.5 m -150.02 161.4 42.4 Favored 'General case' 0 C--N 1.326 -0.452 0 O-C-N 124.529 0.782 . . . . 0.0 110.383 -179.975 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 10' ' ' CYS . . . . . 0.402 ' SG ' ' O ' ' A' ' 16' ' ' THR . 72.3 m -119.11 156.37 29.88 Favored 'General case' 0 C--N 1.325 -0.489 0 O-C-N 124.468 1.105 . . . . 0.0 108.327 179.974 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 17.6 t30 -97.98 -58.17 2.05 Favored 'General case' 0 C--N 1.325 -0.475 0 O-C-N 124.518 1.136 . . . . 0.0 109.341 179.97 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.66 HG23 ' HD2' ' A' ' 13' ' ' PRO . 5.3 m -44.69 142.64 2.45 Favored Pre-proline 0 C--N 1.324 -0.501 0 O-C-N 124.558 1.161 . . . . 0.0 110.405 179.954 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.66 ' HD2' HG23 ' A' ' 12' ' ' THR . 20.4 Cg_endo -74.94 129.53 12.49 Favored 'Trans proline' 0 N--CA 1.453 -0.871 0 O-C-N 124.493 1.786 . . . . 0.0 111.023 -168.34 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 78.88 11.57 85.08 Favored Glycine 0 CA--C 1.53 0.986 0 O-C-N 124.513 1.133 . . . . 0.0 111.034 -179.988 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.503 ' SG ' HG22 ' A' ' 12' ' ' THR . 57.7 m -95.29 125.71 40.11 Favored 'General case' 0 C--N 1.325 -0.461 0 N-CA-C 108.306 -0.998 . . . . 0.0 108.306 -179.943 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 16' ' ' THR . . . . . 0.402 ' O ' ' SG ' ' A' ' 10' ' ' CYS . 18.7 p -95.16 157.35 15.93 Favored 'General case' 0 C--N 1.326 -0.449 0 O-C-N 124.469 1.106 . . . . 0.0 110.423 -179.989 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 24.5 t -82.74 95.84 7.99 Favored 'General case' 0 C--N 1.325 -0.486 0 O-C-N 124.543 1.152 . . . . 0.0 108.291 179.989 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 18' ' ' SER . . . . . 0.598 ' HB3' HG23 ' A' ' 23' ' ' THR . 11.2 t -100.45 64.56 1.15 Allowed 'General case' 0 C--N 1.325 -0.469 0 O-C-N 124.504 1.128 . . . . 0.0 110.057 173.855 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 19' ' ' TRP . . . . . 0.611 ' CG ' ' HA ' ' A' ' 20' ' ' PRO . 0.3 OUTLIER -35.39 145.96 0.19 Allowed Pre-proline 0 C--N 1.325 -0.496 0 O-C-N 124.549 1.155 . . . . 0.0 108.033 -174.124 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.611 ' HA ' ' CG ' ' A' ' 19' ' ' TRP . 18.3 Cg_endo -75.04 -14.88 22.92 Favored 'Cis proline' 0 C--N 1.359 1.13 0 C-N-CA 121.021 -2.491 . . . . 0.0 110.973 -8.459 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.492 ' O ' ' C ' ' A' ' 18' ' ' SER . 3.1 m -95.76 177.09 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 O-C-N 124.515 1.134 . . . . 0.0 109.241 -173.101 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 43.9 m -101.85 166.71 10.51 Favored 'General case' 0 C--N 1.325 -0.487 0 O-C-N 124.537 1.148 . . . . 0.0 108.333 179.987 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.598 HG23 ' HB3' ' A' ' 18' ' ' SER . 1.0 OUTLIER -145.04 169.51 17.98 Favored 'General case' 0 C--N 1.325 -0.485 0 O-C-N 124.516 1.135 . . . . 0.0 110.384 179.991 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.569 ' HB3' HG22 ' A' ' 29' ' ' VAL . 0.1 OUTLIER -142.18 118.22 10.65 Favored 'General case' 0 C--N 1.325 -0.474 0 O-C-N 124.524 1.14 . . . . 0.0 110.304 -179.972 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 72.0 m-20 57.77 23.37 9.51 Favored 'General case' 0 C--N 1.325 -0.466 0 O-C-N 124.557 1.16 . . . . 0.0 109.357 -179.957 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 82.17 24.14 55.41 Favored Glycine 0 CA--C 1.531 1.036 0 O-C-N 124.524 1.14 . . . . 0.0 111.039 -179.994 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 7.5 mt -143.31 129.57 10.34 Favored Pre-proline 0 C--N 1.325 -0.467 0 O-C-N 124.487 0.757 . . . . 0.0 109.317 -179.973 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 20.4 Cg_endo -74.89 82.18 2.03 Favored 'Trans proline' 0 N--CA 1.453 -0.904 0 O-C-N 124.535 1.808 . . . . 0.0 111.02 -168.348 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.569 HG22 ' HB3' ' A' ' 24' ' ' ARG . 32.7 m . . . . . 0 C--N 1.324 -0.51 0 O-C-N 124.526 1.141 . . . . 0.0 109.308 179.997 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 95.2 m . . . . . 0 N--CA 1.452 -0.327 0 N-CA-C 108.266 -1.013 . . . . 0.0 108.266 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 91.03 -27.22 9.35 Favored Glycine 0 CA--C 1.53 0.975 0 O-C-N 124.569 1.168 . . . . 0.0 111.041 -179.976 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 23.5 tt0 -83.53 151.88 25.18 Favored 'General case' 0 C--N 1.325 -0.495 0 O-C-N 124.503 0.767 . . . . 0.0 110.292 -179.988 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.63 HG22 HG23 ' A' ' 21' ' ' VAL . 60.2 p -112.83 137.93 50.43 Favored 'General case' 0 C--N 1.324 -0.505 0 O-C-N 124.532 1.145 . . . . 0.0 110.372 179.995 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.407 ' SG ' ' O ' ' A' ' 5' ' ' CYS . 15.0 p -100.88 52.79 0.85 Allowed 'General case' 0 C--N 1.325 -0.477 0 O-C-N 124.551 1.157 . . . . 0.0 108.29 179.99 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 10.3 t -59.22 -24.14 26.74 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 O-C-N 124.508 1.13 . . . . 0.0 109.288 -179.996 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -84.75 -34.6 15.26 Favored Glycine 0 CA--C 1.53 1.006 0 O-C-N 124.524 1.14 . . . . 0.0 110.968 -179.976 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 127.19 14.78 2.64 Favored Glycine 0 CA--C 1.531 1.043 0 O-C-N 125.138 1.14 . . . . 0.0 111.029 177.62 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -150.08 166.73 28.88 Favored 'General case' 0 C--N 1.325 -0.476 0 O-C-N 124.489 0.758 . . . . 0.0 110.386 -179.971 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 10' ' ' CYS . . . . . 0.414 ' SG ' ' O ' ' A' ' 16' ' ' THR . 72.3 m -124.56 140.71 52.69 Favored 'General case' 0 C--N 1.325 -0.486 0 O-C-N 124.525 1.14 . . . . 0.0 108.298 180.0 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 3.0 m120 -89.58 -40.13 12.81 Favored 'General case' 0 C--N 1.325 -0.465 0 O-C-N 124.428 1.08 . . . . 0.0 109.291 -179.989 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.608 HG23 ' HD2' ' A' ' 13' ' ' PRO . 20.9 m -60.05 142.69 89.08 Favored Pre-proline 0 C--N 1.325 -0.467 0 O-C-N 124.465 1.103 . . . . 0.0 110.393 179.995 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.608 ' HD2' HG23 ' A' ' 12' ' ' THR . 20.2 Cg_endo -74.97 132.08 15.05 Favored 'Trans proline' 0 N--CA 1.453 -0.877 0 O-C-N 124.485 1.781 . . . . 0.0 110.947 -168.269 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 73.34 13.35 79.85 Favored Glycine 0 CA--C 1.53 0.999 0 O-C-N 124.563 1.165 . . . . 0.0 110.999 179.974 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.513 ' SG ' HG22 ' A' ' 12' ' ' THR . 68.7 m -97.97 125.64 42.99 Favored 'General case' 0 C--N 1.325 -0.486 0 N-CA-C 108.306 -0.998 . . . . 0.0 108.306 -179.989 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 16' ' ' THR . . . . . 0.414 ' O ' ' SG ' ' A' ' 10' ' ' CYS . 44.4 p -93.73 157.56 16.1 Favored 'General case' 0 C--N 1.325 -0.498 0 O-C-N 124.479 1.112 . . . . 0.0 110.387 179.985 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 46.8 t -83.09 95.04 7.94 Favored 'General case' 0 C--N 1.326 -0.454 0 O-C-N 124.491 1.12 . . . . 0.0 108.273 -179.948 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 18' ' ' SER . . . . . 0.52 ' O ' ' C ' ' A' ' 19' ' ' TRP . 1.0 OUTLIER -102.79 66.92 0.96 Allowed 'General case' 0 C--N 1.325 -0.469 0 O-C-N 124.459 1.099 . . . . 0.0 110.029 173.96 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 19' ' ' TRP . . . . . 0.612 ' CG ' ' HA ' ' A' ' 20' ' ' PRO . 0.0 OUTLIER -35.7 147.46 0.17 Allowed Pre-proline 0 C--N 1.326 -0.455 0 O-C-N 124.496 1.123 . . . . 0.0 107.982 -174.009 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.612 ' HA ' ' CG ' ' A' ' 19' ' ' TRP . 18.3 Cg_endo -75.01 -13.5 23.62 Favored 'Cis proline' 0 C--N 1.361 1.206 0 C-N-CA 121.001 -2.5 . . . . 0.0 111.025 -8.572 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.689 HG22 ' H ' ' A' ' 22' ' ' CYS . 4.8 p -100.05 178.84 0.63 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 O-C-N 124.547 1.154 . . . . 0.0 109.323 -173.006 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.689 ' H ' HG22 ' A' ' 21' ' ' VAL . 81.4 m -102.22 174.0 6.12 Favored 'General case' 0 C--N 1.325 -0.492 0 O-C-N 124.503 1.127 . . . . 0.0 108.285 179.991 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.515 HG23 ' CB ' ' A' ' 18' ' ' SER . 7.2 p -147.02 159.19 43.88 Favored 'General case' 0 C--N 1.325 -0.496 0 O-C-N 124.519 1.137 . . . . 0.0 110.402 179.985 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.581 ' HB3' HG22 ' A' ' 29' ' ' VAL . 3.4 ttt180 -130.5 116.49 18.26 Favored 'General case' 0 C--N 1.325 -0.465 0 O-C-N 124.513 1.133 . . . . 0.0 110.326 179.948 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 74.9 m-20 57.61 23.46 9.34 Favored 'General case' 0 C--N 1.325 -0.476 0 O-C-N 124.51 1.131 . . . . 0.0 109.329 -179.939 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 84.27 24.72 46.57 Favored Glycine 0 CA--C 1.53 1.002 0 O-C-N 124.522 1.139 . . . . 0.0 111.013 180.0 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 10.7 mt -144.84 130.31 9.44 Favored Pre-proline 0 C--N 1.325 -0.481 0 O-C-N 124.495 0.762 . . . . 0.0 109.262 -179.984 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 20.2 Cg_endo -74.99 88.24 1.26 Allowed 'Trans proline' 0 N--CA 1.453 -0.891 0 O-C-N 124.5 1.789 . . . . 0.0 110.986 -168.312 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.581 HG22 ' HB3' ' A' ' 24' ' ' ARG . 32.4 m . . . . . 0 C--N 1.325 -0.482 0 O-C-N 124.51 1.131 . . . . 0.0 109.294 -179.998 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 58.5 m . . . . . 0 N--CA 1.453 -0.307 0 N-CA-C 108.301 -1.0 . . . . 0.0 108.301 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 90.93 -15.76 60.06 Favored Glycine 0 CA--C 1.531 1.042 0 O-C-N 124.483 1.115 . . . . 0.0 110.96 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 15.6 tt0 -88.76 162.72 16.07 Favored 'General case' 0 C--N 1.325 -0.471 0 O-C-N 124.541 0.789 . . . . 0.0 110.316 179.999 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.604 HG22 HG23 ' A' ' 21' ' ' VAL . 53.0 p -120.39 134.97 55.18 Favored 'General case' 0 C--N 1.324 -0.502 0 O-C-N 124.496 1.123 . . . . 0.0 110.425 179.998 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . 0.417 ' O ' ' CD1' ' A' ' 19' ' ' TRP . 13.8 p -105.05 49.06 0.82 Allowed 'General case' 0 C--N 1.325 -0.487 0 O-C-N 124.487 1.117 . . . . 0.0 108.334 179.982 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 37.9 t -59.12 -23.37 24.35 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 O-C-N 124.491 1.12 . . . . 0.0 109.327 179.986 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -82.89 -32.69 26.04 Favored Glycine 0 CA--C 1.531 1.033 0 O-C-N 124.477 1.111 . . . . 0.0 110.985 -179.967 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 125.64 10.8 4.3 Favored Glycine 0 CA--C 1.53 0.997 0 O-C-N 125.068 1.099 . . . . 0.0 110.959 178.183 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 83.6 m -150.19 165.38 33.08 Favored 'General case' 0 C--N 1.325 -0.495 0 O-C-N 124.493 0.761 . . . . 0.0 110.398 179.947 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 91.4 m -118.45 141.85 48.14 Favored 'General case' 0 C--N 1.325 -0.473 0 O-C-N 124.498 1.124 . . . . 0.0 108.29 -179.976 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 13.0 t-20 -89.79 -39.9 12.81 Favored 'General case' 0 C--N 1.325 -0.488 0 O-C-N 124.526 1.141 . . . . 0.0 109.342 179.959 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.642 HG23 ' HD2' ' A' ' 13' ' ' PRO . 17.6 m -62.32 142.99 95.9 Favored Pre-proline 0 C--N 1.325 -0.49 0 O-C-N 124.458 1.099 . . . . 0.0 110.383 -179.989 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.642 ' HD2' HG23 ' A' ' 12' ' ' THR . 20.3 Cg_endo -74.9 132.06 15.12 Favored 'Trans proline' 0 N--CA 1.453 -0.875 0 O-C-N 124.524 1.802 . . . . 0.0 110.983 -168.314 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 74.37 12.46 82.04 Favored Glycine 0 CA--C 1.53 1.023 0 O-C-N 124.465 1.103 . . . . 0.0 110.962 179.935 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.503 ' SG ' HG22 ' A' ' 12' ' ' THR . 67.3 m -96.71 127.64 42.89 Favored 'General case' 0 C--N 1.325 -0.465 0 N-CA-C 108.307 -0.997 . . . . 0.0 108.307 179.97 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 77.5 p -95.15 152.85 17.99 Favored 'General case' 0 C--N 1.325 -0.457 0 O-C-N 124.511 1.132 . . . . 0.0 110.383 -179.986 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 54.1 t -77.72 93.86 4.35 Favored 'General case' 0 C--N 1.325 -0.493 0 O-C-N 124.487 1.117 . . . . 0.0 108.33 179.983 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . 0.609 ' HB3' HG23 ' A' ' 23' ' ' THR . 3.1 t -100.41 65.9 1.23 Allowed 'General case' 0 C--N 1.324 -0.526 0 O-C-N 124.494 1.121 . . . . 0.0 109.992 174.321 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' TRP . . . . . 0.583 ' CG ' ' HA ' ' A' ' 20' ' ' PRO . 0.0 OUTLIER -36.93 147.89 0.2 Allowed Pre-proline 0 C--N 1.325 -0.472 0 O-C-N 124.52 1.138 . . . . 0.0 108.009 -173.973 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.583 ' HA ' ' CG ' ' A' ' 19' ' ' TRP . 18.5 Cg_endo -74.98 -12.11 23.98 Favored 'Cis proline' 0 C--N 1.36 1.176 0 C-N-CA 121.023 -2.49 . . . . 0.0 111.047 -8.5 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.675 HG22 ' H ' ' A' ' 22' ' ' CYS . 3.7 p -99.33 -179.55 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 O-C-N 124.5 1.125 . . . . 0.0 109.232 -173.465 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.675 ' H ' HG22 ' A' ' 21' ' ' VAL . 43.2 m -101.32 168.4 9.57 Favored 'General case' 0 C--N 1.325 -0.478 0 O-C-N 124.509 1.131 . . . . 0.0 108.3 179.99 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . 0.609 HG23 ' HB3' ' A' ' 18' ' ' SER . 0.7 OUTLIER -144.95 164.95 29.56 Favored 'General case' 0 C--N 1.325 -0.478 0 O-C-N 124.553 1.158 . . . . 0.0 110.383 -179.983 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.574 ' HB3' HG22 ' A' ' 29' ' ' VAL . 0.0 OUTLIER -133.87 117.55 16.94 Favored 'General case' 0 C--N 1.325 -0.463 0 O-C-N 124.539 1.149 . . . . 0.0 110.298 179.969 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 74.0 m-20 57.68 23.42 9.43 Favored 'General case' 0 C--N 1.326 -0.456 0 O-C-N 124.447 1.092 . . . . 0.0 109.332 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 84.01 24.59 48.11 Favored Glycine 0 CA--C 1.53 0.993 0 O-C-N 124.52 1.137 . . . . 0.0 110.994 179.986 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 9.6 mt -143.67 130.32 10.37 Favored Pre-proline 0 C--N 1.325 -0.471 0 O-C-N 124.485 0.756 . . . . 0.0 109.339 -179.992 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 20.1 Cg_endo -74.95 89.32 1.16 Allowed 'Trans proline' 0 N--CA 1.453 -0.899 0 O-C-N 124.5 1.79 . . . . 0.0 110.981 -168.294 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.574 HG22 ' HB3' ' A' ' 24' ' ' ARG . 22.4 m . . . . . 0 C--N 1.325 -0.496 0 O-C-N 124.501 1.125 . . . . 0.0 109.312 179.991 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 64.8 m . . . . . 0 N--CA 1.453 -0.294 0 N-CA-C 108.305 -0.998 . . . . 0.0 108.305 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 89.63 -17.35 53.02 Favored Glycine 0 CA--C 1.53 0.979 0 O-C-N 124.507 1.129 . . . . 0.0 111.03 179.999 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 14.8 tt0 -87.94 162.62 16.78 Favored 'General case' 0 C--N 1.325 -0.499 0 O-C-N 124.491 0.759 . . . . 0.0 110.291 179.99 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.791 HG22 HG13 ' A' ' 21' ' ' VAL . 40.0 p -121.52 137.71 54.61 Favored 'General case' 0 C--N 1.326 -0.445 0 O-C-N 124.497 1.123 . . . . 0.0 110.424 179.98 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . 0.448 ' O ' ' CD1' ' A' ' 19' ' ' TRP . 14.3 p -105.87 51.13 0.76 Allowed 'General case' 0 C--N 1.325 -0.487 0 O-C-N 124.511 1.132 . . . . 0.0 108.289 -179.967 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 6.0 t -59.1 -24.74 27.99 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 O-C-N 124.482 1.114 . . . . 0.0 109.312 179.994 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -83.91 -33.8 20.18 Favored Glycine 0 CA--C 1.53 0.969 0 O-C-N 124.45 1.093 . . . . 0.0 110.982 -179.992 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 126.27 13.96 3.09 Favored Glycine 0 CA--C 1.53 1.012 0 O-C-N 125.044 1.085 . . . . 0.0 111.031 177.78 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 28.8 m -149.91 163.64 37.54 Favored 'General case' 0 C--N 1.325 -0.483 0 O-C-N 124.509 0.77 . . . . 0.0 110.364 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . 0.409 ' SG ' ' O ' ' A' ' 16' ' ' THR . 90.2 m -120.55 143.13 48.75 Favored 'General case' 0 C--N 1.325 -0.475 0 O-C-N 124.481 1.113 . . . . 0.0 108.331 179.987 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 76.2 m-20 -89.96 -46.99 8.14 Favored 'General case' 0 C--N 1.325 -0.462 0 O-C-N 124.462 1.101 . . . . 0.0 109.287 -179.968 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.613 HG23 ' HD2' ' A' ' 13' ' ' PRO . 20.7 m -55.23 142.71 57.66 Favored Pre-proline 0 C--N 1.325 -0.489 0 O-C-N 124.524 1.14 . . . . 0.0 110.343 -179.958 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.613 ' HD2' HG23 ' A' ' 12' ' ' THR . 20.3 Cg_endo -74.92 132.0 15.03 Favored 'Trans proline' 0 N--CA 1.453 -0.872 0 O-C-N 124.572 1.827 . . . . 0.0 111.028 -168.334 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 74.76 12.29 82.92 Favored Glycine 0 CA--C 1.53 1.011 0 O-C-N 124.478 1.111 . . . . 0.0 110.956 179.976 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.498 ' SG ' ' CG2' ' A' ' 12' ' ' THR . 69.6 m -95.52 126.02 40.52 Favored 'General case' 0 C--N 1.324 -0.507 0 N-CA-C 108.262 -1.014 . . . . 0.0 108.262 -179.986 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . 0.409 ' O ' ' SG ' ' A' ' 10' ' ' CYS . 29.1 p -93.75 156.2 16.81 Favored 'General case' 0 C--N 1.325 -0.492 0 O-C-N 124.526 1.141 . . . . 0.0 110.387 179.999 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 51.6 t -81.34 94.06 6.69 Favored 'General case' 0 C--N 1.325 -0.498 0 O-C-N 124.531 1.144 . . . . 0.0 108.291 179.997 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . 0.567 ' HB2' HG23 ' A' ' 23' ' ' THR . 1.9 m -101.07 66.39 1.14 Allowed 'General case' 0 C--N 1.325 -0.488 0 O-C-N 124.552 1.157 . . . . 0.0 109.989 174.26 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' TRP . . . . . 0.592 ' CG ' ' HA ' ' A' ' 20' ' ' PRO . 0.0 OUTLIER -36.74 148.19 0.19 Allowed Pre-proline 0 C--N 1.325 -0.481 0 N-CA-C 107.964 -1.124 . . . . 0.0 107.964 -174.019 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.592 ' HA ' ' CG ' ' A' ' 19' ' ' TRP . 18.2 Cg_endo -75.03 -11.87 24.19 Favored 'Cis proline' 0 C--N 1.361 1.192 0 C-N-CA 120.967 -2.514 . . . . 0.0 110.997 -8.474 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.791 HG13 HG22 ' A' ' 4' ' ' THR . 2.2 t -100.2 179.92 0.58 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 O-C-N 124.521 1.138 . . . . 0.0 109.285 -173.386 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.663 ' H ' HG12 ' A' ' 21' ' ' VAL . 57.0 m -101.63 168.43 9.48 Favored 'General case' 0 C--N 1.325 -0.491 0 O-C-N 124.494 1.121 . . . . 0.0 108.312 179.987 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . 0.567 HG23 ' HB2' ' A' ' 18' ' ' SER . 0.8 OUTLIER -145.25 165.06 29.47 Favored 'General case' 0 C--N 1.325 -0.476 0 O-C-N 124.558 1.161 . . . . 0.0 110.427 179.975 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.58 ' HB3' HG22 ' A' ' 29' ' ' VAL . 1.3 ttt-85 -132.81 116.26 16.32 Favored 'General case' 0 C--N 1.324 -0.5 0 O-C-N 124.523 1.139 . . . . 0.0 110.327 -179.991 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 78.4 m-20 57.79 23.08 9.21 Favored 'General case' 0 C--N 1.324 -0.502 0 O-C-N 124.501 1.126 . . . . 0.0 109.291 179.996 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 84.78 23.51 49.54 Favored Glycine 0 CA--C 1.529 0.968 0 O-C-N 124.487 1.117 . . . . 0.0 111.012 -179.966 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 7.2 mt -142.46 129.93 11.26 Favored Pre-proline 0 C--N 1.325 -0.497 0 O-C-N 124.496 0.762 . . . . 0.0 109.288 -179.935 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 20.2 Cg_endo -74.98 89.59 1.15 Allowed 'Trans proline' 0 N--CA 1.453 -0.876 0 O-C-N 124.534 1.807 . . . . 0.0 110.987 -168.323 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.58 HG22 ' HB3' ' A' ' 24' ' ' ARG . 32.6 m . . . . . 0 C--N 1.325 -0.479 0 O-C-N 124.487 1.117 . . . . 0.0 109.276 179.997 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 32.9 m . . . . . 0 N--CA 1.453 -0.282 0 N-CA-C 108.28 -1.008 . . . . 0.0 108.28 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 88.54 -16.01 55.02 Favored Glycine 0 CA--C 1.531 1.044 0 O-C-N 124.503 1.127 . . . . 0.0 110.985 -179.992 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 16.4 tt0 -90.21 161.92 15.49 Favored 'General case' 0 C--N 1.325 -0.483 0 O-C-N 124.515 0.774 . . . . 0.0 110.329 179.982 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.787 HG22 HG12 ' A' ' 21' ' ' VAL . 37.3 p -122.67 135.99 54.75 Favored 'General case' 0 C--N 1.324 -0.518 0 O-C-N 124.481 1.113 . . . . 0.0 110.417 179.992 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . 0.406 ' SG ' ' O ' ' A' ' 5' ' ' CYS . 15.3 p -102.65 53.04 0.79 Allowed 'General case' 0 C--N 1.325 -0.484 0 O-C-N 124.528 1.142 . . . . 0.0 108.281 -179.971 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 15.6 t -59.43 -24.51 28.41 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 O-C-N 124.471 1.107 . . . . 0.0 109.331 179.97 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -84.54 -30.96 25.79 Favored Glycine 0 CA--C 1.53 0.982 0 O-C-N 124.485 1.116 . . . . 0.0 110.992 179.97 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 122.6 13.26 4.74 Favored Glycine 0 CA--C 1.53 1.012 0 O-C-N 124.953 1.031 . . . . 0.0 110.979 178.611 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 5.9 m -150.14 158.76 44.5 Favored 'General case' 0 C--N 1.325 -0.497 0 O-C-N 124.512 0.772 . . . . 0.0 110.41 179.973 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . 0.403 ' SG ' ' O ' ' A' ' 16' ' ' THR . 97.2 m -114.3 141.58 47.41 Favored 'General case' 0 C--N 1.325 -0.461 0 O-C-N 124.491 1.12 . . . . 0.0 108.307 -179.971 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 64.3 t30 -89.83 -44.5 9.91 Favored 'General case' 0 C--N 1.325 -0.48 0 O-C-N 124.518 1.136 . . . . 0.0 109.284 -179.965 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.625 HG23 ' HD2' ' A' ' 13' ' ' PRO . 18.9 m -57.65 142.85 77.07 Favored Pre-proline 0 C--N 1.325 -0.472 0 O-C-N 124.487 1.117 . . . . 0.0 110.348 -179.987 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.625 ' HD2' HG23 ' A' ' 12' ' ' THR . 20.3 Cg_endo -75.01 130.57 13.38 Favored 'Trans proline' 0 N--CA 1.452 -0.925 0 O-C-N 124.488 1.783 . . . . 0.0 111.026 -168.328 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 75.59 14.09 82.36 Favored Glycine 0 CA--C 1.531 1.034 0 O-C-N 124.518 1.136 . . . . 0.0 110.975 -179.989 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.5 ' SG ' ' CG2' ' A' ' 12' ' ' THR . 62.3 m -95.69 129.54 42.86 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 108.274 -1.01 . . . . 0.0 108.274 -179.971 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . 0.403 ' O ' ' SG ' ' A' ' 10' ' ' CYS . 7.7 p -95.54 152.35 18.5 Favored 'General case' 0 C--N 1.325 -0.481 0 O-C-N 124.491 1.12 . . . . 0.0 110.388 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 45.6 t -81.67 94.92 7.06 Favored 'General case' 0 C--N 1.325 -0.497 0 O-C-N 124.515 1.134 . . . . 0.0 108.328 179.999 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . 0.566 ' CB ' HG23 ' A' ' 23' ' ' THR . 1.2 t -104.13 67.05 0.84 Allowed 'General case' 0 C--N 1.324 -0.504 0 O-C-N 124.551 1.157 . . . . 0.0 109.98 174.221 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' TRP . . . . . 0.623 ' CG ' ' HA ' ' A' ' 20' ' ' PRO . 0.1 OUTLIER -36.1 147.23 0.19 Allowed Pre-proline 0 C--N 1.325 -0.485 0 O-C-N 124.502 1.127 . . . . 0.0 108.011 -174.257 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.623 ' HA ' ' CG ' ' A' ' 19' ' ' TRP . 18.1 Cg_endo -74.98 -14.0 23.26 Favored 'Cis proline' 0 C--N 1.36 1.136 0 C-N-CA 121.014 -2.494 . . . . 0.0 110.996 -8.659 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.787 HG12 HG22 ' A' ' 4' ' ' THR . 3.0 m -97.67 177.83 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.478 0 O-C-N 124.496 1.123 . . . . 0.0 109.294 -173.075 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 52.9 m -102.18 172.5 6.86 Favored 'General case' 0 C--N 1.325 -0.485 0 O-C-N 124.477 1.111 . . . . 0.0 108.317 179.98 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . 0.566 HG23 ' CB ' ' A' ' 18' ' ' SER . 6.5 p -145.56 165.1 29.64 Favored 'General case' 0 C--N 1.324 -0.504 0 O-C-N 124.539 1.149 . . . . 0.0 110.416 -179.982 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.666 ' HB3' HG22 ' A' ' 29' ' ' VAL . 0.1 OUTLIER -131.89 112.97 12.9 Favored 'General case' 0 C--N 1.325 -0.464 0 O-C-N 124.459 1.099 . . . . 0.0 110.293 179.986 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 2.6 m-80 57.12 22.96 7.99 Favored 'General case' 0 C--N 1.326 -0.451 0 O-C-N 124.498 1.124 . . . . 0.0 109.319 -179.986 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 86.15 25.3 37.56 Favored Glycine 0 CA--C 1.53 0.985 0 O-C-N 124.522 1.139 . . . . 0.0 111.016 -179.986 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 7.9 mt -143.37 130.01 10.48 Favored Pre-proline 0 C--N 1.325 -0.477 0 O-C-N 124.511 0.771 . . . . 0.0 109.3 179.983 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 20.2 Cg_endo -74.97 85.99 1.46 Allowed 'Trans proline' 0 N--CA 1.453 -0.891 0 O-C-N 124.55 1.816 . . . . 0.0 111.043 -168.34 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.666 HG22 ' HB3' ' A' ' 24' ' ' ARG . 21.6 m . . . . . 0 C--N 1.325 -0.469 0 O-C-N 124.512 1.133 . . . . 0.0 109.3 179.995 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 37.6 m . . . . . 0 N--CA 1.453 -0.304 0 N-CA-C 108.294 -1.002 . . . . 0.0 108.294 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 91.42 -21.64 34.21 Favored Glycine 0 CA--C 1.531 1.06 0 O-C-N 124.505 1.128 . . . . 0.0 110.999 179.989 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 16.0 tt0 -85.23 161.1 19.71 Favored 'General case' 0 C--N 1.325 -0.466 0 O-C-N 124.541 0.789 . . . . 0.0 110.274 -179.987 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.866 HG22 HG23 ' A' ' 21' ' ' VAL . 72.5 p -121.94 136.2 54.91 Favored 'General case' 0 C--N 1.325 -0.457 0 O-C-N 124.445 1.09 . . . . 0.0 110.455 179.996 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . 0.426 ' O ' ' CD1' ' A' ' 19' ' ' TRP . 15.2 p -102.1 53.78 0.8 Allowed 'General case' 0 C--N 1.325 -0.493 0 O-C-N 124.573 1.17 . . . . 0.0 108.283 -179.978 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 4.7 t -59.5 -24.85 29.54 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 O-C-N 124.515 1.135 . . . . 0.0 109.302 -179.993 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -85.42 -32.97 18.11 Favored Glycine 0 CA--C 1.53 0.991 0 O-C-N 124.524 1.14 . . . . 0.0 110.978 -179.979 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 124.31 15.34 3.4 Favored Glycine 0 CA--C 1.53 0.983 0 O-C-N 125.021 1.071 . . . . 0.0 110.977 178.057 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 6.0 m -150.17 158.95 44.7 Favored 'General case' 0 C--N 1.325 -0.48 0 O-C-N 124.494 0.761 . . . . 0.0 110.397 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 74.9 m -117.8 141.75 48.07 Favored 'General case' 0 C--N 1.325 -0.476 0 O-C-N 124.496 1.123 . . . . 0.0 108.302 179.975 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 4.6 m120 -89.7 -47.62 7.81 Favored 'General case' 0 C--N 1.325 -0.475 0 O-C-N 124.498 1.124 . . . . 0.0 109.294 179.997 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.607 HG23 ' HD2' ' A' ' 13' ' ' PRO . 20.8 m -53.87 142.75 43.57 Favored Pre-proline 0 C--N 1.325 -0.479 0 O-C-N 124.442 1.089 . . . . 0.0 110.392 -179.975 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.607 ' HD2' HG23 ' A' ' 12' ' ' THR . 20.2 Cg_endo -75.04 130.78 13.54 Favored 'Trans proline' 0 N--CA 1.453 -0.866 0 O-C-N 124.443 1.759 . . . . 0.0 110.928 -168.237 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 75.36 13.55 82.75 Favored Glycine 0 CA--C 1.53 0.986 0 O-C-N 124.497 1.123 . . . . 0.0 111.022 -179.978 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.498 ' SG ' ' CG2' ' A' ' 12' ' ' THR . 64.2 m -95.54 126.65 40.97 Favored 'General case' 0 C--N 1.325 -0.476 0 N-CA-C 108.316 -0.994 . . . . 0.0 108.316 -179.967 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 17.6 p -94.0 155.23 17.24 Favored 'General case' 0 C--N 1.325 -0.485 0 O-C-N 124.48 1.112 . . . . 0.0 110.437 179.991 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 43.4 t -83.4 94.27 7.94 Favored 'General case' 0 C--N 1.325 -0.48 0 O-C-N 124.482 1.114 . . . . 0.0 108.325 -179.965 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . 0.564 ' HB3' HG23 ' A' ' 23' ' ' THR . 47.9 t -102.53 66.67 0.98 Allowed 'General case' 0 C--N 1.325 -0.497 0 O-C-N 124.486 1.116 . . . . 0.0 109.971 174.166 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' TRP . . . . . 0.603 ' CG ' ' HA ' ' A' ' 20' ' ' PRO . 0.0 OUTLIER -36.0 147.3 0.18 Allowed Pre-proline 0 C--N 1.325 -0.485 0 O-C-N 124.483 1.114 . . . . 0.0 108.022 -174.167 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.603 ' HA ' ' CG ' ' A' ' 19' ' ' TRP . 18.3 Cg_endo -74.94 -13.69 23.34 Favored 'Cis proline' 0 C--N 1.36 1.159 0 C-N-CA 121.006 -2.498 . . . . 0.0 111.038 -8.513 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.866 HG23 HG22 ' A' ' 4' ' ' THR . 1.1 p -98.42 177.75 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 O-C-N 124.512 1.132 . . . . 0.0 109.305 -173.083 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.505 ' H ' HG22 ' A' ' 21' ' ' VAL . 56.6 m -102.1 170.52 8.05 Favored 'General case' 0 C--N 1.325 -0.472 0 O-C-N 124.502 1.126 . . . . 0.0 108.271 -179.983 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . 0.564 HG23 ' HB3' ' A' ' 18' ' ' SER . 1.1 p -144.98 164.86 29.86 Favored 'General case' 0 C--N 1.325 -0.466 0 O-C-N 124.561 1.163 . . . . 0.0 110.423 179.974 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.53 ' HB3' HG22 ' A' ' 29' ' ' VAL . 7.5 ttt180 -132.87 116.91 17.08 Favored 'General case' 0 C--N 1.325 -0.488 0 O-C-N 124.476 1.11 . . . . 0.0 110.341 179.966 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 75.7 m-20 57.39 23.37 8.89 Favored 'General case' 0 C--N 1.325 -0.48 0 O-C-N 124.452 1.095 . . . . 0.0 109.278 -179.991 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 83.89 25.22 46.26 Favored Glycine 0 CA--C 1.53 1.004 0 O-C-N 124.453 1.096 . . . . 0.0 110.995 -179.982 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 10.0 mt -144.22 131.19 10.31 Favored Pre-proline 0 C--N 1.325 -0.492 0 O-C-N 124.516 0.774 . . . . 0.0 109.268 179.995 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 20.1 Cg_endo -74.97 89.08 1.18 Allowed 'Trans proline' 0 N--CA 1.453 -0.872 0 O-C-N 124.462 1.77 . . . . 0.0 110.986 -168.308 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.53 HG22 ' HB3' ' A' ' 24' ' ' ARG . 33.5 m . . . . . 0 C--N 1.325 -0.485 0 O-C-N 124.443 1.09 . . . . 0.0 109.327 179.99 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 52.7 m . . . . . 0 N--CA 1.453 -0.279 0 N-CA-C 108.32 -0.993 . . . . 0.0 108.32 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 100.81 -10.16 58.75 Favored Glycine 0 CA--C 1.53 0.995 0 O-C-N 124.527 1.142 . . . . 0.0 110.997 -179.976 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 14.6 tt0 -99.17 162.77 12.87 Favored 'General case' 0 C--N 1.325 -0.484 0 O-C-N 124.51 0.77 . . . . 0.0 110.262 -179.96 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.674 HG22 HG23 ' A' ' 21' ' ' VAL . 80.9 p -120.12 138.09 53.77 Favored 'General case' 0 C--N 1.326 -0.446 0 O-C-N 124.541 1.151 . . . . 0.0 110.395 179.945 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . 0.431 ' O ' ' CD1' ' A' ' 19' ' ' TRP . 14.5 p -107.72 51.26 0.75 Allowed 'General case' 0 C--N 1.325 -0.482 0 O-C-N 124.515 1.134 . . . . 0.0 108.301 179.999 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 15.0 t -59.15 -23.89 25.86 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.468 0 O-C-N 124.461 1.101 . . . . 0.0 109.28 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -85.68 -34.07 14.5 Favored Glycine 0 CA--C 1.53 1.025 0 O-C-N 124.523 1.139 . . . . 0.0 111.019 179.981 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 126.19 17.57 2.44 Favored Glycine 0 C--N 1.344 0.993 0 O-C-N 125.223 1.19 . . . . 0.0 111.003 177.32 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -150.34 166.02 31.29 Favored 'General case' 0 C--N 1.325 -0.488 0 O-C-N 124.534 0.785 . . . . 0.0 110.377 -179.987 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . 0.41 ' SG ' ' O ' ' A' ' 16' ' ' THR . 80.1 m -125.97 142.76 51.38 Favored 'General case' 0 C--N 1.325 -0.468 0 O-C-N 124.485 1.116 . . . . 0.0 108.285 179.996 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 4.3 m-20 -89.99 -48.3 7.3 Favored 'General case' 0 C--N 1.324 -0.514 0 O-C-N 124.489 1.118 . . . . 0.0 109.286 -179.992 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.623 HG23 ' HD2' ' A' ' 13' ' ' PRO . 18.9 m -53.04 142.78 34.79 Favored Pre-proline 0 C--N 1.326 -0.453 0 O-C-N 124.497 1.123 . . . . 0.0 110.417 179.971 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.623 ' HD2' HG23 ' A' ' 12' ' ' THR . 20.1 Cg_endo -75.01 131.39 14.22 Favored 'Trans proline' 0 N--CA 1.453 -0.906 0 O-C-N 124.495 1.787 . . . . 0.0 110.969 -168.3 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 74.2 15.11 80.15 Favored Glycine 0 CA--C 1.53 0.999 0 O-C-N 124.46 1.1 . . . . 0.0 110.984 179.965 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.504 ' SG ' ' CG2' ' A' ' 12' ' ' THR . 63.7 m -97.47 125.93 42.44 Favored 'General case' 0 C--N 1.325 -0.483 0 N-CA-C 108.285 -1.006 . . . . 0.0 108.285 179.996 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . 0.41 ' O ' ' SG ' ' A' ' 10' ' ' CYS . 18.6 p -94.11 158.61 15.53 Favored 'General case' 0 C--N 1.324 -0.504 0 O-C-N 124.489 1.118 . . . . 0.0 110.393 -179.993 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 42.4 t -81.72 94.11 6.93 Favored 'General case' 0 C--N 1.325 -0.473 0 O-C-N 124.467 1.104 . . . . 0.0 108.334 179.951 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . 0.606 ' HB3' HG23 ' A' ' 23' ' ' THR . 2.5 t -100.98 65.57 1.11 Allowed 'General case' 0 C--N 1.325 -0.457 0 O-C-N 124.475 1.109 . . . . 0.0 109.989 174.214 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' TRP . . . . . 0.585 ' CG ' ' HA ' ' A' ' 20' ' ' PRO . 0.0 OUTLIER -36.64 148.04 0.19 Allowed Pre-proline 0 C--N 1.324 -0.507 0 O-C-N 124.489 1.118 . . . . 0.0 108.0 -174.067 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.585 ' HA ' ' CG ' ' A' ' 19' ' ' TRP . 18.1 Cg_endo -75.02 -11.49 24.25 Favored 'Cis proline' 0 C--N 1.361 1.186 0 C-N-CA 121.017 -2.493 . . . . 0.0 110.97 -8.309 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.674 HG23 HG22 ' A' ' 4' ' ' THR . 3.2 p -100.5 -179.6 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 O-C-N 124.499 1.124 . . . . 0.0 109.291 -173.528 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.661 ' H ' HG22 ' A' ' 21' ' ' VAL . 60.4 m -101.67 167.01 10.39 Favored 'General case' 0 C--N 1.326 -0.456 0 O-C-N 124.526 1.141 . . . . 0.0 108.316 179.999 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . 0.606 HG23 ' HB3' ' A' ' 18' ' ' SER . 0.8 OUTLIER -144.45 165.7 27.22 Favored 'General case' 0 C--N 1.324 -0.517 0 O-C-N 124.487 1.117 . . . . 0.0 110.412 179.958 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.425 ' HB3' ' CG2' ' A' ' 29' ' ' VAL . 15.0 ttt180 -135.18 120.2 18.67 Favored 'General case' 0 C--N 1.325 -0.495 0 O-C-N 124.542 1.151 . . . . 0.0 110.293 -179.958 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 28.5 t-20 56.46 25.42 9.64 Favored 'General case' 0 C--N 1.324 -0.5 0 O-C-N 124.493 1.121 . . . . 0.0 109.296 179.977 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 79.41 27.93 53.78 Favored Glycine 0 CA--C 1.529 0.966 0 O-C-N 124.457 1.098 . . . . 0.0 111.021 179.999 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 40.1 mt -146.8 132.49 9.32 Favored Pre-proline 0 C--N 1.325 -0.469 0 O-C-N 124.47 0.747 . . . . 0.0 109.26 -179.986 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 20.1 Cg_endo -74.99 87.52 1.32 Allowed 'Trans proline' 0 N--CA 1.453 -0.895 0 O-C-N 124.543 1.812 . . . . 0.0 110.968 -168.319 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.425 ' CG2' ' HB3' ' A' ' 24' ' ' ARG . 18.2 m . . . . . 0 C--N 1.325 -0.465 0 O-C-N 124.532 1.145 . . . . 0.0 109.287 179.993 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 72.9 m . . . . . 0 N--CA 1.452 -0.336 0 N-CA-C 108.332 -0.988 . . . . 0.0 108.332 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 83.42 -10.96 57.67 Favored Glycine 0 CA--C 1.53 0.981 0 O-C-N 124.551 1.157 . . . . 0.0 110.988 179.981 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 7.7 pt-20 -100.28 171.59 7.68 Favored 'General case' 0 C--N 1.325 -0.46 0 O-C-N 124.493 0.76 . . . . 0.0 110.346 179.994 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 1.039 HG22 HG23 ' A' ' 21' ' ' VAL . 67.8 p -129.62 145.1 51.52 Favored 'General case' 0 C--N 1.325 -0.486 0 O-C-N 124.469 1.106 . . . . 0.0 110.455 179.997 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . 0.429 ' O ' ' CD1' ' A' ' 19' ' ' TRP . 22.6 p -107.35 56.41 0.64 Allowed 'General case' 0 C--N 1.324 -0.524 0 O-C-N 124.52 1.138 . . . . 0.0 108.292 -179.95 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.4 t -59.45 -24.87 29.46 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 O-C-N 124.508 1.13 . . . . 0.0 109.284 -179.956 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -84.85 -35.1 13.55 Favored Glycine 0 CA--C 1.53 1.009 0 O-C-N 124.509 1.13 . . . . 0.0 110.981 -179.986 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 125.48 17.22 2.67 Favored Glycine 0 C--N 1.344 1.025 0 O-C-N 125.055 1.091 . . . . 0.0 111.047 177.698 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 2.4 m -150.33 155.62 39.99 Favored 'General case' 0 C--N 1.326 -0.45 0 O-C-N 124.484 0.755 . . . . 0.0 110.436 179.969 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 94.5 m -110.89 140.56 45.26 Favored 'General case' 0 C--N 1.325 -0.477 0 O-C-N 124.501 1.126 . . . . 0.0 108.268 -179.969 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 30.5 m-20 -90.01 -38.74 13.41 Favored 'General case' 0 C--N 1.325 -0.477 0 O-C-N 124.47 1.106 . . . . 0.0 109.306 -179.999 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.667 HG23 ' HD2' ' A' ' 13' ' ' PRO . 15.6 m -65.58 143.25 98.58 Favored Pre-proline 0 C--N 1.325 -0.474 0 O-C-N 124.521 1.138 . . . . 0.0 110.43 179.988 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.667 ' HD2' HG23 ' A' ' 12' ' ' THR . 20.3 Cg_endo -74.92 131.05 13.96 Favored 'Trans proline' 0 N--CA 1.453 -0.894 0 O-C-N 124.496 1.787 . . . . 0.0 110.976 -168.302 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 75.04 15.13 81.25 Favored Glycine 0 CA--C 1.53 1.02 0 O-C-N 124.504 1.128 . . . . 0.0 110.97 179.963 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.494 ' SG ' HG22 ' A' ' 12' ' ' THR . 64.3 m -98.1 127.61 44.14 Favored 'General case' 0 C--N 1.325 -0.464 0 N-CA-C 108.308 -0.997 . . . . 0.0 108.308 179.971 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 71.0 p -94.28 152.25 18.81 Favored 'General case' 0 C--N 1.325 -0.484 0 O-C-N 124.48 1.112 . . . . 0.0 110.44 179.97 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 47.4 t -78.18 98.09 5.72 Favored 'General case' 0 C--N 1.325 -0.492 0 O-C-N 124.479 1.112 . . . . 0.0 108.243 -179.951 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . 0.567 ' HB3' HG23 ' A' ' 23' ' ' THR . 10.8 t -104.78 65.89 0.76 Allowed 'General case' 0 C--N 1.324 -0.51 0 O-C-N 124.553 1.158 . . . . 0.0 109.958 174.442 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' TRP . . . . . 0.604 ' CG ' ' HA ' ' A' ' 20' ' ' PRO . 0.0 OUTLIER -36.88 147.87 0.2 Allowed Pre-proline 0 C--N 1.325 -0.489 0 O-C-N 124.505 1.128 . . . . 0.0 107.99 -174.18 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.604 ' HA ' ' CG ' ' A' ' 19' ' ' TRP . 18.1 Cg_endo -75.04 -12.57 24.07 Favored 'Cis proline' 0 C--N 1.36 1.144 0 C-N-CA 120.974 -2.511 . . . . 0.0 110.957 -8.505 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 1.039 HG23 HG22 ' A' ' 4' ' ' THR . 4.4 p -98.09 178.85 0.6 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 O-C-N 124.521 1.138 . . . . 0.0 109.289 -173.628 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.683 ' H ' HG22 ' A' ' 21' ' ' VAL . 1.7 m -101.95 168.51 9.36 Favored 'General case' 0 C--N 1.325 -0.477 0 O-C-N 124.49 1.119 . . . . 0.0 108.348 -179.993 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . 0.567 HG23 ' HB3' ' A' ' 18' ' ' SER . 0.8 OUTLIER -145.34 168.31 20.8 Favored 'General case' 0 C--N 1.325 -0.488 0 O-C-N 124.486 1.116 . . . . 0.0 110.399 -179.976 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.468 ' HB3' ' CG2' ' A' ' 29' ' ' VAL . 29.3 ttt-85 -144.64 119.39 9.85 Favored 'General case' 0 C--N 1.324 -0.506 0 O-C-N 124.514 1.133 . . . . 0.0 110.332 -179.979 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 17.9 t-20 57.42 23.28 8.84 Favored 'General case' 0 C--N 1.325 -0.491 0 O-C-N 124.506 1.129 . . . . 0.0 109.293 -179.997 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 83.44 24.27 51.37 Favored Glycine 0 CA--C 1.53 0.974 0 O-C-N 124.514 1.134 . . . . 0.0 111.027 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 19.1 mt -147.3 128.27 7.09 Favored Pre-proline 0 C--N 1.325 -0.463 0 O-C-N 124.464 0.744 . . . . 0.0 109.325 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 20.2 Cg_endo -74.97 80.96 2.31 Favored 'Trans proline' 0 N--CA 1.453 -0.891 0 O-C-N 124.474 1.776 . . . . 0.0 110.972 -168.271 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.468 ' CG2' ' HB3' ' A' ' 24' ' ' ARG . 17.6 m . . . . . 0 C--N 1.325 -0.46 0 O-C-N 124.482 1.114 . . . . 0.0 109.289 -179.982 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 80.8 m . . . . . 0 N--CA 1.453 -0.319 0 N-CA-C 108.317 -0.994 . . . . 0.0 108.317 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 82.75 -10.69 55.96 Favored Glycine 0 CA--C 1.53 0.992 0 O-C-N 124.525 1.141 . . . . 0.0 111.042 -179.993 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 7.6 pt-20 -100.28 171.87 7.51 Favored 'General case' 0 C--N 1.325 -0.478 0 O-C-N 124.497 0.763 . . . . 0.0 110.288 179.98 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.975 HG22 HG23 ' A' ' 21' ' ' VAL . 46.1 p -128.92 144.36 51.16 Favored 'General case' 0 C--N 1.326 -0.452 0 O-C-N 124.463 1.102 . . . . 0.0 110.394 179.965 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . 0.526 ' O ' ' CD1' ' A' ' 19' ' ' TRP . 15.1 p -103.08 52.39 0.78 Allowed 'General case' 0 C--N 1.325 -0.472 0 O-C-N 124.505 1.128 . . . . 0.0 108.291 -179.984 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.8 t -59.26 -25.01 29.26 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 O-C-N 124.502 1.127 . . . . 0.0 109.328 -179.986 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -84.63 -32.91 20.68 Favored Glycine 0 CA--C 1.529 0.966 0 O-C-N 124.522 1.138 . . . . 0.0 110.982 179.988 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 124.4 14.63 3.55 Favored Glycine 0 CA--C 1.531 1.049 0 O-C-N 124.892 0.995 . . . . 0.0 110.97 177.996 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 49.1 m -150.29 165.15 33.88 Favored 'General case' 0 C--N 1.325 -0.468 0 O-C-N 124.483 0.755 . . . . 0.0 110.374 -180.0 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 98.4 m -118.37 141.4 48.57 Favored 'General case' 0 C--N 1.326 -0.449 0 O-C-N 124.458 1.099 . . . . 0.0 108.272 -179.989 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 47.2 t30 -89.89 -39.84 12.79 Favored 'General case' 0 C--N 1.325 -0.467 0 O-C-N 124.51 1.131 . . . . 0.0 109.33 179.973 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.652 HG23 ' HD2' ' A' ' 13' ' ' PRO . 16.9 m -64.68 143.02 98.64 Favored Pre-proline 0 C--N 1.325 -0.472 0 O-C-N 124.495 1.122 . . . . 0.0 110.377 -179.993 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.652 ' HD2' HG23 ' A' ' 12' ' ' THR . 20.1 Cg_endo -75.01 130.65 13.46 Favored 'Trans proline' 0 N--CA 1.453 -0.875 0 O-C-N 124.502 1.791 . . . . 0.0 110.955 -168.298 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 76.22 12.82 83.85 Favored Glycine 0 CA--C 1.53 0.979 0 O-C-N 124.514 1.134 . . . . 0.0 111.02 -179.987 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.498 ' SG ' ' CG2' ' A' ' 12' ' ' THR . 64.9 m -95.7 127.48 41.76 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 108.318 -0.993 . . . . 0.0 108.318 179.964 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 29.9 p -94.5 150.16 20.53 Favored 'General case' 0 C--N 1.325 -0.472 0 O-C-N 124.456 1.098 . . . . 0.0 110.466 179.958 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 37.5 t -76.96 96.18 4.31 Favored 'General case' 0 C--N 1.324 -0.523 0 O-C-N 124.557 1.161 . . . . 0.0 108.283 179.988 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . 0.51 ' O ' ' C ' ' A' ' 19' ' ' TRP . 1.8 m -102.31 65.51 0.95 Allowed 'General case' 0 C--N 1.325 -0.482 0 O-C-N 124.506 1.128 . . . . 0.0 110.003 174.326 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' TRP . . . . . 0.602 ' CG ' ' HA ' ' A' ' 20' ' ' PRO . 0.0 OUTLIER -36.71 148.05 0.19 Allowed Pre-proline 0 C--N 1.325 -0.498 0 O-C-N 124.525 1.141 . . . . 0.0 108.008 -173.995 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.602 ' HA ' ' CG ' ' A' ' 19' ' ' TRP . 18.5 Cg_endo -74.93 -12.53 23.78 Favored 'Cis proline' 0 C--N 1.36 1.149 0 C-N-CA 121.03 -2.487 . . . . 0.0 111.015 -8.509 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.975 HG23 HG22 ' A' ' 4' ' ' THR . 5.8 p -98.87 177.38 0.69 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 O-C-N 124.475 1.11 . . . . 0.0 109.324 -173.279 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.683 ' H ' HG22 ' A' ' 21' ' ' VAL . 1.8 m -102.07 169.74 8.56 Favored 'General case' 0 C--N 1.324 -0.507 0 O-C-N 124.521 1.138 . . . . 0.0 108.314 179.973 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . 0.416 ' O ' ' HA ' ' A' ' 15' ' ' CYS . 0.9 OUTLIER -149.5 165.05 33.35 Favored 'General case' 0 C--N 1.324 -0.518 0 O-C-N 124.49 1.119 . . . . 0.0 110.429 -179.931 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.555 ' HB3' HG22 ' A' ' 29' ' ' VAL . 10.9 ttt85 -141.22 119.68 12.32 Favored 'General case' 0 C--N 1.325 -0.488 0 O-C-N 124.49 1.119 . . . . 0.0 110.289 179.952 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . 0.405 ' O ' ' OD1' ' A' ' 25' ' ' ASN . 16.5 t-20 57.58 22.71 8.47 Favored 'General case' 0 C--N 1.325 -0.488 0 O-C-N 124.534 1.146 . . . . 0.0 109.329 -179.965 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . 0.463 ' O ' HD23 ' A' ' 27' ' ' LEU . . . 83.9 23.93 50.85 Favored Glycine 0 CA--C 1.53 0.997 0 O-C-N 124.533 1.146 . . . . 0.0 110.975 179.978 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . 0.463 HD23 ' O ' ' A' ' 26' ' ' GLY . 13.8 mt -145.93 128.37 7.94 Favored Pre-proline 0 C--N 1.325 -0.48 0 O-C-N 124.551 0.795 . . . . 0.0 109.281 179.976 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 20.3 Cg_endo -74.98 77.42 3.13 Favored 'Trans proline' 0 N--CA 1.453 -0.892 0 O-C-N 124.503 1.791 . . . . 0.0 111.014 -168.327 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.555 HG22 ' HB3' ' A' ' 24' ' ' ARG . 36.0 m . . . . . 0 C--N 1.325 -0.458 0 O-C-N 124.527 1.142 . . . . 0.0 109.259 -179.994 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 87.2 m . . . . . 0 N--CA 1.452 -0.33 0 N-CA-C 108.322 -0.992 . . . . 0.0 108.322 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 91.31 -15.27 61.6 Favored Glycine 0 CA--C 1.53 1.023 0 O-C-N 124.504 1.127 . . . . 0.0 110.98 179.996 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 15.2 tt0 -88.3 162.25 16.7 Favored 'General case' 0 C--N 1.324 -0.509 0 O-C-N 124.534 0.785 . . . . 0.0 110.291 179.98 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.666 HG22 HG23 ' A' ' 21' ' ' VAL . 47.7 p -120.73 131.83 54.73 Favored 'General case' 0 C--N 1.325 -0.484 0 O-C-N 124.456 1.098 . . . . 0.0 110.389 -179.993 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . 0.417 ' SG ' ' O ' ' A' ' 5' ' ' CYS . 14.6 p -100.11 52.08 0.9 Allowed 'General case' 0 C--N 1.325 -0.46 0 O-C-N 124.502 1.126 . . . . 0.0 108.316 179.963 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 11.9 t -59.27 -24.84 28.8 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 O-C-N 124.496 1.123 . . . . 0.0 109.318 179.951 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -84.54 -32.0 23.19 Favored Glycine 0 CA--C 1.53 0.983 0 O-C-N 124.503 1.127 . . . . 0.0 111.008 -179.945 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 123.84 15.91 3.44 Favored Glycine 0 CA--C 1.53 0.992 0 O-C-N 124.896 0.998 . . . . 0.0 110.996 178.112 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 62.2 m -150.11 165.57 32.41 Favored 'General case' 0 C--N 1.325 -0.476 0 O-C-N 124.508 0.769 . . . . 0.0 110.413 179.975 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . 0.405 ' SG ' ' O ' ' A' ' 16' ' ' THR . 96.9 m -122.15 143.45 49.55 Favored 'General case' 0 C--N 1.325 -0.464 0 O-C-N 124.512 1.133 . . . . 0.0 108.295 179.999 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 12.0 m-20 -90.11 -47.03 8.07 Favored 'General case' 0 C--N 1.324 -0.511 0 O-C-N 124.505 1.128 . . . . 0.0 109.26 -179.984 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.616 HG23 ' HD2' ' A' ' 13' ' ' PRO . 20.9 m -54.6 142.68 51.54 Favored Pre-proline 0 C--N 1.325 -0.461 0 O-C-N 124.462 1.101 . . . . 0.0 110.431 179.985 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.616 ' HD2' HG23 ' A' ' 12' ' ' THR . 20.1 Cg_endo -74.99 131.36 14.21 Favored 'Trans proline' 0 N--CA 1.453 -0.867 0 O-C-N 124.531 1.806 . . . . 0.0 110.977 -168.295 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 74.69 14.91 80.94 Favored Glycine 0 CA--C 1.53 1.028 0 O-C-N 124.495 1.122 . . . . 0.0 111.024 179.989 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.504 ' SG ' ' CG2' ' A' ' 12' ' ' THR . 63.9 m -96.08 134.58 38.95 Favored 'General case' 0 C--N 1.325 -0.483 0 N-CA-C 108.297 -1.001 . . . . 0.0 108.297 179.987 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . 0.405 ' O ' ' SG ' ' A' ' 10' ' ' CYS . 82.7 p -101.11 152.97 19.98 Favored 'General case' 0 C--N 1.325 -0.466 0 O-C-N 124.445 1.091 . . . . 0.0 110.401 179.975 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 41.3 t -79.71 94.41 5.72 Favored 'General case' 0 C--N 1.325 -0.481 0 O-C-N 124.52 1.138 . . . . 0.0 108.363 179.942 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . 0.517 ' O ' ' C ' ' A' ' 19' ' ' TRP . 17.5 t -101.45 65.48 1.05 Allowed 'General case' 0 C--N 1.325 -0.488 0 O-C-N 124.456 1.097 . . . . 0.0 110.002 174.236 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' TRP . . . . . 0.621 ' CG ' ' HA ' ' A' ' 20' ' ' PRO . 0.1 OUTLIER -36.14 147.01 0.19 Allowed Pre-proline 0 C--N 1.325 -0.477 0 O-C-N 124.515 1.134 . . . . 0.0 107.997 -174.129 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.621 ' HA ' ' CG ' ' A' ' 19' ' ' TRP . 18.2 Cg_endo -74.97 -13.76 23.37 Favored 'Cis proline' 0 C--N 1.36 1.166 0 C-N-CA 121.009 -2.496 . . . . 0.0 111.003 -8.557 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.666 HG23 HG22 ' A' ' 4' ' ' THR . 0.9 OUTLIER -97.35 178.04 0.63 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 O-C-N 124.449 1.093 . . . . 0.0 109.29 -173.148 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.491 ' H ' HG22 ' A' ' 21' ' ' VAL . 36.8 m -101.72 170.48 8.14 Favored 'General case' 0 C--N 1.325 -0.461 0 O-C-N 124.549 1.156 . . . . 0.0 108.289 -179.991 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . 0.501 HG23 ' HB3' ' A' ' 18' ' ' SER . 0.8 OUTLIER -146.88 166.81 25.61 Favored 'General case' 0 C--N 1.325 -0.487 0 O-C-N 124.483 1.115 . . . . 0.0 110.404 179.985 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.581 ' HB3' HG22 ' A' ' 29' ' ' VAL . 2.5 ttt180 -139.05 119.28 13.61 Favored 'General case' 0 C--N 1.325 -0.487 0 O-C-N 124.514 1.134 . . . . 0.0 110.327 179.995 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 81.1 m-20 57.16 22.99 8.08 Favored 'General case' 0 C--N 1.325 -0.478 0 O-C-N 124.515 1.134 . . . . 0.0 109.333 -179.973 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 83.7 25.58 45.64 Favored Glycine 0 CA--C 1.53 0.997 0 O-C-N 124.519 1.137 . . . . 0.0 110.968 179.949 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 12.9 mt -145.57 130.38 9.01 Favored Pre-proline 0 C--N 1.325 -0.488 0 O-C-N 124.457 0.739 . . . . 0.0 109.309 179.991 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 20.1 Cg_endo -75.01 82.48 2.0 Allowed 'Trans proline' 0 N--CA 1.453 -0.91 0 O-C-N 124.505 1.792 . . . . 0.0 110.955 -168.309 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.581 HG22 ' HB3' ' A' ' 24' ' ' ARG . 28.2 m . . . . . 0 C--N 1.325 -0.465 0 O-C-N 124.528 1.142 . . . . 0.0 109.346 179.951 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 93.5 m . . . . . 0 N--CA 1.453 -0.287 0 N-CA-C 108.32 -0.993 . . . . 0.0 108.32 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 95.54 -15.2 63.66 Favored Glycine 0 CA--C 1.53 1.03 0 O-C-N 124.486 1.116 . . . . 0.0 110.995 179.987 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 15.1 tt0 -86.4 161.82 18.47 Favored 'General case' 0 C--N 1.325 -0.459 0 O-C-N 124.504 0.767 . . . . 0.0 110.287 -179.992 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.404 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 48.0 p -119.03 132.23 56.03 Favored 'General case' 0 C--N 1.324 -0.508 0 O-C-N 124.505 1.128 . . . . 0.0 110.406 179.987 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . 0.427 ' O ' ' CD1' ' A' ' 19' ' ' TRP . 14.3 p -102.18 51.29 0.82 Allowed 'General case' 0 C--N 1.324 -0.509 0 O-C-N 124.531 1.144 . . . . 0.0 108.295 -179.965 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 6.6 t -59.27 -24.5 27.89 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 O-C-N 124.458 1.099 . . . . 0.0 109.289 -179.97 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -85.52 -34.31 14.25 Favored Glycine 0 CA--C 1.53 0.976 0 O-C-N 124.503 1.127 . . . . 0.0 111.041 -180.0 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 125.1 16.75 2.86 Favored Glycine 0 CA--C 1.53 1.0 0 O-C-N 124.945 1.026 . . . . 0.0 111.043 177.818 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 2.6 m -150.21 157.92 43.6 Favored 'General case' 0 C--N 1.325 -0.473 0 O-C-N 124.533 0.784 . . . . 0.0 110.414 -179.963 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . 0.411 ' SG ' ' O ' ' A' ' 16' ' ' THR . 84.0 m -118.59 144.56 46.03 Favored 'General case' 0 C--N 1.325 -0.471 0 O-C-N 124.487 1.117 . . . . 0.0 108.313 179.989 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 76.1 m-20 -89.86 -51.78 5.32 Favored 'General case' 0 C--N 1.325 -0.481 0 O-C-N 124.512 1.133 . . . . 0.0 109.314 179.977 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.605 HG23 ' HD2' ' A' ' 13' ' ' PRO . 22.0 m -49.72 142.58 12.19 Favored Pre-proline 0 C--N 1.325 -0.49 0 O-C-N 124.551 1.157 . . . . 0.0 110.405 179.982 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.605 ' HD2' HG23 ' A' ' 12' ' ' THR . 20.2 Cg_endo -74.99 131.7 14.59 Favored 'Trans proline' 0 N--CA 1.452 -0.947 0 O-C-N 124.45 1.763 . . . . 0.0 111.011 -168.267 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 74.36 13.78 81.31 Favored Glycine 0 CA--C 1.53 1.022 0 O-C-N 124.49 1.118 . . . . 0.0 111.009 -179.978 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.505 ' SG ' ' CG2' ' A' ' 12' ' ' THR . 67.4 m -96.31 126.18 41.34 Favored 'General case' 0 C--N 1.324 -0.504 0 N-CA-C 108.336 -0.987 . . . . 0.0 108.336 179.971 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . 0.411 ' O ' ' SG ' ' A' ' 10' ' ' CYS . 30.8 p -94.24 158.32 15.65 Favored 'General case' 0 C--N 1.325 -0.481 0 O-C-N 124.482 1.114 . . . . 0.0 110.387 -180.0 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 42.4 t -82.37 94.99 7.5 Favored 'General case' 0 C--N 1.325 -0.484 0 O-C-N 124.524 1.14 . . . . 0.0 108.339 179.968 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . 0.515 ' O ' ' C ' ' A' ' 19' ' ' TRP . 3.0 t -100.54 65.57 1.19 Allowed 'General case' 0 C--N 1.325 -0.463 0 O-C-N 124.526 1.141 . . . . 0.0 109.993 174.198 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' TRP . . . . . 0.592 ' CG ' ' HA ' ' A' ' 20' ' ' PRO . 0.0 OUTLIER -36.73 147.47 0.2 Allowed Pre-proline 0 C--N 1.325 -0.484 0 N-CA-C 107.958 -1.127 . . . . 0.0 107.958 -173.93 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.592 ' HA ' ' CG ' ' A' ' 19' ' ' TRP . 18.2 Cg_endo -75.04 -12.83 23.99 Favored 'Cis proline' 0 C--N 1.36 1.184 0 C-N-CA 120.968 -2.513 . . . . 0.0 111.003 -8.478 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.492 ' O ' ' C ' ' A' ' 18' ' ' SER . 16.3 m -98.05 179.24 0.58 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.494 0 O-C-N 124.514 1.134 . . . . 0.0 109.293 -173.478 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 51.9 m -101.77 168.08 9.68 Favored 'General case' 0 C--N 1.325 -0.488 0 O-C-N 124.54 1.15 . . . . 0.0 108.311 179.979 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . 0.498 HG23 ' HB3' ' A' ' 18' ' ' SER . 0.8 OUTLIER -146.97 168.06 22.44 Favored 'General case' 0 C--N 1.325 -0.458 0 O-C-N 124.515 1.135 . . . . 0.0 110.382 179.999 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.485 ' HB3' HG22 ' A' ' 29' ' ' VAL . 0.3 OUTLIER -141.54 119.69 12.12 Favored 'General case' 0 C--N 1.325 -0.468 0 O-C-N 124.506 1.128 . . . . 0.0 110.279 179.993 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 17.5 t-20 57.84 23.07 9.27 Favored 'General case' 0 C--N 1.326 -0.455 0 O-C-N 124.479 1.112 . . . . 0.0 109.303 179.967 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . 0.441 ' O ' HD23 ' A' ' 27' ' ' LEU . . . 82.43 23.34 56.78 Favored Glycine 0 CA--C 1.53 1.019 0 O-C-N 124.467 1.104 . . . . 0.0 110.976 179.992 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . 0.441 HD23 ' O ' ' A' ' 26' ' ' GLY . 11.9 mt -143.53 129.62 10.19 Favored Pre-proline 0 C--N 1.325 -0.498 0 O-C-N 124.461 0.742 . . . . 0.0 109.331 -179.997 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 20.5 Cg_endo -74.92 82.53 1.97 Allowed 'Trans proline' 0 N--CA 1.453 -0.861 0 O-C-N 124.516 1.798 . . . . 0.0 111.031 -168.343 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.485 HG22 ' HB3' ' A' ' 24' ' ' ARG . 27.4 m . . . . . 0 C--N 1.325 -0.484 0 O-C-N 124.489 1.118 . . . . 0.0 109.343 179.982 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 69.1 m . . . . . 0 N--CA 1.452 -0.328 0 N-CA-C 108.276 -1.009 . . . . 0.0 108.276 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 93.89 -15.7 62.51 Favored Glycine 0 CA--C 1.53 1.004 0 O-C-N 124.524 1.14 . . . . 0.0 110.995 179.97 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 15.5 tt0 -86.75 162.53 17.8 Favored 'General case' 0 C--N 1.326 -0.446 0 O-C-N 124.474 0.749 . . . . 0.0 110.322 -179.971 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.504 HG22 HG23 ' A' ' 21' ' ' VAL . 65.9 p -120.16 132.97 55.59 Favored 'General case' 0 C--N 1.325 -0.486 0 O-C-N 124.452 1.095 . . . . 0.0 110.398 179.961 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . 0.425 ' SG ' ' O ' ' A' ' 5' ' ' CYS . 13.8 p -102.44 49.96 0.84 Allowed 'General case' 0 C--N 1.325 -0.457 0 O-C-N 124.449 1.093 . . . . 0.0 108.279 -179.981 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 15.1 t -59.09 -24.0 25.97 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 O-C-N 124.562 1.164 . . . . 0.0 109.351 179.947 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -83.61 -33.67 21.45 Favored Glycine 0 CA--C 1.53 1.0 0 O-C-N 124.488 1.118 . . . . 0.0 111.033 179.972 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 126.88 10.85 3.74 Favored Glycine 0 C--N 1.345 1.074 0 C-N-CA 119.774 -1.203 . . . . 0.0 110.989 177.917 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -149.92 166.96 28.0 Favored 'General case' 0 C--N 1.325 -0.496 0 O-C-N 124.522 0.778 . . . . 0.0 110.416 -179.994 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . 0.412 ' SG ' ' O ' ' A' ' 16' ' ' THR . 80.2 m -121.8 146.37 47.14 Favored 'General case' 0 C--N 1.325 -0.469 0 O-C-N 124.484 1.115 . . . . 0.0 108.293 179.996 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 22.2 t30 -92.41 -44.17 8.83 Favored 'General case' 0 C--N 1.325 -0.479 0 O-C-N 124.518 1.136 . . . . 0.0 109.306 -179.995 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.632 HG23 ' HD2' ' A' ' 13' ' ' PRO . 18.4 m -57.75 142.89 77.62 Favored Pre-proline 0 C--N 1.324 -0.506 0 O-C-N 124.495 1.122 . . . . 0.0 110.391 179.976 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.632 ' HD2' HG23 ' A' ' 12' ' ' THR . 20.3 Cg_endo -74.96 131.68 14.62 Favored 'Trans proline' 0 N--CA 1.453 -0.879 0 O-C-N 124.533 1.807 . . . . 0.0 111.003 -168.335 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 76.42 7.23 85.08 Favored Glycine 0 CA--C 1.53 0.985 0 O-C-N 124.428 1.08 . . . . 0.0 111.007 179.985 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.5 ' SG ' ' CG2' ' A' ' 12' ' ' THR . 69.2 m -92.14 126.28 37.16 Favored 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 108.283 -1.006 . . . . 0.0 108.283 -179.998 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . 0.412 ' O ' ' SG ' ' A' ' 10' ' ' CYS . 34.3 p -95.28 156.52 16.29 Favored 'General case' 0 C--N 1.325 -0.484 0 O-C-N 124.543 1.152 . . . . 0.0 110.378 179.997 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 42.7 t -80.99 94.12 6.49 Favored 'General case' 0 C--N 1.325 -0.478 0 O-C-N 124.532 1.145 . . . . 0.0 108.276 -179.964 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . 0.518 ' O ' ' C ' ' A' ' 19' ' ' TRP . 3.6 t -100.36 65.51 1.22 Allowed 'General case' 0 C--N 1.325 -0.484 0 O-C-N 124.506 1.128 . . . . 0.0 110.006 174.172 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' TRP . . . . . 0.603 ' CG ' ' HA ' ' A' ' 20' ' ' PRO . 0.0 OUTLIER -36.3 147.42 0.19 Allowed Pre-proline 0 C--N 1.325 -0.465 0 N-CA-C 107.992 -1.114 . . . . 0.0 107.992 -173.981 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.603 ' HA ' ' CG ' ' A' ' 19' ' ' TRP . 18.3 Cg_endo -75.03 -12.92 23.97 Favored 'Cis proline' 0 C--N 1.36 1.166 0 C-N-CA 121.035 -2.485 . . . . 0.0 110.981 -8.374 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.69 HG22 ' H ' ' A' ' 22' ' ' CYS . 4.6 p -99.02 179.16 0.6 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.5 0 O-C-N 124.502 1.126 . . . . 0.0 109.292 -173.284 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.69 ' H ' HG22 ' A' ' 21' ' ' VAL . 53.3 m -101.63 168.9 9.18 Favored 'General case' 0 C--N 1.325 -0.473 0 O-C-N 124.476 1.11 . . . . 0.0 108.358 179.986 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . 0.441 ' OG1' ' CB ' ' A' ' 18' ' ' SER . 0.8 OUTLIER -148.36 167.54 24.97 Favored 'General case' 0 C--N 1.325 -0.488 0 O-C-N 124.5 1.125 . . . . 0.0 110.389 -179.986 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.552 ' HB3' HG22 ' A' ' 29' ' ' VAL . 1.4 ttt85 -137.72 120.04 15.8 Favored 'General case' 0 C--N 1.325 -0.472 0 O-C-N 124.493 1.121 . . . . 0.0 110.263 -179.961 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 58.4 t30 56.3 23.33 7.11 Favored 'General case' 0 C--N 1.325 -0.48 0 O-C-N 124.521 1.138 . . . . 0.0 109.288 179.972 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . 0.615 ' O ' HD23 ' A' ' 27' ' ' LEU . . . 81.99 28.85 40.08 Favored Glycine 0 CA--C 1.53 0.992 0 O-C-N 124.513 1.133 . . . . 0.0 111.014 -179.988 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . 0.615 HD23 ' O ' ' A' ' 26' ' ' GLY . 22.9 mt -147.27 130.2 7.96 Favored Pre-proline 0 C--N 1.325 -0.461 0 O-C-N 124.513 0.772 . . . . 0.0 109.284 179.957 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 20.2 Cg_endo -75.0 84.28 1.69 Allowed 'Trans proline' 0 N--CA 1.453 -0.881 0 O-C-N 124.488 1.783 . . . . 0.0 110.995 -168.332 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.552 HG22 ' HB3' ' A' ' 24' ' ' ARG . 30.4 m . . . . . 0 C--N 1.326 -0.447 0 O-C-N 124.482 1.114 . . . . 0.0 109.308 179.962 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 16.7 m . . . . . 0 N--CA 1.453 -0.303 0 N-CA-C 108.314 -0.995 . . . . 0.0 108.314 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 92.96 -20.03 48.24 Favored Glycine 0 CA--C 1.53 1.021 0 O-C-N 124.49 1.119 . . . . 0.0 111.001 179.97 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 15.6 tt0 -83.86 162.07 20.67 Favored 'General case' 0 C--N 1.325 -0.475 0 O-C-N 124.487 0.757 . . . . 0.0 110.353 179.976 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.544 HG22 HG13 ' A' ' 21' ' ' VAL . 53.3 p -123.13 132.84 54.24 Favored 'General case' 0 C--N 1.325 -0.478 0 O-C-N 124.455 1.097 . . . . 0.0 110.371 -179.98 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . 0.404 ' SG ' ' O ' ' A' ' 5' ' ' CYS . 16.4 p -100.34 55.22 0.9 Allowed 'General case' 0 C--N 1.326 -0.447 0 O-C-N 124.508 1.13 . . . . 0.0 108.337 179.94 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 9.6 t -59.33 -25.35 30.52 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 O-C-N 124.45 1.094 . . . . 0.0 109.245 -179.944 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -83.79 -30.68 28.68 Favored Glycine 0 CA--C 1.529 0.964 0 O-C-N 124.52 1.138 . . . . 0.0 111.006 179.991 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 122.3 14.23 4.55 Favored Glycine 0 CA--C 1.53 1.013 0 O-C-N 125.006 1.062 . . . . 0.0 110.988 178.694 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 42.5 m -149.95 164.15 36.2 Favored 'General case' 0 C--N 1.325 -0.484 0 O-C-N 124.54 0.788 . . . . 0.0 110.362 -180.0 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . 0.401 ' SG ' ' O ' ' A' ' 16' ' ' THR . 97.2 m -120.45 140.98 50.59 Favored 'General case' 0 C--N 1.326 -0.447 0 O-C-N 124.467 1.104 . . . . 0.0 108.292 179.991 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 37.6 t30 -89.74 -45.02 9.59 Favored 'General case' 0 C--N 1.325 -0.463 0 O-C-N 124.493 1.121 . . . . 0.0 109.298 179.977 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.634 HG23 ' HD2' ' A' ' 13' ' ' PRO . 18.3 m -56.02 143.05 63.9 Favored Pre-proline 0 C--N 1.326 -0.453 0 O-C-N 124.462 1.101 . . . . 0.0 110.417 179.973 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.634 ' HD2' HG23 ' A' ' 12' ' ' THR . 20.2 Cg_endo -74.97 130.3 13.18 Favored 'Trans proline' 0 N--CA 1.452 -0.917 0 O-C-N 124.508 1.793 . . . . 0.0 110.987 -168.329 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 75.12 15.29 81.19 Favored Glycine 0 CA--C 1.53 0.995 0 O-C-N 124.442 1.089 . . . . 0.0 111.035 -179.999 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.5 ' SG ' ' CG2' ' A' ' 12' ' ' THR . 57.6 m -96.62 129.88 43.92 Favored 'General case' 0 C--N 1.325 -0.489 0 N-CA-C 108.323 -0.991 . . . . 0.0 108.323 179.999 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . 0.401 ' O ' ' SG ' ' A' ' 10' ' ' CYS . 21.6 p -95.99 152.7 18.28 Favored 'General case' 0 C--N 1.325 -0.472 0 O-C-N 124.497 1.123 . . . . 0.0 110.366 -179.965 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 45.0 t -82.99 95.86 8.14 Favored 'General case' 0 C--N 1.325 -0.498 0 O-C-N 124.483 1.115 . . . . 0.0 108.285 179.973 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . 0.778 ' OG ' HG23 ' A' ' 23' ' ' THR . 34.6 p -105.88 66.39 0.72 Allowed 'General case' 0 C--N 1.326 -0.453 0 O-C-N 124.464 1.102 . . . . 0.0 110.023 174.144 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' TRP . . . . . 0.642 ' CG ' ' HA ' ' A' ' 20' ' ' PRO . 0.8 OUTLIER -35.79 146.7 0.19 Allowed Pre-proline 0 C--N 1.324 -0.51 0 O-C-N 124.552 1.158 . . . . 0.0 107.975 -174.399 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.642 ' HA ' ' CG ' ' A' ' 19' ' ' TRP . 18.2 Cg_endo -75.04 -14.83 22.94 Favored 'Cis proline' 0 C--N 1.36 1.159 0 C-N-CA 120.954 -2.519 . . . . 0.0 111.005 -8.67 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.614 HG12 ' H ' ' A' ' 22' ' ' CYS . 2.2 t -96.38 175.97 0.74 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.479 0 O-C-N 124.496 1.122 . . . . 0.0 109.31 -172.992 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.614 ' H ' HG12 ' A' ' 21' ' ' VAL . 33.4 m -102.47 170.13 8.24 Favored 'General case' 0 C--N 1.325 -0.481 0 O-C-N 124.465 1.103 . . . . 0.0 108.298 179.977 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . 0.778 HG23 ' OG ' ' A' ' 18' ' ' SER . 1.0 OUTLIER -141.7 168.4 19.85 Favored 'General case' 0 C--N 1.325 -0.469 0 O-C-N 124.483 1.115 . . . . 0.0 110.427 179.949 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.643 ' HB3' HG22 ' A' ' 29' ' ' VAL . 0.1 OUTLIER -137.0 115.33 11.77 Favored 'General case' 0 C--N 1.325 -0.478 0 O-C-N 124.514 1.133 . . . . 0.0 110.297 -179.984 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 86.9 m-20 57.2 21.84 6.98 Favored 'General case' 0 C--N 1.325 -0.47 0 O-C-N 124.48 1.113 . . . . 0.0 109.295 -179.986 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 87.15 25.52 33.73 Favored Glycine 0 CA--C 1.531 1.049 0 O-C-N 124.464 1.102 . . . . 0.0 110.966 179.975 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 12.8 mt -145.03 130.29 9.3 Favored Pre-proline 0 C--N 1.325 -0.485 0 O-C-N 124.535 0.785 . . . . 0.0 109.289 -179.961 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 20.1 Cg_endo -74.97 79.99 2.53 Favored 'Trans proline' 0 N--CA 1.452 -0.927 0 O-C-N 124.515 1.797 . . . . 0.0 111.008 -168.285 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.643 HG22 ' HB3' ' A' ' 24' ' ' ARG . 18.0 m . . . . . 0 C--N 1.325 -0.482 0 O-C-N 124.51 1.131 . . . . 0.0 109.307 -179.99 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 83.6 m . . . . . 0 N--CA 1.454 -0.266 0 N-CA-C 108.297 -1.001 . . . . 0.0 108.297 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 103.53 -21.09 40.1 Favored Glycine 0 CA--C 1.53 1.01 0 O-C-N 124.515 1.135 . . . . 0.0 110.989 179.981 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 28.5 tt0 -84.4 150.45 25.33 Favored 'General case' 0 C--N 1.324 -0.5 0 O-C-N 124.456 0.739 . . . . 0.0 110.333 179.977 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.427 HG22 HG13 ' A' ' 21' ' ' VAL . 66.0 p -109.74 129.91 55.57 Favored 'General case' 0 C--N 1.325 -0.499 0 O-C-N 124.508 1.13 . . . . 0.0 110.429 -179.983 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . 0.42 ' SG ' ' O ' ' A' ' 5' ' ' CYS . 14.2 p -97.16 51.06 1.09 Allowed 'General case' 0 C--N 1.325 -0.474 0 O-C-N 124.523 1.14 . . . . 0.0 108.292 -179.988 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 9.4 t -59.03 -24.74 27.78 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 O-C-N 124.481 1.113 . . . . 0.0 109.317 179.966 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -83.96 -32.6 23.3 Favored Glycine 0 CA--C 1.53 1.028 0 O-C-N 124.512 1.132 . . . . 0.0 110.989 179.999 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 124.73 14.21 3.54 Favored Glycine 0 C--N 1.344 1.004 0 O-C-N 125.103 1.12 . . . . 0.0 111.013 177.972 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -149.6 166.73 28.39 Favored 'General case' 0 C--N 1.325 -0.476 0 O-C-N 124.501 0.765 . . . . 0.0 110.384 179.95 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . 0.406 ' SG ' ' O ' ' A' ' 16' ' ' THR . 75.9 m -123.78 141.96 51.54 Favored 'General case' 0 C--N 1.326 -0.449 0 O-C-N 124.466 1.104 . . . . 0.0 108.279 -179.981 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 34.0 t-20 -89.87 -43.07 10.86 Favored 'General case' 0 C--N 1.325 -0.457 0 O-C-N 124.492 1.12 . . . . 0.0 109.29 -179.998 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.617 HG23 ' HD2' ' A' ' 13' ' ' PRO . 20.2 m -58.35 142.8 81.17 Favored Pre-proline 0 C--N 1.325 -0.485 0 O-C-N 124.427 1.079 . . . . 0.0 110.355 -179.981 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.617 ' HD2' HG23 ' A' ' 12' ' ' THR . 20.2 Cg_endo -74.99 131.59 14.48 Favored 'Trans proline' 0 N--CA 1.453 -0.868 0 O-C-N 124.501 1.79 . . . . 0.0 110.997 -168.322 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 74.1 13.73 80.91 Favored Glycine 0 CA--C 1.53 1.025 0 O-C-N 124.482 1.114 . . . . 0.0 110.985 179.975 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.496 ' SG ' ' CG2' ' A' ' 12' ' ' THR . 66.8 m -97.29 125.93 42.19 Favored 'General case' 0 C--N 1.325 -0.469 0 N-CA-C 108.313 -0.995 . . . . 0.0 108.313 179.97 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . 0.406 ' O ' ' SG ' ' A' ' 10' ' ' CYS . 68.9 p -93.48 156.07 16.97 Favored 'General case' 0 C--N 1.325 -0.483 0 O-C-N 124.481 1.113 . . . . 0.0 110.383 -179.969 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 43.1 t -82.26 91.53 6.78 Favored 'General case' 0 C--N 1.325 -0.486 0 O-C-N 124.535 1.147 . . . . 0.0 108.301 -179.985 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . 0.598 ' HB2' HG23 ' A' ' 23' ' ' THR . 3.8 m -98.87 65.81 1.54 Allowed 'General case' 0 C--N 1.325 -0.488 0 O-C-N 124.477 1.111 . . . . 0.0 110.008 174.052 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' TRP . . . . . 0.608 ' CG ' ' HA ' ' A' ' 20' ' ' PRO . 0.1 OUTLIER -35.63 147.12 0.17 Allowed Pre-proline 0 C--N 1.325 -0.5 0 O-C-N 124.556 1.16 . . . . 0.0 107.971 -173.996 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.608 ' HA ' ' CG ' ' A' ' 19' ' ' TRP . 18.4 Cg_endo -74.91 -13.48 23.37 Favored 'Cis proline' 0 C--N 1.36 1.16 0 C-N-CA 121.01 -2.496 . . . . 0.0 111.037 -8.647 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.635 HG12 ' H ' ' A' ' 22' ' ' CYS . 2.2 t -99.11 177.91 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 O-C-N 124.472 1.108 . . . . 0.0 109.288 -173.032 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.635 ' H ' HG12 ' A' ' 21' ' ' VAL . 69.3 m -101.98 169.1 8.98 Favored 'General case' 0 C--N 1.325 -0.485 0 O-C-N 124.501 1.126 . . . . 0.0 108.288 -179.957 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . 0.598 HG23 ' HB2' ' A' ' 18' ' ' SER . 1.1 p -144.26 160.54 40.82 Favored 'General case' 0 C--N 1.325 -0.484 0 O-C-N 124.458 1.099 . . . . 0.0 110.398 179.982 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.607 ' HB3' HG22 ' A' ' 29' ' ' VAL . 1.1 ttt85 -132.23 118.33 19.37 Favored 'General case' 0 C--N 1.325 -0.471 0 O-C-N 124.537 1.148 . . . . 0.0 110.292 -179.985 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 76.2 m-20 57.47 24.55 10.37 Favored 'General case' 0 C--N 1.324 -0.514 0 O-C-N 124.535 1.147 . . . . 0.0 109.289 -179.973 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 82.59 23.36 56.43 Favored Glycine 0 CA--C 1.53 1.024 0 O-C-N 124.586 1.179 . . . . 0.0 111.002 179.982 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 8.0 mt -143.26 129.91 10.52 Favored Pre-proline 0 C--N 1.325 -0.499 0 O-C-N 124.548 0.793 . . . . 0.0 109.337 179.978 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 20.1 Cg_endo -74.99 81.95 2.1 Favored 'Trans proline' 0 N--CA 1.453 -0.87 0 O-C-N 124.511 1.795 . . . . 0.0 110.997 -168.279 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.607 HG22 ' HB3' ' A' ' 24' ' ' ARG . 21.9 m . . . . . 0 C--N 1.325 -0.477 0 O-C-N 124.517 1.136 . . . . 0.0 109.312 179.991 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 83.5 m . . . . . 0 N--CA 1.453 -0.301 0 N-CA-C 108.28 -1.007 . . . . 0.0 108.28 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 91.62 -17.58 55.75 Favored Glycine 0 CA--C 1.53 1.006 0 O-C-N 124.431 1.082 . . . . 0.0 110.994 -179.961 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 15.5 tt0 -85.59 161.72 19.17 Favored 'General case' 0 C--N 1.325 -0.471 0 O-C-N 124.47 0.747 . . . . 0.0 110.314 179.976 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.692 HG22 HG23 ' A' ' 21' ' ' VAL . 47.5 p -120.54 132.0 54.96 Favored 'General case' 0 C--N 1.325 -0.498 0 O-C-N 124.52 1.138 . . . . 0.0 110.456 179.978 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . 0.417 ' SG ' ' O ' ' A' ' 5' ' ' CYS . 14.5 p -98.97 51.64 0.96 Allowed 'General case' 0 C--N 1.325 -0.475 0 O-C-N 124.475 1.109 . . . . 0.0 108.286 -179.977 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 9.0 t -59.22 -24.99 29.07 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 O-C-N 124.497 1.123 . . . . 0.0 109.288 -179.988 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -84.32 -32.25 23.18 Favored Glycine 0 CA--C 1.53 0.979 0 O-C-N 124.507 1.129 . . . . 0.0 111.062 179.961 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 124.37 13.98 3.75 Favored Glycine 0 CA--C 1.529 0.969 0 O-C-N 125.024 1.073 . . . . 0.0 111.036 178.176 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 45.8 m -149.93 164.76 34.58 Favored 'General case' 0 C--N 1.325 -0.47 0 O-C-N 124.514 0.773 . . . . 0.0 110.427 179.995 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . 0.405 ' SG ' ' O ' ' A' ' 16' ' ' THR . 94.2 m -121.67 143.16 49.5 Favored 'General case' 0 C--N 1.325 -0.491 0 O-C-N 124.469 1.106 . . . . 0.0 108.254 -179.955 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 76.1 m-20 -90.26 -47.84 7.53 Favored 'General case' 0 C--N 1.325 -0.458 0 O-C-N 124.439 1.087 . . . . 0.0 109.273 -179.982 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.62 HG23 ' HD2' ' A' ' 13' ' ' PRO . 19.5 m -53.16 142.7 36.3 Favored Pre-proline 0 C--N 1.325 -0.474 0 O-C-N 124.495 1.122 . . . . 0.0 110.397 180.0 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.62 ' HD2' HG23 ' A' ' 12' ' ' THR . 20.4 Cg_endo -74.94 131.63 14.59 Favored 'Trans proline' 0 N--CA 1.453 -0.856 0 O-C-N 124.495 1.787 . . . . 0.0 110.975 -168.328 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 73.97 15.81 79.64 Favored Glycine 0 CA--C 1.53 0.977 0 O-C-N 124.524 1.14 . . . . 0.0 110.984 179.953 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.503 ' SG ' ' CG2' ' A' ' 12' ' ' THR . 63.8 m -97.64 131.5 44.15 Favored 'General case' 0 C--N 1.325 -0.47 0 N-CA-C 108.265 -1.013 . . . . 0.0 108.265 -179.991 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . 0.405 ' O ' ' SG ' ' A' ' 10' ' ' CYS . 73.1 p -98.37 154.68 17.67 Favored 'General case' 0 C--N 1.325 -0.494 0 O-C-N 124.533 1.145 . . . . 0.0 110.405 -180.0 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 44.4 t -82.19 94.69 7.33 Favored 'General case' 0 C--N 1.325 -0.478 0 O-C-N 124.461 1.101 . . . . 0.0 108.261 -179.976 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . 0.517 ' O ' ' C ' ' A' ' 19' ' ' TRP . 40.8 t -102.23 66.02 0.98 Allowed 'General case' 0 C--N 1.325 -0.494 0 O-C-N 124.506 1.129 . . . . 0.0 109.964 174.045 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' TRP . . . . . 0.619 ' CG ' ' HA ' ' A' ' 20' ' ' PRO . 0.1 OUTLIER -35.92 147.13 0.18 Allowed Pre-proline 0 C--N 1.325 -0.464 0 O-C-N 124.48 1.112 . . . . 0.0 108.02 -174.211 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.619 ' HA ' ' CG ' ' A' ' 19' ' ' TRP . 18.3 Cg_endo -75.03 -13.9 23.44 Favored 'Cis proline' 0 C--N 1.36 1.148 0 C-N-CA 120.991 -2.504 . . . . 0.0 110.972 -8.69 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.692 HG23 HG22 ' A' ' 4' ' ' THR . 0.8 OUTLIER -97.63 177.0 0.69 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 O-C-N 124.512 1.132 . . . . 0.0 109.301 -172.977 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.467 ' H ' HG22 ' A' ' 21' ' ' VAL . 52.7 m -102.0 171.19 7.65 Favored 'General case' 0 C--N 1.325 -0.493 0 O-C-N 124.508 1.13 . . . . 0.0 108.292 -179.995 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . 0.425 ' O ' ' HA ' ' A' ' 15' ' ' CYS . 0.9 OUTLIER -148.83 168.09 23.92 Favored 'General case' 0 C--N 1.325 -0.486 0 O-C-N 124.543 1.152 . . . . 0.0 110.342 179.993 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.495 ' HB3' HG22 ' A' ' 29' ' ' VAL . 8.6 ttt180 -140.57 118.67 11.94 Favored 'General case' 0 C--N 1.326 -0.451 0 O-C-N 124.459 1.099 . . . . 0.0 110.335 179.982 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 14.6 t-20 58.2 22.75 9.51 Favored 'General case' 0 C--N 1.325 -0.465 0 O-C-N 124.494 1.121 . . . . 0.0 109.319 -179.967 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 82.72 22.67 57.69 Favored Glycine 0 CA--C 1.53 0.982 0 O-C-N 124.435 1.085 . . . . 0.0 111.012 -179.997 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 6.2 mt -141.68 130.56 12.28 Favored Pre-proline 0 C--N 1.325 -0.467 0 O-C-N 124.478 0.752 . . . . 0.0 109.286 -179.985 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 20.1 Cg_endo -74.98 83.82 1.75 Allowed 'Trans proline' 0 N--CA 1.453 -0.904 0 O-C-N 124.468 1.773 . . . . 0.0 110.975 -168.258 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.495 HG22 ' HB3' ' A' ' 24' ' ' ARG . 35.5 m . . . . . 0 C--N 1.325 -0.477 0 O-C-N 124.507 1.13 . . . . 0.0 109.29 179.982 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 99.6 m . . . . . 0 N--CA 1.453 -0.286 0 N-CA-C 108.316 -0.994 . . . . 0.0 108.316 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 91.78 -26.92 10.83 Favored Glycine 0 CA--C 1.53 1.015 0 O-C-N 124.477 1.11 . . . . 0.0 111.005 179.98 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 25.3 tt0 -81.46 152.73 27.22 Favored 'General case' 0 C--N 1.326 -0.453 0 O-C-N 124.49 0.759 . . . . 0.0 110.258 -179.959 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.659 HG22 HG23 ' A' ' 21' ' ' VAL . 76.2 p -113.26 134.88 54.38 Favored 'General case' 0 C--N 1.325 -0.495 0 O-C-N 124.519 1.137 . . . . 0.0 110.394 179.962 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . 0.41 ' SG ' ' O ' ' A' ' 5' ' ' CYS . 15.0 p -98.79 52.65 0.99 Allowed 'General case' 0 C--N 1.326 -0.454 0 O-C-N 124.495 1.122 . . . . 0.0 108.332 179.965 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 8.6 t -59.32 -24.73 28.68 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 O-C-N 124.492 1.12 . . . . 0.0 109.301 -179.97 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -84.13 -34.06 18.79 Favored Glycine 0 CA--C 1.529 0.968 0 O-C-N 124.505 1.128 . . . . 0.0 110.975 -179.984 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 126.54 14.63 2.85 Favored Glycine 0 C--N 1.345 1.047 0 O-C-N 125.13 1.135 . . . . 0.0 110.998 177.776 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -150.0 166.94 28.15 Favored 'General case' 0 C--N 1.325 -0.488 0 O-C-N 124.53 0.782 . . . . 0.0 110.413 179.981 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . 0.408 ' SG ' ' O ' ' A' ' 16' ' ' THR . 72.8 m -124.22 141.78 51.78 Favored 'General case' 0 C--N 1.324 -0.52 0 O-C-N 124.54 1.15 . . . . 0.0 108.343 179.946 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 32.4 t-20 -89.65 -43.29 10.84 Favored 'General case' 0 C--N 1.325 -0.474 0 O-C-N 124.527 1.142 . . . . 0.0 109.335 -180.0 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.614 HG23 ' HD2' ' A' ' 13' ' ' PRO . 20.0 m -57.67 142.71 77.41 Favored Pre-proline 0 C--N 1.326 -0.448 0 O-C-N 124.505 1.128 . . . . 0.0 110.399 179.989 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.614 ' HD2' HG23 ' A' ' 12' ' ' THR . 20.1 Cg_endo -75.01 132.33 15.28 Favored 'Trans proline' 0 N--CA 1.453 -0.895 0 O-C-N 124.506 1.793 . . . . 0.0 110.99 -168.306 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 73.62 13.28 80.37 Favored Glycine 0 CA--C 1.529 0.969 0 O-C-N 124.476 1.11 . . . . 0.0 111.016 -179.98 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.511 ' SG ' HG22 ' A' ' 12' ' ' THR . 68.7 m -97.49 125.65 42.3 Favored 'General case' 0 C--N 1.325 -0.479 0 N-CA-C 108.29 -1.004 . . . . 0.0 108.29 -179.983 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . 0.468 ' HG1' ' HG1' ' A' ' 23' ' ' THR . 70.7 p -93.61 156.82 16.5 Favored 'General case' 0 C--N 1.325 -0.491 0 O-C-N 124.558 1.161 . . . . 0.0 110.437 179.977 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 42.7 t -82.86 94.98 7.8 Favored 'General case' 0 C--N 1.325 -0.482 0 O-C-N 124.447 1.092 . . . . 0.0 108.315 -179.993 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . 0.528 ' CB ' HG23 ' A' ' 23' ' ' THR . 1.0 OUTLIER -102.48 66.39 0.97 Allowed 'General case' 0 C--N 1.325 -0.486 0 O-C-N 124.494 1.121 . . . . 0.0 109.968 173.987 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' TRP . . . . . 0.614 ' CG ' ' HA ' ' A' ' 20' ' ' PRO . 0.1 OUTLIER -35.51 147.15 0.17 Allowed Pre-proline 0 C--N 1.326 -0.453 0 O-C-N 124.497 1.123 . . . . 0.0 108.0 -174.085 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.614 ' HA ' ' CG ' ' A' ' 19' ' ' TRP . 18.3 Cg_endo -75.0 -13.85 23.39 Favored 'Cis proline' 0 C--N 1.36 1.135 0 C-N-CA 120.967 -2.514 . . . . 0.0 111.013 -8.645 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.659 HG23 HG22 ' A' ' 4' ' ' THR . 2.8 p -99.13 178.08 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 O-C-N 124.512 1.132 . . . . 0.0 109.34 -172.964 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.603 ' H ' HG22 ' A' ' 21' ' ' VAL . 66.7 m -102.29 172.75 6.71 Favored 'General case' 0 C--N 1.325 -0.471 0 O-C-N 124.486 1.116 . . . . 0.0 108.301 179.993 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . 0.528 HG23 ' CB ' ' A' ' 18' ' ' SER . 8.4 p -146.59 159.31 43.61 Favored 'General case' 0 C--N 1.325 -0.467 0 O-C-N 124.486 1.117 . . . . 0.0 110.391 -179.985 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.56 ' HB3' HG22 ' A' ' 29' ' ' VAL . 0.5 OUTLIER -131.81 117.68 18.87 Favored 'General case' 0 C--N 1.325 -0.483 0 O-C-N 124.498 1.124 . . . . 0.0 110.291 179.965 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 78.8 m-20 57.52 23.4 9.14 Favored 'General case' 0 C--N 1.325 -0.469 0 O-C-N 124.491 1.119 . . . . 0.0 109.298 -179.987 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 84.04 23.01 53.71 Favored Glycine 0 CA--C 1.53 0.99 0 O-C-N 124.428 1.08 . . . . 0.0 110.983 179.988 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 8.1 mt -143.06 129.99 10.71 Favored Pre-proline 0 C--N 1.325 -0.481 0 O-C-N 124.476 0.751 . . . . 0.0 109.29 179.972 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 20.2 Cg_endo -74.99 85.66 1.5 Allowed 'Trans proline' 0 N--CA 1.453 -0.88 0 O-C-N 124.508 1.794 . . . . 0.0 110.965 -168.287 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.56 HG22 ' HB3' ' A' ' 24' ' ' ARG . 33.5 m . . . . . 0 C--N 1.325 -0.472 0 O-C-N 124.542 1.151 . . . . 0.0 109.324 179.968 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . 0.406 ' SG ' ' O ' ' A' ' 23' ' ' THR . 20.0 m . . . . . 0 N--CA 1.452 -0.333 0 N-CA-C 108.302 -0.999 . . . . 0.0 108.302 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 108.48 -11.0 36.03 Favored Glycine 0 CA--C 1.53 0.985 0 O-C-N 124.524 1.14 . . . . 0.0 111.011 179.982 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 15.4 mt-10 -99.99 164.4 12.01 Favored 'General case' 0 C--N 1.326 -0.449 0 O-C-N 124.465 0.744 . . . . 0.0 110.282 -179.975 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 76.5 p -122.22 134.81 54.7 Favored 'General case' 0 C--N 1.325 -0.499 0 O-C-N 124.455 1.097 . . . . 0.0 110.44 179.99 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . 0.441 ' SG ' ' O ' ' A' ' 5' ' ' CYS . 11.8 p -101.7 48.23 0.89 Allowed 'General case' 0 C--N 1.325 -0.475 0 O-C-N 124.493 1.121 . . . . 0.0 108.295 -179.965 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 27.0 t -59.06 -23.61 24.82 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 O-C-N 124.511 1.132 . . . . 0.0 109.266 -179.992 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -87.82 -29.14 21.78 Favored Glycine 0 CA--C 1.53 1.027 0 O-C-N 124.51 1.132 . . . . 0.0 111.002 179.986 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 121.7 16.1 4.24 Favored Glycine 0 CA--C 1.531 1.036 0 O-C-N 124.964 1.038 . . . . 0.0 111.015 178.398 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 89.8 m -150.18 166.29 30.3 Favored 'General case' 0 C--N 1.325 -0.493 0 O-C-N 124.513 0.772 . . . . 0.0 110.415 179.942 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . 0.407 ' SG ' ' O ' ' A' ' 16' ' ' THR . 87.9 m -124.38 143.95 50.31 Favored 'General case' 0 C--N 1.325 -0.476 0 O-C-N 124.526 1.141 . . . . 0.0 108.306 179.979 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 18.9 t30 -89.78 -50.44 6.05 Favored 'General case' 0 C--N 1.325 -0.486 0 O-C-N 124.489 1.118 . . . . 0.0 109.353 179.978 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.632 HG23 ' HD2' ' A' ' 13' ' ' PRO . 18.5 m -52.32 142.77 28.4 Favored Pre-proline 0 C--N 1.325 -0.479 0 O-C-N 124.464 1.102 . . . . 0.0 110.406 -179.999 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.632 ' HD2' HG23 ' A' ' 12' ' ' THR . 20.1 Cg_endo -74.95 129.52 12.47 Favored 'Trans proline' 0 N--CA 1.453 -0.892 0 O-C-N 124.504 1.792 . . . . 0.0 110.991 -168.284 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . 0.416 ' HA3' ' NH1' ' A' ' 24' ' ' ARG . . . 76.01 15.15 81.58 Favored Glycine 0 CA--C 1.53 0.997 0 O-C-N 124.497 1.123 . . . . 0.0 110.999 179.988 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.505 ' SG ' ' CG2' ' A' ' 12' ' ' THR . 55.9 m -95.78 126.33 40.97 Favored 'General case' 0 C--N 1.325 -0.481 0 N-CA-C 108.282 -1.007 . . . . 0.0 108.282 -179.952 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . 0.414 ' HG1' ' HG1' ' A' ' 23' ' ' THR . 12.3 p -92.45 154.36 18.54 Favored 'General case' 0 C--N 1.325 -0.497 0 O-C-N 124.51 1.131 . . . . 0.0 110.408 -179.998 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 21.9 t -83.59 94.81 8.16 Favored 'General case' 0 C--N 1.324 -0.508 0 O-C-N 124.497 1.123 . . . . 0.0 108.3 -179.996 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . 0.566 ' CB ' HG23 ' A' ' 23' ' ' THR . 1.1 t -102.68 68.06 1.02 Allowed 'General case' 0 C--N 1.325 -0.474 0 O-C-N 124.501 1.126 . . . . 0.0 110.011 174.02 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' TRP . . . . . 0.602 ' CG ' ' HA ' ' A' ' 20' ' ' PRO . 0.0 OUTLIER -36.03 147.02 0.19 Allowed Pre-proline 0 C--N 1.325 -0.5 0 O-C-N 124.501 1.125 . . . . 0.0 107.972 -174.213 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.602 ' HA ' ' CG ' ' A' ' 19' ' ' TRP . 18.2 Cg_endo -75.04 -14.34 23.23 Favored 'Cis proline' 0 C--N 1.361 1.194 0 C-N-CA 120.988 -2.505 . . . . 0.0 110.998 -8.67 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.644 HG22 ' H ' ' A' ' 22' ' ' CYS . 3.8 p -97.61 178.46 0.61 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 O-C-N 124.508 1.13 . . . . 0.0 109.277 -172.984 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.644 ' H ' HG22 ' A' ' 21' ' ' VAL . 35.3 m -102.14 172.76 6.71 Favored 'General case' 0 C--N 1.326 -0.439 0 O-C-N 124.497 1.123 . . . . 0.0 108.279 -179.97 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . 0.566 HG23 ' CB ' ' A' ' 18' ' ' SER . 5.9 p -145.53 160.57 41.42 Favored 'General case' 0 C--N 1.325 -0.497 0 O-C-N 124.51 1.131 . . . . 0.0 110.446 179.965 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.536 ' HB3' HG22 ' A' ' 29' ' ' VAL . 15.1 tpt180 -127.92 114.69 17.5 Favored 'General case' 0 C--N 1.325 -0.485 0 O-C-N 124.515 1.134 . . . . 0.0 110.304 -179.984 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 66.1 t30 57.07 25.55 10.94 Favored 'General case' 0 C--N 1.325 -0.49 0 O-C-N 124.496 1.123 . . . . 0.0 109.281 -179.997 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 82.74 22.18 58.46 Favored Glycine 0 CA--C 1.53 1.019 0 O-C-N 124.487 1.117 . . . . 0.0 110.999 -179.999 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 52.3 mt -140.35 132.23 14.37 Favored Pre-proline 0 C--N 1.325 -0.475 0 O-C-N 124.512 0.772 . . . . 0.0 109.261 179.996 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 20.2 Cg_endo -75.0 86.29 1.44 Allowed 'Trans proline' 0 N--CA 1.453 -0.89 0 O-C-N 124.465 1.771 . . . . 0.0 110.967 -168.321 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.536 HG22 ' HB3' ' A' ' 24' ' ' ARG . 19.0 m . . . . . 0 C--N 1.325 -0.477 0 O-C-N 124.467 1.104 . . . . 0.0 109.311 179.983 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 79.0 m . . . . . 0 N--CA 1.453 -0.306 0 N-CA-C 108.295 -1.002 . . . . 0.0 108.295 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 82.82 -9.74 58.93 Favored Glycine 0 CA--C 1.53 0.994 0 O-C-N 124.501 1.126 . . . . 0.0 111.057 -179.966 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 11.4 pt-20 -100.24 167.85 10.17 Favored 'General case' 0 C--N 1.326 -0.446 0 O-C-N 124.495 0.762 . . . . 0.0 110.272 -179.99 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.678 HG22 HG13 ' A' ' 21' ' ' VAL . 50.9 p -127.07 143.94 51.15 Favored 'General case' 0 C--N 1.325 -0.481 0 O-C-N 124.52 1.138 . . . . 0.0 110.392 179.998 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . 0.419 ' HB2' ' N ' ' A' ' 9' ' ' THR . 20.5 p -104.26 56.98 0.71 Allowed 'General case' 0 C--N 1.324 -0.5 0 O-C-N 124.494 1.121 . . . . 0.0 108.324 179.976 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 4.9 t -59.48 -24.74 29.18 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 O-C-N 124.493 1.121 . . . . 0.0 109.319 179.981 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -85.23 -33.94 15.95 Favored Glycine 0 CA--C 1.53 1.016 0 O-C-N 124.527 1.142 . . . . 0.0 110.952 -179.932 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 125.14 17.3 2.75 Favored Glycine 0 CA--C 1.53 1.023 0 O-C-N 124.889 0.994 . . . . 0.0 111.005 177.766 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . 0.419 ' N ' ' HB2' ' A' ' 5' ' ' CYS . 32.1 m -150.38 164.01 36.92 Favored 'General case' 0 C--N 1.325 -0.485 0 O-C-N 124.495 0.762 . . . . 0.0 110.397 179.978 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . 0.405 ' SG ' ' O ' ' A' ' 16' ' ' THR . 74.9 m -118.55 142.41 47.63 Favored 'General case' 0 C--N 1.325 -0.485 0 O-C-N 124.505 1.128 . . . . 0.0 108.312 -179.998 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 3.9 m120 -90.87 -40.9 11.49 Favored 'General case' 0 C--N 1.325 -0.469 0 O-C-N 124.485 1.115 . . . . 0.0 109.275 -179.998 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.64 HG23 ' HD2' ' A' ' 13' ' ' PRO . 17.5 m -63.76 142.82 98.09 Favored Pre-proline 0 C--N 1.325 -0.484 0 O-C-N 124.483 1.115 . . . . 0.0 110.426 -179.993 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.64 ' HD2' HG23 ' A' ' 12' ' ' THR . 20.1 Cg_endo -74.97 130.73 13.58 Favored 'Trans proline' 0 N--CA 1.453 -0.876 0 O-C-N 124.481 1.779 . . . . 0.0 110.969 -168.246 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 77.16 10.37 86.29 Favored Glycine 0 CA--C 1.53 1.022 0 O-C-N 124.511 1.132 . . . . 0.0 111.001 179.985 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.5 ' SG ' ' CG2' ' A' ' 12' ' ' THR . 68.1 m -93.78 126.75 39.15 Favored 'General case' 0 C--N 1.325 -0.464 0 N-CA-C 108.268 -1.012 . . . . 0.0 108.268 -179.973 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . 0.405 ' O ' ' SG ' ' A' ' 10' ' ' CYS . 11.2 p -93.8 152.41 18.93 Favored 'General case' 0 C--N 1.324 -0.511 0 O-C-N 124.456 1.098 . . . . 0.0 110.393 -179.981 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 43.4 t -80.0 98.14 7.07 Favored 'General case' 0 C--N 1.325 -0.473 0 O-C-N 124.475 1.109 . . . . 0.0 108.331 179.983 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . 0.519 ' O ' ' C ' ' A' ' 19' ' ' TRP . 30.0 t -105.72 64.92 0.7 Allowed 'General case' 0 C--N 1.325 -0.472 0 O-C-N 124.502 1.126 . . . . 0.0 109.986 174.242 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' TRP . . . . . 0.643 ' CG ' ' HA ' ' A' ' 20' ' ' PRO . 0.4 OUTLIER -35.42 147.0 0.17 Allowed Pre-proline 0 C--N 1.325 -0.472 0 O-C-N 124.537 1.148 . . . . 0.0 108.024 -174.284 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.643 ' HA ' ' CG ' ' A' ' 19' ' ' TRP . 18.3 Cg_endo -74.98 -13.97 23.3 Favored 'Cis proline' 0 C--N 1.36 1.148 0 C-N-CA 121.013 -2.495 . . . . 0.0 111.006 -8.605 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.678 HG13 HG22 ' A' ' 4' ' ' THR . 3.8 t -97.94 175.31 0.82 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 O-C-N 124.478 1.111 . . . . 0.0 109.239 -173.022 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.638 ' H ' HG12 ' A' ' 21' ' ' VAL . 3.5 m -102.36 170.0 8.34 Favored 'General case' 0 C--N 1.325 -0.483 0 O-C-N 124.463 1.102 . . . . 0.0 108.338 179.995 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . 0.462 HG23 ' HB3' ' A' ' 18' ' ' SER . 1.9 p -147.27 163.41 36.49 Favored 'General case' 0 C--N 1.325 -0.495 0 O-C-N 124.49 1.119 . . . . 0.0 110.385 179.996 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.566 ' HB3' HG22 ' A' ' 29' ' ' VAL . 0.3 OUTLIER -139.77 118.91 12.7 Favored 'General case' 0 C--N 1.324 -0.509 0 O-C-N 124.573 1.17 . . . . 0.0 110.33 179.937 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 18.0 t-20 57.91 22.36 8.64 Favored 'General case' 0 C--N 1.325 -0.48 0 O-C-N 124.528 1.142 . . . . 0.0 109.277 -179.988 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . 0.473 ' O ' HD23 ' A' ' 27' ' ' LEU . . . 84.55 23.21 51.49 Favored Glycine 0 CA--C 1.531 1.042 0 O-C-N 124.504 1.128 . . . . 0.0 110.959 179.952 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . 0.473 HD23 ' O ' ' A' ' 26' ' ' GLY . 12.1 mt -145.96 128.04 7.79 Favored Pre-proline 0 C--N 1.325 -0.491 0 O-C-N 124.515 0.773 . . . . 0.0 109.311 -179.976 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 20.3 Cg_endo -74.92 78.25 2.91 Favored 'Trans proline' 0 N--CA 1.453 -0.889 0 O-C-N 124.515 1.797 . . . . 0.0 110.966 -168.294 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.566 HG22 ' HB3' ' A' ' 24' ' ' ARG . 30.8 m . . . . . 0 C--N 1.324 -0.517 0 O-C-N 124.509 1.131 . . . . 0.0 109.289 179.985 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 99.7 m . . . . . 0 N--CA 1.453 -0.311 0 N-CA-C 108.319 -0.993 . . . . 0.0 108.319 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 84.61 -13.21 53.47 Favored Glycine 0 CA--C 1.53 1.004 0 O-C-N 124.475 1.109 . . . . 0.0 110.958 179.936 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . 0.402 ' HG3' ' SG ' ' A' ' 22' ' ' CYS . 23.1 pt-20 -100.42 171.72 7.57 Favored 'General case' 0 C--N 1.325 -0.495 0 O-C-N 124.504 0.767 . . . . 0.0 110.262 -179.983 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 1.053 HG22 HG23 ' A' ' 21' ' ' VAL . 38.4 p -129.72 143.16 50.68 Favored 'General case' 0 C--N 1.325 -0.482 0 O-C-N 124.506 1.128 . . . . 0.0 110.377 179.991 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . 0.584 ' O ' ' CD1' ' A' ' 19' ' ' TRP . 14.8 p -96.67 52.46 1.2 Allowed 'General case' 0 C--N 1.325 -0.469 0 O-C-N 124.474 1.109 . . . . 0.0 108.301 179.953 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 4.5 t -59.01 -24.9 28.13 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 O-C-N 124.428 1.08 . . . . 0.0 109.309 179.992 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -84.02 -35.09 16.28 Favored Glycine 0 CA--C 1.53 1.028 0 O-C-N 124.467 1.104 . . . . 0.0 111.021 179.996 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . 0.4 ' O ' ' SG ' ' A' ' 17' ' ' CYS . . . 133.34 -13.24 4.91 Favored Glycine 0 C--N 1.346 1.106 0 O-C-N 125.139 1.14 . . . . 0.0 110.979 178.327 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -131.1 162.93 28.78 Favored 'General case' 0 C--N 1.324 -0.502 0 O-C-N 124.517 0.775 . . . . 0.0 110.411 -179.96 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . 0.406 ' SG ' ' O ' ' A' ' 16' ' ' THR . 86.9 m -107.16 141.64 38.11 Favored 'General case' 0 C--N 1.325 -0.49 0 O-C-N 124.499 1.124 . . . . 0.0 108.268 -179.951 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 64.1 t-20 -89.59 -38.13 14.17 Favored 'General case' 0 C--N 1.325 -0.481 0 O-C-N 124.522 1.139 . . . . 0.0 109.329 179.961 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.657 HG23 ' HD2' ' A' ' 13' ' ' PRO . 16.5 m -67.44 143.11 96.97 Favored Pre-proline 0 C--N 1.326 -0.454 0 O-C-N 124.509 1.131 . . . . 0.0 110.429 -179.996 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.657 ' HD2' HG23 ' A' ' 12' ' ' THR . 20.2 Cg_endo -74.98 129.15 12.09 Favored 'Trans proline' 0 N--CA 1.453 -0.88 0 O-C-N 124.569 1.826 . . . . 0.0 110.99 -168.27 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 76.86 14.27 82.76 Favored Glycine 0 CA--C 1.529 0.951 0 O-C-N 124.517 1.135 . . . . 0.0 111.035 -179.964 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.494 ' SG ' ' CG2' ' A' ' 12' ' ' THR . 57.7 m -96.45 129.38 43.82 Favored 'General case' 0 C--N 1.325 -0.459 0 N-CA-C 108.315 -0.994 . . . . 0.0 108.315 179.976 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . 0.406 ' O ' ' SG ' ' A' ' 10' ' ' CYS . 23.4 p -93.57 148.71 21.84 Favored 'General case' 0 C--N 1.325 -0.474 0 O-C-N 124.492 1.12 . . . . 0.0 110.358 -179.977 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . 0.4 ' SG ' ' O ' ' A' ' 8' ' ' GLY . 11.9 t -81.23 95.06 6.82 Favored 'General case' 0 C--N 1.325 -0.462 0 O-C-N 124.5 1.125 . . . . 0.0 108.293 179.988 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . 0.718 ' OG ' HG23 ' A' ' 23' ' ' THR . 20.4 p -102.31 65.79 0.97 Allowed 'General case' 0 C--N 1.325 -0.497 0 O-C-N 124.493 1.121 . . . . 0.0 110.036 173.993 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' TRP . . . . . 0.59 ' CG ' ' HA ' ' A' ' 20' ' ' PRO . 0.0 OUTLIER -36.02 147.23 0.18 Allowed Pre-proline 0 C--N 1.325 -0.459 0 N-CA-C 107.998 -1.112 . . . . 0.0 107.998 -174.047 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.59 ' HA ' ' CG ' ' A' ' 19' ' ' TRP . 18.4 Cg_endo -74.95 -13.53 23.44 Favored 'Cis proline' 0 C--N 1.36 1.161 0 C-N-CA 120.995 -2.502 . . . . 0.0 111.01 -8.641 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 1.053 HG23 HG22 ' A' ' 4' ' ' THR . 2.3 p -96.35 173.99 0.9 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.478 0 O-C-N 124.53 1.144 . . . . 0.0 109.331 -173.224 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.524 ' H ' HG22 ' A' ' 21' ' ' VAL . 1.7 m -102.09 169.2 8.9 Favored 'General case' 0 C--N 1.325 -0.488 0 O-C-N 124.485 1.115 . . . . 0.0 108.324 -179.973 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . 0.718 HG23 ' OG ' ' A' ' 18' ' ' SER . 1.1 p -141.99 169.1 18.22 Favored 'General case' 0 C--N 1.325 -0.488 0 O-C-N 124.494 1.121 . . . . 0.0 110.413 -179.981 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.554 ' HB3' HG22 ' A' ' 29' ' ' VAL . 6.0 ttt180 -143.74 117.02 9.0 Favored 'General case' 0 C--N 1.325 -0.475 0 O-C-N 124.527 1.142 . . . . 0.0 110.279 -179.986 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 71.1 m-20 58.47 22.23 9.36 Favored 'General case' 0 C--N 1.325 -0.482 0 O-C-N 124.516 1.135 . . . . 0.0 109.31 179.992 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . 0.41 ' O ' HD23 ' A' ' 27' ' ' LEU . . . 86.48 20.64 53.99 Favored Glycine 0 CA--C 1.53 0.974 0 O-C-N 124.498 1.124 . . . . 0.0 111.009 -179.997 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . 0.41 HD23 ' O ' ' A' ' 26' ' ' GLY . 9.7 mt -144.7 128.81 8.92 Favored Pre-proline 0 C--N 1.325 -0.493 0 O-C-N 124.514 0.773 . . . . 0.0 109.29 -179.98 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 20.2 Cg_endo -74.97 84.68 1.62 Allowed 'Trans proline' 0 N--CA 1.453 -0.895 0 O-C-N 124.499 1.789 . . . . 0.0 111.014 -168.321 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.554 HG22 ' HB3' ' A' ' 24' ' ' ARG . 28.4 m . . . . . 0 C--N 1.324 -0.508 0 O-C-N 124.547 1.154 . . . . 0.0 109.295 -179.968 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 83.0 m . . . . . 0 N--CA 1.453 -0.296 0 N-CA-C 108.286 -1.005 . . . . 0.0 108.286 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 100.56 -25.33 28.71 Favored Glycine 0 CA--C 1.53 1.017 0 O-C-N 124.475 1.109 . . . . 0.0 110.99 -179.996 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 28.6 tt0 -78.51 150.47 32.9 Favored 'General case' 0 C--N 1.324 -0.511 0 O-C-N 124.519 0.776 . . . . 0.0 110.293 -179.969 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.608 HG22 HG12 ' A' ' 21' ' ' VAL . 75.2 p -110.21 130.94 55.45 Favored 'General case' 0 C--N 1.325 -0.476 0 O-C-N 124.453 1.095 . . . . 0.0 110.42 179.977 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . 0.416 ' SG ' ' O ' ' A' ' 5' ' ' CYS . 14.5 p -99.0 51.58 0.96 Allowed 'General case' 0 C--N 1.325 -0.46 0 O-C-N 124.452 1.095 . . . . 0.0 108.301 -179.975 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 9.6 t -59.22 -24.59 27.94 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 O-C-N 124.553 1.158 . . . . 0.0 109.334 -179.991 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -83.89 -33.42 21.31 Favored Glycine 0 CA--C 1.53 0.984 0 O-C-N 124.52 1.138 . . . . 0.0 110.972 -179.978 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 125.95 14.24 3.12 Favored Glycine 0 C--N 1.346 1.086 0 C-N-CA 119.776 -1.202 . . . . 0.0 110.982 177.846 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -150.07 166.25 30.31 Favored 'General case' 0 C--N 1.325 -0.494 0 O-C-N 124.456 0.739 . . . . 0.0 110.355 -179.997 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . 0.405 ' SG ' ' O ' ' A' ' 16' ' ' THR . 74.8 m -123.14 144.28 49.45 Favored 'General case' 0 C--N 1.326 -0.439 0 O-C-N 124.477 1.11 . . . . 0.0 108.288 -179.989 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 9.8 t-20 -91.18 -44.39 9.27 Favored 'General case' 0 C--N 1.325 -0.464 0 O-C-N 124.463 1.102 . . . . 0.0 109.313 -179.971 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.609 HG23 ' HD2' ' A' ' 13' ' ' PRO . 20.6 m -58.03 142.73 79.47 Favored Pre-proline 0 C--N 1.325 -0.48 0 O-C-N 124.487 1.117 . . . . 0.0 110.392 -179.984 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.609 ' HD2' HG23 ' A' ' 12' ' ' THR . 20.2 Cg_endo -74.98 132.34 15.34 Favored 'Trans proline' 0 N--CA 1.453 -0.871 0 O-C-N 124.443 1.76 . . . . 0.0 110.937 -168.251 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 75.47 8.71 84.2 Favored Glycine 0 CA--C 1.53 1.014 0 O-C-N 124.472 1.107 . . . . 0.0 111.028 179.993 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.496 ' SG ' ' CG2' ' A' ' 12' ' ' THR . 81.5 m -93.29 125.43 37.89 Favored 'General case' 0 C--N 1.324 -0.509 0 N-CA-C 108.279 -1.008 . . . . 0.0 108.279 179.995 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . 0.405 ' O ' ' SG ' ' A' ' 10' ' ' CYS . 2.2 p -94.0 156.07 16.8 Favored 'General case' 0 C--N 1.325 -0.483 0 O-C-N 124.524 1.14 . . . . 0.0 110.393 -179.994 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 48.5 t -81.25 91.14 6.16 Favored 'General case' 0 C--N 1.325 -0.495 0 O-C-N 124.512 1.133 . . . . 0.0 108.336 179.968 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . 0.525 ' O ' ' C ' ' A' ' 19' ' ' TRP . 1.9 m -98.09 65.23 1.73 Allowed 'General case' 0 C--N 1.324 -0.502 0 O-C-N 124.503 1.127 . . . . 0.0 110.001 174.231 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' TRP . . . . . 0.607 ' CG ' ' HA ' ' A' ' 20' ' ' PRO . 0.0 OUTLIER -35.52 147.1 0.17 Allowed Pre-proline 0 C--N 1.324 -0.506 0 O-C-N 124.503 1.127 . . . . 0.0 107.993 -173.882 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.607 ' HA ' ' CG ' ' A' ' 19' ' ' TRP . 18.4 Cg_endo -74.98 -13.27 23.65 Favored 'Cis proline' 0 C--N 1.36 1.143 0 C-N-CA 121.012 -2.495 . . . . 0.0 110.98 -8.386 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.608 HG12 HG22 ' A' ' 4' ' ' THR . 2.4 m -99.92 178.65 0.64 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.494 0 O-C-N 124.468 1.105 . . . . 0.0 109.295 -173.117 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 82.7 m -102.21 171.75 7.3 Favored 'General case' 0 C--N 1.325 -0.486 0 O-C-N 124.524 1.14 . . . . 0.0 108.281 -179.997 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . 0.408 ' O ' ' HA ' ' A' ' 15' ' ' CYS . 0.8 OUTLIER -150.3 161.0 43.3 Favored 'General case' 0 C--N 1.325 -0.477 0 O-C-N 124.526 1.141 . . . . 0.0 110.396 179.991 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.475 ' HB3' ' CG2' ' A' ' 29' ' ' VAL . 8.6 ttt180 -132.4 119.08 20.18 Favored 'General case' 0 C--N 1.325 -0.493 0 O-C-N 124.552 1.157 . . . . 0.0 110.289 -179.99 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . 0.404 ' OD1' ' O ' ' A' ' 25' ' ' ASN . 22.9 t-20 57.24 28.87 15.8 Favored 'General case' 0 C--N 1.325 -0.484 0 O-C-N 124.507 1.129 . . . . 0.0 109.291 179.992 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 76.05 23.3 72.04 Favored Glycine 0 CA--C 1.531 1.038 0 O-C-N 124.504 1.127 . . . . 0.0 110.989 179.988 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 7.3 mt -141.4 129.22 11.99 Favored Pre-proline 0 C--N 1.324 -0.509 0 O-C-N 124.554 0.796 . . . . 0.0 109.311 -179.971 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 20.2 Cg_endo -75.0 88.3 1.25 Allowed 'Trans proline' 0 N--CA 1.453 -0.875 0 O-C-N 124.487 1.783 . . . . 0.0 110.944 -168.261 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.475 ' CG2' ' HB3' ' A' ' 24' ' ' ARG . 27.1 m . . . . . 0 C--N 1.325 -0.468 0 O-C-N 124.476 1.11 . . . . 0.0 109.345 179.958 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 91.6 m . . . . . 0 N--CA 1.453 -0.284 0 N-CA-C 108.271 -1.011 . . . . 0.0 108.271 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 92.57 7.93 62.83 Favored Glycine 0 CA--C 1.53 1.023 0 O-C-N 124.486 1.116 . . . . 0.0 110.972 -179.985 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 89.8 mt-10 -100.23 165.01 11.7 Favored 'General case' 0 C--N 1.325 -0.495 0 O-C-N 124.493 0.761 . . . . 0.0 110.308 179.999 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 23.9 p -121.51 114.99 22.01 Favored 'General case' 0 C--N 1.325 -0.485 0 O-C-N 124.456 1.098 . . . . 0.0 110.4 -179.984 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . 0.432 ' O ' ' SG ' ' A' ' 5' ' ' CYS . 13.3 p -91.08 49.62 1.66 Allowed 'General case' 0 C--N 1.325 -0.474 0 O-C-N 124.5 1.125 . . . . 0.0 108.315 -179.976 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 17.5 t -59.19 -24.54 27.75 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 O-C-N 124.5 1.125 . . . . 0.0 109.355 -179.985 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -84.62 -34.25 16.73 Favored Glycine 0 CA--C 1.531 1.036 0 O-C-N 124.498 1.124 . . . . 0.0 110.981 -179.994 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 125.84 13.1 3.43 Favored Glycine 0 CA--C 1.53 1.006 0 O-C-N 125.1 1.118 . . . . 0.0 111.041 178.05 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 2.5 m -150.02 161.4 42.4 Favored 'General case' 0 C--N 1.326 -0.452 0 O-C-N 124.529 0.782 . . . . 0.0 110.383 -179.975 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . 0.402 ' SG ' ' O ' ' A' ' 16' ' ' THR . 72.3 m -119.11 156.37 29.88 Favored 'General case' 0 C--N 1.325 -0.489 0 O-C-N 124.468 1.105 . . . . 0.0 108.327 179.974 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 17.6 t30 -97.98 -58.17 2.05 Favored 'General case' 0 C--N 1.325 -0.475 0 O-C-N 124.518 1.136 . . . . 0.0 109.341 179.97 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.66 HG23 ' HD2' ' A' ' 13' ' ' PRO . 5.3 m -44.69 142.64 2.45 Favored Pre-proline 0 C--N 1.324 -0.501 0 O-C-N 124.558 1.161 . . . . 0.0 110.405 179.954 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.66 ' HD2' HG23 ' A' ' 12' ' ' THR . 20.4 Cg_endo -74.94 129.53 12.49 Favored 'Trans proline' 0 N--CA 1.453 -0.871 0 O-C-N 124.493 1.786 . . . . 0.0 111.023 -168.34 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 78.88 11.57 85.08 Favored Glycine 0 CA--C 1.53 0.986 0 O-C-N 124.513 1.133 . . . . 0.0 111.034 -179.988 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.503 ' SG ' HG22 ' A' ' 12' ' ' THR . 57.7 m -95.29 125.71 40.11 Favored 'General case' 0 C--N 1.325 -0.461 0 N-CA-C 108.306 -0.998 . . . . 0.0 108.306 -179.943 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . 0.402 ' O ' ' SG ' ' A' ' 10' ' ' CYS . 18.7 p -95.16 157.35 15.93 Favored 'General case' 0 C--N 1.326 -0.449 0 O-C-N 124.469 1.106 . . . . 0.0 110.423 -179.989 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 24.5 t -82.74 95.84 7.99 Favored 'General case' 0 C--N 1.325 -0.486 0 O-C-N 124.543 1.152 . . . . 0.0 108.291 179.989 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . 0.598 ' HB3' HG23 ' A' ' 23' ' ' THR . 11.2 t -100.45 64.56 1.15 Allowed 'General case' 0 C--N 1.325 -0.469 0 O-C-N 124.504 1.128 . . . . 0.0 110.057 173.855 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' TRP . . . . . 0.611 ' CG ' ' HA ' ' A' ' 20' ' ' PRO . 0.3 OUTLIER -35.39 145.96 0.19 Allowed Pre-proline 0 C--N 1.325 -0.496 0 O-C-N 124.549 1.155 . . . . 0.0 108.033 -174.124 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.611 ' HA ' ' CG ' ' A' ' 19' ' ' TRP . 18.3 Cg_endo -75.04 -14.88 22.92 Favored 'Cis proline' 0 C--N 1.359 1.13 0 C-N-CA 121.021 -2.491 . . . . 0.0 110.973 -8.459 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.492 ' O ' ' C ' ' A' ' 18' ' ' SER . 3.1 m -95.76 177.09 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 O-C-N 124.515 1.134 . . . . 0.0 109.241 -173.101 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 43.9 m -101.85 166.71 10.51 Favored 'General case' 0 C--N 1.325 -0.487 0 O-C-N 124.537 1.148 . . . . 0.0 108.333 179.987 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . 0.598 HG23 ' HB3' ' A' ' 18' ' ' SER . 1.0 OUTLIER -145.04 169.51 17.98 Favored 'General case' 0 C--N 1.325 -0.485 0 O-C-N 124.516 1.135 . . . . 0.0 110.384 179.991 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.569 ' HB3' HG22 ' A' ' 29' ' ' VAL . 0.1 OUTLIER -142.18 118.22 10.65 Favored 'General case' 0 C--N 1.325 -0.474 0 O-C-N 124.524 1.14 . . . . 0.0 110.304 -179.972 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 72.0 m-20 57.77 23.37 9.51 Favored 'General case' 0 C--N 1.325 -0.466 0 O-C-N 124.557 1.16 . . . . 0.0 109.357 -179.957 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 82.17 24.14 55.41 Favored Glycine 0 CA--C 1.531 1.036 0 O-C-N 124.524 1.14 . . . . 0.0 111.039 -179.994 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 7.5 mt -143.31 129.57 10.34 Favored Pre-proline 0 C--N 1.325 -0.467 0 O-C-N 124.487 0.757 . . . . 0.0 109.317 -179.973 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 20.4 Cg_endo -74.89 82.18 2.03 Favored 'Trans proline' 0 N--CA 1.453 -0.904 0 O-C-N 124.535 1.808 . . . . 0.0 111.02 -168.348 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.569 HG22 ' HB3' ' A' ' 24' ' ' ARG . 32.7 m . . . . . 0 C--N 1.324 -0.51 0 O-C-N 124.526 1.141 . . . . 0.0 109.308 179.997 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 95.2 m . . . . . 0 N--CA 1.452 -0.327 0 N-CA-C 108.266 -1.013 . . . . 0.0 108.266 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 91.03 -27.22 9.35 Favored Glycine 0 CA--C 1.53 0.975 0 O-C-N 124.569 1.168 . . . . 0.0 111.041 -179.976 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 23.5 tt0 -83.53 151.88 25.18 Favored 'General case' 0 C--N 1.325 -0.495 0 O-C-N 124.503 0.767 . . . . 0.0 110.292 -179.988 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.63 HG22 HG23 ' A' ' 21' ' ' VAL . 60.2 p -112.83 137.93 50.43 Favored 'General case' 0 C--N 1.324 -0.505 0 O-C-N 124.532 1.145 . . . . 0.0 110.372 179.995 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . 0.407 ' SG ' ' O ' ' A' ' 5' ' ' CYS . 15.0 p -100.88 52.79 0.85 Allowed 'General case' 0 C--N 1.325 -0.477 0 O-C-N 124.551 1.157 . . . . 0.0 108.29 179.99 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 10.3 t -59.22 -24.14 26.74 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 O-C-N 124.508 1.13 . . . . 0.0 109.288 -179.996 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -84.75 -34.6 15.26 Favored Glycine 0 CA--C 1.53 1.006 0 O-C-N 124.524 1.14 . . . . 0.0 110.968 -179.976 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 127.19 14.78 2.64 Favored Glycine 0 CA--C 1.531 1.043 0 O-C-N 125.138 1.14 . . . . 0.0 111.029 177.62 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -150.08 166.73 28.88 Favored 'General case' 0 C--N 1.325 -0.476 0 O-C-N 124.489 0.758 . . . . 0.0 110.386 -179.971 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . 0.414 ' SG ' ' O ' ' A' ' 16' ' ' THR . 72.3 m -124.56 140.71 52.69 Favored 'General case' 0 C--N 1.325 -0.486 0 O-C-N 124.525 1.14 . . . . 0.0 108.298 180.0 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 3.0 m120 -89.58 -40.13 12.81 Favored 'General case' 0 C--N 1.325 -0.465 0 O-C-N 124.428 1.08 . . . . 0.0 109.291 -179.989 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.608 HG23 ' HD2' ' A' ' 13' ' ' PRO . 20.9 m -60.05 142.69 89.08 Favored Pre-proline 0 C--N 1.325 -0.467 0 O-C-N 124.465 1.103 . . . . 0.0 110.393 179.995 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.608 ' HD2' HG23 ' A' ' 12' ' ' THR . 20.2 Cg_endo -74.97 132.08 15.05 Favored 'Trans proline' 0 N--CA 1.453 -0.877 0 O-C-N 124.485 1.781 . . . . 0.0 110.947 -168.269 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 73.34 13.35 79.85 Favored Glycine 0 CA--C 1.53 0.999 0 O-C-N 124.563 1.165 . . . . 0.0 110.999 179.974 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.513 ' SG ' HG22 ' A' ' 12' ' ' THR . 68.7 m -97.97 125.64 42.99 Favored 'General case' 0 C--N 1.325 -0.486 0 N-CA-C 108.306 -0.998 . . . . 0.0 108.306 -179.989 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . 0.414 ' O ' ' SG ' ' A' ' 10' ' ' CYS . 44.4 p -93.73 157.56 16.1 Favored 'General case' 0 C--N 1.325 -0.498 0 O-C-N 124.479 1.112 . . . . 0.0 110.387 179.985 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 46.8 t -83.09 95.04 7.94 Favored 'General case' 0 C--N 1.326 -0.454 0 O-C-N 124.491 1.12 . . . . 0.0 108.273 -179.948 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . 0.52 ' O ' ' C ' ' A' ' 19' ' ' TRP . 1.0 OUTLIER -102.79 66.92 0.96 Allowed 'General case' 0 C--N 1.325 -0.469 0 O-C-N 124.459 1.099 . . . . 0.0 110.029 173.96 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 19' ' ' TRP . . . . . 0.612 ' CG ' ' HA ' ' A' ' 20' ' ' PRO . 0.0 OUTLIER -35.7 147.46 0.17 Allowed Pre-proline 0 C--N 1.326 -0.455 0 O-C-N 124.496 1.123 . . . . 0.0 107.982 -174.009 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.612 ' HA ' ' CG ' ' A' ' 19' ' ' TRP . 18.3 Cg_endo -75.01 -13.5 23.62 Favored 'Cis proline' 0 C--N 1.361 1.206 0 C-N-CA 121.001 -2.5 . . . . 0.0 111.025 -8.572 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.689 HG22 ' H ' ' A' ' 22' ' ' CYS . 4.8 p -100.05 178.84 0.63 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 O-C-N 124.547 1.154 . . . . 0.0 109.323 -173.006 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.689 ' H ' HG22 ' A' ' 21' ' ' VAL . 81.4 m -102.22 174.0 6.12 Favored 'General case' 0 C--N 1.325 -0.492 0 O-C-N 124.503 1.127 . . . . 0.0 108.285 179.991 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . 0.515 HG23 ' CB ' ' A' ' 18' ' ' SER . 7.2 p -147.02 159.19 43.88 Favored 'General case' 0 C--N 1.325 -0.496 0 O-C-N 124.519 1.137 . . . . 0.0 110.402 179.985 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.581 ' HB3' HG22 ' A' ' 29' ' ' VAL . 3.4 ttt180 -130.5 116.49 18.26 Favored 'General case' 0 C--N 1.325 -0.465 0 O-C-N 124.513 1.133 . . . . 0.0 110.326 179.948 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 74.9 m-20 57.61 23.46 9.34 Favored 'General case' 0 C--N 1.325 -0.476 0 O-C-N 124.51 1.131 . . . . 0.0 109.329 -179.939 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 84.27 24.72 46.57 Favored Glycine 0 CA--C 1.53 1.002 0 O-C-N 124.522 1.139 . . . . 0.0 111.013 180.0 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 10.7 mt -144.84 130.31 9.44 Favored Pre-proline 0 C--N 1.325 -0.481 0 O-C-N 124.495 0.762 . . . . 0.0 109.262 -179.984 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 20.2 Cg_endo -74.99 88.24 1.26 Allowed 'Trans proline' 0 N--CA 1.453 -0.891 0 O-C-N 124.5 1.789 . . . . 0.0 110.986 -168.312 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.581 HG22 ' HB3' ' A' ' 24' ' ' ARG . 32.4 m . . . . . 0 C--N 1.325 -0.482 0 O-C-N 124.51 1.131 . . . . 0.0 109.294 -179.998 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 58.5 m . . . . . 0 N--CA 1.453 -0.307 0 N-CA-C 108.301 -1.0 . . . . 0.0 108.301 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 90.93 -15.76 60.06 Favored Glycine 0 CA--C 1.531 1.042 0 O-C-N 124.483 1.115 . . . . 0.0 110.96 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 15.6 tt0 -88.76 162.72 16.07 Favored 'General case' 0 C--N 1.325 -0.471 0 O-C-N 124.541 0.789 . . . . 0.0 110.316 179.999 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.604 HG22 HG23 ' A' ' 21' ' ' VAL . 53.0 p -120.39 134.97 55.18 Favored 'General case' 0 C--N 1.324 -0.502 0 O-C-N 124.496 1.123 . . . . 0.0 110.425 179.998 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.417 ' O ' ' CD1' ' A' ' 19' ' ' TRP . 13.8 p -105.05 49.06 0.82 Allowed 'General case' 0 C--N 1.325 -0.487 0 O-C-N 124.487 1.117 . . . . 0.0 108.334 179.982 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 37.9 t -59.12 -23.37 24.35 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 O-C-N 124.491 1.12 . . . . 0.0 109.327 179.986 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -82.89 -32.69 26.04 Favored Glycine 0 CA--C 1.531 1.033 0 O-C-N 124.477 1.111 . . . . 0.0 110.985 -179.967 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 125.64 10.8 4.3 Favored Glycine 0 CA--C 1.53 0.997 0 O-C-N 125.068 1.099 . . . . 0.0 110.959 178.183 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 83.6 m -150.19 165.38 33.08 Favored 'General case' 0 C--N 1.325 -0.495 0 O-C-N 124.493 0.761 . . . . 0.0 110.398 179.947 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 91.4 m -118.45 141.85 48.14 Favored 'General case' 0 C--N 1.325 -0.473 0 O-C-N 124.498 1.124 . . . . 0.0 108.29 -179.976 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 13.0 t-20 -89.79 -39.9 12.81 Favored 'General case' 0 C--N 1.325 -0.488 0 O-C-N 124.526 1.141 . . . . 0.0 109.342 179.959 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.642 HG23 ' HD2' ' A' ' 13' ' ' PRO . 17.6 m -62.32 142.99 95.9 Favored Pre-proline 0 C--N 1.325 -0.49 0 O-C-N 124.458 1.099 . . . . 0.0 110.383 -179.989 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.642 ' HD2' HG23 ' A' ' 12' ' ' THR . 20.3 Cg_endo -74.9 132.06 15.12 Favored 'Trans proline' 0 N--CA 1.453 -0.875 0 O-C-N 124.524 1.802 . . . . 0.0 110.983 -168.314 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 74.37 12.46 82.04 Favored Glycine 0 CA--C 1.53 1.023 0 O-C-N 124.465 1.103 . . . . 0.0 110.962 179.935 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.503 ' SG ' HG22 ' A' ' 12' ' ' THR . 67.3 m -96.71 127.64 42.89 Favored 'General case' 0 C--N 1.325 -0.465 0 N-CA-C 108.307 -0.997 . . . . 0.0 108.307 179.97 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 77.5 p -95.15 152.85 17.99 Favored 'General case' 0 C--N 1.325 -0.457 0 O-C-N 124.511 1.132 . . . . 0.0 110.383 -179.986 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 54.1 t -77.72 93.86 4.35 Favored 'General case' 0 C--N 1.325 -0.493 0 O-C-N 124.487 1.117 . . . . 0.0 108.33 179.983 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . 0.609 ' HB3' HG23 ' A' ' 23' ' ' THR . 3.1 t -100.41 65.9 1.23 Allowed 'General case' 0 C--N 1.324 -0.526 0 O-C-N 124.494 1.121 . . . . 0.0 109.992 174.321 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' TRP . . . . . 0.583 ' CG ' ' HA ' ' A' ' 20' ' ' PRO . 0.0 OUTLIER -36.93 147.89 0.2 Allowed Pre-proline 0 C--N 1.325 -0.472 0 O-C-N 124.52 1.138 . . . . 0.0 108.009 -173.973 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.583 ' HA ' ' CG ' ' A' ' 19' ' ' TRP . 18.5 Cg_endo -74.98 -12.11 23.98 Favored 'Cis proline' 0 C--N 1.36 1.176 0 C-N-CA 121.023 -2.49 . . . . 0.0 111.047 -8.5 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.675 HG22 ' H ' ' A' ' 22' ' ' CYS . 3.7 p -99.33 -179.55 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 O-C-N 124.5 1.125 . . . . 0.0 109.232 -173.465 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.675 ' H ' HG22 ' A' ' 21' ' ' VAL . 43.2 m -101.32 168.4 9.57 Favored 'General case' 0 C--N 1.325 -0.478 0 O-C-N 124.509 1.131 . . . . 0.0 108.3 179.99 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.609 HG23 ' HB3' ' A' ' 18' ' ' SER . 0.7 OUTLIER -144.95 164.95 29.56 Favored 'General case' 0 C--N 1.325 -0.478 0 O-C-N 124.553 1.158 . . . . 0.0 110.383 -179.983 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.574 ' HB3' HG22 ' A' ' 29' ' ' VAL . 0.0 OUTLIER -133.87 117.55 16.94 Favored 'General case' 0 C--N 1.325 -0.463 0 O-C-N 124.539 1.149 . . . . 0.0 110.298 179.969 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 74.0 m-20 57.68 23.42 9.43 Favored 'General case' 0 C--N 1.326 -0.456 0 O-C-N 124.447 1.092 . . . . 0.0 109.332 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 84.01 24.59 48.11 Favored Glycine 0 CA--C 1.53 0.993 0 O-C-N 124.52 1.137 . . . . 0.0 110.994 179.986 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 9.6 mt -143.67 130.32 10.37 Favored Pre-proline 0 C--N 1.325 -0.471 0 O-C-N 124.485 0.756 . . . . 0.0 109.339 -179.992 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 20.1 Cg_endo -74.95 89.32 1.16 Allowed 'Trans proline' 0 N--CA 1.453 -0.899 0 O-C-N 124.5 1.79 . . . . 0.0 110.981 -168.294 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.574 HG22 ' HB3' ' A' ' 24' ' ' ARG . 22.4 m . . . . . 0 C--N 1.325 -0.496 0 O-C-N 124.501 1.125 . . . . 0.0 109.312 179.991 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 64.8 m . . . . . 0 N--CA 1.453 -0.294 0 N-CA-C 108.305 -0.998 . . . . 0.0 108.305 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 89.63 -17.35 53.02 Favored Glycine 0 CA--C 1.53 0.979 0 O-C-N 124.507 1.129 . . . . 0.0 111.03 179.999 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 14.8 tt0 -87.94 162.62 16.78 Favored 'General case' 0 C--N 1.325 -0.499 0 O-C-N 124.491 0.759 . . . . 0.0 110.291 179.99 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.791 HG22 HG13 ' A' ' 21' ' ' VAL . 40.0 p -121.52 137.71 54.61 Favored 'General case' 0 C--N 1.326 -0.445 0 O-C-N 124.497 1.123 . . . . 0.0 110.424 179.98 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.448 ' O ' ' CD1' ' A' ' 19' ' ' TRP . 14.3 p -105.87 51.13 0.76 Allowed 'General case' 0 C--N 1.325 -0.487 0 O-C-N 124.511 1.132 . . . . 0.0 108.289 -179.967 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 6.0 t -59.1 -24.74 27.99 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 O-C-N 124.482 1.114 . . . . 0.0 109.312 179.994 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -83.91 -33.8 20.18 Favored Glycine 0 CA--C 1.53 0.969 0 O-C-N 124.45 1.093 . . . . 0.0 110.982 -179.992 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 126.27 13.96 3.09 Favored Glycine 0 CA--C 1.53 1.012 0 O-C-N 125.044 1.085 . . . . 0.0 111.031 177.78 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 28.8 m -149.91 163.64 37.54 Favored 'General case' 0 C--N 1.325 -0.483 0 O-C-N 124.509 0.77 . . . . 0.0 110.364 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . 0.409 ' SG ' ' O ' ' A' ' 16' ' ' THR . 90.2 m -120.55 143.13 48.75 Favored 'General case' 0 C--N 1.325 -0.475 0 O-C-N 124.481 1.113 . . . . 0.0 108.331 179.987 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 76.2 m-20 -89.96 -46.99 8.14 Favored 'General case' 0 C--N 1.325 -0.462 0 O-C-N 124.462 1.101 . . . . 0.0 109.287 -179.968 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.613 HG23 ' HD2' ' A' ' 13' ' ' PRO . 20.7 m -55.23 142.71 57.66 Favored Pre-proline 0 C--N 1.325 -0.489 0 O-C-N 124.524 1.14 . . . . 0.0 110.343 -179.958 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.613 ' HD2' HG23 ' A' ' 12' ' ' THR . 20.3 Cg_endo -74.92 132.0 15.03 Favored 'Trans proline' 0 N--CA 1.453 -0.872 0 O-C-N 124.572 1.827 . . . . 0.0 111.028 -168.334 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 74.76 12.29 82.92 Favored Glycine 0 CA--C 1.53 1.011 0 O-C-N 124.478 1.111 . . . . 0.0 110.956 179.976 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.498 ' SG ' ' CG2' ' A' ' 12' ' ' THR . 69.6 m -95.52 126.02 40.52 Favored 'General case' 0 C--N 1.324 -0.507 0 N-CA-C 108.262 -1.014 . . . . 0.0 108.262 -179.986 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . 0.409 ' O ' ' SG ' ' A' ' 10' ' ' CYS . 29.1 p -93.75 156.2 16.81 Favored 'General case' 0 C--N 1.325 -0.492 0 O-C-N 124.526 1.141 . . . . 0.0 110.387 179.999 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 51.6 t -81.34 94.06 6.69 Favored 'General case' 0 C--N 1.325 -0.498 0 O-C-N 124.531 1.144 . . . . 0.0 108.291 179.997 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . 0.567 ' HB2' HG23 ' A' ' 23' ' ' THR . 1.9 m -101.07 66.39 1.14 Allowed 'General case' 0 C--N 1.325 -0.488 0 O-C-N 124.552 1.157 . . . . 0.0 109.989 174.26 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' TRP . . . . . 0.592 ' CG ' ' HA ' ' A' ' 20' ' ' PRO . 0.0 OUTLIER -36.74 148.19 0.19 Allowed Pre-proline 0 C--N 1.325 -0.481 0 N-CA-C 107.964 -1.124 . . . . 0.0 107.964 -174.019 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.592 ' HA ' ' CG ' ' A' ' 19' ' ' TRP . 18.2 Cg_endo -75.03 -11.87 24.19 Favored 'Cis proline' 0 C--N 1.361 1.192 0 C-N-CA 120.967 -2.514 . . . . 0.0 110.997 -8.474 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.791 HG13 HG22 ' A' ' 4' ' ' THR . 2.2 t -100.2 179.92 0.58 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 O-C-N 124.521 1.138 . . . . 0.0 109.285 -173.386 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.663 ' H ' HG12 ' A' ' 21' ' ' VAL . 57.0 m -101.63 168.43 9.48 Favored 'General case' 0 C--N 1.325 -0.491 0 O-C-N 124.494 1.121 . . . . 0.0 108.312 179.987 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.567 HG23 ' HB2' ' A' ' 18' ' ' SER . 0.8 OUTLIER -145.25 165.06 29.47 Favored 'General case' 0 C--N 1.325 -0.476 0 O-C-N 124.558 1.161 . . . . 0.0 110.427 179.975 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.58 ' HB3' HG22 ' A' ' 29' ' ' VAL . 1.3 ttt-85 -132.81 116.26 16.32 Favored 'General case' 0 C--N 1.324 -0.5 0 O-C-N 124.523 1.139 . . . . 0.0 110.327 -179.991 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 78.4 m-20 57.79 23.08 9.21 Favored 'General case' 0 C--N 1.324 -0.502 0 O-C-N 124.501 1.126 . . . . 0.0 109.291 179.996 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 84.78 23.51 49.54 Favored Glycine 0 CA--C 1.529 0.968 0 O-C-N 124.487 1.117 . . . . 0.0 111.012 -179.966 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 7.2 mt -142.46 129.93 11.26 Favored Pre-proline 0 C--N 1.325 -0.497 0 O-C-N 124.496 0.762 . . . . 0.0 109.288 -179.935 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 20.2 Cg_endo -74.98 89.59 1.15 Allowed 'Trans proline' 0 N--CA 1.453 -0.876 0 O-C-N 124.534 1.807 . . . . 0.0 110.987 -168.323 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.58 HG22 ' HB3' ' A' ' 24' ' ' ARG . 32.6 m . . . . . 0 C--N 1.325 -0.479 0 O-C-N 124.487 1.117 . . . . 0.0 109.276 179.997 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 32.9 m . . . . . 0 N--CA 1.453 -0.282 0 N-CA-C 108.28 -1.008 . . . . 0.0 108.28 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 88.54 -16.01 55.02 Favored Glycine 0 CA--C 1.531 1.044 0 O-C-N 124.503 1.127 . . . . 0.0 110.985 -179.992 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 16.4 tt0 -90.21 161.92 15.49 Favored 'General case' 0 C--N 1.325 -0.483 0 O-C-N 124.515 0.774 . . . . 0.0 110.329 179.982 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.787 HG22 HG12 ' A' ' 21' ' ' VAL . 37.3 p -122.67 135.99 54.75 Favored 'General case' 0 C--N 1.324 -0.518 0 O-C-N 124.481 1.113 . . . . 0.0 110.417 179.992 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.406 ' SG ' ' O ' ' A' ' 5' ' ' CYS . 15.3 p -102.65 53.04 0.79 Allowed 'General case' 0 C--N 1.325 -0.484 0 O-C-N 124.528 1.142 . . . . 0.0 108.281 -179.971 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 15.6 t -59.43 -24.51 28.41 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 O-C-N 124.471 1.107 . . . . 0.0 109.331 179.97 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -84.54 -30.96 25.79 Favored Glycine 0 CA--C 1.53 0.982 0 O-C-N 124.485 1.116 . . . . 0.0 110.992 179.97 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 122.6 13.26 4.74 Favored Glycine 0 CA--C 1.53 1.012 0 O-C-N 124.953 1.031 . . . . 0.0 110.979 178.611 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 5.9 m -150.14 158.76 44.5 Favored 'General case' 0 C--N 1.325 -0.497 0 O-C-N 124.512 0.772 . . . . 0.0 110.41 179.973 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . 0.403 ' SG ' ' O ' ' A' ' 16' ' ' THR . 97.2 m -114.3 141.58 47.41 Favored 'General case' 0 C--N 1.325 -0.461 0 O-C-N 124.491 1.12 . . . . 0.0 108.307 -179.971 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 64.3 t30 -89.83 -44.5 9.91 Favored 'General case' 0 C--N 1.325 -0.48 0 O-C-N 124.518 1.136 . . . . 0.0 109.284 -179.965 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.625 HG23 ' HD2' ' A' ' 13' ' ' PRO . 18.9 m -57.65 142.85 77.07 Favored Pre-proline 0 C--N 1.325 -0.472 0 O-C-N 124.487 1.117 . . . . 0.0 110.348 -179.987 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.625 ' HD2' HG23 ' A' ' 12' ' ' THR . 20.3 Cg_endo -75.01 130.57 13.38 Favored 'Trans proline' 0 N--CA 1.452 -0.925 0 O-C-N 124.488 1.783 . . . . 0.0 111.026 -168.328 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 75.59 14.09 82.36 Favored Glycine 0 CA--C 1.531 1.034 0 O-C-N 124.518 1.136 . . . . 0.0 110.975 -179.989 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.5 ' SG ' ' CG2' ' A' ' 12' ' ' THR . 62.3 m -95.69 129.54 42.86 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 108.274 -1.01 . . . . 0.0 108.274 -179.971 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . 0.403 ' O ' ' SG ' ' A' ' 10' ' ' CYS . 7.7 p -95.54 152.35 18.5 Favored 'General case' 0 C--N 1.325 -0.481 0 O-C-N 124.491 1.12 . . . . 0.0 110.388 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 45.6 t -81.67 94.92 7.06 Favored 'General case' 0 C--N 1.325 -0.497 0 O-C-N 124.515 1.134 . . . . 0.0 108.328 179.999 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . 0.566 ' CB ' HG23 ' A' ' 23' ' ' THR . 1.2 t -104.13 67.05 0.84 Allowed 'General case' 0 C--N 1.324 -0.504 0 O-C-N 124.551 1.157 . . . . 0.0 109.98 174.221 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' TRP . . . . . 0.623 ' CG ' ' HA ' ' A' ' 20' ' ' PRO . 0.1 OUTLIER -36.1 147.23 0.19 Allowed Pre-proline 0 C--N 1.325 -0.485 0 O-C-N 124.502 1.127 . . . . 0.0 108.011 -174.257 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.623 ' HA ' ' CG ' ' A' ' 19' ' ' TRP . 18.1 Cg_endo -74.98 -14.0 23.26 Favored 'Cis proline' 0 C--N 1.36 1.136 0 C-N-CA 121.014 -2.494 . . . . 0.0 110.996 -8.659 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.787 HG12 HG22 ' A' ' 4' ' ' THR . 3.0 m -97.67 177.83 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.478 0 O-C-N 124.496 1.123 . . . . 0.0 109.294 -173.075 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 52.9 m -102.18 172.5 6.86 Favored 'General case' 0 C--N 1.325 -0.485 0 O-C-N 124.477 1.111 . . . . 0.0 108.317 179.98 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.566 HG23 ' CB ' ' A' ' 18' ' ' SER . 6.5 p -145.56 165.1 29.64 Favored 'General case' 0 C--N 1.324 -0.504 0 O-C-N 124.539 1.149 . . . . 0.0 110.416 -179.982 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.666 ' HB3' HG22 ' A' ' 29' ' ' VAL . 0.1 OUTLIER -131.89 112.97 12.9 Favored 'General case' 0 C--N 1.325 -0.464 0 O-C-N 124.459 1.099 . . . . 0.0 110.293 179.986 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 2.6 m-80 57.12 22.96 7.99 Favored 'General case' 0 C--N 1.326 -0.451 0 O-C-N 124.498 1.124 . . . . 0.0 109.319 -179.986 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 86.15 25.3 37.56 Favored Glycine 0 CA--C 1.53 0.985 0 O-C-N 124.522 1.139 . . . . 0.0 111.016 -179.986 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 7.9 mt -143.37 130.01 10.48 Favored Pre-proline 0 C--N 1.325 -0.477 0 O-C-N 124.511 0.771 . . . . 0.0 109.3 179.983 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 20.2 Cg_endo -74.97 85.99 1.46 Allowed 'Trans proline' 0 N--CA 1.453 -0.891 0 O-C-N 124.55 1.816 . . . . 0.0 111.043 -168.34 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.666 HG22 ' HB3' ' A' ' 24' ' ' ARG . 21.6 m . . . . . 0 C--N 1.325 -0.469 0 O-C-N 124.512 1.133 . . . . 0.0 109.3 179.995 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 37.6 m . . . . . 0 N--CA 1.453 -0.304 0 N-CA-C 108.294 -1.002 . . . . 0.0 108.294 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 91.42 -21.64 34.21 Favored Glycine 0 CA--C 1.531 1.06 0 O-C-N 124.505 1.128 . . . . 0.0 110.999 179.989 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 16.0 tt0 -85.23 161.1 19.71 Favored 'General case' 0 C--N 1.325 -0.466 0 O-C-N 124.541 0.789 . . . . 0.0 110.274 -179.987 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.866 HG22 HG23 ' A' ' 21' ' ' VAL . 72.5 p -121.94 136.2 54.91 Favored 'General case' 0 C--N 1.325 -0.457 0 O-C-N 124.445 1.09 . . . . 0.0 110.455 179.996 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.426 ' O ' ' CD1' ' A' ' 19' ' ' TRP . 15.2 p -102.1 53.78 0.8 Allowed 'General case' 0 C--N 1.325 -0.493 0 O-C-N 124.573 1.17 . . . . 0.0 108.283 -179.978 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 4.7 t -59.5 -24.85 29.54 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 O-C-N 124.515 1.135 . . . . 0.0 109.302 -179.993 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -85.42 -32.97 18.11 Favored Glycine 0 CA--C 1.53 0.991 0 O-C-N 124.524 1.14 . . . . 0.0 110.978 -179.979 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 124.31 15.34 3.4 Favored Glycine 0 CA--C 1.53 0.983 0 O-C-N 125.021 1.071 . . . . 0.0 110.977 178.057 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 6.0 m -150.17 158.95 44.7 Favored 'General case' 0 C--N 1.325 -0.48 0 O-C-N 124.494 0.761 . . . . 0.0 110.397 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 74.9 m -117.8 141.75 48.07 Favored 'General case' 0 C--N 1.325 -0.476 0 O-C-N 124.496 1.123 . . . . 0.0 108.302 179.975 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 4.6 m120 -89.7 -47.62 7.81 Favored 'General case' 0 C--N 1.325 -0.475 0 O-C-N 124.498 1.124 . . . . 0.0 109.294 179.997 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.607 HG23 ' HD2' ' A' ' 13' ' ' PRO . 20.8 m -53.87 142.75 43.57 Favored Pre-proline 0 C--N 1.325 -0.479 0 O-C-N 124.442 1.089 . . . . 0.0 110.392 -179.975 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.607 ' HD2' HG23 ' A' ' 12' ' ' THR . 20.2 Cg_endo -75.04 130.78 13.54 Favored 'Trans proline' 0 N--CA 1.453 -0.866 0 O-C-N 124.443 1.759 . . . . 0.0 110.928 -168.237 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 75.36 13.55 82.75 Favored Glycine 0 CA--C 1.53 0.986 0 O-C-N 124.497 1.123 . . . . 0.0 111.022 -179.978 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.498 ' SG ' ' CG2' ' A' ' 12' ' ' THR . 64.2 m -95.54 126.65 40.97 Favored 'General case' 0 C--N 1.325 -0.476 0 N-CA-C 108.316 -0.994 . . . . 0.0 108.316 -179.967 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 17.6 p -94.0 155.23 17.24 Favored 'General case' 0 C--N 1.325 -0.485 0 O-C-N 124.48 1.112 . . . . 0.0 110.437 179.991 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 43.4 t -83.4 94.27 7.94 Favored 'General case' 0 C--N 1.325 -0.48 0 O-C-N 124.482 1.114 . . . . 0.0 108.325 -179.965 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . 0.564 ' HB3' HG23 ' A' ' 23' ' ' THR . 47.9 t -102.53 66.67 0.98 Allowed 'General case' 0 C--N 1.325 -0.497 0 O-C-N 124.486 1.116 . . . . 0.0 109.971 174.166 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' TRP . . . . . 0.603 ' CG ' ' HA ' ' A' ' 20' ' ' PRO . 0.0 OUTLIER -36.0 147.3 0.18 Allowed Pre-proline 0 C--N 1.325 -0.485 0 O-C-N 124.483 1.114 . . . . 0.0 108.022 -174.167 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.603 ' HA ' ' CG ' ' A' ' 19' ' ' TRP . 18.3 Cg_endo -74.94 -13.69 23.34 Favored 'Cis proline' 0 C--N 1.36 1.159 0 C-N-CA 121.006 -2.498 . . . . 0.0 111.038 -8.513 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.866 HG23 HG22 ' A' ' 4' ' ' THR . 1.1 p -98.42 177.75 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 O-C-N 124.512 1.132 . . . . 0.0 109.305 -173.083 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.505 ' H ' HG22 ' A' ' 21' ' ' VAL . 56.6 m -102.1 170.52 8.05 Favored 'General case' 0 C--N 1.325 -0.472 0 O-C-N 124.502 1.126 . . . . 0.0 108.271 -179.983 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.564 HG23 ' HB3' ' A' ' 18' ' ' SER . 1.1 p -144.98 164.86 29.86 Favored 'General case' 0 C--N 1.325 -0.466 0 O-C-N 124.561 1.163 . . . . 0.0 110.423 179.974 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.53 ' HB3' HG22 ' A' ' 29' ' ' VAL . 7.5 ttt180 -132.87 116.91 17.08 Favored 'General case' 0 C--N 1.325 -0.488 0 O-C-N 124.476 1.11 . . . . 0.0 110.341 179.966 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 75.7 m-20 57.39 23.37 8.89 Favored 'General case' 0 C--N 1.325 -0.48 0 O-C-N 124.452 1.095 . . . . 0.0 109.278 -179.991 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 83.89 25.22 46.26 Favored Glycine 0 CA--C 1.53 1.004 0 O-C-N 124.453 1.096 . . . . 0.0 110.995 -179.982 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 10.0 mt -144.22 131.19 10.31 Favored Pre-proline 0 C--N 1.325 -0.492 0 O-C-N 124.516 0.774 . . . . 0.0 109.268 179.995 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 20.1 Cg_endo -74.97 89.08 1.18 Allowed 'Trans proline' 0 N--CA 1.453 -0.872 0 O-C-N 124.462 1.77 . . . . 0.0 110.986 -168.308 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.53 HG22 ' HB3' ' A' ' 24' ' ' ARG . 33.5 m . . . . . 0 C--N 1.325 -0.485 0 O-C-N 124.443 1.09 . . . . 0.0 109.327 179.99 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 52.7 m . . . . . 0 N--CA 1.453 -0.279 0 N-CA-C 108.32 -0.993 . . . . 0.0 108.32 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 100.81 -10.16 58.75 Favored Glycine 0 CA--C 1.53 0.995 0 O-C-N 124.527 1.142 . . . . 0.0 110.997 -179.976 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 14.6 tt0 -99.17 162.77 12.87 Favored 'General case' 0 C--N 1.325 -0.484 0 O-C-N 124.51 0.77 . . . . 0.0 110.262 -179.96 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.674 HG22 HG23 ' A' ' 21' ' ' VAL . 80.9 p -120.12 138.09 53.77 Favored 'General case' 0 C--N 1.326 -0.446 0 O-C-N 124.541 1.151 . . . . 0.0 110.395 179.945 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.431 ' O ' ' CD1' ' A' ' 19' ' ' TRP . 14.5 p -107.72 51.26 0.75 Allowed 'General case' 0 C--N 1.325 -0.482 0 O-C-N 124.515 1.134 . . . . 0.0 108.301 179.999 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 15.0 t -59.15 -23.89 25.86 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.468 0 O-C-N 124.461 1.101 . . . . 0.0 109.28 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -85.68 -34.07 14.5 Favored Glycine 0 CA--C 1.53 1.025 0 O-C-N 124.523 1.139 . . . . 0.0 111.019 179.981 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 126.19 17.57 2.44 Favored Glycine 0 C--N 1.344 0.993 0 O-C-N 125.223 1.19 . . . . 0.0 111.003 177.32 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -150.34 166.02 31.29 Favored 'General case' 0 C--N 1.325 -0.488 0 O-C-N 124.534 0.785 . . . . 0.0 110.377 -179.987 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . 0.41 ' SG ' ' O ' ' A' ' 16' ' ' THR . 80.1 m -125.97 142.76 51.38 Favored 'General case' 0 C--N 1.325 -0.468 0 O-C-N 124.485 1.116 . . . . 0.0 108.285 179.996 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 4.3 m-20 -89.99 -48.3 7.3 Favored 'General case' 0 C--N 1.324 -0.514 0 O-C-N 124.489 1.118 . . . . 0.0 109.286 -179.992 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.623 HG23 ' HD2' ' A' ' 13' ' ' PRO . 18.9 m -53.04 142.78 34.79 Favored Pre-proline 0 C--N 1.326 -0.453 0 O-C-N 124.497 1.123 . . . . 0.0 110.417 179.971 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.623 ' HD2' HG23 ' A' ' 12' ' ' THR . 20.1 Cg_endo -75.01 131.39 14.22 Favored 'Trans proline' 0 N--CA 1.453 -0.906 0 O-C-N 124.495 1.787 . . . . 0.0 110.969 -168.3 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 74.2 15.11 80.15 Favored Glycine 0 CA--C 1.53 0.999 0 O-C-N 124.46 1.1 . . . . 0.0 110.984 179.965 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.504 ' SG ' ' CG2' ' A' ' 12' ' ' THR . 63.7 m -97.47 125.93 42.44 Favored 'General case' 0 C--N 1.325 -0.483 0 N-CA-C 108.285 -1.006 . . . . 0.0 108.285 179.996 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . 0.41 ' O ' ' SG ' ' A' ' 10' ' ' CYS . 18.6 p -94.11 158.61 15.53 Favored 'General case' 0 C--N 1.324 -0.504 0 O-C-N 124.489 1.118 . . . . 0.0 110.393 -179.993 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 42.4 t -81.72 94.11 6.93 Favored 'General case' 0 C--N 1.325 -0.473 0 O-C-N 124.467 1.104 . . . . 0.0 108.334 179.951 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . 0.606 ' HB3' HG23 ' A' ' 23' ' ' THR . 2.5 t -100.98 65.57 1.11 Allowed 'General case' 0 C--N 1.325 -0.457 0 O-C-N 124.475 1.109 . . . . 0.0 109.989 174.214 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' TRP . . . . . 0.585 ' CG ' ' HA ' ' A' ' 20' ' ' PRO . 0.0 OUTLIER -36.64 148.04 0.19 Allowed Pre-proline 0 C--N 1.324 -0.507 0 O-C-N 124.489 1.118 . . . . 0.0 108.0 -174.067 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.585 ' HA ' ' CG ' ' A' ' 19' ' ' TRP . 18.1 Cg_endo -75.02 -11.49 24.25 Favored 'Cis proline' 0 C--N 1.361 1.186 0 C-N-CA 121.017 -2.493 . . . . 0.0 110.97 -8.309 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.674 HG23 HG22 ' A' ' 4' ' ' THR . 3.2 p -100.5 -179.6 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 O-C-N 124.499 1.124 . . . . 0.0 109.291 -173.528 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.661 ' H ' HG22 ' A' ' 21' ' ' VAL . 60.4 m -101.67 167.01 10.39 Favored 'General case' 0 C--N 1.326 -0.456 0 O-C-N 124.526 1.141 . . . . 0.0 108.316 179.999 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.606 HG23 ' HB3' ' A' ' 18' ' ' SER . 0.8 OUTLIER -144.45 165.7 27.22 Favored 'General case' 0 C--N 1.324 -0.517 0 O-C-N 124.487 1.117 . . . . 0.0 110.412 179.958 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.425 ' HB3' ' CG2' ' A' ' 29' ' ' VAL . 15.0 ttt180 -135.18 120.2 18.67 Favored 'General case' 0 C--N 1.325 -0.495 0 O-C-N 124.542 1.151 . . . . 0.0 110.293 -179.958 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 28.5 t-20 56.46 25.42 9.64 Favored 'General case' 0 C--N 1.324 -0.5 0 O-C-N 124.493 1.121 . . . . 0.0 109.296 179.977 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 79.41 27.93 53.78 Favored Glycine 0 CA--C 1.529 0.966 0 O-C-N 124.457 1.098 . . . . 0.0 111.021 179.999 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 40.1 mt -146.8 132.49 9.32 Favored Pre-proline 0 C--N 1.325 -0.469 0 O-C-N 124.47 0.747 . . . . 0.0 109.26 -179.986 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 20.1 Cg_endo -74.99 87.52 1.32 Allowed 'Trans proline' 0 N--CA 1.453 -0.895 0 O-C-N 124.543 1.812 . . . . 0.0 110.968 -168.319 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.425 ' CG2' ' HB3' ' A' ' 24' ' ' ARG . 18.2 m . . . . . 0 C--N 1.325 -0.465 0 O-C-N 124.532 1.145 . . . . 0.0 109.287 179.993 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 72.9 m . . . . . 0 N--CA 1.452 -0.336 0 N-CA-C 108.332 -0.988 . . . . 0.0 108.332 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 83.42 -10.96 57.67 Favored Glycine 0 CA--C 1.53 0.981 0 O-C-N 124.551 1.157 . . . . 0.0 110.988 179.981 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 7.7 pt-20 -100.28 171.59 7.68 Favored 'General case' 0 C--N 1.325 -0.46 0 O-C-N 124.493 0.76 . . . . 0.0 110.346 179.994 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 1.039 HG22 HG23 ' A' ' 21' ' ' VAL . 67.8 p -129.62 145.1 51.52 Favored 'General case' 0 C--N 1.325 -0.486 0 O-C-N 124.469 1.106 . . . . 0.0 110.455 179.997 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.429 ' O ' ' CD1' ' A' ' 19' ' ' TRP . 22.6 p -107.35 56.41 0.64 Allowed 'General case' 0 C--N 1.324 -0.524 0 O-C-N 124.52 1.138 . . . . 0.0 108.292 -179.95 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.4 t -59.45 -24.87 29.46 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 O-C-N 124.508 1.13 . . . . 0.0 109.284 -179.956 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -84.85 -35.1 13.55 Favored Glycine 0 CA--C 1.53 1.009 0 O-C-N 124.509 1.13 . . . . 0.0 110.981 -179.986 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 125.48 17.22 2.67 Favored Glycine 0 C--N 1.344 1.025 0 O-C-N 125.055 1.091 . . . . 0.0 111.047 177.698 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 2.4 m -150.33 155.62 39.99 Favored 'General case' 0 C--N 1.326 -0.45 0 O-C-N 124.484 0.755 . . . . 0.0 110.436 179.969 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 94.5 m -110.89 140.56 45.26 Favored 'General case' 0 C--N 1.325 -0.477 0 O-C-N 124.501 1.126 . . . . 0.0 108.268 -179.969 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 30.5 m-20 -90.01 -38.74 13.41 Favored 'General case' 0 C--N 1.325 -0.477 0 O-C-N 124.47 1.106 . . . . 0.0 109.306 -179.999 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.667 HG23 ' HD2' ' A' ' 13' ' ' PRO . 15.6 m -65.58 143.25 98.58 Favored Pre-proline 0 C--N 1.325 -0.474 0 O-C-N 124.521 1.138 . . . . 0.0 110.43 179.988 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.667 ' HD2' HG23 ' A' ' 12' ' ' THR . 20.3 Cg_endo -74.92 131.05 13.96 Favored 'Trans proline' 0 N--CA 1.453 -0.894 0 O-C-N 124.496 1.787 . . . . 0.0 110.976 -168.302 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 75.04 15.13 81.25 Favored Glycine 0 CA--C 1.53 1.02 0 O-C-N 124.504 1.128 . . . . 0.0 110.97 179.963 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.494 ' SG ' HG22 ' A' ' 12' ' ' THR . 64.3 m -98.1 127.61 44.14 Favored 'General case' 0 C--N 1.325 -0.464 0 N-CA-C 108.308 -0.997 . . . . 0.0 108.308 179.971 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 71.0 p -94.28 152.25 18.81 Favored 'General case' 0 C--N 1.325 -0.484 0 O-C-N 124.48 1.112 . . . . 0.0 110.44 179.97 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 47.4 t -78.18 98.09 5.72 Favored 'General case' 0 C--N 1.325 -0.492 0 O-C-N 124.479 1.112 . . . . 0.0 108.243 -179.951 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . 0.567 ' HB3' HG23 ' A' ' 23' ' ' THR . 10.8 t -104.78 65.89 0.76 Allowed 'General case' 0 C--N 1.324 -0.51 0 O-C-N 124.553 1.158 . . . . 0.0 109.958 174.442 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' TRP . . . . . 0.604 ' CG ' ' HA ' ' A' ' 20' ' ' PRO . 0.0 OUTLIER -36.88 147.87 0.2 Allowed Pre-proline 0 C--N 1.325 -0.489 0 O-C-N 124.505 1.128 . . . . 0.0 107.99 -174.18 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.604 ' HA ' ' CG ' ' A' ' 19' ' ' TRP . 18.1 Cg_endo -75.04 -12.57 24.07 Favored 'Cis proline' 0 C--N 1.36 1.144 0 C-N-CA 120.974 -2.511 . . . . 0.0 110.957 -8.505 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 1.039 HG23 HG22 ' A' ' 4' ' ' THR . 4.4 p -98.09 178.85 0.6 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 O-C-N 124.521 1.138 . . . . 0.0 109.289 -173.628 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.683 ' H ' HG22 ' A' ' 21' ' ' VAL . 1.7 m -101.95 168.51 9.36 Favored 'General case' 0 C--N 1.325 -0.477 0 O-C-N 124.49 1.119 . . . . 0.0 108.348 -179.993 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.567 HG23 ' HB3' ' A' ' 18' ' ' SER . 0.8 OUTLIER -145.34 168.31 20.8 Favored 'General case' 0 C--N 1.325 -0.488 0 O-C-N 124.486 1.116 . . . . 0.0 110.399 -179.976 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.468 ' HB3' ' CG2' ' A' ' 29' ' ' VAL . 29.3 ttt-85 -144.64 119.39 9.85 Favored 'General case' 0 C--N 1.324 -0.506 0 O-C-N 124.514 1.133 . . . . 0.0 110.332 -179.979 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 17.9 t-20 57.42 23.28 8.84 Favored 'General case' 0 C--N 1.325 -0.491 0 O-C-N 124.506 1.129 . . . . 0.0 109.293 -179.997 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 83.44 24.27 51.37 Favored Glycine 0 CA--C 1.53 0.974 0 O-C-N 124.514 1.134 . . . . 0.0 111.027 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 19.1 mt -147.3 128.27 7.09 Favored Pre-proline 0 C--N 1.325 -0.463 0 O-C-N 124.464 0.744 . . . . 0.0 109.325 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 20.2 Cg_endo -74.97 80.96 2.31 Favored 'Trans proline' 0 N--CA 1.453 -0.891 0 O-C-N 124.474 1.776 . . . . 0.0 110.972 -168.271 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.468 ' CG2' ' HB3' ' A' ' 24' ' ' ARG . 17.6 m . . . . . 0 C--N 1.325 -0.46 0 O-C-N 124.482 1.114 . . . . 0.0 109.289 -179.982 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 80.8 m . . . . . 0 N--CA 1.453 -0.319 0 N-CA-C 108.317 -0.994 . . . . 0.0 108.317 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 82.75 -10.69 55.96 Favored Glycine 0 CA--C 1.53 0.992 0 O-C-N 124.525 1.141 . . . . 0.0 111.042 -179.993 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 7.6 pt-20 -100.28 171.87 7.51 Favored 'General case' 0 C--N 1.325 -0.478 0 O-C-N 124.497 0.763 . . . . 0.0 110.288 179.98 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.975 HG22 HG23 ' A' ' 21' ' ' VAL . 46.1 p -128.92 144.36 51.16 Favored 'General case' 0 C--N 1.326 -0.452 0 O-C-N 124.463 1.102 . . . . 0.0 110.394 179.965 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.526 ' O ' ' CD1' ' A' ' 19' ' ' TRP . 15.1 p -103.08 52.39 0.78 Allowed 'General case' 0 C--N 1.325 -0.472 0 O-C-N 124.505 1.128 . . . . 0.0 108.291 -179.984 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.8 t -59.26 -25.01 29.26 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 O-C-N 124.502 1.127 . . . . 0.0 109.328 -179.986 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -84.63 -32.91 20.68 Favored Glycine 0 CA--C 1.529 0.966 0 O-C-N 124.522 1.138 . . . . 0.0 110.982 179.988 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 124.4 14.63 3.55 Favored Glycine 0 CA--C 1.531 1.049 0 O-C-N 124.892 0.995 . . . . 0.0 110.97 177.996 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 49.1 m -150.29 165.15 33.88 Favored 'General case' 0 C--N 1.325 -0.468 0 O-C-N 124.483 0.755 . . . . 0.0 110.374 -180.0 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 98.4 m -118.37 141.4 48.57 Favored 'General case' 0 C--N 1.326 -0.449 0 O-C-N 124.458 1.099 . . . . 0.0 108.272 -179.989 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 47.2 t30 -89.89 -39.84 12.79 Favored 'General case' 0 C--N 1.325 -0.467 0 O-C-N 124.51 1.131 . . . . 0.0 109.33 179.973 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.652 HG23 ' HD2' ' A' ' 13' ' ' PRO . 16.9 m -64.68 143.02 98.64 Favored Pre-proline 0 C--N 1.325 -0.472 0 O-C-N 124.495 1.122 . . . . 0.0 110.377 -179.993 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.652 ' HD2' HG23 ' A' ' 12' ' ' THR . 20.1 Cg_endo -75.01 130.65 13.46 Favored 'Trans proline' 0 N--CA 1.453 -0.875 0 O-C-N 124.502 1.791 . . . . 0.0 110.955 -168.298 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 76.22 12.82 83.85 Favored Glycine 0 CA--C 1.53 0.979 0 O-C-N 124.514 1.134 . . . . 0.0 111.02 -179.987 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.498 ' SG ' ' CG2' ' A' ' 12' ' ' THR . 64.9 m -95.7 127.48 41.76 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 108.318 -0.993 . . . . 0.0 108.318 179.964 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 29.9 p -94.5 150.16 20.53 Favored 'General case' 0 C--N 1.325 -0.472 0 O-C-N 124.456 1.098 . . . . 0.0 110.466 179.958 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 37.5 t -76.96 96.18 4.31 Favored 'General case' 0 C--N 1.324 -0.523 0 O-C-N 124.557 1.161 . . . . 0.0 108.283 179.988 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . 0.51 ' O ' ' C ' ' A' ' 19' ' ' TRP . 1.8 m -102.31 65.51 0.95 Allowed 'General case' 0 C--N 1.325 -0.482 0 O-C-N 124.506 1.128 . . . . 0.0 110.003 174.326 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' TRP . . . . . 0.602 ' CG ' ' HA ' ' A' ' 20' ' ' PRO . 0.0 OUTLIER -36.71 148.05 0.19 Allowed Pre-proline 0 C--N 1.325 -0.498 0 O-C-N 124.525 1.141 . . . . 0.0 108.008 -173.995 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.602 ' HA ' ' CG ' ' A' ' 19' ' ' TRP . 18.5 Cg_endo -74.93 -12.53 23.78 Favored 'Cis proline' 0 C--N 1.36 1.149 0 C-N-CA 121.03 -2.487 . . . . 0.0 111.015 -8.509 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.975 HG23 HG22 ' A' ' 4' ' ' THR . 5.8 p -98.87 177.38 0.69 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 O-C-N 124.475 1.11 . . . . 0.0 109.324 -173.279 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.683 ' H ' HG22 ' A' ' 21' ' ' VAL . 1.8 m -102.07 169.74 8.56 Favored 'General case' 0 C--N 1.324 -0.507 0 O-C-N 124.521 1.138 . . . . 0.0 108.314 179.973 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.416 ' O ' ' HA ' ' A' ' 15' ' ' CYS . 0.9 OUTLIER -149.5 165.05 33.35 Favored 'General case' 0 C--N 1.324 -0.518 0 O-C-N 124.49 1.119 . . . . 0.0 110.429 -179.931 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.555 ' HB3' HG22 ' A' ' 29' ' ' VAL . 10.9 ttt85 -141.22 119.68 12.32 Favored 'General case' 0 C--N 1.325 -0.488 0 O-C-N 124.49 1.119 . . . . 0.0 110.289 179.952 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . 0.405 ' O ' ' OD1' ' A' ' 25' ' ' ASN . 16.5 t-20 57.58 22.71 8.47 Favored 'General case' 0 C--N 1.325 -0.488 0 O-C-N 124.534 1.146 . . . . 0.0 109.329 -179.965 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . 0.463 ' O ' HD23 ' A' ' 27' ' ' LEU . . . 83.9 23.93 50.85 Favored Glycine 0 CA--C 1.53 0.997 0 O-C-N 124.533 1.146 . . . . 0.0 110.975 179.978 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.463 HD23 ' O ' ' A' ' 26' ' ' GLY . 13.8 mt -145.93 128.37 7.94 Favored Pre-proline 0 C--N 1.325 -0.48 0 O-C-N 124.551 0.795 . . . . 0.0 109.281 179.976 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 20.3 Cg_endo -74.98 77.42 3.13 Favored 'Trans proline' 0 N--CA 1.453 -0.892 0 O-C-N 124.503 1.791 . . . . 0.0 111.014 -168.327 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.555 HG22 ' HB3' ' A' ' 24' ' ' ARG . 36.0 m . . . . . 0 C--N 1.325 -0.458 0 O-C-N 124.527 1.142 . . . . 0.0 109.259 -179.994 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 87.2 m . . . . . 0 N--CA 1.452 -0.33 0 N-CA-C 108.322 -0.992 . . . . 0.0 108.322 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 91.31 -15.27 61.6 Favored Glycine 0 CA--C 1.53 1.023 0 O-C-N 124.504 1.127 . . . . 0.0 110.98 179.996 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 15.2 tt0 -88.3 162.25 16.7 Favored 'General case' 0 C--N 1.324 -0.509 0 O-C-N 124.534 0.785 . . . . 0.0 110.291 179.98 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.666 HG22 HG23 ' A' ' 21' ' ' VAL . 47.7 p -120.73 131.83 54.73 Favored 'General case' 0 C--N 1.325 -0.484 0 O-C-N 124.456 1.098 . . . . 0.0 110.389 -179.993 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.417 ' SG ' ' O ' ' A' ' 5' ' ' CYS . 14.6 p -100.11 52.08 0.9 Allowed 'General case' 0 C--N 1.325 -0.46 0 O-C-N 124.502 1.126 . . . . 0.0 108.316 179.963 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 11.9 t -59.27 -24.84 28.8 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 O-C-N 124.496 1.123 . . . . 0.0 109.318 179.951 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -84.54 -32.0 23.19 Favored Glycine 0 CA--C 1.53 0.983 0 O-C-N 124.503 1.127 . . . . 0.0 111.008 -179.945 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 123.84 15.91 3.44 Favored Glycine 0 CA--C 1.53 0.992 0 O-C-N 124.896 0.998 . . . . 0.0 110.996 178.112 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 62.2 m -150.11 165.57 32.41 Favored 'General case' 0 C--N 1.325 -0.476 0 O-C-N 124.508 0.769 . . . . 0.0 110.413 179.975 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . 0.405 ' SG ' ' O ' ' A' ' 16' ' ' THR . 96.9 m -122.15 143.45 49.55 Favored 'General case' 0 C--N 1.325 -0.464 0 O-C-N 124.512 1.133 . . . . 0.0 108.295 179.999 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 12.0 m-20 -90.11 -47.03 8.07 Favored 'General case' 0 C--N 1.324 -0.511 0 O-C-N 124.505 1.128 . . . . 0.0 109.26 -179.984 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.616 HG23 ' HD2' ' A' ' 13' ' ' PRO . 20.9 m -54.6 142.68 51.54 Favored Pre-proline 0 C--N 1.325 -0.461 0 O-C-N 124.462 1.101 . . . . 0.0 110.431 179.985 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.616 ' HD2' HG23 ' A' ' 12' ' ' THR . 20.1 Cg_endo -74.99 131.36 14.21 Favored 'Trans proline' 0 N--CA 1.453 -0.867 0 O-C-N 124.531 1.806 . . . . 0.0 110.977 -168.295 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 74.69 14.91 80.94 Favored Glycine 0 CA--C 1.53 1.028 0 O-C-N 124.495 1.122 . . . . 0.0 111.024 179.989 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.504 ' SG ' ' CG2' ' A' ' 12' ' ' THR . 63.9 m -96.08 134.58 38.95 Favored 'General case' 0 C--N 1.325 -0.483 0 N-CA-C 108.297 -1.001 . . . . 0.0 108.297 179.987 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . 0.405 ' O ' ' SG ' ' A' ' 10' ' ' CYS . 82.7 p -101.11 152.97 19.98 Favored 'General case' 0 C--N 1.325 -0.466 0 O-C-N 124.445 1.091 . . . . 0.0 110.401 179.975 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 41.3 t -79.71 94.41 5.72 Favored 'General case' 0 C--N 1.325 -0.481 0 O-C-N 124.52 1.138 . . . . 0.0 108.363 179.942 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . 0.517 ' O ' ' C ' ' A' ' 19' ' ' TRP . 17.5 t -101.45 65.48 1.05 Allowed 'General case' 0 C--N 1.325 -0.488 0 O-C-N 124.456 1.097 . . . . 0.0 110.002 174.236 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' TRP . . . . . 0.621 ' CG ' ' HA ' ' A' ' 20' ' ' PRO . 0.1 OUTLIER -36.14 147.01 0.19 Allowed Pre-proline 0 C--N 1.325 -0.477 0 O-C-N 124.515 1.134 . . . . 0.0 107.997 -174.129 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.621 ' HA ' ' CG ' ' A' ' 19' ' ' TRP . 18.2 Cg_endo -74.97 -13.76 23.37 Favored 'Cis proline' 0 C--N 1.36 1.166 0 C-N-CA 121.009 -2.496 . . . . 0.0 111.003 -8.557 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.666 HG23 HG22 ' A' ' 4' ' ' THR . 0.9 OUTLIER -97.35 178.04 0.63 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 O-C-N 124.449 1.093 . . . . 0.0 109.29 -173.148 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.491 ' H ' HG22 ' A' ' 21' ' ' VAL . 36.8 m -101.72 170.48 8.14 Favored 'General case' 0 C--N 1.325 -0.461 0 O-C-N 124.549 1.156 . . . . 0.0 108.289 -179.991 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.501 HG23 ' HB3' ' A' ' 18' ' ' SER . 0.8 OUTLIER -146.88 166.81 25.61 Favored 'General case' 0 C--N 1.325 -0.487 0 O-C-N 124.483 1.115 . . . . 0.0 110.404 179.985 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.581 ' HB3' HG22 ' A' ' 29' ' ' VAL . 2.5 ttt180 -139.05 119.28 13.61 Favored 'General case' 0 C--N 1.325 -0.487 0 O-C-N 124.514 1.134 . . . . 0.0 110.327 179.995 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 81.1 m-20 57.16 22.99 8.08 Favored 'General case' 0 C--N 1.325 -0.478 0 O-C-N 124.515 1.134 . . . . 0.0 109.333 -179.973 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 83.7 25.58 45.64 Favored Glycine 0 CA--C 1.53 0.997 0 O-C-N 124.519 1.137 . . . . 0.0 110.968 179.949 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 12.9 mt -145.57 130.38 9.01 Favored Pre-proline 0 C--N 1.325 -0.488 0 O-C-N 124.457 0.739 . . . . 0.0 109.309 179.991 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 20.1 Cg_endo -75.01 82.48 2.0 Allowed 'Trans proline' 0 N--CA 1.453 -0.91 0 O-C-N 124.505 1.792 . . . . 0.0 110.955 -168.309 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.581 HG22 ' HB3' ' A' ' 24' ' ' ARG . 28.2 m . . . . . 0 C--N 1.325 -0.465 0 O-C-N 124.528 1.142 . . . . 0.0 109.346 179.951 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 93.5 m . . . . . 0 N--CA 1.453 -0.287 0 N-CA-C 108.32 -0.993 . . . . 0.0 108.32 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 95.54 -15.2 63.66 Favored Glycine 0 CA--C 1.53 1.03 0 O-C-N 124.486 1.116 . . . . 0.0 110.995 179.987 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 15.1 tt0 -86.4 161.82 18.47 Favored 'General case' 0 C--N 1.325 -0.459 0 O-C-N 124.504 0.767 . . . . 0.0 110.287 -179.992 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.404 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 48.0 p -119.03 132.23 56.03 Favored 'General case' 0 C--N 1.324 -0.508 0 O-C-N 124.505 1.128 . . . . 0.0 110.406 179.987 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.427 ' O ' ' CD1' ' A' ' 19' ' ' TRP . 14.3 p -102.18 51.29 0.82 Allowed 'General case' 0 C--N 1.324 -0.509 0 O-C-N 124.531 1.144 . . . . 0.0 108.295 -179.965 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 6.6 t -59.27 -24.5 27.89 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 O-C-N 124.458 1.099 . . . . 0.0 109.289 -179.97 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -85.52 -34.31 14.25 Favored Glycine 0 CA--C 1.53 0.976 0 O-C-N 124.503 1.127 . . . . 0.0 111.041 -180.0 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 125.1 16.75 2.86 Favored Glycine 0 CA--C 1.53 1.0 0 O-C-N 124.945 1.026 . . . . 0.0 111.043 177.818 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 2.6 m -150.21 157.92 43.6 Favored 'General case' 0 C--N 1.325 -0.473 0 O-C-N 124.533 0.784 . . . . 0.0 110.414 -179.963 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . 0.411 ' SG ' ' O ' ' A' ' 16' ' ' THR . 84.0 m -118.59 144.56 46.03 Favored 'General case' 0 C--N 1.325 -0.471 0 O-C-N 124.487 1.117 . . . . 0.0 108.313 179.989 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 76.1 m-20 -89.86 -51.78 5.32 Favored 'General case' 0 C--N 1.325 -0.481 0 O-C-N 124.512 1.133 . . . . 0.0 109.314 179.977 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.605 HG23 ' HD2' ' A' ' 13' ' ' PRO . 22.0 m -49.72 142.58 12.19 Favored Pre-proline 0 C--N 1.325 -0.49 0 O-C-N 124.551 1.157 . . . . 0.0 110.405 179.982 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.605 ' HD2' HG23 ' A' ' 12' ' ' THR . 20.2 Cg_endo -74.99 131.7 14.59 Favored 'Trans proline' 0 N--CA 1.452 -0.947 0 O-C-N 124.45 1.763 . . . . 0.0 111.011 -168.267 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 74.36 13.78 81.31 Favored Glycine 0 CA--C 1.53 1.022 0 O-C-N 124.49 1.118 . . . . 0.0 111.009 -179.978 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.505 ' SG ' ' CG2' ' A' ' 12' ' ' THR . 67.4 m -96.31 126.18 41.34 Favored 'General case' 0 C--N 1.324 -0.504 0 N-CA-C 108.336 -0.987 . . . . 0.0 108.336 179.971 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . 0.411 ' O ' ' SG ' ' A' ' 10' ' ' CYS . 30.8 p -94.24 158.32 15.65 Favored 'General case' 0 C--N 1.325 -0.481 0 O-C-N 124.482 1.114 . . . . 0.0 110.387 -180.0 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 42.4 t -82.37 94.99 7.5 Favored 'General case' 0 C--N 1.325 -0.484 0 O-C-N 124.524 1.14 . . . . 0.0 108.339 179.968 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . 0.515 ' O ' ' C ' ' A' ' 19' ' ' TRP . 3.0 t -100.54 65.57 1.19 Allowed 'General case' 0 C--N 1.325 -0.463 0 O-C-N 124.526 1.141 . . . . 0.0 109.993 174.198 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' TRP . . . . . 0.592 ' CG ' ' HA ' ' A' ' 20' ' ' PRO . 0.0 OUTLIER -36.73 147.47 0.2 Allowed Pre-proline 0 C--N 1.325 -0.484 0 N-CA-C 107.958 -1.127 . . . . 0.0 107.958 -173.93 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.592 ' HA ' ' CG ' ' A' ' 19' ' ' TRP . 18.2 Cg_endo -75.04 -12.83 23.99 Favored 'Cis proline' 0 C--N 1.36 1.184 0 C-N-CA 120.968 -2.513 . . . . 0.0 111.003 -8.478 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.492 ' O ' ' C ' ' A' ' 18' ' ' SER . 16.3 m -98.05 179.24 0.58 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.494 0 O-C-N 124.514 1.134 . . . . 0.0 109.293 -173.478 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 51.9 m -101.77 168.08 9.68 Favored 'General case' 0 C--N 1.325 -0.488 0 O-C-N 124.54 1.15 . . . . 0.0 108.311 179.979 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.498 HG23 ' HB3' ' A' ' 18' ' ' SER . 0.8 OUTLIER -146.97 168.06 22.44 Favored 'General case' 0 C--N 1.325 -0.458 0 O-C-N 124.515 1.135 . . . . 0.0 110.382 179.999 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.485 ' HB3' HG22 ' A' ' 29' ' ' VAL . 0.3 OUTLIER -141.54 119.69 12.12 Favored 'General case' 0 C--N 1.325 -0.468 0 O-C-N 124.506 1.128 . . . . 0.0 110.279 179.993 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 17.5 t-20 57.84 23.07 9.27 Favored 'General case' 0 C--N 1.326 -0.455 0 O-C-N 124.479 1.112 . . . . 0.0 109.303 179.967 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . 0.441 ' O ' HD23 ' A' ' 27' ' ' LEU . . . 82.43 23.34 56.78 Favored Glycine 0 CA--C 1.53 1.019 0 O-C-N 124.467 1.104 . . . . 0.0 110.976 179.992 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.441 HD23 ' O ' ' A' ' 26' ' ' GLY . 11.9 mt -143.53 129.62 10.19 Favored Pre-proline 0 C--N 1.325 -0.498 0 O-C-N 124.461 0.742 . . . . 0.0 109.331 -179.997 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 20.5 Cg_endo -74.92 82.53 1.97 Allowed 'Trans proline' 0 N--CA 1.453 -0.861 0 O-C-N 124.516 1.798 . . . . 0.0 111.031 -168.343 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.485 HG22 ' HB3' ' A' ' 24' ' ' ARG . 27.4 m . . . . . 0 C--N 1.325 -0.484 0 O-C-N 124.489 1.118 . . . . 0.0 109.343 179.982 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 69.1 m . . . . . 0 N--CA 1.452 -0.328 0 N-CA-C 108.276 -1.009 . . . . 0.0 108.276 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 93.89 -15.7 62.51 Favored Glycine 0 CA--C 1.53 1.004 0 O-C-N 124.524 1.14 . . . . 0.0 110.995 179.97 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 15.5 tt0 -86.75 162.53 17.8 Favored 'General case' 0 C--N 1.326 -0.446 0 O-C-N 124.474 0.749 . . . . 0.0 110.322 -179.971 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.504 HG22 HG23 ' A' ' 21' ' ' VAL . 65.9 p -120.16 132.97 55.59 Favored 'General case' 0 C--N 1.325 -0.486 0 O-C-N 124.452 1.095 . . . . 0.0 110.398 179.961 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.425 ' SG ' ' O ' ' A' ' 5' ' ' CYS . 13.8 p -102.44 49.96 0.84 Allowed 'General case' 0 C--N 1.325 -0.457 0 O-C-N 124.449 1.093 . . . . 0.0 108.279 -179.981 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 15.1 t -59.09 -24.0 25.97 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 O-C-N 124.562 1.164 . . . . 0.0 109.351 179.947 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -83.61 -33.67 21.45 Favored Glycine 0 CA--C 1.53 1.0 0 O-C-N 124.488 1.118 . . . . 0.0 111.033 179.972 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 126.88 10.85 3.74 Favored Glycine 0 C--N 1.345 1.074 0 C-N-CA 119.774 -1.203 . . . . 0.0 110.989 177.917 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -149.92 166.96 28.0 Favored 'General case' 0 C--N 1.325 -0.496 0 O-C-N 124.522 0.778 . . . . 0.0 110.416 -179.994 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . 0.412 ' SG ' ' O ' ' A' ' 16' ' ' THR . 80.2 m -121.8 146.37 47.14 Favored 'General case' 0 C--N 1.325 -0.469 0 O-C-N 124.484 1.115 . . . . 0.0 108.293 179.996 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 22.2 t30 -92.41 -44.17 8.83 Favored 'General case' 0 C--N 1.325 -0.479 0 O-C-N 124.518 1.136 . . . . 0.0 109.306 -179.995 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.632 HG23 ' HD2' ' A' ' 13' ' ' PRO . 18.4 m -57.75 142.89 77.62 Favored Pre-proline 0 C--N 1.324 -0.506 0 O-C-N 124.495 1.122 . . . . 0.0 110.391 179.976 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.632 ' HD2' HG23 ' A' ' 12' ' ' THR . 20.3 Cg_endo -74.96 131.68 14.62 Favored 'Trans proline' 0 N--CA 1.453 -0.879 0 O-C-N 124.533 1.807 . . . . 0.0 111.003 -168.335 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 76.42 7.23 85.08 Favored Glycine 0 CA--C 1.53 0.985 0 O-C-N 124.428 1.08 . . . . 0.0 111.007 179.985 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.5 ' SG ' ' CG2' ' A' ' 12' ' ' THR . 69.2 m -92.14 126.28 37.16 Favored 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 108.283 -1.006 . . . . 0.0 108.283 -179.998 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . 0.412 ' O ' ' SG ' ' A' ' 10' ' ' CYS . 34.3 p -95.28 156.52 16.29 Favored 'General case' 0 C--N 1.325 -0.484 0 O-C-N 124.543 1.152 . . . . 0.0 110.378 179.997 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 42.7 t -80.99 94.12 6.49 Favored 'General case' 0 C--N 1.325 -0.478 0 O-C-N 124.532 1.145 . . . . 0.0 108.276 -179.964 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . 0.518 ' O ' ' C ' ' A' ' 19' ' ' TRP . 3.6 t -100.36 65.51 1.22 Allowed 'General case' 0 C--N 1.325 -0.484 0 O-C-N 124.506 1.128 . . . . 0.0 110.006 174.172 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' TRP . . . . . 0.603 ' CG ' ' HA ' ' A' ' 20' ' ' PRO . 0.0 OUTLIER -36.3 147.42 0.19 Allowed Pre-proline 0 C--N 1.325 -0.465 0 N-CA-C 107.992 -1.114 . . . . 0.0 107.992 -173.981 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.603 ' HA ' ' CG ' ' A' ' 19' ' ' TRP . 18.3 Cg_endo -75.03 -12.92 23.97 Favored 'Cis proline' 0 C--N 1.36 1.166 0 C-N-CA 121.035 -2.485 . . . . 0.0 110.981 -8.374 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.69 HG22 ' H ' ' A' ' 22' ' ' CYS . 4.6 p -99.02 179.16 0.6 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.5 0 O-C-N 124.502 1.126 . . . . 0.0 109.292 -173.284 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.69 ' H ' HG22 ' A' ' 21' ' ' VAL . 53.3 m -101.63 168.9 9.18 Favored 'General case' 0 C--N 1.325 -0.473 0 O-C-N 124.476 1.11 . . . . 0.0 108.358 179.986 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.441 ' OG1' ' CB ' ' A' ' 18' ' ' SER . 0.8 OUTLIER -148.36 167.54 24.97 Favored 'General case' 0 C--N 1.325 -0.488 0 O-C-N 124.5 1.125 . . . . 0.0 110.389 -179.986 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.552 ' HB3' HG22 ' A' ' 29' ' ' VAL . 1.4 ttt85 -137.72 120.04 15.8 Favored 'General case' 0 C--N 1.325 -0.472 0 O-C-N 124.493 1.121 . . . . 0.0 110.263 -179.961 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 58.4 t30 56.3 23.33 7.11 Favored 'General case' 0 C--N 1.325 -0.48 0 O-C-N 124.521 1.138 . . . . 0.0 109.288 179.972 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . 0.615 ' O ' HD23 ' A' ' 27' ' ' LEU . . . 81.99 28.85 40.08 Favored Glycine 0 CA--C 1.53 0.992 0 O-C-N 124.513 1.133 . . . . 0.0 111.014 -179.988 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.615 HD23 ' O ' ' A' ' 26' ' ' GLY . 22.9 mt -147.27 130.2 7.96 Favored Pre-proline 0 C--N 1.325 -0.461 0 O-C-N 124.513 0.772 . . . . 0.0 109.284 179.957 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 20.2 Cg_endo -75.0 84.28 1.69 Allowed 'Trans proline' 0 N--CA 1.453 -0.881 0 O-C-N 124.488 1.783 . . . . 0.0 110.995 -168.332 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.552 HG22 ' HB3' ' A' ' 24' ' ' ARG . 30.4 m . . . . . 0 C--N 1.326 -0.447 0 O-C-N 124.482 1.114 . . . . 0.0 109.308 179.962 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 16.7 m . . . . . 0 N--CA 1.453 -0.303 0 N-CA-C 108.314 -0.995 . . . . 0.0 108.314 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 92.96 -20.03 48.24 Favored Glycine 0 CA--C 1.53 1.021 0 O-C-N 124.49 1.119 . . . . 0.0 111.001 179.97 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 15.6 tt0 -83.86 162.07 20.67 Favored 'General case' 0 C--N 1.325 -0.475 0 O-C-N 124.487 0.757 . . . . 0.0 110.353 179.976 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.544 HG22 HG13 ' A' ' 21' ' ' VAL . 53.3 p -123.13 132.84 54.24 Favored 'General case' 0 C--N 1.325 -0.478 0 O-C-N 124.455 1.097 . . . . 0.0 110.371 -179.98 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.404 ' SG ' ' O ' ' A' ' 5' ' ' CYS . 16.4 p -100.34 55.22 0.9 Allowed 'General case' 0 C--N 1.326 -0.447 0 O-C-N 124.508 1.13 . . . . 0.0 108.337 179.94 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 9.6 t -59.33 -25.35 30.52 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 O-C-N 124.45 1.094 . . . . 0.0 109.245 -179.944 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -83.79 -30.68 28.68 Favored Glycine 0 CA--C 1.529 0.964 0 O-C-N 124.52 1.138 . . . . 0.0 111.006 179.991 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 122.3 14.23 4.55 Favored Glycine 0 CA--C 1.53 1.013 0 O-C-N 125.006 1.062 . . . . 0.0 110.988 178.694 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 42.5 m -149.95 164.15 36.2 Favored 'General case' 0 C--N 1.325 -0.484 0 O-C-N 124.54 0.788 . . . . 0.0 110.362 -180.0 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . 0.401 ' SG ' ' O ' ' A' ' 16' ' ' THR . 97.2 m -120.45 140.98 50.59 Favored 'General case' 0 C--N 1.326 -0.447 0 O-C-N 124.467 1.104 . . . . 0.0 108.292 179.991 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 37.6 t30 -89.74 -45.02 9.59 Favored 'General case' 0 C--N 1.325 -0.463 0 O-C-N 124.493 1.121 . . . . 0.0 109.298 179.977 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.634 HG23 ' HD2' ' A' ' 13' ' ' PRO . 18.3 m -56.02 143.05 63.9 Favored Pre-proline 0 C--N 1.326 -0.453 0 O-C-N 124.462 1.101 . . . . 0.0 110.417 179.973 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.634 ' HD2' HG23 ' A' ' 12' ' ' THR . 20.2 Cg_endo -74.97 130.3 13.18 Favored 'Trans proline' 0 N--CA 1.452 -0.917 0 O-C-N 124.508 1.793 . . . . 0.0 110.987 -168.329 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 75.12 15.29 81.19 Favored Glycine 0 CA--C 1.53 0.995 0 O-C-N 124.442 1.089 . . . . 0.0 111.035 -179.999 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.5 ' SG ' ' CG2' ' A' ' 12' ' ' THR . 57.6 m -96.62 129.88 43.92 Favored 'General case' 0 C--N 1.325 -0.489 0 N-CA-C 108.323 -0.991 . . . . 0.0 108.323 179.999 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . 0.401 ' O ' ' SG ' ' A' ' 10' ' ' CYS . 21.6 p -95.99 152.7 18.28 Favored 'General case' 0 C--N 1.325 -0.472 0 O-C-N 124.497 1.123 . . . . 0.0 110.366 -179.965 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 45.0 t -82.99 95.86 8.14 Favored 'General case' 0 C--N 1.325 -0.498 0 O-C-N 124.483 1.115 . . . . 0.0 108.285 179.973 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . 0.778 ' OG ' HG23 ' A' ' 23' ' ' THR . 34.6 p -105.88 66.39 0.72 Allowed 'General case' 0 C--N 1.326 -0.453 0 O-C-N 124.464 1.102 . . . . 0.0 110.023 174.144 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' TRP . . . . . 0.642 ' CG ' ' HA ' ' A' ' 20' ' ' PRO . 0.8 OUTLIER -35.79 146.7 0.19 Allowed Pre-proline 0 C--N 1.324 -0.51 0 O-C-N 124.552 1.158 . . . . 0.0 107.975 -174.399 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.642 ' HA ' ' CG ' ' A' ' 19' ' ' TRP . 18.2 Cg_endo -75.04 -14.83 22.94 Favored 'Cis proline' 0 C--N 1.36 1.159 0 C-N-CA 120.954 -2.519 . . . . 0.0 111.005 -8.67 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.614 HG12 ' H ' ' A' ' 22' ' ' CYS . 2.2 t -96.38 175.97 0.74 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.479 0 O-C-N 124.496 1.122 . . . . 0.0 109.31 -172.992 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.614 ' H ' HG12 ' A' ' 21' ' ' VAL . 33.4 m -102.47 170.13 8.24 Favored 'General case' 0 C--N 1.325 -0.481 0 O-C-N 124.465 1.103 . . . . 0.0 108.298 179.977 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.778 HG23 ' OG ' ' A' ' 18' ' ' SER . 1.0 OUTLIER -141.7 168.4 19.85 Favored 'General case' 0 C--N 1.325 -0.469 0 O-C-N 124.483 1.115 . . . . 0.0 110.427 179.949 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.643 ' HB3' HG22 ' A' ' 29' ' ' VAL . 0.1 OUTLIER -137.0 115.33 11.77 Favored 'General case' 0 C--N 1.325 -0.478 0 O-C-N 124.514 1.133 . . . . 0.0 110.297 -179.984 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 86.9 m-20 57.2 21.84 6.98 Favored 'General case' 0 C--N 1.325 -0.47 0 O-C-N 124.48 1.113 . . . . 0.0 109.295 -179.986 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 87.15 25.52 33.73 Favored Glycine 0 CA--C 1.531 1.049 0 O-C-N 124.464 1.102 . . . . 0.0 110.966 179.975 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 12.8 mt -145.03 130.29 9.3 Favored Pre-proline 0 C--N 1.325 -0.485 0 O-C-N 124.535 0.785 . . . . 0.0 109.289 -179.961 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 20.1 Cg_endo -74.97 79.99 2.53 Favored 'Trans proline' 0 N--CA 1.452 -0.927 0 O-C-N 124.515 1.797 . . . . 0.0 111.008 -168.285 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.643 HG22 ' HB3' ' A' ' 24' ' ' ARG . 18.0 m . . . . . 0 C--N 1.325 -0.482 0 O-C-N 124.51 1.131 . . . . 0.0 109.307 -179.99 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 83.6 m . . . . . 0 N--CA 1.454 -0.266 0 N-CA-C 108.297 -1.001 . . . . 0.0 108.297 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 103.53 -21.09 40.1 Favored Glycine 0 CA--C 1.53 1.01 0 O-C-N 124.515 1.135 . . . . 0.0 110.989 179.981 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 28.5 tt0 -84.4 150.45 25.33 Favored 'General case' 0 C--N 1.324 -0.5 0 O-C-N 124.456 0.739 . . . . 0.0 110.333 179.977 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.427 HG22 HG13 ' A' ' 21' ' ' VAL . 66.0 p -109.74 129.91 55.57 Favored 'General case' 0 C--N 1.325 -0.499 0 O-C-N 124.508 1.13 . . . . 0.0 110.429 -179.983 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.42 ' SG ' ' O ' ' A' ' 5' ' ' CYS . 14.2 p -97.16 51.06 1.09 Allowed 'General case' 0 C--N 1.325 -0.474 0 O-C-N 124.523 1.14 . . . . 0.0 108.292 -179.988 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 9.4 t -59.03 -24.74 27.78 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 O-C-N 124.481 1.113 . . . . 0.0 109.317 179.966 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -83.96 -32.6 23.3 Favored Glycine 0 CA--C 1.53 1.028 0 O-C-N 124.512 1.132 . . . . 0.0 110.989 179.999 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 124.73 14.21 3.54 Favored Glycine 0 C--N 1.344 1.004 0 O-C-N 125.103 1.12 . . . . 0.0 111.013 177.972 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -149.6 166.73 28.39 Favored 'General case' 0 C--N 1.325 -0.476 0 O-C-N 124.501 0.765 . . . . 0.0 110.384 179.95 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . 0.406 ' SG ' ' O ' ' A' ' 16' ' ' THR . 75.9 m -123.78 141.96 51.54 Favored 'General case' 0 C--N 1.326 -0.449 0 O-C-N 124.466 1.104 . . . . 0.0 108.279 -179.981 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 34.0 t-20 -89.87 -43.07 10.86 Favored 'General case' 0 C--N 1.325 -0.457 0 O-C-N 124.492 1.12 . . . . 0.0 109.29 -179.998 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.617 HG23 ' HD2' ' A' ' 13' ' ' PRO . 20.2 m -58.35 142.8 81.17 Favored Pre-proline 0 C--N 1.325 -0.485 0 O-C-N 124.427 1.079 . . . . 0.0 110.355 -179.981 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.617 ' HD2' HG23 ' A' ' 12' ' ' THR . 20.2 Cg_endo -74.99 131.59 14.48 Favored 'Trans proline' 0 N--CA 1.453 -0.868 0 O-C-N 124.501 1.79 . . . . 0.0 110.997 -168.322 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 74.1 13.73 80.91 Favored Glycine 0 CA--C 1.53 1.025 0 O-C-N 124.482 1.114 . . . . 0.0 110.985 179.975 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.496 ' SG ' ' CG2' ' A' ' 12' ' ' THR . 66.8 m -97.29 125.93 42.19 Favored 'General case' 0 C--N 1.325 -0.469 0 N-CA-C 108.313 -0.995 . . . . 0.0 108.313 179.97 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . 0.406 ' O ' ' SG ' ' A' ' 10' ' ' CYS . 68.9 p -93.48 156.07 16.97 Favored 'General case' 0 C--N 1.325 -0.483 0 O-C-N 124.481 1.113 . . . . 0.0 110.383 -179.969 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 43.1 t -82.26 91.53 6.78 Favored 'General case' 0 C--N 1.325 -0.486 0 O-C-N 124.535 1.147 . . . . 0.0 108.301 -179.985 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . 0.598 ' HB2' HG23 ' A' ' 23' ' ' THR . 3.8 m -98.87 65.81 1.54 Allowed 'General case' 0 C--N 1.325 -0.488 0 O-C-N 124.477 1.111 . . . . 0.0 110.008 174.052 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' TRP . . . . . 0.608 ' CG ' ' HA ' ' A' ' 20' ' ' PRO . 0.1 OUTLIER -35.63 147.12 0.17 Allowed Pre-proline 0 C--N 1.325 -0.5 0 O-C-N 124.556 1.16 . . . . 0.0 107.971 -173.996 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.608 ' HA ' ' CG ' ' A' ' 19' ' ' TRP . 18.4 Cg_endo -74.91 -13.48 23.37 Favored 'Cis proline' 0 C--N 1.36 1.16 0 C-N-CA 121.01 -2.496 . . . . 0.0 111.037 -8.647 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.635 HG12 ' H ' ' A' ' 22' ' ' CYS . 2.2 t -99.11 177.91 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 O-C-N 124.472 1.108 . . . . 0.0 109.288 -173.032 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.635 ' H ' HG12 ' A' ' 21' ' ' VAL . 69.3 m -101.98 169.1 8.98 Favored 'General case' 0 C--N 1.325 -0.485 0 O-C-N 124.501 1.126 . . . . 0.0 108.288 -179.957 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.598 HG23 ' HB2' ' A' ' 18' ' ' SER . 1.1 p -144.26 160.54 40.82 Favored 'General case' 0 C--N 1.325 -0.484 0 O-C-N 124.458 1.099 . . . . 0.0 110.398 179.982 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.607 ' HB3' HG22 ' A' ' 29' ' ' VAL . 1.1 ttt85 -132.23 118.33 19.37 Favored 'General case' 0 C--N 1.325 -0.471 0 O-C-N 124.537 1.148 . . . . 0.0 110.292 -179.985 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 76.2 m-20 57.47 24.55 10.37 Favored 'General case' 0 C--N 1.324 -0.514 0 O-C-N 124.535 1.147 . . . . 0.0 109.289 -179.973 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 82.59 23.36 56.43 Favored Glycine 0 CA--C 1.53 1.024 0 O-C-N 124.586 1.179 . . . . 0.0 111.002 179.982 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 8.0 mt -143.26 129.91 10.52 Favored Pre-proline 0 C--N 1.325 -0.499 0 O-C-N 124.548 0.793 . . . . 0.0 109.337 179.978 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 20.1 Cg_endo -74.99 81.95 2.1 Favored 'Trans proline' 0 N--CA 1.453 -0.87 0 O-C-N 124.511 1.795 . . . . 0.0 110.997 -168.279 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.607 HG22 ' HB3' ' A' ' 24' ' ' ARG . 21.9 m . . . . . 0 C--N 1.325 -0.477 0 O-C-N 124.517 1.136 . . . . 0.0 109.312 179.991 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 83.5 m . . . . . 0 N--CA 1.453 -0.301 0 N-CA-C 108.28 -1.007 . . . . 0.0 108.28 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 91.62 -17.58 55.75 Favored Glycine 0 CA--C 1.53 1.006 0 O-C-N 124.431 1.082 . . . . 0.0 110.994 -179.961 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 15.5 tt0 -85.59 161.72 19.17 Favored 'General case' 0 C--N 1.325 -0.471 0 O-C-N 124.47 0.747 . . . . 0.0 110.314 179.976 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.692 HG22 HG23 ' A' ' 21' ' ' VAL . 47.5 p -120.54 132.0 54.96 Favored 'General case' 0 C--N 1.325 -0.498 0 O-C-N 124.52 1.138 . . . . 0.0 110.456 179.978 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.417 ' SG ' ' O ' ' A' ' 5' ' ' CYS . 14.5 p -98.97 51.64 0.96 Allowed 'General case' 0 C--N 1.325 -0.475 0 O-C-N 124.475 1.109 . . . . 0.0 108.286 -179.977 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 9.0 t -59.22 -24.99 29.07 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 O-C-N 124.497 1.123 . . . . 0.0 109.288 -179.988 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -84.32 -32.25 23.18 Favored Glycine 0 CA--C 1.53 0.979 0 O-C-N 124.507 1.129 . . . . 0.0 111.062 179.961 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 124.37 13.98 3.75 Favored Glycine 0 CA--C 1.529 0.969 0 O-C-N 125.024 1.073 . . . . 0.0 111.036 178.176 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 45.8 m -149.93 164.76 34.58 Favored 'General case' 0 C--N 1.325 -0.47 0 O-C-N 124.514 0.773 . . . . 0.0 110.427 179.995 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . 0.405 ' SG ' ' O ' ' A' ' 16' ' ' THR . 94.2 m -121.67 143.16 49.5 Favored 'General case' 0 C--N 1.325 -0.491 0 O-C-N 124.469 1.106 . . . . 0.0 108.254 -179.955 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 76.1 m-20 -90.26 -47.84 7.53 Favored 'General case' 0 C--N 1.325 -0.458 0 O-C-N 124.439 1.087 . . . . 0.0 109.273 -179.982 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.62 HG23 ' HD2' ' A' ' 13' ' ' PRO . 19.5 m -53.16 142.7 36.3 Favored Pre-proline 0 C--N 1.325 -0.474 0 O-C-N 124.495 1.122 . . . . 0.0 110.397 180.0 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.62 ' HD2' HG23 ' A' ' 12' ' ' THR . 20.4 Cg_endo -74.94 131.63 14.59 Favored 'Trans proline' 0 N--CA 1.453 -0.856 0 O-C-N 124.495 1.787 . . . . 0.0 110.975 -168.328 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 73.97 15.81 79.64 Favored Glycine 0 CA--C 1.53 0.977 0 O-C-N 124.524 1.14 . . . . 0.0 110.984 179.953 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.503 ' SG ' ' CG2' ' A' ' 12' ' ' THR . 63.8 m -97.64 131.5 44.15 Favored 'General case' 0 C--N 1.325 -0.47 0 N-CA-C 108.265 -1.013 . . . . 0.0 108.265 -179.991 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . 0.405 ' O ' ' SG ' ' A' ' 10' ' ' CYS . 73.1 p -98.37 154.68 17.67 Favored 'General case' 0 C--N 1.325 -0.494 0 O-C-N 124.533 1.145 . . . . 0.0 110.405 -180.0 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 44.4 t -82.19 94.69 7.33 Favored 'General case' 0 C--N 1.325 -0.478 0 O-C-N 124.461 1.101 . . . . 0.0 108.261 -179.976 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . 0.517 ' O ' ' C ' ' A' ' 19' ' ' TRP . 40.8 t -102.23 66.02 0.98 Allowed 'General case' 0 C--N 1.325 -0.494 0 O-C-N 124.506 1.129 . . . . 0.0 109.964 174.045 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' TRP . . . . . 0.619 ' CG ' ' HA ' ' A' ' 20' ' ' PRO . 0.1 OUTLIER -35.92 147.13 0.18 Allowed Pre-proline 0 C--N 1.325 -0.464 0 O-C-N 124.48 1.112 . . . . 0.0 108.02 -174.211 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.619 ' HA ' ' CG ' ' A' ' 19' ' ' TRP . 18.3 Cg_endo -75.03 -13.9 23.44 Favored 'Cis proline' 0 C--N 1.36 1.148 0 C-N-CA 120.991 -2.504 . . . . 0.0 110.972 -8.69 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.692 HG23 HG22 ' A' ' 4' ' ' THR . 0.8 OUTLIER -97.63 177.0 0.69 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 O-C-N 124.512 1.132 . . . . 0.0 109.301 -172.977 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.467 ' H ' HG22 ' A' ' 21' ' ' VAL . 52.7 m -102.0 171.19 7.65 Favored 'General case' 0 C--N 1.325 -0.493 0 O-C-N 124.508 1.13 . . . . 0.0 108.292 -179.995 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.425 ' O ' ' HA ' ' A' ' 15' ' ' CYS . 0.9 OUTLIER -148.83 168.09 23.92 Favored 'General case' 0 C--N 1.325 -0.486 0 O-C-N 124.543 1.152 . . . . 0.0 110.342 179.993 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.495 ' HB3' HG22 ' A' ' 29' ' ' VAL . 8.6 ttt180 -140.57 118.67 11.94 Favored 'General case' 0 C--N 1.326 -0.451 0 O-C-N 124.459 1.099 . . . . 0.0 110.335 179.982 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 14.6 t-20 58.2 22.75 9.51 Favored 'General case' 0 C--N 1.325 -0.465 0 O-C-N 124.494 1.121 . . . . 0.0 109.319 -179.967 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 82.72 22.67 57.69 Favored Glycine 0 CA--C 1.53 0.982 0 O-C-N 124.435 1.085 . . . . 0.0 111.012 -179.997 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 6.2 mt -141.68 130.56 12.28 Favored Pre-proline 0 C--N 1.325 -0.467 0 O-C-N 124.478 0.752 . . . . 0.0 109.286 -179.985 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 20.1 Cg_endo -74.98 83.82 1.75 Allowed 'Trans proline' 0 N--CA 1.453 -0.904 0 O-C-N 124.468 1.773 . . . . 0.0 110.975 -168.258 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.495 HG22 ' HB3' ' A' ' 24' ' ' ARG . 35.5 m . . . . . 0 C--N 1.325 -0.477 0 O-C-N 124.507 1.13 . . . . 0.0 109.29 179.982 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 99.6 m . . . . . 0 N--CA 1.453 -0.286 0 N-CA-C 108.316 -0.994 . . . . 0.0 108.316 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 91.78 -26.92 10.83 Favored Glycine 0 CA--C 1.53 1.015 0 O-C-N 124.477 1.11 . . . . 0.0 111.005 179.98 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 25.3 tt0 -81.46 152.73 27.22 Favored 'General case' 0 C--N 1.326 -0.453 0 O-C-N 124.49 0.759 . . . . 0.0 110.258 -179.959 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.659 HG22 HG23 ' A' ' 21' ' ' VAL . 76.2 p -113.26 134.88 54.38 Favored 'General case' 0 C--N 1.325 -0.495 0 O-C-N 124.519 1.137 . . . . 0.0 110.394 179.962 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.41 ' SG ' ' O ' ' A' ' 5' ' ' CYS . 15.0 p -98.79 52.65 0.99 Allowed 'General case' 0 C--N 1.326 -0.454 0 O-C-N 124.495 1.122 . . . . 0.0 108.332 179.965 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 8.6 t -59.32 -24.73 28.68 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 O-C-N 124.492 1.12 . . . . 0.0 109.301 -179.97 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -84.13 -34.06 18.79 Favored Glycine 0 CA--C 1.529 0.968 0 O-C-N 124.505 1.128 . . . . 0.0 110.975 -179.984 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 126.54 14.63 2.85 Favored Glycine 0 C--N 1.345 1.047 0 O-C-N 125.13 1.135 . . . . 0.0 110.998 177.776 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -150.0 166.94 28.15 Favored 'General case' 0 C--N 1.325 -0.488 0 O-C-N 124.53 0.782 . . . . 0.0 110.413 179.981 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . 0.408 ' SG ' ' O ' ' A' ' 16' ' ' THR . 72.8 m -124.22 141.78 51.78 Favored 'General case' 0 C--N 1.324 -0.52 0 O-C-N 124.54 1.15 . . . . 0.0 108.343 179.946 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 32.4 t-20 -89.65 -43.29 10.84 Favored 'General case' 0 C--N 1.325 -0.474 0 O-C-N 124.527 1.142 . . . . 0.0 109.335 -180.0 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.614 HG23 ' HD2' ' A' ' 13' ' ' PRO . 20.0 m -57.67 142.71 77.41 Favored Pre-proline 0 C--N 1.326 -0.448 0 O-C-N 124.505 1.128 . . . . 0.0 110.399 179.989 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.614 ' HD2' HG23 ' A' ' 12' ' ' THR . 20.1 Cg_endo -75.01 132.33 15.28 Favored 'Trans proline' 0 N--CA 1.453 -0.895 0 O-C-N 124.506 1.793 . . . . 0.0 110.99 -168.306 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 73.62 13.28 80.37 Favored Glycine 0 CA--C 1.529 0.969 0 O-C-N 124.476 1.11 . . . . 0.0 111.016 -179.98 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.511 ' SG ' HG22 ' A' ' 12' ' ' THR . 68.7 m -97.49 125.65 42.3 Favored 'General case' 0 C--N 1.325 -0.479 0 N-CA-C 108.29 -1.004 . . . . 0.0 108.29 -179.983 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . 0.468 ' HG1' ' HG1' ' A' ' 23' ' ' THR . 70.7 p -93.61 156.82 16.5 Favored 'General case' 0 C--N 1.325 -0.491 0 O-C-N 124.558 1.161 . . . . 0.0 110.437 179.977 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 42.7 t -82.86 94.98 7.8 Favored 'General case' 0 C--N 1.325 -0.482 0 O-C-N 124.447 1.092 . . . . 0.0 108.315 -179.993 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . 0.528 ' CB ' HG23 ' A' ' 23' ' ' THR . 1.0 OUTLIER -102.48 66.39 0.97 Allowed 'General case' 0 C--N 1.325 -0.486 0 O-C-N 124.494 1.121 . . . . 0.0 109.968 173.987 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' TRP . . . . . 0.614 ' CG ' ' HA ' ' A' ' 20' ' ' PRO . 0.1 OUTLIER -35.51 147.15 0.17 Allowed Pre-proline 0 C--N 1.326 -0.453 0 O-C-N 124.497 1.123 . . . . 0.0 108.0 -174.085 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.614 ' HA ' ' CG ' ' A' ' 19' ' ' TRP . 18.3 Cg_endo -75.0 -13.85 23.39 Favored 'Cis proline' 0 C--N 1.36 1.135 0 C-N-CA 120.967 -2.514 . . . . 0.0 111.013 -8.645 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.659 HG23 HG22 ' A' ' 4' ' ' THR . 2.8 p -99.13 178.08 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 O-C-N 124.512 1.132 . . . . 0.0 109.34 -172.964 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.603 ' H ' HG22 ' A' ' 21' ' ' VAL . 66.7 m -102.29 172.75 6.71 Favored 'General case' 0 C--N 1.325 -0.471 0 O-C-N 124.486 1.116 . . . . 0.0 108.301 179.993 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.528 HG23 ' CB ' ' A' ' 18' ' ' SER . 8.4 p -146.59 159.31 43.61 Favored 'General case' 0 C--N 1.325 -0.467 0 O-C-N 124.486 1.117 . . . . 0.0 110.391 -179.985 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.56 ' HB3' HG22 ' A' ' 29' ' ' VAL . 0.5 OUTLIER -131.81 117.68 18.87 Favored 'General case' 0 C--N 1.325 -0.483 0 O-C-N 124.498 1.124 . . . . 0.0 110.291 179.965 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 78.8 m-20 57.52 23.4 9.14 Favored 'General case' 0 C--N 1.325 -0.469 0 O-C-N 124.491 1.119 . . . . 0.0 109.298 -179.987 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 84.04 23.01 53.71 Favored Glycine 0 CA--C 1.53 0.99 0 O-C-N 124.428 1.08 . . . . 0.0 110.983 179.988 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 8.1 mt -143.06 129.99 10.71 Favored Pre-proline 0 C--N 1.325 -0.481 0 O-C-N 124.476 0.751 . . . . 0.0 109.29 179.972 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 20.2 Cg_endo -74.99 85.66 1.5 Allowed 'Trans proline' 0 N--CA 1.453 -0.88 0 O-C-N 124.508 1.794 . . . . 0.0 110.965 -168.287 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.56 HG22 ' HB3' ' A' ' 24' ' ' ARG . 33.5 m . . . . . 0 C--N 1.325 -0.472 0 O-C-N 124.542 1.151 . . . . 0.0 109.324 179.968 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . 0.406 ' SG ' ' O ' ' A' ' 23' ' ' THR . 20.0 m . . . . . 0 N--CA 1.452 -0.333 0 N-CA-C 108.302 -0.999 . . . . 0.0 108.302 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 108.48 -11.0 36.03 Favored Glycine 0 CA--C 1.53 0.985 0 O-C-N 124.524 1.14 . . . . 0.0 111.011 179.982 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 15.4 mt-10 -99.99 164.4 12.01 Favored 'General case' 0 C--N 1.326 -0.449 0 O-C-N 124.465 0.744 . . . . 0.0 110.282 -179.975 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 76.5 p -122.22 134.81 54.7 Favored 'General case' 0 C--N 1.325 -0.499 0 O-C-N 124.455 1.097 . . . . 0.0 110.44 179.99 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.441 ' SG ' ' O ' ' A' ' 5' ' ' CYS . 11.8 p -101.7 48.23 0.89 Allowed 'General case' 0 C--N 1.325 -0.475 0 O-C-N 124.493 1.121 . . . . 0.0 108.295 -179.965 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 27.0 t -59.06 -23.61 24.82 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 O-C-N 124.511 1.132 . . . . 0.0 109.266 -179.992 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -87.82 -29.14 21.78 Favored Glycine 0 CA--C 1.53 1.027 0 O-C-N 124.51 1.132 . . . . 0.0 111.002 179.986 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 121.7 16.1 4.24 Favored Glycine 0 CA--C 1.531 1.036 0 O-C-N 124.964 1.038 . . . . 0.0 111.015 178.398 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 89.8 m -150.18 166.29 30.3 Favored 'General case' 0 C--N 1.325 -0.493 0 O-C-N 124.513 0.772 . . . . 0.0 110.415 179.942 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . 0.407 ' SG ' ' O ' ' A' ' 16' ' ' THR . 87.9 m -124.38 143.95 50.31 Favored 'General case' 0 C--N 1.325 -0.476 0 O-C-N 124.526 1.141 . . . . 0.0 108.306 179.979 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 18.9 t30 -89.78 -50.44 6.05 Favored 'General case' 0 C--N 1.325 -0.486 0 O-C-N 124.489 1.118 . . . . 0.0 109.353 179.978 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.632 HG23 ' HD2' ' A' ' 13' ' ' PRO . 18.5 m -52.32 142.77 28.4 Favored Pre-proline 0 C--N 1.325 -0.479 0 O-C-N 124.464 1.102 . . . . 0.0 110.406 -179.999 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.632 ' HD2' HG23 ' A' ' 12' ' ' THR . 20.1 Cg_endo -74.95 129.52 12.47 Favored 'Trans proline' 0 N--CA 1.453 -0.892 0 O-C-N 124.504 1.792 . . . . 0.0 110.991 -168.284 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.416 ' HA3' ' NH1' ' A' ' 24' ' ' ARG . . . 76.01 15.15 81.58 Favored Glycine 0 CA--C 1.53 0.997 0 O-C-N 124.497 1.123 . . . . 0.0 110.999 179.988 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.505 ' SG ' ' CG2' ' A' ' 12' ' ' THR . 55.9 m -95.78 126.33 40.97 Favored 'General case' 0 C--N 1.325 -0.481 0 N-CA-C 108.282 -1.007 . . . . 0.0 108.282 -179.952 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . 0.414 ' HG1' ' HG1' ' A' ' 23' ' ' THR . 12.3 p -92.45 154.36 18.54 Favored 'General case' 0 C--N 1.325 -0.497 0 O-C-N 124.51 1.131 . . . . 0.0 110.408 -179.998 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 21.9 t -83.59 94.81 8.16 Favored 'General case' 0 C--N 1.324 -0.508 0 O-C-N 124.497 1.123 . . . . 0.0 108.3 -179.996 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . 0.566 ' CB ' HG23 ' A' ' 23' ' ' THR . 1.1 t -102.68 68.06 1.02 Allowed 'General case' 0 C--N 1.325 -0.474 0 O-C-N 124.501 1.126 . . . . 0.0 110.011 174.02 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' TRP . . . . . 0.602 ' CG ' ' HA ' ' A' ' 20' ' ' PRO . 0.0 OUTLIER -36.03 147.02 0.19 Allowed Pre-proline 0 C--N 1.325 -0.5 0 O-C-N 124.501 1.125 . . . . 0.0 107.972 -174.213 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.602 ' HA ' ' CG ' ' A' ' 19' ' ' TRP . 18.2 Cg_endo -75.04 -14.34 23.23 Favored 'Cis proline' 0 C--N 1.361 1.194 0 C-N-CA 120.988 -2.505 . . . . 0.0 110.998 -8.67 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.644 HG22 ' H ' ' A' ' 22' ' ' CYS . 3.8 p -97.61 178.46 0.61 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 O-C-N 124.508 1.13 . . . . 0.0 109.277 -172.984 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.644 ' H ' HG22 ' A' ' 21' ' ' VAL . 35.3 m -102.14 172.76 6.71 Favored 'General case' 0 C--N 1.326 -0.439 0 O-C-N 124.497 1.123 . . . . 0.0 108.279 -179.97 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.566 HG23 ' CB ' ' A' ' 18' ' ' SER . 5.9 p -145.53 160.57 41.42 Favored 'General case' 0 C--N 1.325 -0.497 0 O-C-N 124.51 1.131 . . . . 0.0 110.446 179.965 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.536 ' HB3' HG22 ' A' ' 29' ' ' VAL . 15.1 tpt180 -127.92 114.69 17.5 Favored 'General case' 0 C--N 1.325 -0.485 0 O-C-N 124.515 1.134 . . . . 0.0 110.304 -179.984 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 66.1 t30 57.07 25.55 10.94 Favored 'General case' 0 C--N 1.325 -0.49 0 O-C-N 124.496 1.123 . . . . 0.0 109.281 -179.997 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 82.74 22.18 58.46 Favored Glycine 0 CA--C 1.53 1.019 0 O-C-N 124.487 1.117 . . . . 0.0 110.999 -179.999 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 52.3 mt -140.35 132.23 14.37 Favored Pre-proline 0 C--N 1.325 -0.475 0 O-C-N 124.512 0.772 . . . . 0.0 109.261 179.996 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 20.2 Cg_endo -75.0 86.29 1.44 Allowed 'Trans proline' 0 N--CA 1.453 -0.89 0 O-C-N 124.465 1.771 . . . . 0.0 110.967 -168.321 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.536 HG22 ' HB3' ' A' ' 24' ' ' ARG . 19.0 m . . . . . 0 C--N 1.325 -0.477 0 O-C-N 124.467 1.104 . . . . 0.0 109.311 179.983 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 79.0 m . . . . . 0 N--CA 1.453 -0.306 0 N-CA-C 108.295 -1.002 . . . . 0.0 108.295 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 82.82 -9.74 58.93 Favored Glycine 0 CA--C 1.53 0.994 0 O-C-N 124.501 1.126 . . . . 0.0 111.057 -179.966 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 11.4 pt-20 -100.24 167.85 10.17 Favored 'General case' 0 C--N 1.326 -0.446 0 O-C-N 124.495 0.762 . . . . 0.0 110.272 -179.99 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.678 HG22 HG13 ' A' ' 21' ' ' VAL . 50.9 p -127.07 143.94 51.15 Favored 'General case' 0 C--N 1.325 -0.481 0 O-C-N 124.52 1.138 . . . . 0.0 110.392 179.998 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.419 ' HB2' ' N ' ' A' ' 9' ' ' THR . 20.5 p -104.26 56.98 0.71 Allowed 'General case' 0 C--N 1.324 -0.5 0 O-C-N 124.494 1.121 . . . . 0.0 108.324 179.976 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 4.9 t -59.48 -24.74 29.18 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 O-C-N 124.493 1.121 . . . . 0.0 109.319 179.981 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -85.23 -33.94 15.95 Favored Glycine 0 CA--C 1.53 1.016 0 O-C-N 124.527 1.142 . . . . 0.0 110.952 -179.932 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 125.14 17.3 2.75 Favored Glycine 0 CA--C 1.53 1.023 0 O-C-N 124.889 0.994 . . . . 0.0 111.005 177.766 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . 0.419 ' N ' ' HB2' ' A' ' 5' ' ' CYS . 32.1 m -150.38 164.01 36.92 Favored 'General case' 0 C--N 1.325 -0.485 0 O-C-N 124.495 0.762 . . . . 0.0 110.397 179.978 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . 0.405 ' SG ' ' O ' ' A' ' 16' ' ' THR . 74.9 m -118.55 142.41 47.63 Favored 'General case' 0 C--N 1.325 -0.485 0 O-C-N 124.505 1.128 . . . . 0.0 108.312 -179.998 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 3.9 m120 -90.87 -40.9 11.49 Favored 'General case' 0 C--N 1.325 -0.469 0 O-C-N 124.485 1.115 . . . . 0.0 109.275 -179.998 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.64 HG23 ' HD2' ' A' ' 13' ' ' PRO . 17.5 m -63.76 142.82 98.09 Favored Pre-proline 0 C--N 1.325 -0.484 0 O-C-N 124.483 1.115 . . . . 0.0 110.426 -179.993 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.64 ' HD2' HG23 ' A' ' 12' ' ' THR . 20.1 Cg_endo -74.97 130.73 13.58 Favored 'Trans proline' 0 N--CA 1.453 -0.876 0 O-C-N 124.481 1.779 . . . . 0.0 110.969 -168.246 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 77.16 10.37 86.29 Favored Glycine 0 CA--C 1.53 1.022 0 O-C-N 124.511 1.132 . . . . 0.0 111.001 179.985 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.5 ' SG ' ' CG2' ' A' ' 12' ' ' THR . 68.1 m -93.78 126.75 39.15 Favored 'General case' 0 C--N 1.325 -0.464 0 N-CA-C 108.268 -1.012 . . . . 0.0 108.268 -179.973 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . 0.405 ' O ' ' SG ' ' A' ' 10' ' ' CYS . 11.2 p -93.8 152.41 18.93 Favored 'General case' 0 C--N 1.324 -0.511 0 O-C-N 124.456 1.098 . . . . 0.0 110.393 -179.981 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 43.4 t -80.0 98.14 7.07 Favored 'General case' 0 C--N 1.325 -0.473 0 O-C-N 124.475 1.109 . . . . 0.0 108.331 179.983 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . 0.519 ' O ' ' C ' ' A' ' 19' ' ' TRP . 30.0 t -105.72 64.92 0.7 Allowed 'General case' 0 C--N 1.325 -0.472 0 O-C-N 124.502 1.126 . . . . 0.0 109.986 174.242 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' TRP . . . . . 0.643 ' CG ' ' HA ' ' A' ' 20' ' ' PRO . 0.4 OUTLIER -35.42 147.0 0.17 Allowed Pre-proline 0 C--N 1.325 -0.472 0 O-C-N 124.537 1.148 . . . . 0.0 108.024 -174.284 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.643 ' HA ' ' CG ' ' A' ' 19' ' ' TRP . 18.3 Cg_endo -74.98 -13.97 23.3 Favored 'Cis proline' 0 C--N 1.36 1.148 0 C-N-CA 121.013 -2.495 . . . . 0.0 111.006 -8.605 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.678 HG13 HG22 ' A' ' 4' ' ' THR . 3.8 t -97.94 175.31 0.82 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 O-C-N 124.478 1.111 . . . . 0.0 109.239 -173.022 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.638 ' H ' HG12 ' A' ' 21' ' ' VAL . 3.5 m -102.36 170.0 8.34 Favored 'General case' 0 C--N 1.325 -0.483 0 O-C-N 124.463 1.102 . . . . 0.0 108.338 179.995 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.462 HG23 ' HB3' ' A' ' 18' ' ' SER . 1.9 p -147.27 163.41 36.49 Favored 'General case' 0 C--N 1.325 -0.495 0 O-C-N 124.49 1.119 . . . . 0.0 110.385 179.996 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.566 ' HB3' HG22 ' A' ' 29' ' ' VAL . 0.3 OUTLIER -139.77 118.91 12.7 Favored 'General case' 0 C--N 1.324 -0.509 0 O-C-N 124.573 1.17 . . . . 0.0 110.33 179.937 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 18.0 t-20 57.91 22.36 8.64 Favored 'General case' 0 C--N 1.325 -0.48 0 O-C-N 124.528 1.142 . . . . 0.0 109.277 -179.988 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . 0.473 ' O ' HD23 ' A' ' 27' ' ' LEU . . . 84.55 23.21 51.49 Favored Glycine 0 CA--C 1.531 1.042 0 O-C-N 124.504 1.128 . . . . 0.0 110.959 179.952 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.473 HD23 ' O ' ' A' ' 26' ' ' GLY . 12.1 mt -145.96 128.04 7.79 Favored Pre-proline 0 C--N 1.325 -0.491 0 O-C-N 124.515 0.773 . . . . 0.0 109.311 -179.976 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 20.3 Cg_endo -74.92 78.25 2.91 Favored 'Trans proline' 0 N--CA 1.453 -0.889 0 O-C-N 124.515 1.797 . . . . 0.0 110.966 -168.294 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.566 HG22 ' HB3' ' A' ' 24' ' ' ARG . 30.8 m . . . . . 0 C--N 1.324 -0.517 0 O-C-N 124.509 1.131 . . . . 0.0 109.289 179.985 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 99.7 m . . . . . 0 N--CA 1.453 -0.311 0 N-CA-C 108.319 -0.993 . . . . 0.0 108.319 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 84.61 -13.21 53.47 Favored Glycine 0 CA--C 1.53 1.004 0 O-C-N 124.475 1.109 . . . . 0.0 110.958 179.936 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . 0.402 ' HG3' ' SG ' ' A' ' 22' ' ' CYS . 23.1 pt-20 -100.42 171.72 7.57 Favored 'General case' 0 C--N 1.325 -0.495 0 O-C-N 124.504 0.767 . . . . 0.0 110.262 -179.983 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 1.053 HG22 HG23 ' A' ' 21' ' ' VAL . 38.4 p -129.72 143.16 50.68 Favored 'General case' 0 C--N 1.325 -0.482 0 O-C-N 124.506 1.128 . . . . 0.0 110.377 179.991 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.584 ' O ' ' CD1' ' A' ' 19' ' ' TRP . 14.8 p -96.67 52.46 1.2 Allowed 'General case' 0 C--N 1.325 -0.469 0 O-C-N 124.474 1.109 . . . . 0.0 108.301 179.953 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 4.5 t -59.01 -24.9 28.13 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 O-C-N 124.428 1.08 . . . . 0.0 109.309 179.992 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -84.02 -35.09 16.28 Favored Glycine 0 CA--C 1.53 1.028 0 O-C-N 124.467 1.104 . . . . 0.0 111.021 179.996 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . 0.4 ' O ' ' SG ' ' A' ' 17' ' ' CYS . . . 133.34 -13.24 4.91 Favored Glycine 0 C--N 1.346 1.106 0 O-C-N 125.139 1.14 . . . . 0.0 110.979 178.327 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -131.1 162.93 28.78 Favored 'General case' 0 C--N 1.324 -0.502 0 O-C-N 124.517 0.775 . . . . 0.0 110.411 -179.96 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . 0.406 ' SG ' ' O ' ' A' ' 16' ' ' THR . 86.9 m -107.16 141.64 38.11 Favored 'General case' 0 C--N 1.325 -0.49 0 O-C-N 124.499 1.124 . . . . 0.0 108.268 -179.951 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 64.1 t-20 -89.59 -38.13 14.17 Favored 'General case' 0 C--N 1.325 -0.481 0 O-C-N 124.522 1.139 . . . . 0.0 109.329 179.961 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.657 HG23 ' HD2' ' A' ' 13' ' ' PRO . 16.5 m -67.44 143.11 96.97 Favored Pre-proline 0 C--N 1.326 -0.454 0 O-C-N 124.509 1.131 . . . . 0.0 110.429 -179.996 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.657 ' HD2' HG23 ' A' ' 12' ' ' THR . 20.2 Cg_endo -74.98 129.15 12.09 Favored 'Trans proline' 0 N--CA 1.453 -0.88 0 O-C-N 124.569 1.826 . . . . 0.0 110.99 -168.27 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 76.86 14.27 82.76 Favored Glycine 0 CA--C 1.529 0.951 0 O-C-N 124.517 1.135 . . . . 0.0 111.035 -179.964 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.494 ' SG ' ' CG2' ' A' ' 12' ' ' THR . 57.7 m -96.45 129.38 43.82 Favored 'General case' 0 C--N 1.325 -0.459 0 N-CA-C 108.315 -0.994 . . . . 0.0 108.315 179.976 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . 0.406 ' O ' ' SG ' ' A' ' 10' ' ' CYS . 23.4 p -93.57 148.71 21.84 Favored 'General case' 0 C--N 1.325 -0.474 0 O-C-N 124.492 1.12 . . . . 0.0 110.358 -179.977 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . 0.4 ' SG ' ' O ' ' A' ' 8' ' ' GLY . 11.9 t -81.23 95.06 6.82 Favored 'General case' 0 C--N 1.325 -0.462 0 O-C-N 124.5 1.125 . . . . 0.0 108.293 179.988 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . 0.718 ' OG ' HG23 ' A' ' 23' ' ' THR . 20.4 p -102.31 65.79 0.97 Allowed 'General case' 0 C--N 1.325 -0.497 0 O-C-N 124.493 1.121 . . . . 0.0 110.036 173.993 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' TRP . . . . . 0.59 ' CG ' ' HA ' ' A' ' 20' ' ' PRO . 0.0 OUTLIER -36.02 147.23 0.18 Allowed Pre-proline 0 C--N 1.325 -0.459 0 N-CA-C 107.998 -1.112 . . . . 0.0 107.998 -174.047 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.59 ' HA ' ' CG ' ' A' ' 19' ' ' TRP . 18.4 Cg_endo -74.95 -13.53 23.44 Favored 'Cis proline' 0 C--N 1.36 1.161 0 C-N-CA 120.995 -2.502 . . . . 0.0 111.01 -8.641 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 1.053 HG23 HG22 ' A' ' 4' ' ' THR . 2.3 p -96.35 173.99 0.9 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.478 0 O-C-N 124.53 1.144 . . . . 0.0 109.331 -173.224 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.524 ' H ' HG22 ' A' ' 21' ' ' VAL . 1.7 m -102.09 169.2 8.9 Favored 'General case' 0 C--N 1.325 -0.488 0 O-C-N 124.485 1.115 . . . . 0.0 108.324 -179.973 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.718 HG23 ' OG ' ' A' ' 18' ' ' SER . 1.1 p -141.99 169.1 18.22 Favored 'General case' 0 C--N 1.325 -0.488 0 O-C-N 124.494 1.121 . . . . 0.0 110.413 -179.981 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.554 ' HB3' HG22 ' A' ' 29' ' ' VAL . 6.0 ttt180 -143.74 117.02 9.0 Favored 'General case' 0 C--N 1.325 -0.475 0 O-C-N 124.527 1.142 . . . . 0.0 110.279 -179.986 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 71.1 m-20 58.47 22.23 9.36 Favored 'General case' 0 C--N 1.325 -0.482 0 O-C-N 124.516 1.135 . . . . 0.0 109.31 179.992 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . 0.41 ' O ' HD23 ' A' ' 27' ' ' LEU . . . 86.48 20.64 53.99 Favored Glycine 0 CA--C 1.53 0.974 0 O-C-N 124.498 1.124 . . . . 0.0 111.009 -179.997 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.41 HD23 ' O ' ' A' ' 26' ' ' GLY . 9.7 mt -144.7 128.81 8.92 Favored Pre-proline 0 C--N 1.325 -0.493 0 O-C-N 124.514 0.773 . . . . 0.0 109.29 -179.98 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 20.2 Cg_endo -74.97 84.68 1.62 Allowed 'Trans proline' 0 N--CA 1.453 -0.895 0 O-C-N 124.499 1.789 . . . . 0.0 111.014 -168.321 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.554 HG22 ' HB3' ' A' ' 24' ' ' ARG . 28.4 m . . . . . 0 C--N 1.324 -0.508 0 O-C-N 124.547 1.154 . . . . 0.0 109.295 -179.968 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 83.0 m . . . . . 0 N--CA 1.453 -0.296 0 N-CA-C 108.286 -1.005 . . . . 0.0 108.286 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 100.56 -25.33 28.71 Favored Glycine 0 CA--C 1.53 1.017 0 O-C-N 124.475 1.109 . . . . 0.0 110.99 -179.996 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 28.6 tt0 -78.51 150.47 32.9 Favored 'General case' 0 C--N 1.324 -0.511 0 O-C-N 124.519 0.776 . . . . 0.0 110.293 -179.969 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.608 HG22 HG12 ' A' ' 21' ' ' VAL . 75.2 p -110.21 130.94 55.45 Favored 'General case' 0 C--N 1.325 -0.476 0 O-C-N 124.453 1.095 . . . . 0.0 110.42 179.977 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.416 ' SG ' ' O ' ' A' ' 5' ' ' CYS . 14.5 p -99.0 51.58 0.96 Allowed 'General case' 0 C--N 1.325 -0.46 0 O-C-N 124.452 1.095 . . . . 0.0 108.301 -179.975 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 9.6 t -59.22 -24.59 27.94 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 O-C-N 124.553 1.158 . . . . 0.0 109.334 -179.991 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -83.89 -33.42 21.31 Favored Glycine 0 CA--C 1.53 0.984 0 O-C-N 124.52 1.138 . . . . 0.0 110.972 -179.978 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 125.95 14.24 3.12 Favored Glycine 0 C--N 1.346 1.086 0 C-N-CA 119.776 -1.202 . . . . 0.0 110.982 177.846 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -150.07 166.25 30.31 Favored 'General case' 0 C--N 1.325 -0.494 0 O-C-N 124.456 0.739 . . . . 0.0 110.355 -179.997 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . 0.405 ' SG ' ' O ' ' A' ' 16' ' ' THR . 74.8 m -123.14 144.28 49.45 Favored 'General case' 0 C--N 1.326 -0.439 0 O-C-N 124.477 1.11 . . . . 0.0 108.288 -179.989 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 9.8 t-20 -91.18 -44.39 9.27 Favored 'General case' 0 C--N 1.325 -0.464 0 O-C-N 124.463 1.102 . . . . 0.0 109.313 -179.971 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.609 HG23 ' HD2' ' A' ' 13' ' ' PRO . 20.6 m -58.03 142.73 79.47 Favored Pre-proline 0 C--N 1.325 -0.48 0 O-C-N 124.487 1.117 . . . . 0.0 110.392 -179.984 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.609 ' HD2' HG23 ' A' ' 12' ' ' THR . 20.2 Cg_endo -74.98 132.34 15.34 Favored 'Trans proline' 0 N--CA 1.453 -0.871 0 O-C-N 124.443 1.76 . . . . 0.0 110.937 -168.251 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 75.47 8.71 84.2 Favored Glycine 0 CA--C 1.53 1.014 0 O-C-N 124.472 1.107 . . . . 0.0 111.028 179.993 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.496 ' SG ' ' CG2' ' A' ' 12' ' ' THR . 81.5 m -93.29 125.43 37.89 Favored 'General case' 0 C--N 1.324 -0.509 0 N-CA-C 108.279 -1.008 . . . . 0.0 108.279 179.995 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . 0.405 ' O ' ' SG ' ' A' ' 10' ' ' CYS . 2.2 p -94.0 156.07 16.8 Favored 'General case' 0 C--N 1.325 -0.483 0 O-C-N 124.524 1.14 . . . . 0.0 110.393 -179.994 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 48.5 t -81.25 91.14 6.16 Favored 'General case' 0 C--N 1.325 -0.495 0 O-C-N 124.512 1.133 . . . . 0.0 108.336 179.968 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . 0.525 ' O ' ' C ' ' A' ' 19' ' ' TRP . 1.9 m -98.09 65.23 1.73 Allowed 'General case' 0 C--N 1.324 -0.502 0 O-C-N 124.503 1.127 . . . . 0.0 110.001 174.231 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' TRP . . . . . 0.607 ' CG ' ' HA ' ' A' ' 20' ' ' PRO . 0.0 OUTLIER -35.52 147.1 0.17 Allowed Pre-proline 0 C--N 1.324 -0.506 0 O-C-N 124.503 1.127 . . . . 0.0 107.993 -173.882 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.607 ' HA ' ' CG ' ' A' ' 19' ' ' TRP . 18.4 Cg_endo -74.98 -13.27 23.65 Favored 'Cis proline' 0 C--N 1.36 1.143 0 C-N-CA 121.012 -2.495 . . . . 0.0 110.98 -8.386 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.608 HG12 HG22 ' A' ' 4' ' ' THR . 2.4 m -99.92 178.65 0.64 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.494 0 O-C-N 124.468 1.105 . . . . 0.0 109.295 -173.117 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 82.7 m -102.21 171.75 7.3 Favored 'General case' 0 C--N 1.325 -0.486 0 O-C-N 124.524 1.14 . . . . 0.0 108.281 -179.997 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.408 ' O ' ' HA ' ' A' ' 15' ' ' CYS . 0.8 OUTLIER -150.3 161.0 43.3 Favored 'General case' 0 C--N 1.325 -0.477 0 O-C-N 124.526 1.141 . . . . 0.0 110.396 179.991 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.475 ' HB3' ' CG2' ' A' ' 29' ' ' VAL . 8.6 ttt180 -132.4 119.08 20.18 Favored 'General case' 0 C--N 1.325 -0.493 0 O-C-N 124.552 1.157 . . . . 0.0 110.289 -179.99 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . 0.404 ' OD1' ' O ' ' A' ' 25' ' ' ASN . 22.9 t-20 57.24 28.87 15.8 Favored 'General case' 0 C--N 1.325 -0.484 0 O-C-N 124.507 1.129 . . . . 0.0 109.291 179.992 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 76.05 23.3 72.04 Favored Glycine 0 CA--C 1.531 1.038 0 O-C-N 124.504 1.127 . . . . 0.0 110.989 179.988 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 7.3 mt -141.4 129.22 11.99 Favored Pre-proline 0 C--N 1.324 -0.509 0 O-C-N 124.554 0.796 . . . . 0.0 109.311 -179.971 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 20.2 Cg_endo -75.0 88.3 1.25 Allowed 'Trans proline' 0 N--CA 1.453 -0.875 0 O-C-N 124.487 1.783 . . . . 0.0 110.944 -168.261 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.475 ' CG2' ' HB3' ' A' ' 24' ' ' ARG . 27.1 m . . . . . 0 C--N 1.325 -0.468 0 O-C-N 124.476 1.11 . . . . 0.0 109.345 179.958 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 91.6 m . . . . . 0 N--CA 1.453 -0.284 0 N-CA-C 108.271 -1.011 . . . . 0.0 108.271 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 92.57 7.93 62.83 Favored Glycine 0 CA--C 1.53 1.023 0 O-C-N 124.486 1.116 . . . . 0.0 110.972 -179.985 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 89.8 mt-10 -100.23 165.01 11.7 Favored 'General case' 0 C--N 1.325 -0.495 0 O-C-N 124.493 0.761 . . . . 0.0 110.308 179.999 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 23.9 p -121.51 114.99 22.01 Favored 'General case' 0 C--N 1.325 -0.485 0 O-C-N 124.456 1.098 . . . . 0.0 110.4 -179.984 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.432 ' O ' ' SG ' ' A' ' 5' ' ' CYS . 13.3 p -91.08 49.62 1.66 Allowed 'General case' 0 C--N 1.325 -0.474 0 O-C-N 124.5 1.125 . . . . 0.0 108.315 -179.976 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 17.5 t -59.19 -24.54 27.75 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 O-C-N 124.5 1.125 . . . . 0.0 109.355 -179.985 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -84.62 -34.25 16.73 Favored Glycine 0 CA--C 1.531 1.036 0 O-C-N 124.498 1.124 . . . . 0.0 110.981 -179.994 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 125.84 13.1 3.43 Favored Glycine 0 CA--C 1.53 1.006 0 O-C-N 125.1 1.118 . . . . 0.0 111.041 178.05 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 2.5 m -150.02 161.4 42.4 Favored 'General case' 0 C--N 1.326 -0.452 0 O-C-N 124.529 0.782 . . . . 0.0 110.383 -179.975 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . 0.402 ' SG ' ' O ' ' A' ' 16' ' ' THR . 72.3 m -119.11 156.37 29.88 Favored 'General case' 0 C--N 1.325 -0.489 0 O-C-N 124.468 1.105 . . . . 0.0 108.327 179.974 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 17.6 t30 -97.98 -58.17 2.05 Favored 'General case' 0 C--N 1.325 -0.475 0 O-C-N 124.518 1.136 . . . . 0.0 109.341 179.97 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.66 HG23 ' HD2' ' A' ' 13' ' ' PRO . 5.3 m -44.69 142.64 2.45 Favored Pre-proline 0 C--N 1.324 -0.501 0 O-C-N 124.558 1.161 . . . . 0.0 110.405 179.954 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.66 ' HD2' HG23 ' A' ' 12' ' ' THR . 20.4 Cg_endo -74.94 129.53 12.49 Favored 'Trans proline' 0 N--CA 1.453 -0.871 0 O-C-N 124.493 1.786 . . . . 0.0 111.023 -168.34 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 78.88 11.57 85.08 Favored Glycine 0 CA--C 1.53 0.986 0 O-C-N 124.513 1.133 . . . . 0.0 111.034 -179.988 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.503 ' SG ' HG22 ' A' ' 12' ' ' THR . 57.7 m -95.29 125.71 40.11 Favored 'General case' 0 C--N 1.325 -0.461 0 N-CA-C 108.306 -0.998 . . . . 0.0 108.306 -179.943 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . 0.402 ' O ' ' SG ' ' A' ' 10' ' ' CYS . 18.7 p -95.16 157.35 15.93 Favored 'General case' 0 C--N 1.326 -0.449 0 O-C-N 124.469 1.106 . . . . 0.0 110.423 -179.989 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 24.5 t -82.74 95.84 7.99 Favored 'General case' 0 C--N 1.325 -0.486 0 O-C-N 124.543 1.152 . . . . 0.0 108.291 179.989 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . 0.598 ' HB3' HG23 ' A' ' 23' ' ' THR . 11.2 t -100.45 64.56 1.15 Allowed 'General case' 0 C--N 1.325 -0.469 0 O-C-N 124.504 1.128 . . . . 0.0 110.057 173.855 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' TRP . . . . . 0.611 ' CG ' ' HA ' ' A' ' 20' ' ' PRO . 0.3 OUTLIER -35.39 145.96 0.19 Allowed Pre-proline 0 C--N 1.325 -0.496 0 O-C-N 124.549 1.155 . . . . 0.0 108.033 -174.124 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.611 ' HA ' ' CG ' ' A' ' 19' ' ' TRP . 18.3 Cg_endo -75.04 -14.88 22.92 Favored 'Cis proline' 0 C--N 1.359 1.13 0 C-N-CA 121.021 -2.491 . . . . 0.0 110.973 -8.459 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.492 ' O ' ' C ' ' A' ' 18' ' ' SER . 3.1 m -95.76 177.09 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 O-C-N 124.515 1.134 . . . . 0.0 109.241 -173.101 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 43.9 m -101.85 166.71 10.51 Favored 'General case' 0 C--N 1.325 -0.487 0 O-C-N 124.537 1.148 . . . . 0.0 108.333 179.987 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.598 HG23 ' HB3' ' A' ' 18' ' ' SER . 1.0 OUTLIER -145.04 169.51 17.98 Favored 'General case' 0 C--N 1.325 -0.485 0 O-C-N 124.516 1.135 . . . . 0.0 110.384 179.991 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.569 ' HB3' HG22 ' A' ' 29' ' ' VAL . 0.1 OUTLIER -142.18 118.22 10.65 Favored 'General case' 0 C--N 1.325 -0.474 0 O-C-N 124.524 1.14 . . . . 0.0 110.304 -179.972 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 72.0 m-20 57.77 23.37 9.51 Favored 'General case' 0 C--N 1.325 -0.466 0 O-C-N 124.557 1.16 . . . . 0.0 109.357 -179.957 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 82.17 24.14 55.41 Favored Glycine 0 CA--C 1.531 1.036 0 O-C-N 124.524 1.14 . . . . 0.0 111.039 -179.994 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 7.5 mt -143.31 129.57 10.34 Favored Pre-proline 0 C--N 1.325 -0.467 0 O-C-N 124.487 0.757 . . . . 0.0 109.317 -179.973 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 20.4 Cg_endo -74.89 82.18 2.03 Favored 'Trans proline' 0 N--CA 1.453 -0.904 0 O-C-N 124.535 1.808 . . . . 0.0 111.02 -168.348 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.569 HG22 ' HB3' ' A' ' 24' ' ' ARG . 32.7 m . . . . . 0 C--N 1.324 -0.51 0 O-C-N 124.526 1.141 . . . . 0.0 109.308 179.997 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 95.2 m . . . . . 0 N--CA 1.452 -0.327 0 N-CA-C 108.266 -1.013 . . . . 0.0 108.266 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 91.03 -27.22 9.35 Favored Glycine 0 CA--C 1.53 0.975 0 O-C-N 124.569 1.168 . . . . 0.0 111.041 -179.976 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 23.5 tt0 -83.53 151.88 25.18 Favored 'General case' 0 C--N 1.325 -0.495 0 O-C-N 124.503 0.767 . . . . 0.0 110.292 -179.988 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.63 HG22 HG23 ' A' ' 21' ' ' VAL . 60.2 p -112.83 137.93 50.43 Favored 'General case' 0 C--N 1.324 -0.505 0 O-C-N 124.532 1.145 . . . . 0.0 110.372 179.995 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.407 ' SG ' ' O ' ' A' ' 5' ' ' CYS . 15.0 p -100.88 52.79 0.85 Allowed 'General case' 0 C--N 1.325 -0.477 0 O-C-N 124.551 1.157 . . . . 0.0 108.29 179.99 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 10.3 t -59.22 -24.14 26.74 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 O-C-N 124.508 1.13 . . . . 0.0 109.288 -179.996 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -84.75 -34.6 15.26 Favored Glycine 0 CA--C 1.53 1.006 0 O-C-N 124.524 1.14 . . . . 0.0 110.968 -179.976 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 127.19 14.78 2.64 Favored Glycine 0 CA--C 1.531 1.043 0 O-C-N 125.138 1.14 . . . . 0.0 111.029 177.62 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -150.08 166.73 28.88 Favored 'General case' 0 C--N 1.325 -0.476 0 O-C-N 124.489 0.758 . . . . 0.0 110.386 -179.971 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . 0.414 ' SG ' ' O ' ' A' ' 16' ' ' THR . 72.3 m -124.56 140.71 52.69 Favored 'General case' 0 C--N 1.325 -0.486 0 O-C-N 124.525 1.14 . . . . 0.0 108.298 180.0 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 3.0 m120 -89.58 -40.13 12.81 Favored 'General case' 0 C--N 1.325 -0.465 0 O-C-N 124.428 1.08 . . . . 0.0 109.291 -179.989 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.608 HG23 ' HD2' ' A' ' 13' ' ' PRO . 20.9 m -60.05 142.69 89.08 Favored Pre-proline 0 C--N 1.325 -0.467 0 O-C-N 124.465 1.103 . . . . 0.0 110.393 179.995 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.608 ' HD2' HG23 ' A' ' 12' ' ' THR . 20.2 Cg_endo -74.97 132.08 15.05 Favored 'Trans proline' 0 N--CA 1.453 -0.877 0 O-C-N 124.485 1.781 . . . . 0.0 110.947 -168.269 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 73.34 13.35 79.85 Favored Glycine 0 CA--C 1.53 0.999 0 O-C-N 124.563 1.165 . . . . 0.0 110.999 179.974 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.513 ' SG ' HG22 ' A' ' 12' ' ' THR . 68.7 m -97.97 125.64 42.99 Favored 'General case' 0 C--N 1.325 -0.486 0 N-CA-C 108.306 -0.998 . . . . 0.0 108.306 -179.989 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . 0.414 ' O ' ' SG ' ' A' ' 10' ' ' CYS . 44.4 p -93.73 157.56 16.1 Favored 'General case' 0 C--N 1.325 -0.498 0 O-C-N 124.479 1.112 . . . . 0.0 110.387 179.985 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 46.8 t -83.09 95.04 7.94 Favored 'General case' 0 C--N 1.326 -0.454 0 O-C-N 124.491 1.12 . . . . 0.0 108.273 -179.948 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . 0.52 ' O ' ' C ' ' A' ' 19' ' ' TRP . 1.0 OUTLIER -102.79 66.92 0.96 Allowed 'General case' 0 C--N 1.325 -0.469 0 O-C-N 124.459 1.099 . . . . 0.0 110.029 173.96 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' TRP . . . . . 0.612 ' CG ' ' HA ' ' A' ' 20' ' ' PRO . 0.0 OUTLIER -35.7 147.46 0.17 Allowed Pre-proline 0 C--N 1.326 -0.455 0 O-C-N 124.496 1.123 . . . . 0.0 107.982 -174.009 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.612 ' HA ' ' CG ' ' A' ' 19' ' ' TRP . 18.3 Cg_endo -75.01 -13.5 23.62 Favored 'Cis proline' 0 C--N 1.361 1.206 0 C-N-CA 121.001 -2.5 . . . . 0.0 111.025 -8.572 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.689 HG22 ' H ' ' A' ' 22' ' ' CYS . 4.8 p -100.05 178.84 0.63 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 O-C-N 124.547 1.154 . . . . 0.0 109.323 -173.006 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.689 ' H ' HG22 ' A' ' 21' ' ' VAL . 81.4 m -102.22 174.0 6.12 Favored 'General case' 0 C--N 1.325 -0.492 0 O-C-N 124.503 1.127 . . . . 0.0 108.285 179.991 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.515 HG23 ' CB ' ' A' ' 18' ' ' SER . 7.2 p -147.02 159.19 43.88 Favored 'General case' 0 C--N 1.325 -0.496 0 O-C-N 124.519 1.137 . . . . 0.0 110.402 179.985 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.581 ' HB3' HG22 ' A' ' 29' ' ' VAL . 3.4 ttt180 -130.5 116.49 18.26 Favored 'General case' 0 C--N 1.325 -0.465 0 O-C-N 124.513 1.133 . . . . 0.0 110.326 179.948 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 74.9 m-20 57.61 23.46 9.34 Favored 'General case' 0 C--N 1.325 -0.476 0 O-C-N 124.51 1.131 . . . . 0.0 109.329 -179.939 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 84.27 24.72 46.57 Favored Glycine 0 CA--C 1.53 1.002 0 O-C-N 124.522 1.139 . . . . 0.0 111.013 180.0 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 10.7 mt -144.84 130.31 9.44 Favored Pre-proline 0 C--N 1.325 -0.481 0 O-C-N 124.495 0.762 . . . . 0.0 109.262 -179.984 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 20.2 Cg_endo -74.99 88.24 1.26 Allowed 'Trans proline' 0 N--CA 1.453 -0.891 0 O-C-N 124.5 1.789 . . . . 0.0 110.986 -168.312 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.581 HG22 ' HB3' ' A' ' 24' ' ' ARG . 32.4 m . . . . . 0 C--N 1.325 -0.482 0 O-C-N 124.51 1.131 . . . . 0.0 109.294 -179.998 . . . . . . . . 1 1 . 1 stop_ save_